EZH2	O
and	O
ZFX	O
oncogenes	O
in	O
malignant	O
behaviour	O
of	O
parathyroid	O
neoplasms	O
.	O

Several	O
studies	O
reported	O
somatic	O
mutations	O
of	O
many	O
genes	O
(	O
MEN1	O
,	O
CTNNB1	O
,	O
CDKIs	O
and	O
others	O
)	O
in	O
parathyroid	O
adenoma	O
,	O
although	O
with	O
different	O
prevalence	O
.	O

Recently	O
,	O
activating	O
mutations	O
of	O
the	O
EZH2	O
and	O
ZFX	O
oncogenes	O
were	O
identified	O
in	O
benign	O
parathyroid	O
adenoma	O
by	O
whole	O
exome	O
sequencing	O
.	O

The	O
same	O
mutations	O
had	O
been	O
found	O
in	O
blood	O
and	O
ovary	O
malignant	O
tumours	O
.	O

On	O
one	O
hand	O
,	O
this	O
result	O
raised	O
the	O
hypothesis	O
that	O
these	O
oncogenes	O
may	O
play	O
a	O
role	O
in	O
the	O
onset	O
of	O
parathyroid	O
tumour	O
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	O
,	O
rather	O
benign	O
,	O
parathyroid	O
neoplasm	O
.	O

Our	O
aim	O
was	O
to	O
verify	O
the	O
occurrence	O
of	O
selected	O
mutations	O
of	O
the	O
EZH2	O
and	O
ZFX	O
genes	O
in	O
an	O
Italian	O
cohort	O
of	O
23	O
sporadic	O
parathyroid	O
carcinomas	O
,	O
12	O
atypical	O
and	O
45	O
typical	O
adenomas	O
.	O

DNA	O
was	O
extracted	B-P
from	O
paraffin-embedded	O
tissues	O
,	O
PCR	O
amplified	O
and	O
directly	O
sequenced	O
.	O

No	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
and	O
boundaries	O
of	O
both	O
genes	O
in	O
any	O
of	O
the	O
samples	O
.	O

Two	O
polymorphisms	O
of	O
the	O
EZH2	O
gene	O
were	O
identified	O
with	O
different	O
prevalence	O
:	O
the	O
rs2072407	O
variant	O
was	O
present	O
in	O
the	O
30	O
%	O
of	O
the	O
samples	O
,	O
in	O
keeping	O
with	O
the	O
overall	O
frequency	O
in	O
larger	O
populations	O
,	O
while	O
the	O
rs78589034	O
variant	O
,	O
located	O
close	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
exon	O
16	O
,	O
was	O
detected	O
in	O
only	O
one	O
proband	O
with	O
familial	O
isolated	O
hyperparathyroidism	O
;	O
we	O
investigated	O
the	O
possible	O
outcome	O
on	O
the	O
splicing	O
process	O
.	O

EZH2	O
and	O
ZFX	O
genes	O
do	O
not	O
seem	O
to	O
have	O
an	O
impact	O
on	O
the	O
onset	O
of	O
most	O
parathyroid	O
tumours	O
,	O
both	O
benign	O
and	O
malignant	O
,	O
though	O
further	O
studies	O
on	O
larger	O
cohorts	O
of	O
different	O
ethnicity	O
are	O
needed	O
.	O

Perfusion	O
deconvolution	O
in	O
DSC-MRI	B-P
with	O
dispersion-compliant	O
bases	O
.	O

Perfusion	B-P
imaging	I-P
of	O
the	O
brain	O
via	O
Dynamic	B-P
Susceptibility	I-P
Contrast	I-P
MRI	I-P
(	O
DSC-MRI	B-P
)	O
allows	O
tissue	O
perfusion	O
characterization	O
by	O
recovering	O
the	O
tissue	O
impulse	O
response	O
function	O
and	O
scalar	O
parameters	O
such	O
as	O
the	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
,	O
blood	O
volume	O
(	O
CBV	O
)	O
,	O
and	O
mean	O
transit	O
time	O
(	O
MTT	O
)	O
.	O

However	O
,	O
the	O
presence	O
of	O
bolus	O
dispersion	O
causes	O
the	O
data	O
to	O
reflect	O
macrovascular	O
properties	O
,	O
in	O
addition	O
to	O
tissue	O
perfusion	O
.	O

In	O
this	O
case	O
,	O
when	O
performing	O
deconvolution	O
of	O
the	O
measured	O
arterial	O
and	O
tissue	O
concentration	O
time-curves	O
it	O
is	O
only	O
possible	O
to	O
recover	O
the	O
effective	O
,	O
i.e	O
.	O

dispersed	O
,	O
response	O
function	O
and	O
parameters	O
.	O

We	O
introduce	O
Dispersion-Compliant	O
Bases	O
(	O
DCB	O
)	O
to	O
represent	O
the	O
response	O
function	O
in	O
the	O
presence	O
and	O
absence	O
of	O
dispersion	O
.	O

We	O
perform	O
in	O
silico	O
and	O
in	O
vivo	O
experiments	O
,	O
and	O
show	O
that	O
DCB	O
deconvolution	O
outperforms	O
oSVD	O
and	O
the	O
state-of-the-art	O
CPI+VTF	O
techniques	O
in	O
the	O
estimation	O
of	O
effective	O
perfusion	O
parameters	O
,	O
regardless	O
of	O
the	O
presence	O
and	O
amount	O
of	O
dispersion	O
.	O

We	O
also	O
show	O
that	O
DCB	O
deconvolution	O
can	O
be	O
used	O
as	O
a	O
pre-processing	O
step	O
to	O
improve	O
the	O
estimation	O
of	O
dispersion	O
-free	O
parameters	O
computed	B-P
with	O
CPI+VTF	O
,	O
which	O
employs	O
a	O
model	O
of	O
the	O
vascular	O
transport	O
function	O
to	O
characterize	O
dispersion	O
.	O

Indeed	O
,	O
in	O
silico	O
results	O
show	O
a	O
reduction	O
of	O
relative	O
errors	O
up	O
to	O
50	O
%	O
for	O
dispersion	O
-free	O
CBF	O
and	O
MTT	O
.	O

Moreover	O
,	O
the	O
DCB	O
method	O
recovers	O
effective	O
response	O
functions	O
that	O
comply	O
with	O
healthy	O
and	O
pathological	O
scenarios	O
,	O
and	O
offers	O
the	O
advantage	O
of	O
making	O
no	O
assumptions	O
about	O
the	O
presence	O
,	O
amount	O
,	O
and	O
nature	O
of	O
dispersion	O
.	O

Recommendations	O
for	O
CSF	O
AD	O
biomarkers	O
in	O
the	O
diagnostic	B-P
evaluation	O
of	O
dementia	O
.	O

This	O
article	O
presents	O
recommendations	O
,	O
based	O
on	O
the	O
Grading	O
of	O
Recommendations	O
,	O
Assessment	O
,	O
Development	O
,	O
and	O
Evaluation	O
method	O
,	O
for	O
the	O
clinical	O
application	O
of	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
amyloid-β1-42	O
,	O
tau	O
,	O
and	O
phosphorylated	O
tau	O
in	O
the	O
diagnostic	B-P
evaluation	O
of	O
patients	O
with	O
dementia	O
.	O

The	O
recommendations	O
were	O
developed	O
by	O
a	O
multidisciplinary	O
working	O
group	O
based	O
on	O
the	O
available	O
evidence	O
and	O
consensus	O
from	O
focused	O
discussions	O
for	O
(	O
i	O
)	O
identification	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
as	O
the	O
cause	O
of	O
dementia	O
,	O
(	O
ii	O
)	O
prediction	O
of	O
rate	O
of	O
decline	O
,	O
(	O
iii	O
)	O
cost-effectiveness	O
,	O
and	O
(	O
iv	O
)	O
interpretation	O
of	O
results	O
.	O

The	O
working	O
group	O
found	O
sufficient	O
evidence	O
to	O
support	O
a	O
recommendation	O
to	O
use	O
CSF	O
AD	O
biomarkers	O
as	O
a	O
supplement	O
to	O
clinical	O
evaluation	O
,	O
particularly	O
in	O
uncertain	O
and	O
atypical	O
cases	O
,	O
to	O
identify	O
or	O
exclude	O
AD	O
as	O
the	O
cause	O
of	O
dementia	O
.	O

Because	O
of	O
insufficient	O
evidence	O
,	O
it	O
was	O
uncertain	O
whether	O
CSF	O
AD	O
biomarkers	O
outperform	O
imaging	O
biomarkers	O
.	O

Operational	O
recommendations	O
for	O
the	O
interpretation	O
of	O
ambiguous	O
CSF	O
biomarker	O
results	O
were	O
also	O
provided	O
.	O

Biological	O
basis	O
of	O
radiation	B-P
protection	I-P
needs	O
rejuvenation	B-P
.	O

Human	O
beings	O
encounter	O
radiation	O
in	O
many	O
different	O
situations	O
-	O
from	O
proximity	O
to	O
radioactive	O
waste	O
sites	O
to	O
participation	O
in	O
medical	O
procedures	O
using	O
X-rays	O
etc	O
.	O

Limits	O
for	O
radiation	O
exposures	O
are	O
legally	O
regulated	O
;	O
however	O
,	O
current	O
radiation	B-P
protection	I-P
policy	O
does	O
not	O
explicitly	O
acknowledge	O
that	O
biological	O
,	O
cellular	B-P
and	O
molecular	O
effects	O
of	O
low	O
doses	O
and	O
low	O
dose	O
rates	O
of	O
radiation	O
differ	O
from	O
effects	O
induced	O
by	O
medium	O
and	O
high	O
dose	O
radiation	O
exposures	O
.	O

Recent	O
technical	O
developments	O
in	O
biology	O
and	O
medicine	O
,	O
from	O
single	B-P
cell	I-P
techniques	I-P
to	O
big	B-P
data	I-P
computational	I-P
research	I-P
,	O
have	O
enabled	O
new	O
approaches	O
for	O
study	O
of	O
biology	O
of	O
low	O
doses	O
of	O
radiation	O
.	O

Results	O
of	O
the	O
work	O
done	O
so	O
far	O
support	O
the	O
idea	O
that	O
low	O
doses	O
of	O
radiation	O
have	O
effects	O
that	O
differ	O
from	O
those	O
associated	O
with	O
high	O
dose	O
exposures	O
;	O
this	O
work	O
,	O
however	O
,	O
is	O
far	O
from	O
sufficient	O
for	O
the	O
development	O
of	O
a	O
new	O
theoretical	O
framework	O
needed	O
for	O
the	O
understanding	O
of	O
low	O
dose	O
radiation	O
exposures	O
.	O

Mechanistic	O
understanding	O
of	O
radiation	O
effects	O
at	O
low	O
doses	O
is	O
necessary	O
in	O
order	O
to	O
develop	O
better	O
radiation	B-P
protection	I-P
policy	O
.	O

Decompression	B-P
Surgery	I-P
Alone	O
Versus	O
Decompression	B-P
Plus	O
Fusion	B-P
in	O
Symptomatic	O
Lumbar	O
Spinal	O
Stenosis	O
:	O
A	O
Swiss	O
Prospective	O
Multi-center	O
Cohort	O
Study	O
with	O
3	O
Years	O
of	O
Follow-up	O
.	O

Retrospective	O
analysis	O
of	O
a	O
prospective	O
,	O
multicenter	O
cohort	O
study	O
.	O

To	O
estimate	O
the	O
added	O
effect	O
of	O
surgical	B-P
fusion	I-P
as	O
compared	O
to	O
decompression	B-P
surgery	I-P
alone	O
in	O
symptomatic	O
lumbar	O
spinal	O
stenosis	O
patients	O
with	O
spondylolisthesis	O
.	O

The	O
optimal	O
surgical	O
management	O
of	O
lumbar	O
spinal	O
stenosis	O
patients	O
with	O
spondylolisthesis	O
remains	O
controversial	O
.	O

Patients	O
of	O
the	O
LSOS	O
with	O
confirmed	O
DLSS	O
and	O
spondylolisthesis	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

The	O
outcomes	O
of	O
this	O
study	O
were	O
Spinal	O
Stenosis	O
Measure	O
(	O
SSM	O
)	O
symptoms	O
(	O
score	O
range	O
1-5	O
,	O
best-worst	O
)	O
and	O
function	O
(	O
1-4	O
)	O
over	O
time	O
,	O
measured	O
at	O
baseline	O
,	O
6	O
,	O
12	O
,	O
24	O
and	O
36	O
months	O
follow-up	O
.	O

In	O
order	O
to	O
quantify	O
the	O
effect	O
of	O
fusion	B-P
surgery	I-P
as	O
compared	O
to	O
decompression	B-P
alone	O
and	O
number	O
of	O
decompressed	O
levels	O
,	O
we	O
used	O
mixed	O
effects	O
models	O
and	O
accounted	O
for	O
the	O
repeated	O
observations	O
in	O
main	O
outcomes	O
(	O
SSM	O
symptoms	O
and	O
SSM	O
function	O
)	O
over	O
time	O
.	O

In	O
addition	O
to	O
individual	O
patients	O
'	O
random	O
effects	O
,	O
we	O
also	O
fitted	O
random	O
slopes	O
for	O
follow-up	O
time	O
points	O
and	O
compared	O
these	O
two	O
approaches	O
with	O
Akaike	O
's	O
Information	O
Criterion	O
(	O
AIC	O
)	O
and	O
the	O
chi-squared	O
test	O
.	O

Confounders	O
were	O
adjusted	O
with	O
fixed	O
effects	O
for	O
age	O
,	O
gender	O
,	O
BMI	O
,	O
diabetes	O
,	O
CIRS	O
musculoskeletal	O
disorders	O
and	O
duration	O
of	O
symptoms	O
.	O

One	O
hundred	O
and	O
thirty-one	O
patients	O
undergoing	O
decompression	B-P
surgery	I-P
alone	O
(	O
n	O
=	O
85	O
)	O
or	O
decompression	B-P
plus	O
fusion	B-P
surgery	I-P
(	O
n	O
=	O
46	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

In	O
the	O
multiple	O
mixed	O
effects	O
model	O
the	O
adjusted	O
effect	O
of	O
fusion	B-P
versus	O
decompression	B-P
alone	I-P
surgery	I-P
on	O
SSM	O
symptoms	O
was	O
0.06	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
:	O
-0.16	O
to	O
0.27	O
)	O
and	O
-0.07	O
(	O
95	O
%	O
CI	O
:	O
-0.25	O
to	O
0.10	O
)	O
on	O
SSM	O
function	O
,	O
respectively	O
.	O

Among	O
the	O
patients	O
with	O
degenerative	O
lumbar	O
spinal	O
stenosis	O
and	O
spondylolisthesis	O
our	O
study	O
confirms	O
that	O
in	O
the	O
two	O
groups	O
,	O
decompression	B-P
alone	O
and	O
decompression	B-P
plus	O
fusion	B-P
,	O
patients	O
distinctively	O
benefited	O
from	O
surgical	B-P
treatment	I-P
.	O

When	O
adjusted	O
for	O
confounders	O
,	O
fusion	B-P
surgery	I-P
was	O
not	O
associated	O
with	O
a	O
more	O
favorable	O
outcome	O
in	O
both	O
SSM	O
scores	O
as	O
compared	O
to	O
decompression	B-P
alone	I-P
surgery	I-P
.	O

3	O
.	O

Self-preserving	O
personal	O
care	O
products	O
.	O

As	O
questions	O
on	O
the	O
safety	O
of	O
some	O
popular	O
preservatives	O
are	O
on	O
the	O
rise	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
developing	O
'	O
self-preserving	O
'	O
personal	O
care	O
products	O
.	O

Use	O
of	O
multifunctional	O
ingredients	O
/	O
actives	O
with	O
antimicrobial	O
properties	O
has	O
been	O
explored	O
as	O
replacements	O
for	O
conventional	O
preservatives	O
.	O

This	O
study	O
explores	O
the	O
use	O
of	O
combinations	O
of	O
multifunctional	O
actives	O
(	O
MFA	O
)	O
and	O
other	O
cosmetic	O
ingredients	O
in	O
various	O
personal	O
care	O
formulations	O
,	O
to	O
deliver	O
microbiologically	O
safe	O
self-preserving	O
products	O
.	O

Products	O
studied	O
in	O
this	O
study	O
include	O
face	O
wash	O
,	O
gel-based	O
leave-on	O
skin	O
care	O
product	O
and	O
face	O
mask	O
.	O

Minimum	B-P
inhibitory	I-P
concentration	I-P
(	O
MIC	B-P
)	O
of	O
several	O
cosmetic	O
ingredients	O
was	O
determined	O
to	O
identify	O
multifunctional	O
actives	O
with	O
antimicrobial	O
activity	O
.	O

Personal	O
care	O
formulations	O
made	O
with	O
multifunctional	O
actives	O
and	O
other	O
cosmetic	O
ingredients	O
were	O
studied	O
for	O
preservative	O
efficacy	O
by	O
challenging	O
the	O
product	O
with	O
six	O
multiple	O
cycles	O
of	O
microbial	O
challenge	O
.	O

Formulations	O
with	O
combinations	O
of	O
multifunctional	O
actives	O
with	O
antioxidant	O
(	O
AO	O
)	O
and	O
chelators	O
(	O
CHL	O
)	O
were	O
found	O
to	O
work	O
synergistically	O
and	O
were	O
highly	O
efficacious	O
in	O
controlling	O
multiple	O
microbial	O
challenges	O
as	O
observed	O
in	O
the	O
preservative	O
efficacy	O
test	O
(	O
PET	O
)	O
studies	O
.	O

The	O
effective	O
combinations	O
were	O
able	O
to	O
withstand	O
up	O
to	O
six	O
multiple	O
microbial	O
challenges	O
without	O
product	O
degradation	O
.	O

The	O
preservative	O
efficacy	O
profile	B-P
was	O
similar	O
to	O
control	O
formula	O
containing	O
preservatives	O
.	O

Self-preserving	O
personal	O
care	O
/	O
cosmetic	O
products	O
can	O
be	O
developed	O
which	O
are	O
as	O
efficacious	O
as	O
preserved	O
products	O
by	O
a	O
prudent	O
selection	O
of	O
multifunctional	O
actives	O
,	O
antioxidants	O
and	O
chelators	O
as	O
a	O
part	O
of	O
the	O
formulation	O
.	O

Physical	O
Stimulation	O
-Based	O
Osteogenesis	O
:	O
Effect	O
of	O
Secretion	O
In	O
Vitro	O
on	O
Fluid	O
Dynamic	O
Shear	O
Stress	O
of	O
Human	O
Alveolar	O
Bone	O
-Derived	O
Mesenchymal	O
Stem	O
Cells	O
.	O

Human	O
alveolar	O
bone	O
-derived	O
mesenchymal	O
stem	O
cells	O
(	O
hABMSCs	O
)	O
are	O
promising	O
candidates	O
for	O
bone	B-P
therapies	I-P
,	O
which	O
have	O
the	O
capacity	O
to	O
differentiate	O
into	O
osteoblasts	O
.	O

Recently	O
,	O
secretion	O
of	O
inducible	O
cytokines	O
and	O
growth	O
factors	O
from	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
has	O
been	O
discovered	O
,	O
and	O
we	O
also	O
have	O
reported	O
the	O
osteogenic	O
effects	O
of	O
cell	O
physical	O
stimulation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
hABMSCs	O
-	O
conditioned	O
secretion	O
media	O
(	O
B-CSM	O
)	O
on	O
osteogenic	O
differentiation	O
of	O
hABMSCs	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
analyzed	O
the	O
B-CSM	O
by	O
proteomics	O
array	O
to	O
identify	O
inducible	O
factors	O
which	O
facilitate	O
osteogenic	O
differentiation	O
.	O

To	O
determine	O
optimal	O
concentration	O
,	O
B-CSM	O
was	O
firstly	O
added	O
at	O
varying	O
amounts	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
,	O
and	O
60	O
%	O
)	O
relative	O
to	O
culture	O
medium	O
.	O

The	O
viability	O
and	O
proliferation	O
of	O
hABMSCs	O
were	O
higher	O
after	O
treating	O
with	O
5-20	O
%	O
B-CSM	O
to	O
the	O
cells	O
,	O
compared	O
to	O
40-60	O
%	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
stem	O
cells	O
markers	O
CD146	O
and	O
STRO-1	O
was	O
increased	O
in	O
the	O
cells	O
treated	O
with	O
5-20	O
%	O
B-CSM	O
,	O
but	O
decreased	O
with	O
40-60	O
%	O
.	O

We	O
also	O
found	O
that	O
B-CSM	O
promoted	O
osteogenic	O
differentiation	O
of	O
hABMSCs	O
such	O
as	O
mineralized	O
nodules	O
were	O
strongly	O
generated	O
by	O
5-20	O
%	O
.	O

B-CSM	O
was	O
most	O
effective	O
in	O
increasing	O
the	O
expression	O
of	O
Vinculin	O
and	O
osteocalcin	O
(	O
OCN	O
)	O
in	O
osteogenic	O
differentiation	O
of	O
hABMSCs	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
our	O
study	O
ultimately	O
indicate	O
that	O
B-CSM	O
from	O
hABMSCs	O
induced	O
by	O
physical	O
stimulation	O
induce	O
the	O
proliferation	O
and	O
osteogenic	O
differentiation	O
of	O
hABMSCs	O
.	O

The	O
Silorane-based	O
Resin	O
Composites	O
:	O
A	O
Review	O
.	O

This	O
article	O
aims	O
to	O
review	O
the	O
research	O
done	O
on	O
the	O
silorane-based	O
resin	O
composites	O
(	O
SBRC	O
)	O
regarding	O
polymerization	O
shrinkage	O
and	O
contraction	O
stresses	O
and	O
their	O
ability	O
to	O
improve	O
the	O
shortcomings	O
of	O
the	O
methacrylate-based	O
resin	O
composites	O
(	O
MRBC	O
)	O
.	O

Special	O
attention	O
is	O
given	O
to	O
their	O
physical	O
and	O
mechanical	O
properties	O
,	O
bond	O
strength	O
,	O
marginal	B-P
adaptation	I-P
,	O
and	O
cusp	O
deflection	O
.	O

The	O
clinical	O
significance	O
of	O
this	O
material	O
is	O
critically	O
appraised	O
with	O
a	O
focus	O
on	O
the	O
ability	O
of	O
SBRC	O
to	O
strengthen	O
the	O
tooth	O
structure	O
as	O
a	O
direct	O
restorative	O
material	O
.	O

A	O
search	O
of	O
English	O
peer-reviewed	O
dental	O
literature	O
(	O
2003-2015	O
)	O
from	O
PubMed	O
and	O
MEDLINE	O
databases	O
was	O
conducted	O
with	O
the	O
terms	O
``	O
low	O
shrinkage	O
``	O
and	O
``	O
silorane	O
composites	O
.	O
''	O

The	O
list	O
was	O
screened	O
,	O
and	O
70	O
articles	O
that	O
were	O
relevant	O
to	O
the	O
objectives	O
of	O
this	O
work	O
were	O
included	O
.	O

Advanced	O
Squamous	O
Cell	O
Carcinoma	O
of	O
the	O
Head	O
and	O
Neck	O
:	O
The	O
Current	O
Role	O
of	O
Cetuximab	O
.	O

We	O
review	O
clinical	O
trials	O
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
(	O
SCCHN	O
)	O
to	O
address	O
the	O
current	O
and	O
potential	O
uses	O
of	O
cetuximab	O
(	O
CTX	O
)	O
.	O

PubMed	O
was	O
reviewed	O
to	O
identify	O
papers	O
published	O
between	O
2010	O
and	O
2016	O
.	O

The	O
search	O
terms	O
used	O
were	O
``	O
cetuximab	O
``	O
and	O
``	O
head	O
and	O
neck	O
cancer	O
.	O
''	O

A	O
total	O
of	O
634	O
articles	O
were	O
identified	O
.	O

Phase	O
II	O
or	O
III	O
studies	O
with	O
CTX	O
in	O
patients	O
with	O
advanced	O
SCCHN	O
without	O
treatment	B-P
or	O
with	O
recurrent	O
/	O
metastatic	O
tumors	O
were	O
selected	O
.	O

Forty-six	O
registries	O
were	O
obtained	O
.	O

Information	O
was	O
critically	O
reviewed	O
and	O
relevant	O
information	O
presented	O
.	O

As	O
definitive	O
treatment	B-P
of	O
advanced	O
squamous	O
cells	O
carcinomas	O
and	O
as	O
palliative	B-P
treatment	I-P
of	O
recurrent	O
/	O
metastatic	O
disease	O
,	O
CTX	O
alone	O
or	O
associated	O
with	O
chemotherapy	B-P
and/or	O
radiotherapy	B-P
is	O
an	O
alternative	O
to	O
chemoradiotherapy	B-P
because	O
of	O
its	O
distinct	O
and	O
favorable	O
toxicity	O
profile	O
.	O

Mechanisms	O
of	O
ear	O
trauma	O
and	O
reconstructive	B-P
techniques	O
in	O
105	O
consecutive	O
patients	O
.	O

Acquired	O
auricular	O
deformities	O
may	O
diminish	O
facial	O
esthetics	O
and	O
cause	O
psychological	O
distress	O
.	O

The	O
aim	O
of	O
this	O
article	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
type	O
of	O
injuries	O
and	O
applied	B-P
reconstructive	I-P
techniques	O
in	O
a	O
large	O
academic	O
hospital	O
in	O
The	O
Netherlands	O
.	O

A	O
retrospective	O
chart	O
review	O
was	O
conducted	O
for	O
the	O
last	O
105	O
patients	O
who	O
underwent	O
auricular	O
reconstruction	B-P
for	O
an	O
acquired	O
deformity	O
.	O

Data	O
concerning	O
gender	O
,	O
affected	O
side	O
,	O
cause	O
of	O
injury	O
,	O
anatomical	O
region	O
,	O
the	O
previous	O
and	O
further	O
surgeries	B-P
,	O
type	O
of	O
cartilage	O
,	O
and	O
skin	O
cover	O
used	O
were	O
collected	O
and	O
analyzed	O
.	O

105	O
patients	O
were	O
included	O
.	O

Acquired	O
auricular	O
deformities	O
were	O
mainly	O
caused	O
by	O
bite	O
injuries	O
(	O
22	O
%	O
)	O
,	O
traffic	O
accidents	O
(	O
17	O
%	O
)	O
,	O
burns	O
(	O
9.5	O
%	O
)	O
,	O
and	O
post-otoplasty	B-P
complications	O
(	O
9.5	O
%	O
)	O
.	O

The	O
upper	O
third	O
of	O
the	O
auricle	O
was	O
most	O
often	O
injured	O
(	O
41	O
%	O
)	O
,	O
followed	O
by	O
the	O
entire	O
auricle	O
(	O
19	O
%	O
)	O
.	O

70	O
%	O
of	O
cases	O
required	O
reconstruction	B-P
with	O
costal	O
cartilage	O
.	O

The	O
most	O
common	O
form	O
of	O
cutaneous	O
cover	O
was	O
a	O
postauricular	B-P
skin	I-P
flap	I-P
(	O
40	O
%	O
of	O
cases	O
)	O
.	O

This	O
study	O
gives	O
a	O
complete	O
overview	O
of	O
causes	O
and	O
treatment	O
of	O
acquired	O
auricular	O
deformities	O
.	O

The	O
results	O
are	O
comparable	O
with	O
the	O
results	O
of	O
similar	O
studies	O
found	O
in	O
literature	O
.	O

Bite	O
wounds	O
are	O
the	O
leading	O
cause	O
of	O
acquired	O
auricular	O
injuries	O
.	O

The	O
upper	O
third	O
is	O
most	O
commonly	O
affected	O
.	O

In	O
the	O
largest	O
percentage	O
of	O
reconstructions	B-P
,	O
costal	O
cartilage	O
and	O
a	O
postauricular	O
flap	O
were	O
used	O
to	O
correct	O
the	O
deformity	O
.	O

Prednisolone	O
is	O
associated	O
with	O
a	O
worse	O
lipid	O
profile	O
than	O
hydrocortisone	O
in	O
patients	O
with	O
adrenal	O
insufficiency	O
.	O

Prednisolone	O
is	O
used	O
as	O
glucocorticoid	O
replacement	B-P
therapy	I-P
for	O
adrenal	O
insufficiency	O
(	O
AI	O
)	O
.	O

Recent	O
data	O
indicate	O
that	O
its	O
use	O
in	O
AI	O
is	O
associated	O
with	O
low	O
bone	O
mineral	O
density	O
.	O

Data	O
on	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
in	O
patients	O
with	O
AI	O
treated	O
with	O
prednisolone	O
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	O
of	O
excess	O
mortality	O
.	O

We	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real-world	O
data	O
from	O
the	O
European	O
Adrenal	O
Insufficiency	O
Registry	O
(	O
EU-AIR	O
)	O
.	O

EU-AIR	O
,	O
comprising	O
of	O
19	O
centres	O
across	O
Germany	O
,	O
the	O
Netherlands	O
,	O
Sweden	O
and	O
the	O
UK	O
,	O
commenced	O
enrolling	O
patients	O
with	O
AI	O
in	O
August	O
2012	O
.	O

Patients	O
receiving	O
prednisolone	O
(	O
3-6	O
mg/day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	O
(	O
15-30	O
mg/day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	O
at	O
a	O
ratio	O
of	O
1:3	O
(	O
prednisolone	O
:	O
hydrocortisone	O
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	O
of	O
disease	O
.	O

Data	O
from	O
baseline	O
and	O
follow-up	O
visits	O
were	O
analysed	O
.	O

Data	O
from	O
patients	O
with	O
congenital	O
adrenal	O
hyperplasia	O
were	O
excluded	O
.	O

Significantly	O
higher	O
mean	O
±	O
s.d	O
.	O

total	O
(	O
6.3	O
±	O
1.6	O
vs	O
5.4	O
±	O
1.1	O
mmol/L	O
;	O
P	O
=	O
0.003	O
)	O
and	O
low-density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	O
levels	O
(	O
3.9	O
±	O
1.4	O
vs	O
3.2	O
±	O
1.0	O
mmol/L	O
;	O
P	O
=	O
0.013	O
)	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	O
vs	O
141	O
receiving	O
hydrocortisone	O
at	O
baseline	O
and	O
at	O
follow-up	O
(	O
P	O
=	O
0.005	O
and	O
P	O
=	O
0.006	O
,	O
respectively	O
)	O
.	O

HbA1c	O
,	O
high-density	O
lipoprotein	O
and	O
triglyceride	O
levels	O
,	O
body	O
mass	O
index	O
,	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
waist	O
circumference	O
were	O
not	O
significantly	O
different	O
.	O

This	O
is	O
the	O
first	O
matched	O
analysis	O
of	O
its	O
kind	O
.	O

Significantly	O
higher	O
LDL	O
levels	O
in	O
patients	O
receiving	O
prednisolone	O
relative	O
to	O
hydrocortisone	O
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	O
disease	O
in	O
the	O
former	O
group	O
.	O

Emergency	B-P
general	I-P
surgery	I-P
specific	O
frailty	O
index	O
:	O
A	O
validation	O
study	O
.	O

Assessment	O
of	O
operative	O
risk	O
in	O
geriatric	O
patients	O
undergoing	O
emergency	B-P
general	I-P
surgery	I-P
(	O
EGS	B-P
)	O
is	O
challenging	O
.	O

Frailty	O
is	O
an	O
established	O
measure	O
for	O
risk	O
assessment	O
in	O
surgical	O
cases	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
validate	O
a	O
modified	O
15	O
variable	O
emergency	O
general	O
surgery	O
specific	O
frailty	O
index	O
(	O
EGSFI	O
)	O
.	O

We	O
prospectively	O
collected	O
geriatric	O
(	O
age	O
>	O
65	O
)	O
emergency	B-P
general	I-P
surgery	I-P
patients	O
for	O
1-	O
year	O
.	O

Post-operative	O
complications	O
were	O
collected	O
.	O

Frailty	O
Index	O
was	O
calculated	B-P
for	O
200	O
patients	O
based	O
on	O
their	O
pre-admission	O
condition	O
using	O
50-	O
variable	O
modified	O
Rockwood	O
Frailty	O
Index	O
(	O
FI	O
)	O
.	O

EGSFI	O
was	O
developed	O
based	O
on	O
the	O
regression	O
model	O
for	O
complications	O
and	O
the	O
most	O
significant	O
factors	O
in	O
the	O
FI	O
.	O

ROC	O
curve	O
analysis	O
was	O
performed	O
to	O
determine	O
cutoff	O
for	O
frail	O
status	O
.	O

We	O
validated	O
our	O
results	O
using	O
60	O
patients	O
for	O
predicting	O
complications	O
.	O

A	O
total	O
of	O
260	O
patients	O
(	O
200	O
developing	O
,	O
60	O
Validation	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Mean	O
age	O
was	O
71	O
±	O
11	O
years	O
,	O
and	O
33	O
%	O
developed	O
complications	O
.	O

Most	O
common	O
complications	O
were	O
pneumonia	O
(	O
12	O
%	O
)	O
,	O
UTI	O
(	O
9	O
%	O
)	O
,	O
and	O
wound	O
infection	O
(	O
7	O
%	O
)	O
.	O

Univariate	O
analysis	O
identified	O
15	O
variables	O
significantly	O
associated	O
with	O
complications	O
that	O
were	O
used	O
to	O
develop	O
the	O
EGSFI	O
.	O

A	O
cutoff	O
frailty	O
score	O
of	O
0.325	O
was	O
identified	O
using	O
ROC	O
curve	O
analysis	O
for	O
frail	O
status	O
.Sixty-	O
patients	O
(	O
frail	O
:	O
18	O
,	O
non-frail	O
:	O
42	O
)	O
were	O
enrolled	O
in	O
the	O
validation	O
cohort	O
.	O

Frail	O
patients	O
were	O
more	O
likely	O
to	O
have	O
post-operative	O
complications	O
(	O
47	O
%	O
vs.	O
20	O
%	O
,	O
p	O
<	O
0.001	O
)	O
compared	O
to	O
nonfrail	O
patients	O
.	O

Frail	O
status	O
based	O
on	O
EGSFI	O
was	O
a	O
significant	O
predictor	O
of	O
post-operative	O
complications	O
(	O
OR	O
=7.3	O
,	O
95	O
%	O
CI	O
=	O
1.7	O
-	O
19.8	O
;	O
p=0.006	O
)	O
.	O

Age	O
was	O
not	O
associated	O
with	O
postoperative	O
complications	O
(	O
OR	O
=0.99	O
,	O
95	O
%	O
CI	O
=	O
0.92	O
-1.06	O
;	O
p=0.86	O
)	O
.	O

The	O
15-	O
variable	O
validated	O
EGSFI	O
is	O
a	O
simple	O
and	O
reliable	O
bedside	O
tool	O
to	O
determine	O
the	O
frailty	O
status	O
of	O
patients	O
undergoing	O
emergency	B-P
general	I-P
surgery	I-P
.	O

Frail	O
status	O
as	O
determined	O
by	O
Abstract	O
the	O
EGSFI	O
is	O
an	O
independent	O
predictor	O
of	O
post-operative	O
complications	O
and	O
mortality	O
in	O
geriatric	O
emergency	B-P
general	I-P
surgery	I-P
patients	O
.	O

Level	O
II	O
,	O
Prognostic	O
Studies	O
-	O
Investigating	O
the	O
Effect	O
of	O
a	O
Patient	O
Characteristic	O
on	O
the	O
Outcome	O
of	O
Disease	O
.	O

On-Site	O
Fertility	B-P
Preservation	I-P
Services	I-P
for	O
Adolescents	O
and	O
Young	O
Adults	O
in	O
a	O
Comprehensive	O
Cancer	O
Center	O
.	O

Adolescents	O
and	O
young	O
adults	O
(	O
AYAs	O
)	O
receiving	O
cancer	B-P
treatments	I-P
that	O
may	O
impair	O
fertility	O
should	O
receive	O
counseling	O
about	O
risk	O
of	O
infertility	O
and	O
options	O
for	O
fertility	B-P
preservation	I-P
(	O
FP	B-P
)	O
before	O
treatment	B-P
and/or	O
during	O
survivorship	O
.	O

Our	O
objective	O
was	O
to	O
define	O
the	O
AYA	O
patient	O
population	O
referred	O
to	O
an	O
on-site	O
fertility	O
consultation	O
service	O
within	O
a	O
comprehensive	O
cancer	O
center	O
and	O
determine	O
factors	O
associated	O
with	O
patients	O
proceeding	O
with	O
FP	B-P
treatment	I-P
.	O

We	O
conducted	O
a	O
retrospective	O
chart	O
review	O
of	O
AYA	O
women	O
who	O
completed	O
a	O
consultation	O
at	O
the	O
MD	O
Anderson	O
Fertility	O
Preservation	O
and	O
Family	O
Building	O
Service	O
during	O
the	O
first	O
year	O
of	O
service	O
.	O

Records	O
of	O
154	O
referred	O
AYA	O
patients	O
were	O
reviewed	O
for	O
age	O
,	O
ethnicity	O
,	O
cancer	O
type	O
gravidity	O
and	O
parity	O
,	O
survivorship	O
status	O
,	O
and	O
decision	O
to	O
pursue	O
FP	B-P
treatment	I-P
.	O

Patients	O
(	O
mean	O
age	O
29.7	O
)	O
were	O
Caucasian	O
(	O
55	O
%	O
)	O
,	O
Hispanic	O
(	O
23	O
%	O
)	O
,	O
and	O
African	O
American	O
(	O
10	O
%	O
)	O
.	O

The	O
majority	O
of	O
women	O
(	O
67	O
%	O
)	O
were	O
seen	O
for	O
FP	B-P
before	O
cancer	B-P
treatment	I-P
and	O
the	O
remaining	O
sought	O
options	O
for	O
family	O
building	O
while	O
in	O
survivorship	O
.	O

The	O
most	O
common	O
cancer	O
types	O
were	O
hematologic	O
(	O
29	O
%	O
)	O
,	O
breast	O
(	O
25	O
%	O
)	O
,	O
and	O
gynecologic	O
(	O
23	O
%	O
)	O
.	O

Patients	O
referred	O
to	O
an	O
on-site	O
fertility	O
consultation	O
service	O
were	O
medically	O
and	O
ethnically	O
diverse	O
.	O

Interest	O
in	O
fertility	O
counseling	O
and	O
treatment	B-P
was	O
apparent	O
in	O
both	O
survivorship	O
pre-	B-P
and	I-P
postcancer	I-P
treatment	I-P
.	O

Although	O
the	O
referral	O
group	O
was	O
ethnically	O
diverse	O
,	O
Caucasian	O
women	O
were	O
most	O
likely	O
to	O
pursue	O
FP	B-P
treatment	I-P
compared	O
to	O
women	O
of	O
other	O
ethnicities	O
.	O

Examining	O
the	O
relationship	O
between	O
home	O
literacy	O
environment	O
and	O
neural	O
correlates	O
of	O
phonological	O
processing	O
in	O
beginning	O
readers	O
with	O
and	O
without	O
a	O
familial	O
risk	O
for	O
dyslexia	O
:	O
an	O
fMRI	B-P
study	I-P
.	O

Developmental	O
dyslexia	O
is	O
a	O
language	O
-	O
based	O
learning	O
disability	O
characterized	O
by	O
persistent	O
difficulty	O
in	O
learning	O
to	O
read	O
.	O

While	O
an	O
understanding	O
of	O
genetic	O
contributions	O
is	O
emerging	O
,	O
the	O
ways	O
the	O
environment	O
affects	O
brain	O
functioning	O
in	O
children	O
with	O
developmental	O
dyslexia	O
are	O
poorly	O
understood	O
.	O

A	O
relationship	O
between	O
the	O
home	O
literacy	O
environment	O
(	O
HLE	O
)	O
and	O
neural	O
correlates	O
of	O
reading	O
has	O
been	O
identified	O
in	O
typically	O
developing	O
children	O
,	O
yet	O
it	O
remains	O
unclear	O
whether	O
similar	O
effects	O
are	O
observable	O
in	O
children	O
with	O
a	O
genetic	O
predisposition	O
for	O
dyslexia	O
.	O

Understanding	O
environmental	O
contributions	O
is	O
important	O
given	O
that	O
we	O
do	O
not	O
understand	O
why	O
some	O
genetically	O
at-risk	O
children	O
do	O
not	O
develop	O
dyslexia	O
.	O

Here	O
,	O
we	O
investigate	O
for	O
the	O
first	O
time	O
the	O
relationship	O
between	O
HLE	O
and	O
the	O
neural	O
correlates	O
of	O
phonological	O
processing	O
in	O
beginning	O
readers	O
with	O
(	O
FHD+	O
,	O
n	O
=	O
29	O
)	O
and	O
without	O
(	O
FHD-	O
,	O
n	O
=	O
21	O
)	O
a	O
family	O
history	O
of	O
developmental	O
dyslexia	O
.	O

We	O
further	O
controlled	O
for	O
socioeconomic	O
status	O
to	O
isolate	O
the	O
neurobiological	O
mechanism	O
by	O
which	O
HLE	O
affects	O
reading	O
development	O
.	O

Group	O
differences	O
revealed	O
stronger	O
correlation	O
of	O
HLE	O
with	O
brain	O
activation	O
in	O
the	O
left	O
inferior	O
/	O
middle	O
frontal	O
and	O
right	O
fusiform	O
gyri	O
in	O
FHD-	O
compared	O
to	O
FHD+	O
children	O
,	O
suggesting	O
greater	O
impact	O
of	O
HLE	O
on	O
manipulation	O
of	O
phonological	O
codes	O
and	O
recruitment	O
of	O
orthographic	O
representations	O
in	O
typically	O
developing	O
children	O
.	O

In	O
contrast	O
,	O
activation	O
in	O
the	O
right	O
precentral	O
gyrus	O
showed	O
a	O
significantly	O
stronger	O
correlation	O
with	O
HLE	O
in	O
FHD+	O
compared	O
to	O
FHD-	O
children	O
,	O
suggesting	O
emerging	O
compensatory	O
networks	O
in	O
genetically	O
at-risk	O
children	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
genetic	O
predisposition	O
for	O
dyslexia	O
alters	O
contributions	O
of	O
HLE	O
to	O
early	O
reading	O
skills	O
before	O
formal	O
reading	O
instruction	O
,	O
which	O
has	O
important	O
implications	O
for	O
educational	O
practice	O
and	O
intervention	O
models	O
.	O

The	O
C	O
Isoform	O
of	O
Dictyostelium	O
Tetraspanins	O
Localizes	O
to	O
the	O
Contractile	O
Vacuole	O
and	O
Contributes	O
to	O
Resistance	O
against	O
Osmotic	O
Stress	O
.	O

Tetraspanins	O
(	O
Tsps	O
)	O
are	O
membrane	O
proteins	O
that	O
are	O
widely	O
expressed	O
in	O
eukaryotic	O
organisms	O
.	O

Only	O
recently	O
,	O
Tsps	O
have	O
started	O
to	O
acquire	O
relevance	O
as	O
potential	O
new	O
drug	O
targets	O
as	O
they	O
contribute	O
,	O
via	O
protein-protein	O
interactions	O
,	O
to	O
numerous	O
pathophysiological	O
processes	O
including	O
infectious	O
diseases	O
and	O
cancer	O
.	O

However	O
,	O
due	O
to	O
a	O
high	O
number	O
of	O
isoforms	O
and	O
functional	O
redundancy	O
,	O
knowledge	O
on	O
specific	O
functions	O
of	O
most	O
Tsps	O
is	O
still	O
scarce	O
.	O

We	O
set	O
out	O
to	O
characterize	O
five	O
previously	O
annotated	O
Tsps	O
,	O
TspA-E	O
,	O
from	O
Dictyostelium	O
discoideum	O
,	O
a	O
model	O
for	O
studying	O
proteins	O
that	O
have	O
human	O
orthologues	O
.	O

Using	O
reverse	O
transcriptase	O
PCRs	O
,	O
we	O
found	O
mRNAs	O
for	O
TspA-E	O
in	O
the	O
multicellular	O
slug	O
stage	O
,	O
whereas	O
vegetative	O
cells	O
expressed	O
only	O
TspA	O
,	O
TspC	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
TspD	O
.	O

We	O
raised	O
antibodies	O
against	O
TspA	O
,	O
TspC	O
and	O
TspD	O
and	O
detected	O
endogenous	O
TspA	O
,	O
as	O
well	O
as	O
heterologously	O
expressed	O
TspA	O
and	O
TspC	O
by	O
Western	B-P
blot	I-P
.	O

N-deglycosylation	O
assays	B-P
and	O
mutational	O
analyses	O
showed	O
glycosylation	O
of	O
TspA	O
and	O
TspC	O
in	O
vivo	O
.	O

GFP	O
-tagged	O
Tsps	O
co-localized	O
with	O
the	O
proton	O
pump	O
on	O
the	O
contractile	O
vacuole	O
network	O
.	O

Deletion	O
strains	O
of	O
TspC	O
and	O
TspD	O
exibited	O
unaltered	O
growth	O
,	O
adhesion	O
,	O
random	O
motility	O
and	O
development	O
.	O

Yet	O
,	O
tspC-	O
cells	O
showed	O
a	O
defect	O
in	O
coping	O
with	O
hypo-osmotic	O
stress	O
,	O
due	O
to	O
accumulation	O
of	O
contractile	O
vacuoles	O
,	O
but	O
heterologous	O
expression	O
of	O
TspC	O
rescued	O
their	O
phenotype	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
fill	O
a	O
gap	O
in	O
Dictyostelium	O
research	O
and	O
open	O
up	O
the	O
possibility	O
that	O
Tsps	O
in	O
contractile	O
vacuoles	O
of	O
e.g	O
.	O

Trypanosoma	O
may	O
one	O
day	O
constitute	O
a	O
valuable	O
drug	O
target	O
for	O
treating	O
sleeping	O
sickness	O
,	O
one	O
of	O
the	O
most	O
threatening	O
tropical	O
diseases	O
.	O

Cytotoxic	O
and	O
antimigratory	O
effects	O
of	O
Cratoxy	O
formosum	O
extract	O
against	O
HepG2	O
liver	O
cancer	O
cells	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
Cratoxylum	O
formosum	O
(	O
CF	O
)	O
Dyer-induced	O
cancer	O
cell	O
death	O
and	O
antimigratory	O
effects	O
in	O
HepG2	O
liver	O
cancer	O
cells	O
.	O

The	O
cytotoxic	O
,	O
antiproliferative	O
and	O
antimigratory	O
effects	O
of	O
CF	O
leaf	O
extract	O
on	O
human	O
liver	O
cancer	O
HepG2	O
cell	O
lines	O
were	O
evaluated	O
using	O
sulforhodamine	O
B	O
,	O
colony	B-P
formation	I-P
,	O
and	O
wound	B-P
healing	I-P
assays	I-P
.	O

In	O
addition	O
,	O
apoptosis	O
induction	O
mechanisms	O
were	O
investigated	O
via	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
formation	O
,	O
caspase	O
3	O
activities	O
,	O
and	O
mitochondrial	O
membrane	O
potential	O
(	O
ΔΨm	O
)	O
disruption	O
.	O

Gene	O
expression	O
and	O
apoptosis	O
-associated	O
protein	O
levels	O
were	O
measured	O
by	O
reverse	O
transcription-quantitative	O
polymerase	O
chain	O
reaction	O
and	O
western	O
blotting	O
.	O

CF	O
induced	O
HepG2	O
cell	O
death	O
in	O
a	O
time-	O
and	O
dose-dependent	O
manner	O
with	O
half	O
maximal	O
inhibitory	O
concentration	O
values	O
of	O
219.03±9.96	O
and	O
124.90±6.86	O
µg/ml	O
at	O
24	O
and	O
48	O
h	O
,	O
respectively	O
.	O

Treatment	B-P
with	O
CF	O
caused	O
a	O
significant	O
and	O
dose-dependent	O
decrease	O
in	O
colony	O
forming	O
ability	O
and	O
cell	O
migration	O
.	O

Furthermore	O
,	O
the	O
present	O
study	O
demonstrated	O
that	O
CF	O
induced	O
ROS	O
formation	O
,	O
increased	O
caspase	O
3	O
activities	O
,	O
decreased	O
the	O
ΔΨm	O
,	O
and	O
caused	O
HepG2	O
apoptosis	O
.	O

CF	O
marginally	O
decreased	O
the	O
expression	O
level	O
of	O
the	O
cell	O
cycle	O
regulatory	O
protein	O
,	O
ras-related	O
C3	O
botulinum	O
toxin	O
substrate	O
1	O
(	O
rho	O
family	O
,	O
small	O
GTP	O
binding	O
protein	O
Rac1	O
)	O
and	O
the	O
downstream	O
protein	O
,	O
cyclin	O
dependent	O
kinase	O
6	O
.	O

Additionally	O
,	O
CF	O
significantly	O
enhanced	O
p21	O
levels	O
,	O
reduced	O
cyclin	O
D1	O
protein	O
levels	O
and	O
triggered	O
cancer	O
cell	O
death	O
.	O

CF	O
leaf	O
extracts	O
induced	O
cell	O
death	O
,	O
stimulated	O
apoptosis	O
and	O
inhibited	O
migration	O
in	O
HepG2	O
cells	O
.	O

Thus	O
,	O
CF	O
may	O
be	O
useful	O
for	O
developing	O
an	O
anticancer	O
drug	O
candidate	O
for	O
the	O
treatment	B-P
of	O
liver	O
cancer	O
.	O

Visualization	B-P
of	O
the	O
Intimal	O
Flap	O
in	O
Intracranial	O
Arterial	O
Dissection	O
Using	O
High-Resolution	B-P
3T	B-P
MRI	I-P
.	O

Presence	O
of	O
an	O
intimal	O
flap	O
is	O
a	O
critical	O
imaging	O
finding	O
in	O
diagnosing	O
intracranial	O
artery	O
dissection	O
(	O
ICAD	O
)	O
.	O

Recent	O
reports	O
showed	O
that	O
high-resolution	B-P
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
was	O
better	O
at	O
identifying	O
intimal	O
flaps	O
as	O
compared	O
with	O
routine	O
MRI	B-P
techniques	I-P
used	O
in	O
clinical	O
settings	O
.	O

However	O
,	O
no	O
current	O
standardized	O
sequence	O
for	O
high-resolution	B-P
MRI	B-P
without	O
gadolinium	O
enhancement	O
produces	O
images	O
of	O
satisfactory	O
quality	O
with	O
clinically	O
tolerable	O
scanning	B-P
times	O
.	O

This	O
study	O
evaluated	O
a	O
nonenhanced	B-P
high-resolution	I-P
fast	I-P
spin	I-P
echo	I-P
(	I-P
HR-FSE	I-P
)	I-P
MRI	I-P
sequence	O
for	O
visualizing	O
intimal	O
flaps	O
in	O
patients	O
with	O
ICAD	O
.	O

Three	O
patients	O
with	O
ICAD	O
underwent	O
plain	O
MRI	B-P
examination	O
using	O
a	O
2-dimensional	O
T2-weighted	B-P
FSE	I-P
imaging	I-P
sequence	O
optimized	O
for	O
our	O
3T	O
system	O
(	O
in-plane	O
pixel	O
size	O
,	O
.23	O
mm	O
×	O
.23	O
mm	O
;	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
)	O
,	O
as	O
well	O
as	O
scanning	B-P
with	O
conventional	O
modalities	O
,	O
including	O
CT	B-P
angiography	I-P
,	O
magnetic	B-P
resonance	I-P
angiography	I-P
,	O
and	O
digital	B-P
subtraction	I-P
angiography	I-P
.	O

We	O
assessed	O
whether	O
these	O
imaging	O
methods	O
could	O
visualize	O
an	O
intimal	O
flap	O
and/or	O
double	O
lumen	O
sign	O
in	O
the	O
participants	O
and	O
compared	O
the	O
results	O
between	O
HR-FSE	B-P
and	O
the	O
other	O
modalities	O
.	O

HR-FSE	B-P
images	O
clearly	O
showed	O
intimal	O
flaps	O
and	O
double	O
lumen	O
signs	O
in	O
all	O
3	O
patients	O
,	O
whereas	O
the	O
conventional	O
modalities	O
identified	O
a	O
double	O
lumen	O
sign	O
in	O
only	O
2	O
of	O
the	O
3	O
patients	O
.	O

The	O
present	O
method	O
of	O
optimized	O
HR-FSE	B-P
imaging	I-P
with	O
a	O
3T	O
system	O
improved	O
visualization	B-P
of	O
intimal	O
flaps	O
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	O
patients	O
with	O
suspected	O
ICAD	O
that	O
can	O
not	O
be	O
definitively	O
diagnosed	O
by	O
conventional	O
imaging	O
modalities	O
.	O

Multimorbidity	O
in	O
Heart	O
Failure	O
:	O
Effect	O
on	O
Outcomes	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
the	O
number	O
and	O
type	O
of	O
comorbid	O
conditions	O
on	O
death	O
and	O
hospitalizations	O
in	O
individuals	O
with	O
incident	O
heart	O
failure	O
(	O
HF	O
)	O
.	O

Population-based	O
cohort	O
study	O
.	O

Olmsted	O
County	O
,	O
Minnesota	O
.	O

Olmsted	O
County	O
,	O
Minnesota	O
,	O
residents	O
with	O
incident	O
HF	O
from	O
2000	O
to	O
2010	O
(	O
mean	O
age	O
76	O
±	O
14	O
,	O
56	O
%	O
female	O
)	O
(	O
N	O
=	O
1,714	O
)	O
.	O

The	O
prevalence	O
of	O
16	O
chronic	O
conditions	O
obtained	O
at	O
HF	O
diagnosis	O
classified	O
into	O
three	O
groups	O
:	O
cardiovascular	O
(	O
CV	O
)	O
related	O
,	O
other	O
physical	O
,	O
and	O
mental	O
.	O

The	O
mean	O
number	O
of	O
conditions	O
per	O
participant	O
was	O
2.6	O
±	O
1.5	O
for	O
CV	O
-related	O
conditions	O
,	O
1.3	O
±	O
1.1	O
for	O
other	O
physical	O
conditions	O
,	O
and	O
0.30	O
±	O
0.61	O
for	O
mental	O
conditions	O
.	O

After	O
a	O
mean	O
follow-up	O
of	O
4.2	O
years	O
,	O
1,073	O
death	O
s	O
and	O
6,306	O
hospitalizations	O
had	O
occurred	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
ejection	B-P
fraction	I-P
,	O
in-	O
or	O
outpatient	O
status	O
,	O
and	O
number	O
of	O
other	O
conditions	O
,	O
an	O
increase	O
of	O
one	O
other	O
physical	O
condition	O
was	O
associated	O
with	O
a	O
14	O
%	O
(	O
HR	O
=	O
1.14	O
,	O
95	O
%	O
CI	O
=	O
1.08-1.20	O
)	O
greater	O
risk	O
of	O
death	O
and	O
a	O
26	O
%	O
(	O
HR	O
=	O
1.26	O
,	O
95	O
%	O
CI	O
=	O
1.20-1.32	O
)	O
greater	O
risk	O
of	O
hospitalization	O
,	O
and	O
an	O
increase	O
of	O
one	O
mental	O
condition	O
was	O
associated	O
with	O
a	O
31	O
%	O
(	O
HR	O
=	O
1.31	O
,	O
95	O
%	O
CI	O
=	O
1.19-1.44	O
)	O
greater	O
risk	O
of	O
death	O
and	O
an	O
18	O
%	O
(	O
HR	O
=	O
1.18	O
,	O
95	O
%	O
CI	O
=	O
1.07-1.29	O
)	O
greater	O
risk	O
of	O
hospitalization	O
.	O

In	O
contrast	O
,	O
an	O
increase	O
of	O
one	O
CV	O
-related	O
condition	O
was	O
not	O
associated	O
with	O
greater	O
risk	O
of	O
death	O
and	O
was	O
associated	O
with	O
a	O
10	O
%	O
(	O
HR	O
=	O
1.10	O
,	O
95	O
%	O
CI	O
=	O
1.06-1.15	O
)	O
greater	O
risk	O
of	O
hospitalization	O
.	O

CV	O
-related	O
conditions	O
are	O
the	O
most	O
common	O
type	O
of	O
comorbid	O
conditions	O
in	O
individuals	O
with	O
HF	O
,	O
but	O
other	O
physical	O
and	O
mental	O
conditions	O
are	O
more	O
strongly	O
associated	O
with	O
death	O
and	O
hospitalizations	O
.	O

This	O
underscores	O
the	O
effect	O
of	O
non-CV	O
conditions	O
on	O
outcomes	O
in	O
HF	O
.	O

Chondrocyte	O
proliferation	O
,	O
viability	O
and	O
differentiation	O
is	O
declined	O
following	O
administration	B-P
of	O
methylphenidate	O
utilized	O
for	O
the	O
treatment	B-P
of	O
attention-deficit/hyperactivity	O
disorder	O
.	O

Methylphenidate	O
(	O
MPH	O
)	O
derivative	O
drugs	O
are	O
used	O
because	O
of	O
psychostimulants	O
effects	O
on	O
attention-deficit	O
hyperactivity	O
disorder	O
in	O
children	O
and	O
adults	O
.	O

As	O
far	O
as	O
we	O
know	O
,	O
toxic	O
or	O
anti-proliferative	O
effects	O
of	O
MPH	O
against	O
cartilage	O
tissue	O
were	O
not	O
studied	O
in	O
the	O
literature	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
possible	O
effects	O
of	O
MPH	O
on	O
the	O
proliferation	O
,	O
viability	O
and	O
differentiation	O
of	O
primary	O
human	O
chondrocytes	O
,	O
in	O
vitro	O
.	O

Monolayer	O
primary	O
chondrocyte	O
cultures	B-P
were	O
prepared	O
using	O
osteochondral	O
tissue	O
obtained	O
from	O
patients	O
who	O
underwent	O
a	O
total	B-P
knee	I-P
prosthesis	I-P
operation	I-P
.	O

Stock	O
solution	O
of	O
MPH	O
was	O
prepared	O
and	O
aliquots	O
having	O
1-1000	O
µM	O
concentrations	O
of	O
the	O
drug	O
was	O
composed	O
.	O

These	O
solutions	O
were	O
applied	O
to	O
the	O
wells	O
containing	O
cultured	O
chondrocyte	O
samples	O
within	O
the	O
well	O
plates	O
.	O

Control	O
groups	O
were	O
composed	O
of	O
pure	O
chondrocyte	O
culture	B-P
and	O
no	O
solution	O
was	O
added	O
into	O
them	O
.	O

All	O
groups	O
were	O
evaluated	O
at	O
24	O
,	O
48	O
and	O
72	O
h	O
in	O
order	O
to	O
determine	O
the	O
possible	O
negative	O
effects	O
of	O
the	O
drug	O
on	O
the	O
chondrocytes	O
.	O

The	O
data	O
were	O
evaluated	O
by	O
Tukey	O
's	O
honestly	O
significantly	O
different	O
test	O
following	O
analysis	O
of	O
variance	O
.	O

In	O
the	O
group	O
where	O
MPH	O
was	O
applied	O
,	O
it	O
was	O
found	O
that	O
viability	O
,	O
proliferation	O
and	O
stage-specific	O
embryonic	O
antigen-1	O
protein	O
expression	O
were	O
decreased	O
in	O
comparison	O
to	O
the	O
control	O
group	O
.	O

It	O
was	O
emphasized	O
that	O
clinicians	O
should	O
not	O
disregard	O
the	O
fact	O
that	O
this	O
drug	O
might	O
suppress	O
chondrocyte	O
cell	O
proliferation	O
and	O
chondrogenic	O
differentiation	O
.	O

An	O
accuracy	O
study	O
of	O
computer	O
-	O
planned	O
implant	B-P
placement	I-P
in	O
the	O
augmented	O
maxilla	O
using	O
osteosynthesis	B-P
screws	I-P
.	O

Previous	O
research	O
on	O
the	O
accuracy	O
of	O
flapless	O
implant	B-P
placement	I-P
of	O
virtually	O
planned	O
implants	O
in	O
the	O
augmented	O
maxilla	O
revealed	O
unfavourable	O
discrepancies	O
between	O
implant	B-P
planning	I-P
and	I-P
placement	I-P
.	O

By	O
using	O
the	O
osteosynthesis	B-P
screws	I-P
placed	O
during	O
the	O
augmentation	B-P
procedure	I-P
,	O
the	O
surgical	O
template	O
could	O
be	O
optimally	O
stabilized	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
validate	O
this	O
method	O
by	O
evaluating	O
its	O
clinically	O
relevant	O
accuracy	O
.	O

Twelve	O
consecutive	O
fully	O
edentulous	O
patients	O
with	O
extreme	O
resorption	O
of	O
the	O
maxilla	O
were	O
treated	O
with	O
a	O
bone	O
augmentation	B-P
procedure	I-P
.	O

Virtual	B-P
implant	I-P
planning	I-P
was	O
performed	O
and	O
a	O
surgical	O
template	O
was	O
manufactured	O
.	O

Subsequently	O
,	O
six	O
implants	O
were	O
installed	O
using	O
the	O
surgical	O
template	O
,	O
which	O
was	O
only	O
supported	O
by	O
the	O
osteosynthesis	B-P
screws	I-P
.	O

Implant	O
deviations	O
between	O
planning	B-P
and	I-P
placement	I-P
were	O
calculated	O
.	O

A	O
total	O
of	O
72	O
implants	O
were	O
installed	O
.	O

Mean	O
deviations	O
found	O
in	O
the	O
mesiodistal	O
direction	O
were	O
0.817mm	O
at	O
the	O
implant	O
tip	O
and	O
0.528mm	O
at	O
the	O
implant	O
shoulder	O
.	O

The	O
angular	O
deviation	O
was	O
2.924°	O
.	O

In	O
the	O
buccolingual	O
direction	O
,	O
a	O
deviation	O
of	O
1.038mm	O
was	O
registered	O
at	O
the	O
implant	O
tip	O
and	O
0.633mm	O
at	O
the	O
implant	O
shoulder	O
.	O

The	O
angular	O
deviation	O
was	O
3.440°	O
.	O

This	O
study	O
showed	O
that	O
implant	B-P
placement	I-P
in	O
the	O
augmented	O
maxilla	O
using	O
a	O
surgical	O
template	O
supported	O
by	O
osteosynthesis	B-P
screws	I-P
is	O
accurate	O
.	O

Panitumumab	O
-Associated	O
Encephalopathy	O
after	O
Accidental	O
Intra-arterial	O
Application	O
through	O
Dislocated	O
Central	O
Venous	O
Access	O
Device	O
.	O

Acute	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxicity	O
and	O
immune	O
-related	O
side	O
effects	O
are	O
increasingly	O
recognized	O
with	O
the	O
use	O
of	O
monoclonal	O
antibodies	O
for	O
cancer	B-P
therapy	I-P
.	O

Here	O
,	O
we	O
report	O
a	O
patient	O
who	O
developed	O
of	O
acute-onset	O
encephalopathy	O
and	O
coma	O
,	O
which	O
began	O
shortly	O
after	O
administration	O
of	O
panitumumab	O
for	O
the	O
treatment	B-P
of	O
metastatic	O
colorectal	O
cancer	O
.	O

Echocardiography	B-P
revealed	O
that	O
the	O
drug	O
had	O
been	O
infused	O
into	O
the	O
left	O
cardiac	O
ventricle	O
via	O
a	O
dislocated	O
central	O
venous	O
line	O
.	O

Diffusion-weighted	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
disclosed	O
multiple	O
cortical	O
hyperintensities	O
,	O
which	O
were	O
preferentially	O
located	O
in	O
the	O
frontal	O
lobes	O
.	O

While	O
the	O
neurological	O
condition	O
improved	O
within	O
a	O
few	O
days	O
,	O
the	O
patient	O
died	O
4	O
weeks	O
later	O
.	O

It	O
seems	O
likely	O
that	O
the	O
administration	O
of	O
the	O
antibody	O
via	O
the	O
intra-arterial	O
route	O
contributed	O
to	O
the	O
development	O
of	O
this	O
condition	O
.	O

Toxic	O
encephalopathy	O
may	O
be	O
a	O
hitherto	O
unrecognized	O
complication	O
of	O
panitumumab	O
treatment	B-P
and	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	O
developing	O
CNS	O
symptoms	O
undergoing	O
this	O
therapy	B-P
.	O

Leprosy	O
Drug	O
Resistance	O
Surveillance	O
in	O
Colombia	O
:	O
The	O
Experience	O
of	O
a	O
Sentinel	O
Country	O
.	O

An	O
active	O
search	O
for	O
Mycobacterium	O
leprae	O
drug	O
resistance	O
was	O
carried	O
out	O
,	O
243	O
multibacillary	O
patients	O
from	O
endemic	O
regions	O
of	O
Colombia	O
were	O
included	O
from	O
2004	O
to	O
2013	O
in	O
a	O
surveillance	O
program	O
.	O

This	O
program	O
was	O
a	O
World	O
Health	O
Organization	O
initiative	O
for	O
drug	O
resistance	O
surveillance	O
in	O
leprosy	O
,	O
where	O
Colombia	O
is	O
a	O
sentinel	O
country	O
.	O

M.	O
leprae	O
DNA	O
from	O
slit	O
skin	O
smear	O
and/or	O
skin	O
biopsy	O
samples	O
was	O
amplified	O
and	O
sequenced	O
to	O
identify	O
mutations	O
in	O
the	O
drug	O
resistance	O
determining	O
region	O
(	O
DRDR	O
)	O
in	O
rpoB	O
,	O
folP1	O
,	O
gyrA	O
,	O
and	O
gyrB	O
,	O
the	O
genes	O
responsible	O
for	O
rifampicin	O
,	O
dapsone	O
and	O
ofloxacin	O
drug-resistance	O
,	O
respectively	O
.	O

Three	O
isolates	O
exhibited	O
mutations	O
in	O
the	O
DRDR	O
rpoB	O
gene	O
(	O
Asp441Tyr	O
,	O
Ser456Leu	O
,	O
Ser458Met	O
)	O
,	O
two	O
in	O
the	O
DRDR	O
folP1	O
gene	O
(	O
Thr53Ala	O
,	O
Pro55Leu	O
)	O
,	O
and	O
one	O
isolate	O
exhibited	O
mutations	O
in	O
both	O
DRDR	O
rpoB	O
(	O
Ser456Met	O
)	O
and	O
DRDR	O
folP1	O
(	O
Pro55Leu	O
)	O
,	O
suggesting	O
multidrug	O
resistance	O
.	O

One	O
isolate	O
had	O
a	O
double	O
mutation	O
in	O
folP1	O
(	O
Thr53Ala	O
and	O
Thr88Pro	O
)	O
.	O

Also	O
,	O
we	O
detected	O
mutations	O
outside	O
of	O
DRDR	O
that	O
required	O
in	O
vivo	O
evaluation	O
of	O
their	O
association	O
or	O
not	O
with	O
drug	O
resistance	O
:	O
rpoB	O
Arg505Trp	O
,	O
folP1	O
Asp91His	O
,	O
Arg94Trp	O
,	O
and	O
Thr88Pro	O
,	O
and	O
gyrA	O
Ala107Leu	O
.	O

Seventy	O
percent	O
of	O
M.	O
leprae	O
mutations	O
were	O
related	O
to	O
drug	O
resistance	O
and	O
were	O
isolated	O
from	O
relapsed	O
patients	O
;	O
the	O
likelihood	O
of	O
relapse	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
confirmed	O
resistance	O
mutations	O
(	O
OR	O
range	O
20.1-88.7	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Five	O
of	O
these	O
relapsed	O
patients	O
received	O
dapsone	O
monotherapy	B-P
as	O
a	O
primary	O
treatment	B-P
.	O

In	O
summary	O
,	O
the	O
current	O
study	O
calls	O
attention	O
to	O
M.	O
leprae	O
resistance	O
in	O
Colombia	O
,	O
especially	O
the	O
significant	O
association	O
between	O
confirmed	O
resistance	O
mutations	O
and	O
relapse	O
in	O
leprosy	O
patients	O
.	O

A	O
high	O
frequency	O
of	O
DRDR	O
mutations	O
for	O
rifampicin	O
was	O
seen	O
in	O
a	O
region	O
where	O
dapsone	O
monotherapy	B-P
was	O
used	O
extensively	O
.	O

Human	O
cathelicidin	O
LL-37	O
enhance	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
Streptococcus	O
mutans	O
.	O

Streptococcus	O
mutans	O
forms	O
biofilms	O
as	O
a	O
resistance	O
mechanism	O
against	O
antimicrobial	O
agents	O
in	O
the	O
human	O
oral	O
cavity	O
.	O

We	O
recently	O
showed	O
that	O
human	O
cathelicidin	O
LL-37	O
exhibits	O
inhibitory	O
effects	O
on	O
biofilm	O
formation	O
of	O
S.	O
mutans	O
through	O
interaction	O
with	O
lipoteichoic	O
acid	O
(	O
LTA	O
)	O
,	O
but	O
without	O
antibacterial	O
or	O
biofilm	O
dispersal	O
abilities	O
.	O

(	O
-	O
)	O
-Epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
is	O
the	O
most	O
abundant	O
constituent	O
of	O
tea	O
catechins	O
that	O
has	O
the	O
greatest	O
anti-infective	O
potential	O
to	O
inhibit	O
the	O
growth	O
of	O
various	O
microorganisms	O
and	O
biofilm	O
formation	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	O
whether	O
LL-37	O
interacts	O
with	O
EGCG	O
to	O
enhance	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
S.	O
mutans	O
biofilm	O
formation	O
.	O

Clinical	O
S.	O
mutans	O
strains	O
(	O
n	O
=	O
10	O
)	O
isolated	O
from	O
children	O
's	O
saliva	O
were	O
tested	O
in	O
a	O
biofilm	O
formation	O
assay	B-P
.	O

The	O
antibiofilm	O
effect	O
of	O
EGCG	O
with	O
and	O
without	O
LL-37	O
was	O
analyzed	O
by	O
the	O
minimum	O
biofilm	O
eradication	O
concentration	O
assay	B-P
and	O
confirmed	O
using	O
field	O
emission-scanning	B-P
electron	I-P
microscopy	I-P
.	O

In	O
addition	O
,	O
the	O
interaction	O
among	O
EGCG	O
,	O
LL-37	O
,	O
and	O
LTA	O
of	O
S.	O
mutans	O
was	O
determined	O
using	O
quartz	O
crystal	O
microbalance	O
analysis	O
.	O

EGCG	O
killed	O
100	O
%	O
of	O
planktonic	O
S.	O
mutans	O
within	O
5	O
h	O
,	O
inhibited	O
biofilm	O
formation	O
within	O
24	O
h	O
,	O
and	O
reduced	O
bacteria	O
cells	O
in	O
preformed	O
biofilms	O
within	O
3	O
h	O
at	O
a	O
concentration	O
of	O
0.2	O
mg/mL	O
.	O

However	O
,	O
EGCG	O
did	O
not	O
appear	O
to	O
interact	O
with	O
LTA	O
.	O

LL-37	O
effectively	O
enhanced	O
the	O
bactericidal	O
activity	O
of	O
EGCG	O
against	O
biofilm	O
formation	O
and	O
preformed	O
biofilms	O
as	O
determined	O
by	O
quantitative	O
crystal	O
violet	O
staining	B-P
and	O
field	O
emission-scanning	B-P
electron	I-P
microscopy	I-P
.	O

In	O
addition	O
,	O
quartz	O
crystal	O
microbalance	O
analysis	O
revealed	O
that	O
LL-37	O
interacted	O
with	O
EGCG	O
and	O
promoted	O
binding	O
between	O
EGCG	O
and	O
LTA	O
of	O
S.	O
mutans	O
.	O

We	O
show	O
that	O
LL-37	O
enhances	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
S.	O
mutans	O
.	O

This	O
finding	O
provides	O
new	O
knowledge	O
for	O
dental	B-P
treatment	I-P
by	O
using	O
LL-37	O
as	O
a	O
potential	O
antibiofilm	O
compound	O
.	O

Design	O
,	O
Synthesis	O
,	O
and	O
Cytotoxic	O
Evaluation	O
of	O
Certain	O
7-Chloro-4-	O
(	O
piperazin-1-yl	O
)	O
quinoline	O
Derivatives	O
as	O
VEGFR-II	O
Inhibitors	O
.	O

Signaling	O
pathway	O
inhibition	O
of	O
VEGFR-II	O
is	O
visualized	O
as	O
valuable	O
tool	O
in	O
cancer	O
management	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
synthesis	O
of	O
novel	O
1-4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
-2-	O
(	O
N-substituted-amino	O
)	O
-ethanone	O
derivatives	O
(	O
4a-t	O
)	O
was	O
achieved	O
through	O
the	O
amination	O
of	O
2-chloro-1-	O
(	O
4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
ethanone	O
(	O
3	O
)	O
with	O
different	O
secondary	O
amines	O
.	O

The	O
structures	O
of	O
the	O
target	O
compounds	O
were	O
confirmed	O
by	O
IR	B-P
,	O
(	B-P
1	I-P
)	I-P
H-NMR	I-P
,	O
(	B-P
13	I-P
)	I-P
C-NMR	I-P
,	O
HRMS	B-P
,	O
and	O
microanalysis	B-P
.	O

Compounds	O
4a-t	O
were	O
subjected	O
to	O
in	O
vitro	O
anticancer	B-P
screening	O
against	O
human	O
breast	O
cancer	O
(	O
MCF-7	O
)	O
and	O
prostate	O
cancer	O
(	O
PC3	O
)	O
cell	O
lines	O
.	O

The	O
highest	O
cytotoxicty	O
against	O
both	O
cell	O
lines	O
was	O
displayed	O
by	O
2-	O
(	O
4-	O
(	O
4-bromobenzyl	O
)	O
piperazin-1-yl	O
)	O
-1-	O
(	O
4-	O
(	O
7-chloroquinolin-4-yl	O
)	O
piperazin-1-yl	O
)	O
ethanone	O
(	O
4q	O
)	O
,	O
with	O
IC50	O
values	O
of	O
6.502	O
and	O
11.751	O
μM	O
against	O
MCF-7	O
and	O
PC3	O
cells	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
standard	O
drug	O
doxorubicin	O
(	O
MCF-7	O
:	O
6.774	O
μM	O
,	O
PC3	O
:	O
7.7316	O
μM	O
)	O
.	O

Due	O
to	O
its	O
notable	O
activity	O
toward	O
MCF-7	O
cells	O
,	O
4q	O
was	O
further	O
evaluated	O
as	O
VEGFR-II	O
inhibitor	O
,	O
showing	O
an	O
IC50	O
of	O
1.38	O
μM	O
compared	O
to	O
sorafenib	O
(	O
0.33	O
μM	O
)	O
.	O

The	O
docking	O
study	O
proved	O
that	O
4q	O
has	O
a	O
binding	O
mode	O
akin	O
to	O
that	O
of	O
VEGFR-II	O
inhibitors	O
.	O

Generation	O
and	O
analyses	O
of	O
human	O
synthetic	O
antibody	O
libraries	O
and	O
their	O
application	O
for	O
protein	O
microarrays	O
.	O

Antibody	O
-based	O
proteomics	O
offers	O
distinct	O
advantages	O
in	O
the	O
analysis	O
of	O
complex	O
samples	O
for	O
discovery	O
and	O
validation	O
of	O
biomarkers	O
associated	O
with	O
disease	O
.	O

However	O
,	O
its	O
large-scale	O
implementation	O
requires	O
tools	O
and	O
technologies	O
that	O
allow	O
development	O
of	O
suitable	O
antibody	O
or	O
antibody	O
fragments	O
in	O
a	O
high-throughput	O
manner	O
.	O

To	O
address	O
this	O
we	O
designed	O
and	O
constructed	O
two	O
human	O
synthetic	O
antibody	O
fragment	O
(	O
scFv	O
)	O
libraries	O
denoted	O
HelL-11	O
and	O
HelL-13	O
.	O

By	O
the	O
use	O
of	O
phage	O
display	O
technology	O
,	O
in	O
total	O
466	O
unique	O
scFv	O
antibodies	O
specific	O
for	O
114	O
different	O
antigens	O
were	O
generated	O
.	O

The	O
specificities	O
of	O
these	O
antibodies	O
were	O
analyzed	O
in	O
a	O
variety	O
of	O
immunochemical	B-P
assays	I-P
and	O
a	O
subset	O
was	O
further	O
evaluated	O
for	O
functionality	O
in	O
protein	O
microarray	O
applications	O
.	O

This	O
high-throughput	O
approach	O
demonstrates	O
the	O
ability	O
to	O
rapidly	O
generate	O
a	O
wealth	O
of	O
reagents	O
not	O
only	O
for	O
proteome	O
research	O
,	O
but	O
potentially	O
also	O
for	O
diagnostics	O
and	O
therapeutics	B-P
.	O

In	O
addition	O
,	O
this	O
work	O
provides	O
a	O
great	O
example	O
on	O
how	O
a	O
synthetic	O
approach	O
can	O
be	O
used	O
to	O
optimize	O
library	O
designs	O
.	O

By	O
having	O
precise	O
control	O
of	O
the	O
diversity	O
introduced	O
into	O
the	O
antigen	O
-	O
binding	O
sites	O
,	O
synthetic	O
libraries	O
offer	O
increased	O
understanding	O
of	O
how	O
different	O
diversity	O
contributes	O
to	O
antibody	O
binding	O
reactivity	O
and	O
stability	O
,	O
thereby	O
providing	O
the	O
key	O
to	O
future	O
library	O
optimization	O
.	O

The	O
Chinese	O
Herbal	O
Mixture	O
Tien-Hsien	O
Liquid	O
Augments	O
the	O
Anticancer	O
Immunity	O
in	O
Tumor	O
Cell	O
-	O
Vaccinated	O
Mice	O
.	O

Background	O
The	O
Chinese	O
herbal	O
mixture	O
,	O
Tien-Hsien	O
liquid	O
(	O
THL	O
)	O
,	O
has	O
been	O
used	O
as	O
an	O
anticancer	O
dietary	O
supplement	O
for	O
more	O
than	O
20	O
years	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
THL	O
can	O
modulate	O
immune	O
response	O
and	O
inhibit	O
tumor	O
growth	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
evaluated	O
the	O
effect	O
of	O
THL	O
on	O
anticancer	O
immune	O
response	O
in	O
mice	O
vaccinated	O
with	O
γ-ray	O
-	O
irradiated	O
tumor	O
cells	O
.	O

Methods	O
The	O
antitumor	O
effect	O
of	O
THL	O
was	O
determined	O
in	O
mice	O
vaccinated	O
with	O
low-tumorigenic	O
CT-26-low	O
colon	O
cancer	O
cells	O
or	O
γ-ray-irradiated	B-P
high-tumorigenic	O
CT-26-high	O
colon	O
cancer	O
cells	O
.	O

The	O
number	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
T	O
lymphocytes	O
in	O
the	O
spleen	O
was	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
.	O

The	O
tumor	O
-	O
killing	O
activities	O
of	O
NK	O
cells	O
and	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
were	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
using	O
YAC-1	O
and	O
CT-26-high	O
cells	O
,	O
respectively	O
,	O
as	O
target	O
cells	O
.	O

The	O
levels	O
of	O
IFN-γ	O
,	O
IL-2	O
,	O
and	O
TNF-α	O
were	O
determined	O
by	O
ELISA	B-P
.	O

Results	O
THL	O
suppressed	O
the	O
growth	O
of	O
CT-26-high	O
tumor	O
in	O
mice	O
previously	O
vaccinated	O
with	O
low-tumorigenic	O
CT-26-low	O
cells	O
or	O
γ-irradiated	B-P
CT-26-high	O
cells	O
.	O

THL	O
increased	O
the	O
populations	O
of	O
NK	O
cells	O
and	O
CD4+	O
T	O
lymphocytes	O
in	O
the	O
spleen	O
and	O
enhanced	O
the	O
tumor	O
-	O
killing	O
activities	O
of	O
NK	O
cells	O
and	O
CTL	O
in	O
mice	O
vaccinated	O
with	O
γ-irradiated	B-P
CT-26-high	O
cells	O
.	O

THL	O
increased	O
the	O
production	O
of	O
IFN-γ	O
,	O
IL-2	O
,	O
and	O
TNF-α	O
in	O
mice	O
vaccinated	O
with	O
γ-irradiated	B-P
CT-26-high	O
cells	O
.	O

Conclusion	O
THL	O
can	O
enhance	O
the	O
antitumor	O
immune	O
responses	O
in	O
mice	O
vaccinated	O
with	O
killed	O
tumor	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
THL	O
may	O
be	O
used	O
as	O
a	O
complementary	O
medicine	O
for	O
cancer	O
patients	O
previously	O
treated	O
with	O
killed	O
tumor	O
cell	O
vaccines	O
,	O
radiotherapy	B-P
,	O
or	O
chemotherapy	B-P
.	O

Percutaneous	B-P
coronary	I-P
intervention	I-P
and	O
heart	B-P
surgery	I-P
learning	O
needs	O
of	O
patients	O
in	O
Jordan	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
and	O
prioritize	O
the	O
perceived	O
learning	O
needs	O
of	O
patients	O
who	O
underwent	O
percutaneous	B-P
coronary	I-P
intervention	I-P
or	O
open-heart	B-P
surgery	I-P
.	O

Identifying	O
learning	O
needs	O
for	O
post-cardiac	B-P
intervention	I-P
patients	O
is	O
essential	O
to	O
establish	O
successful	O
health	O
education	O
programmes	O
based	O
on	O
patient	O
central	O
care	O
.	O

A	O
descriptive	O
comparative	O
design	O
was	O
employed	O
on	O
a	O
convenience	O
sample	O
of	O
260	O
patients	O
who	O
underwent	O
a	O
percutaneous	B-P
coronary	I-P
intervention	I-P
and	O
105	O
patients	O
who	O
underwent	O
open-heart	B-P
surgery	I-P
patients	O
.	O

Participants	O
had	O
completed	O
the	O
Patient	O
Learning	O
Needs	O
Scale	O
.	O

Data	O
were	O
collected	O
between	O
1	O
October	O
2014	O
and	O
31	O
June	O
2015	O
.	O

Patients	O
from	O
the	O
two	O
groups	O
highly	O
requesting	O
health	O
and	O
recovery	O
related	O
information	O
.	O

They	O
scored	O
all	O
learning	O
need	O
topics	O
as	O
important	O
or	O
highly	O
important	O
for	O
them	O
.	O

The	O
top	O
priority	O
learning	O
need	O
for	O
both	O
patient	O
groups	O
was	O
'	O
information	O
about	O
wound	B-P
care	I-P
'	O
,	O
and	O
the	O
lowest	O
priority	O
learning	O
need	O
topic	O
was	O
'	O
physical	O
activity	O
'	O
.	O

The	O
learning	O
needs	O
of	O
both	O
groups	O
were	O
very	O
close	O
,	O
which	O
indicated	O
that	O
educational	O
secondary	O
prevention	O
programmes	O
'	O
content	O
can	O
be	O
prepared	O
in	O
a	O
unified	O
structure	O
for	O
those	O
patients	O
.	O

Although	O
,	O
specific	O
headings	O
can	O
be	O
used	O
to	O
address	O
the	O
unique	O
needs	O
that	O
emerge	O
from	O
having	O
a	O
specific	O
cardiac	O
interventional	B-P
procedure	I-P
.	O

The	O
fact	O
that	O
wound	B-P
care	I-P
and	O
medications	O
are	O
areas	O
of	O
highest	O
learning	O
needs	O
for	O
patients	O
requires	O
health	O
policy	O
decision	O
makers	O
to	O
address	O
these	O
topics	O
at	O
the	O
time	O
of	O
hospital	O
discharge	O
.	O

In	O
addition	O
,	O
a	O
policy	O
focus	O
on	O
considering	O
patients	O
'	O
actual	O
learning	O
needs	O
requires	O
establishment	O
and	O
managerial	O
support	O
.	O

As	O
patients	O
'	O
learning	O
needs	O
might	O
change	O
later	O
after	O
discharge	O
,	O
the	O
health	O
services	O
should	O
be	O
proactive	O
and	O
focus	O
on	O
continuous	O
support	O
for	O
patients	O
after	O
hospital	O
discharge	O
.	O

Secondary	O
prevention	O
programmes	O
should	O
incorporate	O
health	O
education	O
topics	O
based	O
on	O
patients	O
'	O
own	O
views	O
.	O

This	O
can	O
be	O
done	O
by	O
giving	O
higher	O
priority	O
to	O
understand	O
patients	O
'	O
needs	O
,	O
put	O
much	O
more	O
effort	O
into	O
how	O
to	O
meet	O
patients	O
'	O
information	O
needs	O
and	O
to	O
create	O
a	O
more	O
engaging	O
learning	O
environment	O
for	O
patients	O
and	O
their	O
families	O
.	O

Repeatability	O
and	O
agreement	O
of	O
ultrasonography	B-P
with	O
computed	B-P
tomography	I-P
for	O
evaluating	O
forefoot	O
structure	O
in	O
the	O
coronal	O
plane	O
.	O

Forefoot	O
structure	O
is	O
important	O
to	O
understand	O
some	O
foot	O
problems	O
such	O
as	O
hallux	O
valgus	O
and	O
metatarsalgia	O
.	O

Ultrasonography	B-P
(	O
US	B-P
)	O
is	O
a	O
highly	O
portable	O
,	O
noninvasive	O
,	O
low	O
cost	O
,	O
and	O
fast	O
imaging	O
method	O
,	O
especially	O
when	O
compared	O
to	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
,	O
and	O
radiography	B-P
.	O

As	O
the	O
use	O
of	O
US	B-P
for	O
evaluating	O
forefoot	O
bony	O
structure	O
has	O
not	O
been	O
validated	O
,	O
except	O
for	O
the	O
presence	O
of	O
synovitis	O
,	O
erosions	O
and	O
bursitis	O
within	O
the	O
forefoot	O
in	O
people	O
with	O
inflammatory	O
arthritis	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
US	B-P
is	O
a	O
reliable	O
method	O
for	O
evaluating	O
forefoot	O
structure	O
.	O

Sixty	O
feet	O
(	O
30	O
women	O
,	O
age	O
=	O
40.1	O
±	O
11.8	O
years	O
)	O
were	O
examined	O
by	O
US	B-P
and	O
CT	B-P
to	O
assess	O
agreement	O
with	O
CT	B-P
and	O
repeatability	O
of	O
US	B-P
evaluation	O
of	O
the	O
2nd	O
metatarsal	O
head	O
height	O
,	O
length	O
between	O
the	O
medial	O
sesamoid	O
bone	O
and	O
5th	O
metatarsal	O
head	O
,	O
transverse	O
arch	O
height	O
,	O
transverse	O
arch	O
index	O
,	O
sesamoid	O
rotation	O
angle	O
,	O
and	O
area	O
under	O
the	O
transverse	O
arch	O
.	O

The	O
measurement	O
data	O
were	O
evaluated	O
for	O
agreement	O
with	O
CT	B-P
using	O
the	O
intra-class	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
3	O
,	O
1	O
,	O
Pearson	O
correlation	O
coefficient	O
,	O
and	O
Bland-Altman	O
plot	O
,	O
and	O
with	O
ICC1	O
,	O
1	O
for	O
repeatability	O
.	O

The	O
ICC3	O
,	O
1	O
values	O
of	O
0.78-0.89	O
,	O
Pearson	O
correlation	O
coefficient	O
of	O
0.78-0.90	O
,	O
and	O
Bland-Altman	O
plots	O
showed	O
almost	O
perfect	O
agreements	O
between	O
the	O
US	B-P
and	O
CT	B-P
method	O
for	O
all	O
parameters	O
,	O
except	O
the	O
area	O
under	O
the	O
transverse	O
arch	O
(	O
AUTA	O
)	O
.	O

The	O
ICC1	O
,	O
1	O
also	O
showed	O
perfect	O
agreements	O
(	O
0.84-0.92	O
)	O
between	O
two	O
sets	O
of	O
US	B-P
measurements	O
in	O
all	O
parameters	O
.	O

The	O
US	B-P
evaluation	O
of	O
forefoot	O
structure	O
in	O
the	O
coronal	O
plane	O
showed	O
good	O
agreement	O
with	O
CT	B-P
and	O
repeatability	O
of	O
two	O
ultrasonograms	O
in	O
adult	O
women	O
.	O

This	O
reliable	O
evaluation	O
method	O
of	O
forefoot	O
structure	O
can	O
contribute	O
to	O
a	O
quick	O
clinical	O
assessment	O
screening	O
for	O
risk	O
factors	O
of	O
foot	O
problems	O
such	O
as	O
hallux	O
valgus	O
and	O
metatarsalgia	O
.	O

However	O
,	O
because	O
of	O
some	O
limitations	O
such	O
as	O
a	O
lack	O
of	O
inter-observer	O
reliability	O
,	O
more	O
research	O
is	O
needed	O
to	O
validate	O
US	B-P
evaluation	O
of	O
forefoot	O
structure	O
.	O

The	O
current	O
study	O
(	O
trial	O
registration	O
number	O
:	O
R0297	O
)	O
was	O
approved	O
by	O
the	O
Ethical	O
Committee	O
for	O
Human	O
Experiments	O
of	O
Kyoto	O
University	O
(	O
http	O
:	O
//www.ec.med.kyoto-u.ac.jp	O
)	O
on	O
December	O
3	O
,	O
2015	O
.	O

The	O
first	O
participant	O
in	O
this	O
study	O
was	O
enrolled	O
on	O
November	O
17	O
,	O
2015	O
and	O
retrospectively	O
registered	O
.	O

Aptamer	O
-based	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
sensor	O
for	O
thrombin	O
based	O
on	O
supramolecular	O
recognition	O
,	O
oriented	O
assembly	O
,	O
and	O
local	O
field	O
coupling	O
.	O

A	O
supramolecular	O
recognition	O
and	O
oriented	O
assembly	O
system	O
was	O
developed	O
on	O
chip	O
for	O
the	O
highly	O
selective	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
detection	B-P
of	O
thrombin	O
by	O
means	O
of	O
the	O
aptamer	O
-based	O
SERS	O
tag	O
method	O
.	O

A	O
15-base	O
thrombin-binding	O
aptamer	O
(	O
TBA15	O
)	O
with	O
a	O
thiol	O
end	O
was	O
first	O
immobilized	B-P
on	O
an	O
Ag	O
nanoprism	O
array	O
by	O
the	O
S-Ag	O
bond	O
.	O

This	O
aptamer	O
has	O
high	O
binding	O
affinity	O
with	O
thrombin	O
when	O
it	O
folds	O
into	O
a	O
G-quadruplex	O
structure	O
.	O

After	O
the	O
recognition	O
between	O
the	O
aptamer	O
and	O
thrombin	O
,	O
a	O
bridge	O
is	O
built	O
between	O
the	O
SERS	O
tag	O
(	O
4-mercaptobenzoic	O
acid	O
marked	O
Ag	O
nanoparticle	O
)	O
and	O
the	O
fixed	O
thrombin	O
based	O
on	O
the	O
activation	O
of	O
the	O
carboxylic	O
group	O
of	O
4-mercaptobenzoic	O
acid	O
.	O

Thus	O
,	O
the	O
quantitative	O
detection	B-P
of	O
thrombin	O
can	O
be	O
achieved	O
based	O
on	O
the	O
SERS	O
intensity	O
of	O
the	O
immobilized	B-P
SERS	O
tags	O
.	O

The	O
obvious	O
advantages	O
of	O
this	O
sensing	O
method	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
remarkable	O
SERS	O
enhancement	O
due	O
to	O
the	O
high	O
electric	O
field	O
coupling	O
effect	O
via	O
the	O
gap	O
structure	O
formation	O
,	O
which	O
improves	O
the	O
sensitivity	O
of	O
the	O
SERS	O
detection	B-P
and	O
the	O
limit	O
of	O
detection	O
of	O
this	O
method	O
arrives	O
in	O
1.6	O
×	O
10	O
(	O
-11	O
)	O
M	O
,	O
(	O
2	O
)	O
high	O
selectivity	O
based	O
on	O
the	O
specific	O
aptamer	O
recognition	O
toward	O
thrombin	O
,	O
which	O
can	O
be	O
extended	O
to	O
other	O
enzymes	O
easily	O
by	O
changing	O
a	O
proper	O
sequence	O
,	O
(	O
3	O
)	O
high	O
repeatability	O
of	O
SERS	O
signals	O
according	O
to	O
a	O
highly	O
ordered	O
structure	O
,	O
and	O
(	O
4	O
)	O
highly	O
efficient	O
oriented	O
assembly	O
of	O
a	O
sandwich	O
structure	O
over	O
an	O
Ag	O
nanoprism	O
array	O
.	O

The	O
proposed	O
method	O
is	O
expected	O
to	O
be	O
a	O
practical	O
implement	O
in	O
medical	B-P
diagnosis	I-P
.	O

Graphical	O
Abstract	O
Illustration	O
of	O
the	O
aptamer	O
-based	O
SERS	O
sensor	O
for	O
thrombin	O
detection	B-P
.	O

TERT	O
,	O
BRAF	O
and	O
NRAS	O
in	O
primary	O
thyroid	O
cancer	O
and	O
metastatic	O
disease	O
.	O

Little	O
is	O
known	O
about	O
the	O
frequency	O
of	O
key	O
mutations	O
in	O
thyroid	O
cancer	O
metastases	O
and	O
its	O
relationship	O
with	O
the	O
primary	O
tumor	O
genotype	O
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
TERT	O
promoter	O
(	O
TERTp	O
)	O
,	O
BRAF	O
and	O
NRAS	O
mutations	O
in	O
metastatic	O
thyroid	O
carcinomas	O
,	O
analyzing	O
primary	O
thyroid	O
tumors	O
,	O
lymph	O
node	O
metastases	O
(	O
LNM	O
)	O
and	O
distant	O
metastases	O
.	O

Mutation	B-P
analysis	I-P
was	O
performed	O
in	O
437	O
tissue	O
samples	O
from	O
204	O
patients	O
,	O
mainly	O
with	O
papillary	O
thyroid	O
carcinomas	O
(	O
PTC	O
)	O
(	O
n=180	O
)	O
,	O
including	O
196	O
LNM	O
and	O
56	O
distant	O
metastases	O
.	O

All	O
the	O
distant	O
metastases	O
included	O
corresponded	O
to	O
radioiodine	O
-refractory	O
metastatic	O
tissue	O
.	O

We	O
found	O
the	O
following	O
mutation	O
frequency	O
in	O
primary	O
PTC	O
,	O
LNM	O
and	O
distant	O
metastases	O
,	O
respectively	O
:	O
TERTp	O
-	O
12.9	O
%	O
,	O
10.5	O
%	O
,	O
and	O
52.4	O
%	O
;	O
BRAF	O
-	O
44.6	O
%	O
,	O
41.7	O
%	O
,	O
and	O
23.8	O
%	O
;	O
NRAS	O
-	O
1.2	O
%	O
,	O
1.3	O
%	O
,	O
and	O
14.3	O
%	O
.	O

There	O
was	O
a	O
significant	O
concordance	O
between	O
the	O
primary	O
tumor	O
genotype	O
and	O
the	O
corresponding	O
LNM	O
for	O
all	O
the	O
genes	O
,	O
in	O
particular	O
BRAF	O
-mutated	O
PTC	O
.	O

The	O
overall	O
concordance	O
between	O
primary	O
tumors	O
and	O
respective	O
distant	O
metastases	O
was	O
low	O
.	O

In	O
the	O
group	O
of	O
patients	O
with	O
PTC	O
,	O
we	O
found	O
a	O
high	O
frequency	O
of	O
TERTp	O
mutations	O
and	O
a	O
low	O
frequency	O
of	O
BRAF	O
mutations	O
in	O
distant	O
metastases	O
,	O
in	O
comparison	O
to	O
the	O
paired	O
primary	O
tumors	O
.	O

When	O
present	O
in	O
distant	O
metastases	O
,	O
BRAF	O
mutations	O
frequently	O
coexisted	O
with	O
TERTp	O
mutations	O
.	O

When	O
the	O
genotype	O
of	O
primary	O
tumors	O
is	O
compared	O
with	O
the	O
genotype	O
of	O
LNM	O
,	O
the	O
concordance	O
is	O
high	O
for	O
all	O
the	O
genes	O
studied	O
.	O

On	O
the	O
other	O
hand	O
,	O
distant	O
metastases	O
show	O
an	O
enrichment	O
in	O
TERTp	O
mutations	O
and	O
a	O
decrease	O
in	O
BRAF	O
mutations	O
.	O

TERTp	O
mutations	O
may	O
play	O
a	O
role	O
in	O
distant	O
metastases	O
.	O

Fluid-Attenuated	B-P
Inversion	I-P
Recovery	I-P
Hyperintensity	O
Is	O
Associated	O
with	O
Hemorrhagic	O
Transformation	O
following	O
Reperfusion	B-P
Therapy	I-P
.	O

It	O
is	O
still	O
controversial	O
whether	O
early	O
fluid-attenuated	B-P
inversion	I-P
recovery	I-P
(	O
FLAIR	B-P
)	O
hyperintensity	O
within	O
acute	O
ischemic	O
lesions	O
carries	O
the	O
risk	O
of	O
hemorrhagic	O
transformation	O
(	O
HT	O
)	O
after	O
reperfusion	B-P
therapy	I-P
.	O

Furthermore	O
,	O
the	O
association	O
between	O
the	O
location	O
of	O
FLAIR	B-P
hyperintensity	O
and	O
HT	O
has	O
not	O
been	O
investigated	O
.	O

We	O
retrospectively	O
reviewed	O
patients	O
who	O
underwent	O
reperfusion	B-P
therapy	I-P
within	O
6	O
hours	O
of	O
stroke	O
onset	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
including	O
a	O
FLAIR	B-P
sequence	O
before	O
completing	O
reperfusion	B-P
therapy	I-P
.	O

FLAIR	B-P
hyperintensity	O
within	O
the	O
diffusion-weighted	B-P
imaging	I-P
(	O
DWI	B-P
)	O
lesion	O
was	O
rated	O
qualitatively	O
,	O
and	O
HT	O
was	O
assessed	O
on	O
follow-up	O
gradient	O
echo	B-P
imaging	I-P
.	O

The	O
location	O
of	O
the	O
FLAIR	B-P
change	O
and	O
HT	O
was	O
classified	O
as	O
subcortical	O
,	O
cortical	O
,	O
or	O
cortico-subcortical	O
.	O

Of	O
134	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
included	O
in	O
this	O
study	O
,	O
early	O
FLAIR	B-P
changes	O
within	O
DWI	B-P
lesions	O
were	O
identified	O
in	O
56	O
(	O
41.8	O
%	O
)	O
patients	O
,	O
and	O
HT	O
was	O
noted	O
in	O
51	O
(	O
38.1	O
%	O
)	O
patients	O
.	O

FLAIR	B-P
change	O
was	O
independently	O
associated	O
with	O
HT	O
(	O
odds	O
ratio	O
:	O
4.37	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1.72-11.12	O
)	O
.	O

Geographically	O
,	O
48.2	O
%	O
of	O
the	O
patients	O
with	O
a	O
FLAIR	B-P
change	O
developed	O
a	O
matched	O
HT	O
(	O
restricted	O
to	O
the	O
region	O
with	O
the	O
FLAIR	B-P
change	O
)	O
,	O
and	O
the	O
risk	O
of	O
HT	O
was	O
further	O
increased	O
in	O
patients	O
with	O
a	O
FLAIR	B-P
change	O
in	O
the	O
cortico-subcortical	O
region	O
(	O
68.8	O
%	O
)	O
.	O

In	O
patients	O
in	O
the	O
acute	O
stage	O
of	O
stroke	O
,	O
an	O
early	O
FLAIR	B-P
change	O
is	O
associated	O
with	O
the	O
risk	O
of	O
HT	O
following	O
reperfusion	B-P
therapy	I-P
with	O
a	O
highly	O
matched	O
geographic	O
relationship	O
and	O
common	O
risk	O
factors	O
.	O

Thus	O
,	O
identification	O
of	O
FLAIR	B-P
change	O
may	O
be	O
a	O
useful	O
surrogate	O
marker	O
to	O
assess	O
the	O
likelihood	O
of	O
subsequent	O
HT	O
in	O
patients	O
treated	B-P
with	I-P
reperfusion	B-P
therapy	I-P
.	O

Neonatal	O
Heart	O
-Enriched	O
miR-708	O
Promotes	O
Differentiation	O
of	O
Cardiac	O
Progenitor	O
Cells	O
in	O
Rats	O
.	O

Cardiovascular	O
disease	O
is	O
becoming	O
the	O
leading	O
cause	O
of	O
death	O
throughout	O
the	O
world	O
.	O

However	O
,	O
adult	O
hearts	O
have	O
limited	O
potential	O
for	O
regeneration	O
after	O
pathological	O
injury	O
,	O
partly	O
due	O
to	O
the	O
quiescent	O
status	O
of	O
stem	O
/	O
progenitor	O
cells	O
.	O

Reactivation	O
of	O
cardiac	O
stem	O
/	O
progenitor	O
cells	O
to	O
create	O
more	O
myocyte	O
progeny	O
is	O
one	O
of	O
the	O
key	O
steps	O
in	O
the	O
regeneration	O
of	O
a	O
damaged	O
heart	O
.	O

In	O
this	O
study	O
,	O
miR-708	O
was	O
identified	O
to	O
be	O
enriched	O
in	O
the	O
neonatal	O
cardiomyocytes	O
of	O
rats	O
,	O
but	O
this	O
has	O
not	O
yet	O
been	O
proven	O
in	O
adult	O
humans	O
.	O

A	O
lower	O
level	O
of	O
miR-708	O
in	O
c-kit	O
(	O
+	O
)	O
stem	O
/	O
progenitor	O
cells	O
was	O
detected	O
compared	O
to	O
non-progenitors	O
.	O

Overexpression	O
of	O
miR-708	O
induced	O
cardiomyocyte	O
differentiation	O
of	O
cardiac	O
stem	O
/	O
progenitor	O
cells	O
.	O

This	O
finding	O
strengthened	O
the	O
potential	O
of	O
applying	O
miRNAs	O
in	O
the	O
regeneration	O
of	O
injured	O
hearts	O
,	O
and	O
this	O
indicates	O
that	O
miR-708	O
could	O
be	O
a	O
novel	O
candidate	O
for	O
treatment	B-P
of	O
heart	O
diseases	O
.	O

An	O
indirect	O
method	O
for	O
in	O
vivo	O
T2	B-P
mapping	I-P
of	O
[	O
1-	O
(	O
13	O
)	O
C	O
]	O
pyruvate	O
using	O
hyperpolarized	B-P
(	I-P
13	I-P
)	I-P
C	I-P
CSI	I-P
.	O

An	O
indirect	O
method	O
for	O
in	O
vivo	O
T2	B-P
mapping	I-P
of	O
(	O
13	O
)	O
C-labeled	O
metabolites	O
using	O
T2	O
and	O
T2	O
*	O
information	O
of	O
water	O
protons	O
obtained	O
a	O
priori	O
is	O
proposed	O
.	O

The	O
T2	O
values	O
of	O
(	O
13	O
)	O
C	O
metabolites	O
are	O
inferred	O
using	O
the	O
relationship	O
to	O
T2	O
'	O
of	O
coexisting	O
(	O
1	O
)	O
H	O
and	O
the	O
T2	O
*	O
of	O
(	O
13	O
)	O
C	O
metabolites	O
,	O
which	O
is	O
measured	O
using	O
routine	O
hyperpolarized	B-P
(	I-P
13	I-P
)	I-P
C	I-P
CSI	I-P
data	O
.	O

The	O
concept	O
is	O
verified	O
with	O
phantom	O
studies	O
.	O

Simulations	O
were	O
performed	O
to	O
evaluate	O
the	O
extent	O
of	O
T2	O
estimation	B-P
accuracy	O
due	O
to	O
errors	O
in	O
the	O
other	O
measurements	O
.	O

Also	O
,	O
bias	O
in	O
the	O
(	B-P
13	I-P
)	I-P
C	I-P
T2	I-P
*	I-P
estimation	I-P
from	O
the	O
(	B-P
13	I-P
)	I-P
C	I-P
CSI	I-P
data	O
was	O
studied	O
.	O

In	O
vivo	O
experiments	O
were	O
performed	O
from	O
the	O
brains	O
of	O
normal	O
rats	O
and	O
a	O
rat	O
with	O
C6	O
glioma	O
.	O

Simulation	O
results	O
indicate	O
that	O
the	O
proposed	O
method	O
provides	O
accurate	O
and	O
unbiased	O
(	O
13	O
)	O
C	O
T2	O
values	O
within	O
typical	O
experimental	O
settings	O
.	O

The	O
in	O
vivo	O
studies	O
found	O
that	O
the	O
estimated	O
T2	O
of	O
[	O
1-	O
(	O
13	O
)	O
C	O
]	O
pyruvate	O
using	O
the	O
indirect	O
method	O
was	O
longer	O
in	O
tumor	O
than	O
in	O
normal	O
tissues	O
and	O
gave	O
values	O
similar	O
to	O
previous	O
reports	O
.	O

This	O
method	O
can	O
estimate	O
localized	O
T2	O
relaxation	O
times	O
from	O
multiple	O
voxels	O
using	O
conventional	O
hyperpolarized	B-P
(	I-P
13	I-P
)	I-P
C	I-P
CSI	I-P
and	O
can	O
potentially	O
be	O
used	O
with	O
time	B-P
resolved	I-P
fast	I-P
CSI	I-P
.	O

Reaction	O
of	O
Lymphoid	O
Organs	O
to	O
Injection	B-P
of	O
Iron	O
-	O
Carbon	O
Nanoparticles	O
.	O

The	O
distribution	O
of	O
iron	O
-	O
carbon	O
nanoparticles	O
in	O
FeC-DSPE-PEG-2000	O
modification	O
(	O
micellar	O
particles	O
with	O
structure	O
(	O
Fe	O
)	O
core	O
-	O
carbon	O
shell	O
;	O
PEG	O
-based	O
coating	O
)	O
is	O
studied	O
.	O

The	O
greater	O
part	O
of	O
the	O
nanoparticles	O
accumulated	O
in	O
the	O
spleen	O
and	O
liver	O
,	O
a	O
small	O
amount	O
in	O
the	O
lungs	O
,	O
and	O
the	O
minimum	O
amount	O
in	O
the	O
thymus	O
.	O

The	O
structural	O
changes	O
in	O
the	O
lymphoid	O
organs	O
were	O
minor	O
and	O
involved	O
only	O
the	O
microcirculatory	O
bed	O
.	O

Analysis	O
of	O
the	O
peripheral	O
blood	O
showed	O
manifest	O
anemia	O
,	O
thrombocytopenia	O
,	O
and	O
leukocytosis	O
.	O

Higher	O
risk	O
of	O
revision	O
for	O
infection	O
using	O
systemic	O
clindamycin	O
prophylaxis	B-P
than	O
with	O
cloxacillin	O
.	O

Background	O
and	O
purpose	O
-	O
Clindamycin	O
has	O
not	O
been	O
compared	O
with	O
other	O
antibiotics	O
for	O
prophylaxis	B-P
in	O
arthroplasty	B-P
.	O

Since	O
2009	O
,	O
the	O
Swedish	O
Knee	B-P
Arthroplasty	I-P
Register	O
(	O
SKAR	O
)	O
has	O
been	O
collecting	O
information	O
on	O
the	O
prophylactic	B-P
antibiotic	I-P
regime	I-P
used	O
at	O
every	O
individual	O
operation	O
.	O

In	O
Sweden	O
,	O
when	O
there	O
is	O
allergy	O
to	O
penicillin	O
,	O
clindamycin	O
has	O
been	O
the	O
recommended	O
alternative	O
.	O

We	O
examined	O
whether	O
there	O
were	O
differences	O
in	O
the	O
rate	O
of	O
revision	O
due	O
to	O
infection	O
depending	O
on	O
which	O
antibiotic	O
was	O
used	O
as	O
systemic	O
prophylaxis	B-P
.	O

Patients	O
and	O
methods	O
-	O
Patients	O
who	O
had	O
a	O
total	B-P
knee	I-P
arthroplasty	I-P
(	O
TKA	B-P
)	O
performed	O
due	O
to	O
osteoarthritis	O
(	O
OA	O
)	O
during	O
the	O
years	O
2009-2015	O
were	O
included	O
in	O
the	O
study	O
.	O

Information	O
on	O
which	O
antibiotic	O
was	O
used	O
was	O
available	O
for	O
80,018	O
operations	O
(	O
55,530	O
patients	O
)	O
.	O

Survival	O
statistics	O
were	O
used	O
to	O
calculate	O
the	O
rate	O
of	O
revision	O
due	O
to	O
infection	O
until	O
the	O
end	O
of	O
2015	O
,	O
comparing	O
the	O
group	O
of	O
patients	O
who	O
received	O
cloxacillin	O
with	O
those	O
who	O
received	O
clindamycin	O
as	O
systemic	O
prophylaxis	B-P
.	O

Results	O
-	O
Cloxacillin	O
was	O
used	O
in	O
90	O
%	O
of	O
the	O
cases	O
,	O
clindamycin	O
in	O
7	O
%	O
,	O
and	O
cephalosporins	O
in	O
2	O
%	O
.	O

The	O
risk	O
of	O
being	O
revised	O
due	O
to	O
infection	O
was	O
higher	O
when	O
clindamycin	O
was	O
used	O
than	O
when	O
cloxacillin	O
was	O
used	O
(	O
RR	O
=1.5	O
,	O
95	O
%	O
CI	O
:	O
1.2-2.0	O
;	O
p	O
=	O
0.001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
revision	O
rate	O
for	O
other	O
causes	O
(	O
p	O
=	O
0.2	O
)	O
.	O

Interpretation	O
-	O
We	O
advise	O
that	O
patients	O
reporting	O
allergic	O
reaction	O
to	O
penicillin	O
should	O
have	O
their	O
allergic	O
history	O
explored	O
.	O

In	O
the	O
absence	O
of	O
a	O
clear	O
history	O
of	O
type-I	O
allergic	O
reaction	O
(	O
e.g	O
.	O

urticaria	O
,	O
anaphylaxis	O
,	O
or	O
bronchospasm	O
)	O
,	O
we	O
suggest	O
the	O
use	O
of	O
a	O
third-generation	O
cephalosporin	O
instead	O
of	O
clindamycin	O
as	O
perioperative	O
prophylaxis	B-P
when	O
undergoing	O
a	O
TKR	B-P
.	O

No	O
recommendation	O
can	O
be	O
given	O
regarding	O
patients	O
with	O
type-1	O
allergy	O
.	O

On	O
the	O
identity	O
of	O
the	O
Palearctic	O
species	O
of	O
the	O
wolf	O
spider	O
genus	O
<	O
i	O
>	O
Trebacosa	O
<	O
/i	O
>	O
(	O
Araneae	O
:	O
Lycosidae	O
)	O
.	O

In	O
this	O
paper	O
we	O
propose	O
Trebacosa	O
brunhesi	O
Villepoux	O
,	O
2007	O
as	O
a	O
junior	O
synonym	O
of	O
Trebacosa	O
europaea	O
Szinetár	O
&	O
Kan-csal	O
,	O
2007	O
based	O
on	O
the	O
examination	O
of	O
specimens	O
from	O
all	O
the	O
localities	O
from	O
where	O
those	O
species	O
are	O
known	O
.	O

Illustration	O
of	O
the	O
type	O
species	O
of	O
the	O
genus	O
,	O
Trebacosa	O
marxi	O
(	O
Stone	O
,	O
1890	O
)	O
and	O
specimens	O
from	O
all	O
known	O
localities	O
of	O
T.	O
europaea	O
are	O
given	O
to	O
show	O
both	O
the	O
inter-	O
and	O
the	O
intraspecific	O
differences	O
of	O
the	O
genus	O
.	O

Scanning	B-P
electron	I-P
micrographs	I-P
were	O
used	O
to	O
illustrate	O
the	O
detailed	O
structure	O
of	O
the	O
female	O
's	O
genitalia	O
.	O

Targeting	O
accuracy	O
of	O
single-isocenter	O
intensity-modulated	B-P
radiosurgery	B-P
for	O
multiple	O
lesions	O
.	O

To	O
investigate	O
the	O
targeting	O
accuracy	O
of	O
intensity-modulated	B-P
SRS	B-P
(	O
IMRS	B-P
)	O
plans	O
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	O
metastases	O
with	O
a	O
single	O
isocenter	O
.	O

A	O
home-made	O
acrylic	O
phantom	O
able	O
to	O
support	O
a	O
film	O
(	O
EBT3	O
)	O
in	O
its	O
coronal	O
plane	O
was	O
used	O
.	O

The	O
phantom	O
was	O
CT	B-P
scanned	I-P
and	O
three	O
coplanar	O
small	O
targets	O
(	O
a	O
central	O
and	O
two	O
peripheral	O
)	O
were	O
outlined	O
in	O
the	O
Eclipse	B-P
system	I-P
.	O

Peripheral	O
targets	O
were	O
6	O
cm	O
apart	O
from	O
the	O
central	O
one	O
.	O

A	O
reference	O
IMRS	B-P
plan	O
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	O
,	O
but	O
only	O
a	O
single	O
isocenter	O
located	O
at	O
the	O
center	O
of	O
the	O
central	O
target	O
was	O
used	O
.	O

After	O
positioning	O
the	O
phantom	O
on	O
the	O
linac	O
using	O
the	O
room	O
lasers	O
,	O
a	O
CBCT	B-P
scan	I-P
was	O
acquired	O
and	O
the	O
reference	O
plan	O
were	O
mapped	O
on	O
it	O
,	O
by	O
placing	O
the	O
planned	O
isocenter	O
at	O
the	O
intersection	O
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	O
showing	O
the	O
linac	O
isocenter	O
.	O

The	O
mapped	O
plan	O
was	O
then	O
recalculated	O
and	O
delivered	O
.	O

The	O
film	O
dose	B-P
distribution	I-P
was	O
derived	O
using	O
a	O
cloud	O
computing	O
application	O
(	O
www.radiochromic.com	O
)	O
that	O
uses	O
a	O
triple-channel	O
dosimetry	B-P
algorithm	O
.	O

Comparison	O
of	O
dose	B-P
distributions	I-P
using	O
the	O
gamma	O
index	O
(	O
5	O
%	O
/1	O
mm	O
)	O
were	O
performed	O
over	O
a	O
5	O
×	O
5	O
cm	O
(	O
2	O
)	O
region	O
centered	O
over	O
each	O
target	O
.	O

2D	O
shifts	O
required	O
to	O
get	O
the	O
best	O
gamma	O
passing	O
rates	O
on	O
the	O
peripheral	O
target	O
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	O
target	O
.	O

The	O
experiment	O
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	B-P
.	O

Average	O
2D	O
shifts	O
required	O
to	O
achieve	O
optimal	O
gamma	O
passing	O
rates	O
(	O
99	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
)	O
were	O
0.7	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
0.8	O
mm	O
(	O
SD	O
:	O
0.4	O
mm	O
)	O
and	O
0.8	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
for	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
,	O
respectively	O
.	O

No	O
statistical	O
differences	O
(	O
p	O
>	O
0.05	O
)	O
were	O
found	O
for	O
targeting	O
accuracy	O
between	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
.	O

The	O
study	O
revealed	O
a	O
targeting	O
accuracy	O
within	O
1	O
mm	O
for	O
off-	O
isocenter	O
targets	O
within	O
6	O
cm	O
of	O
the	O
linac	O
isocenter	O
,	O
when	O
a	O
single-isocenter	O
IMRS	B-P
plan	O
is	O
designed	O
.	O

A	O
Case	O
of	O
Acute	O
Hepatitis	O
E	O
Infection	O
in	O
a	O
Patient	O
with	O
Non-Hodgkin	O
Lymphoma	O
Treated	B-P
Successfully	O
with	O
Ribavirin	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
man	O
who	O
,	O
following	O
immunosuppressive	B-P
treatment	I-P
for	O
non-Hodgkin	O
lymphoma	O
,	O
became	O
infected	O
with	O
viral	O
hepatitis	O
E.	O
Acute	O
hepatitis	O
E	O
virus	O
infection	O
should	O
be	O
considered	O
in	O
patients	O
with	O
deranged	O
liver	O
function	O
on	O
a	O
background	O
of	O
haematological	O
malignancies	O
or	O
immunosuppression	O
,	O
even	O
without	O
travel	O
to	O
endemic	O
regions	O
.	O

Whilst	O
clearance	O
is	O
usually	O
spontaneous	O
in	O
immune	O
-	O
competent	O
individuals	O
,	O
these	O
at-risk	O
groups	O
may	O
develop	O
a	O
more	O
complicated	O
and	O
protracted	O
disease	O
course	O
.	O

Thus	O
awareness	O
is	O
important	O
as	O
additional	O
treatment	B-P
with	O
ribavirin	O
or	O
pegylated	O
interferon	O
may	O
be	O
required	O
,	O
as	O
in	O
this	O
case	O
,	O
in	O
order	O
to	O
help	O
achieve	O
eradication	O
.	O

Living	O
on	O
the	O
edge	O
:	O
substrate	O
competition	O
explains	O
loss	O
of	O
robustness	O
in	O
mitochondrial	O
fatty-acid	O
oxidation	O
disorders	O
.	O

Defects	O
in	O
genes	O
involved	O
in	O
mitochondrial	O
fatty-acid	O
oxidation	O
(	O
mFAO	O
)	O
reduce	O
the	O
ability	O
of	O
patients	O
to	O
cope	O
with	O
metabolic	O
challenges	O
.	O

mFAO	O
enzymes	O
accept	O
multiple	O
substrates	O
of	O
different	O
chain	O
length	O
,	O
leading	O
to	O
molecular	O
competition	O
among	O
the	O
substrates	O
.	O

Here	O
,	O
we	O
combined	O
computational	B-P
modeling	I-P
with	O
quantitative	O
mouse	O
and	O
patient	O
data	O
to	O
investigate	O
whether	O
substrate	O
competition	O
affects	O
pathway	O
robustness	O
in	O
mFAO	O
disorders	O
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild-type	O
mice	O
and	O
mice	O
deficient	O
for	O
medium-chain	O
acyl-CoA	O
dehydrogenase	O
(	O
MCAD	O
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	O
of	O
mFAO	O
.	O

Model	O
simulations	O
predicted	O
that	O
MCAD	O
deficiency	O
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	O
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mFAO	O
substrate	O
palmitoyl-CoA	O
.	O

However	O
,	O
high	O
concentrations	O
of	O
palmitoyl-CoA	O
would	O
induce	O
a	O
decline	O
in	O
flux	O
and	O
an	O
accumulation	O
of	O
intermediate	O
metabolites	O
.	O

We	O
proved	O
computationally	O
that	O
the	O
predicted	O
overload	O
behavior	O
was	O
due	O
to	O
substrate	O
competition	O
in	O
the	O
pathway	O
.	O

Second	O
,	O
to	O
study	O
the	O
clinical	O
relevance	O
of	O
this	O
mechanism	O
,	O
we	O
used	O
patients	O
'	O
metabolite	O
profiles	O
and	O
generated	O
a	O
humanized	O
version	O
of	O
the	O
computational	O
model	O
.	O

While	O
molecular	O
competition	O
did	O
not	O
affect	O
the	O
plasma	O
metabolite	O
profiles	O
during	O
MCAD	O
deficiency	O
,	O
it	O
was	O
a	O
key	O
factor	O
in	O
explaining	O
the	O
characteristic	O
acylcarnitine	O
profiles	O
of	O
multiple	O
acyl-CoA	O
dehydrogenase	O
deficient	O
patients	O
.	O

The	O
patient-specific	O
computational	O
models	O
allowed	O
us	O
to	O
predict	O
the	O
severity	O
of	O
the	O
disease	O
phenotype	O
,	O
providing	O
a	O
proof	O
of	O
principle	O
for	O
the	O
systems	O
medicine	O
approach	O
.	O

We	O
conclude	O
that	O
substrate	O
competition	O
is	O
at	O
the	O
basis	O
of	O
the	O
physiology	O
seen	O
in	O
patients	O
with	O
mFAO	O
disorders	O
,	O
a	O
finding	O
that	O
may	O
explain	O
why	O
these	O
patients	O
run	O
a	O
risk	O
of	O
a	O
life-threatening	O
metabolic	O
catastrophe	O
.	O

Development	O
and	O
validation	O
of	O
an	O
easy-to-use	O
risk	O
assessment	O
tool	O
for	O
cumulative	O
low	O
back	O
loading	O
:	O
The	O
Lifting	O
Fatigue	O
Failure	O
Tool	O
(	O
LiFFT	O
)	O
.	O

Recent	O
evidence	O
suggests	O
that	O
musculoskeletal	O
disorders	O
(	O
MSDs	O
)	O
may	O
be	O
the	O
result	O
of	O
a	O
fatigue	O
failure	O
process	O
in	O
affected	O
tissues	O
.	O

This	O
paper	O
describes	O
a	O
new	O
low	O
back	O
exposure	O
assessment	O
tool	O
(	O
the	O
Lifting	O
Fatigue	O
Failure	O
Tool	O
[	O
LiFFT	O
]	O
)	O
,	O
which	O
estimates	O
a	O
``	O
daily	O
dose	O
``	O
of	O
cumulative	O
loading	O
on	O
the	O
low	O
back	O
using	O
fatigue	O
failure	O
principles	O
.	O

Only	O
three	O
variables	O
are	O
necessary	O
to	O
derive	O
the	O
cumulative	O
load	O
associated	O
with	O
a	O
lifting	O
task	O
:	O
the	O
weight	O
of	O
the	O
load	O
,	O
the	O
maximum	O
horizontal	O
distance	O
from	O
the	O
spine	O
to	O
the	O
load	O
,	O
and	O
the	O
number	O
of	O
repetitions	O
for	O
tasks	B-P
performed	I-P
during	O
the	O
workday	O
.	O

The	O
new	O
tool	O
was	O
validated	O
using	O
two	O
existing	O
epidemiological	O
databases	O
:	O
the	O
Lumbar	O
Motion	O
Monitor	O
(	O
LMM	O
)	O
database	O
,	O
and	O
a	O
database	O
from	O
a	O
U.S.	O
automotive	O
manufacturer	O
.	O

The	O
LiFFT	O
cumulative	O
damage	O
metric	O
explained	O
92	O
%	O
of	O
the	O
deviance	O
in	O
low	O
back	O
disorders	O
(	O
LBDs	O
)	O
in	O
the	O
LMM	O
database	O
and	O
72-95	O
%	O
of	O
the	O
deviance	O
in	O
low	O
back	O
outcomes	O
in	O
the	O
automotive	O
database	O
(	O
depending	O
on	O
the	O
outcome	O
measure	O
)	O
.	O

Thus	O
,	O
LiFFT	O
is	O
practitioner	O
friendly	O
and	O
its	O
cumulative	O
damage	O
metric	O
highly	O
related	O
to	O
low	O
back	O
outcomes	O
.	O

Effects	O
of	O
Rational-Emotive	B-P
Hospice	I-P
Care	I-P
Therapy	I-P
on	O
Problematic	O
Assumptions	O
,	O
Death	O
Anxiety	O
,	O
and	O
Psychological	O
Distress	O
in	O
a	O
Sample	O
of	O
Cancer	O
Patients	O
and	O
Their	O
Family	O
Caregivers	O
in	O
Nigeria	O
.	O

This	O
study	O
was	O
a	O
preliminary	O
investigation	O
that	O
aimed	O
to	O
examine	O
the	O
effects	O
of	O
rational	B-P
emotive	I-P
hospice	I-P
care	I-P
therapy	I-P
(	O
REHCT	B-P
)	O
on	O
problematic	O
assumptions	O
,	O
death	O
anxiety	O
,	O
and	O
psychological	O
distress	O
in	O
a	O
sample	O
of	O
cancer	O
patients	O
and	O
their	O
family	O
caregivers	O
in	O
Nigeria	O
.	O

The	O
study	O
adopted	O
a	O
pre-posttest	O
randomized	O
control	O
group	O
design	O
.	O

Participants	O
were	O
community-dwelling	O
cancer	O
patients	O
(	O
n	O
=	O
32	O
)	O
and	O
their	O
family	O
caregivers	O
(	O
n	O
=	O
52	O
)	O
.	O

The	O
treatment	B-P
process	I-P
consisted	O
of	O
10	O
weeks	O
of	O
full	O
intervention	B-P
and	O
4	O
weeks	O
of	O
follow-up	O
meetings	O
that	O
marked	O
the	O
end	O
of	O
intervention	B-P
.	O

The	O
study	O
used	O
repeated-measures	O
analysis	O
of	O
variance	O
for	O
data	O
analysis	O
.	O

The	O
findings	O
revealed	O
significant	O
effects	O
of	O
a	O
REHCT	B-P
intervention	B-P
program	I-P
on	O
problematic	O
assumptions	O
,	O
death	O
anxiety	O
,	O
and	O
psychological	O
distress	O
reduction	O
among	O
the	O
cancer	O
patients	O
and	O
their	O
family	O
caregivers	O
at	O
the	O
end	O
of	O
the	O
intervention	B-P
.	O

The	O
improvements	O
were	O
also	O
maintained	O
at	O
follow-up	O
meetings	O
in	O
the	O
treatment	B-P
group	O
compared	O
with	O
the	O
control	O
group	O
who	O
received	O
the	O
usual	O
care	O
and	O
conventional	O
counseling	O
.	O

The	O
researchers	O
have	O
been	O
able	O
to	O
show	O
that	O
REHCT	B-P
intervention	B-P
is	O
more	O
effective	O
than	O
a	O
control	B-P
therapy	I-P
for	O
cancer	O
patients	O
'	O
care	O
,	O
education	O
,	O
and	O
counseling	O
in	O
the	O
Nigerian	O
context	O
.	O

Differential	O
Immunohistochemical	B-P
Profiles	B-P
for	O
Distinguishing	O
Prostate	O
Carcinoma	O
and	O
Urothelial	O
Carcinoma	O
.	O

The	O
pathologic	O
distinction	O
between	O
high-grade	O
prostate	O
adenocarcinoma	O
(	O
PAC	O
)	O
involving	O
the	O
urinary	O
bladder	O
and	O
high-grade	O
urothelial	O
carcinoma	O
(	O
UC	O
)	O
infiltrating	O
the	O
prostate	O
can	O
be	O
difficult	O
.	O

However	O
,	O
making	O
this	O
distinction	O
is	O
clinically	O
important	O
because	O
of	O
the	O
different	O
treatment	B-P
modalities	O
for	O
these	O
two	O
entities	O
.	O

A	O
total	O
of	O
249	O
patient	O
cases	O
(	O
PAC	O
,	O
111	O
cases	O
;	O
UC	O
,	O
138	O
cases	O
)	O
collected	O
between	O
June	O
1995	O
and	O
July	O
2009	O
at	O
Seoul	O
St.	O
Mary	O
's	O
Hospital	O
were	O
studied	O
.	O

An	O
immunohistochemical	B-P
evaluation	B-P
of	O
prostatic	O
markers	O
(	O
prostate-specific	O
antigen	O
[	O
PSA	O
]	O
,	O
prostate-specific	O
membrane	O
antigen	O
[	O
PSMA	O
]	O
,	O
prostate	O
acid	O
phosphatase	O
[	O
PAP	O
]	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
α-methylacyl	O
coenzyme	O
A	O
racemase	O
[	O
AMACR	O
]	O
)	O
and	O
urothelial	O
markers	O
(	O
CK34βE12	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA	O
binding	O
protein	O
3	O
[	O
GATA3	O
]	O
)	O
was	O
performed	O
using	O
tissue	O
microarrays	O
from	O
each	O
tumor	O
.	O

The	O
sensitivities	O
of	O
prostatic	O
markers	O
in	O
PAC	O
were	O
100	O
%	O
for	O
PSA	O
,	O
83.8	O
%	O
for	O
PSMA	O
,	O
91.9	O
%	O
for	O
PAP	O
,	O
93.7	O
%	O
for	O
P501s	O
,	O
88.3	O
%	O
for	O
NKX	O
3.1	O
,	O
and	O
66.7	O
%	O
for	O
AMACR	O
.	O

However	O
,	O
the	O
urothelial	O
markers	O
CK34βE12	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
S100P	O
,	O
and	O
GATA3	O
were	O
also	O
positive	O
in	O
1.8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3.6	O
%	O
,	O
and	O
0	O
%	O
of	O
PAC	O
,	O
respectively	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	O
in	O
UC	O
were	O
75.4	O
%	O
for	O
CK34βE12	O
,	O
73.9	O
%	O
for	O
p63	O
,	O
45.7	O
%	O
for	O
thrombomodulin	O
,	O
22.5	O
%	O
for	O
S100P	O
,	O
and	O
84.8	O
%	O
for	O
GATA3	O
.	O

Conversely	O
,	O
the	O
prostatic	O
markers	O
PSA	O
,	O
PSMA	O
,	O
PAP	O
,	O
P501s	O
,	O
NKX3.1	O
,	O
and	O
AMACR	O
were	O
also	O
positive	O
in	O
9.4	O
%	O
,	O
0.7	O
%	O
,	O
18.8	O
%	O
,	O
0.7	O
%	O
,	O
0	O
%	O
,	O
and	O
8.7	O
%	O
of	O
UC	O
s	O
,	O
respectively	O
.	O

Prostatic	O
and	O
urothelial	O
markers	O
,	O
including	O
PSA	O
,	O
NKX3.1	O
,	O
p63	O
,	O
thrombomodulin	O
,	O
and	O
GATA3	O
are	O
very	O
useful	O
for	O
differentiating	O
PAC	O
from	O
UC	O
.	O

The	O
optimal	O
combination	O
of	O
prostatic	O
and	O
urothelial	O
markers	O
could	O
improve	O
the	O
ability	O
to	O
differentiate	O
PAC	O
from	O
UC	O
pathologically	O
.	O

Teleophthalmology	B-P
image-based	B-P
navigated	I-P
retinal	I-P
laser	I-P
therapy	I-P
for	O
diabetic	O
macular	O
edema	O
:	O
a	O
concept	O
of	O
retinal	B-P
telephotocoagulation	I-P
.	O

To	O
determine	B-P
the	O
feasibility	O
and	O
efficacy	O
of	O
a	O
retinal	B-P
telephotocoagulation	I-P
treatment	O
plan	O
for	O
diabetic	O
macular	O
edema	O
.	O

Prospective	O
,	O
interventional	O
cohort	O
study	O
at	O
two	O
clinical	O
sites	O
.	O

Sixteen	O
eyes	O
of	O
ten	O
subjects	O
with	O
diabetic	O
macular	O
edema	O
underwent	O
navigated	B-P
focal	I-P
laser	I-P
photocoagulation	I-P
using	O
a	O
novel	O
teleretinal	O
treatment	O
plan	O
.	O

Clinic	O
1	O
(	O
King	O
Khaled	O
Eye	O
Specialist	O
Hospital	O
,	O
Riyadh	O
,	O
Saudi	O
Arabia	O
)	O
collected	O
retinal	O
images	O
and	O
fundus	B-P
fluorescein	I-P
angiogram	I-P
.	O

Clinic	O
2	O
(	O
Palmetto	O
Retina	O
Center	O
,	O
West	O
Columbia	O
,	O
SC	O
,	O
USA	O
)	O
created	O
image	O
-based	O
treatment	O
plans	O
based	O
on	O
which	O
macular	O
laser	B-P
photocoagulation	I-P
was	O
performed	O
back	O
at	O
clinic	O
1	O
.	O

The	O
primary	O
outcome	O
of	O
the	O
study	O
was	O
feasibility	O
of	O
image	O
transfer	O
and	O
performing	O
navigated	B-P
laser	I-P
photocoagulation	I-P
for	O
subjects	O
with	O
diabetic	O
macular	O
edema	O
between	O
two	O
distant	O
clinics	O
.	O

Secondary	O
measures	O
were	O
change	O
in	O
best-corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
and	O
central	O
retinal	O
thickness	O
(	O
CRT	O
)	O
by	O
spectral-domain	O
optical	O
coherence	O
tomography	O
at	O
3	O
months	O
after	O
treatment	B-P
.	O

The	O
teleretinal	O
treatment	O
plan	O
was	O
able	O
to	O
be	O
successfully	O
completed	O
in	O
all	O
16	O
eyes	O
.	O

The	O
mean	O
logMAR	O
BCVA	O
at	O
baseline	O
was	O
0.49	O
±	O
0.1	O
,	O
which	O
remained	O
stable	O
(	O
0.45	O
±	O
0.1	O
)	O
3	O
months	O
after	O
treatment	B-P
(	O
p	O
=	O
0.060	O
)	O
.	O

The	O
CRT	O
improved	O
from	O
290.1	O
±	O
37.6	O
μm	O
at	O
baseline	O
to	O
270.8	O
±	O
27.7	O
μm	O
3	O
months	O
after	O
treatment	B-P
(	O
p	O
=	O
0.005	O
)	O
.	O

All	O
eyes	O
demonstrated	O
improvement	O
in	O
the	O
area	O
of	O
retinal	O
edema	O
after	O
laser	B-P
photocoagulation	I-P
,	O
and	O
no	O
eyes	O
demonstrated	O
visual	O
acuity	O
loss	O
3	O
months	O
after	O
treatment	B-P
.	O

This	O
study	O
introduces	O
the	O
concept	O
of	O
retinal	B-P
telephotocoagulation	I-P
for	O
diabetic	O
macular	O
edema	O
,	O
and	O
demonstrates	O
the	O
feasibility	O
and	O
safety	O
of	O
using	O
telemedicine	O
to	O
perform	O
navigated	B-P
retinal	I-P
laser	I-P
treatments	I-P
regardless	O
of	O
geographical	O
distance	O
.	O

KMAP-O	O
framework	O
for	O
care	O
management	O
research	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

To	O
review	O
impacts	O
of	O
interventions	O
involving	O
self-management	O
education	O
,	O
health	O
coaching	O
,	O
and	O
motivational	B-P
interviewing	I-P
for	O
type	O
2	O
diabetes	O
.	O

A	O
thorough	O
review	O
of	O
the	O
scientific	O
literature	O
on	O
diabetes	O
care	O
and	O
management	O
was	O
executed	O
by	O
a	O
research	O
team	O
.	O

This	O
article	O
summarizes	O
important	O
findings	O
in	O
regard	O
to	O
the	O
validity	O
of	O
developing	O
a	O
comprehensive	O
behavioral	O
system	O
as	O
a	O
framework	O
for	O
empirical	O
investigation	O
.	O

The	O
behavioral	O
system	O
framework	O
consists	O
of	O
patients	O
'	O
knowledge	O
(	O
K	O
)	O
,	O
motivation	O
(	O
M	O
)	O
,	O
attitude	O
(	O
A	O
)	O
,	O
and	O
practice	O
(	O
P	O
)	O
as	O
predictor	O
variables	O
for	O
diabetes	O
care	O
outcomes	O
(	O
O	O
)	O
.	O

Care	O
management	O
strategies	O
or	O
health	O
education	O
programs	O
serve	O
as	O
the	O
intervention	O
variable	O
that	O
directly	O
influences	O
K	O
,	O
M	O
,	O
A	O
,	O
and	O
P	O
and	O
then	O
indirectly	O
affects	O
the	O
variability	O
in	O
patient	O
care	O
outcomes	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

This	O
review	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
KMAP-O	O
framework	O
and	O
how	O
it	O
can	O
guide	O
the	O
care	O
management	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

It	O
will	O
allow	O
the	O
tailoring	O
of	O
interventions	O
to	O
be	O
more	O
effective	O
through	O
knowledge	O
enhancement	O
,	O
increased	O
motivation	O
,	O
attitudinal	O
changes	O
,	O
and	O
improved	O
preventive	O
practice	O
to	O
reduce	O
the	O
progression	O
of	O
type	O
2	O
diabetes	O
and	O
comorbidities	O
.	O

Furthermore	O
,	O
the	O
use	O
of	O
health	O
information	O
technology	O
for	O
enhancing	O
changes	O
in	O
KMAP	O
and	O
communications	O
is	O
advocated	O
in	O
health	O
promotion	O
and	O
development	O
.	O

Phytoplankton	O
production	O
and	O
taxon	O
-	O
specific	O
growth	O
rates	O
in	O
the	O
Costa	O
Rica	O
Dome	O
.	O

During	O
summer	O
2010	O
,	O
we	O
investigated	O
phytoplankton	O
production	O
and	O
growth	O
rates	O
at	O
19	O
stations	O
in	O
the	O
eastern	O
tropical	O
Pacific	O
,	O
where	O
winds	O
and	O
strong	O
opposing	O
currents	O
generate	O
the	O
Costa	O
Rica	O
Dome	O
(	O
CRD	O
)	O
,	O
an	O
open	O
-	O
ocean	O
upwelling	O
feature	O
.	O

Primary	O
production	O
(	O
(	O
14	O
)	O
C	O
-	O
incorporation	O
)	O
and	O
group-specific	O
growth	O
and	O
net	O
growth	O
rates	O
(	O
two-treatment	O
seawater	O
dilution	B-P
method	I-P
)	O
were	O
estimated	O
from	O
samples	O
incubated	B-P
in	O
situ	O
at	O
eight	O
depths	O
.	O

Our	O
cruise	O
coincided	O
with	O
a	O
mild	O
El	O
Niño	O
event	O
,	O
and	O
only	O
weak	O
upwelling	O
was	O
observed	O
in	O
the	O
CRD	O
.	O

Nevertheless	O
,	O
the	O
highest	O
phytoplankton	O
abundances	O
were	O
found	O
near	O
the	O
dome	O
center	O
.	O

However	O
,	O
mixed-layer	O
growth	O
rates	O
were	O
lowest	O
in	O
the	O
dome	O
center	O
(	O
∼0.5-0.9	O
day	O
(	O
-1	O
)	O
)	O
,	O
but	O
higher	O
on	O
the	O
edge	O
of	O
the	O
dome	O
(	O
∼0.9-1.0	O
day	O
(	O
-1	O
)	O
)	O
and	O
in	O
adjacent	O
coastal	O
waters	O
(	O
0.9-1.3	O
day	O
(	O
-1	O
)	O
)	O
.	O

We	O
found	O
good	O
agreement	O
between	O
independent	O
methods	O
to	O
estimate	O
growth	O
rates	O
.	O

Mixed-layer	O
growth	O
rates	O
of	O
Prochlorococcus	O
and	O
Synechococcus	O
were	O
largely	O
balanced	O
by	O
mortality	O
,	O
whereas	O
eukaryotic	O
phytoplankton	O
showed	O
positive	O
net	O
growth	O
(	O
∼0.5-0.6	O
day	O
(	O
-1	O
)	O
)	O
,	O
that	O
is	O
,	O
growth	O
available	O
to	O
support	O
larger	O
(	O
mesozooplankton	O
)	O
consumer	O
biomass	O
.	O

These	O
are	O
the	O
first	O
group-specific	O
phytoplankton	O
rate	O
estimates	O
in	O
this	O
region	O
,	O
and	O
they	O
demonstrate	O
that	O
integrated	O
primary	O
production	O
is	O
high	O
,	O
exceeding	O
1	O
g	O
C	O
m	O
(	O
-2	O
)	O
day	O
(	O
-1	O
)	O
on	O
average	O
,	O
even	O
during	O
a	O
period	O
of	O
reduced	O
upwelling	O
.	O

An	O
electrochemically	B-P
reduced	I-P
graphene	O
oxide	O
chemiresistive	O
sensor	O
for	O
sensitive	O
detection	O
of	O
Hg	O
(	O
2+	O
)	O
ion	O
in	O
water	O
samples	O
.	O

Divalent	O
mercuric	O
(	O
Hg	O
(	O
2+	O
)	O
)	O
ion	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
forms	O
of	O
mercury	O
species	O
in	O
waters	O
with	O
high	O
toxicity	O
and	O
bioaccumulation	O
in	O
the	O
human	O
body	O
,	O
for	O
which	O
sensitive	O
and	O
selective	O
detection	O
methods	O
are	O
highly	O
necessary	O
to	O
carry	O
out	O
its	O
recognition	O
and	O
quantification	O
.	O

Here	O
an	O
electrochemically	B-P
reduced	I-P
graphene	O
oxide	O
(	O
RGO	O
)	O
based	O
chemiresistive	O
sensor	O
was	O
constructed	O
and	O
used	O
for	O
the	O
detection	O
of	O
Hg	O
(	O
2+	O
)	O
ion	O
in	O
various	O
water	O
samples	O
.	O

Monolayer	O
GO	O
sheets	O
were	O
assembled	O
onto	O
interdigitated	O
electrodes	O
,	O
followed	O
by	O
reduction	O
through	O
linear	O
sweep	O
voltammetry	O
and	O
then	O
modification	O
with	O
a	O
single-stranded	O
DNA	O
aptamer	O
.	O

The	O
electrochemically	B-P
derived	O
RGO	O
based	O
sensor	O
showed	O
selective	O
response	O
to	O
as	O
low	O
as	O
0.5nM	O
Hg	O
(	O
2+	O
)	O
ion	O
in	O
presence	O
of	O
other	O
metal	O
ions	O
and	O
matrices	O
.	O

A	O
comparison	O
between	O
chemiresistive	O
sensors	O
prepared	O
with	O
electrochemically	B-P
and	O
chemically	O
derived	O
RGO	O
showed	O
that	O
the	O
former	O
had	O
better	O
response	O
performance	O
for	O
sensing	O
Hg	O
(	O
2+	O
)	O
ion	O
.	O

The	O
proposed	O
method	O
provides	O
a	O
simple	O
tool	O
for	O
rapid	O
,	O
selective	O
and	O
sensitive	O
monitoring	O
of	O
Hg	O
(	O
2+	O
)	O
ion	O
in	O
environmental	O
samples	O
.	O

Extended	O
Release	O
Guanfacine	O
in	O
Pediatric	O
Anxiety	O
Disorders	O
:	O
A	O
Pilot	O
,	O
Randomized	O
,	O
Placebo-Controlled	O
Trial	O
.	O

This	O
is	O
a	O
feasibility	O
study	O
evaluating	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
potential	O
anxiolytic	O
efficacy	O
of	O
the	O
α2	O
agonist	O
guanfacine	O
extended-release	O
(	O
GXR	O
)	O
in	O
children	O
and	O
adolescents	O
with	O
generalized	O
anxiety	O
disorder	O
(	O
GAD	O
)	O
,	O
separation	O
anxiety	O
disorder	O
(	O
SAD	O
)	O
,	O
or	O
social	O
phobia	O
/	O
social	O
anxiety	O
disorder	O
.	O

Youth	O
aged	O
6-17	O
years	O
with	O
a	O
primary	O
diagnosis	O
of	O
GAD	O
,	O
SAD	O
,	O
and/or	O
social	O
anxiety	O
disorder	O
were	O
treated	B-P
with	I-P
flexibly	O
dosed	O
GXR	O
(	O
1-6	O
mg	O
daily	O
,	O
n	O
=	O
62	O
)	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
for	O
12	O
weeks	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
GXR	O
in	O
youth	O
with	O
anxiety	O
disorders	O
,	O
which	O
involved	O
the	O
analysis	O
of	O
treatment	B-P
-	O
emergent	O
adverse	O
events	O
(	O
TEAEs	O
)	O
,	O
the	O
emergence	O
of	O
suicidal	O
ideation	O
and	O
behaviors	O
,	O
vital	O
signs	O
,	O
and	O
electrocardiographic	B-P
/	O
laboratory	O
parameters	O
.	O

Exploratory	O
efficacy	O
measures	O
included	O
dimensional	O
anxiety	O
scales	O
(	O
Pediatric	O
Anxiety	O
Rating	O
Scale	O
[	O
PARS	O
]	O
and	O
Screen	O
for	O
Child	O
Anxiety	O
Related	O
Emotional	O
Disorders	O
[	O
SCARED	O
]	O
)	O
,	O
as	O
well	O
as	O
the	O
Clinical	O
Global	O
Impression-Improvement	O
(	O
CGI-I	O
)	O
scale	O
.	O

As	O
this	O
was	O
an	O
exploratory	O
study	O
,	O
no	O
inferential	O
statistical	O
analyses	O
were	O
performed	O
.	O

GXR	O
was	O
safe	O
and	O
well	O
tolerated	O
.	O

Treatment	B-P
-related	O
mean	O
±	O
standard	O
deviation	O
changes	O
in	O
heart	O
rate	O
(	O
GXR	O
:	O
1.8	O
±	O
12	O
beats	O
per	O
minute	O
[	O
bpm	O
]	O
decrease	O
;	O
placebo	O
:	O
0.5	O
±	O
11	O
bpm	O
decrease	O
)	O
,	O
systolic	O
blood	O
pressure	O
(	O
GXR	O
:	O
2.3	O
±	O
11	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
1.7	O
±	O
11	O
mm	O
Hg	O
decrease	O
)	O
,	O
or	O
diastolic	O
blood	O
pressure	O
(	O
GXR	O
:	O
1.3	O
±	O
9	O
mm	O
Hg	O
decrease	O
;	O
placebo	O
:	O
0.9	O
±	O
7	O
mm	O
Hg	O
increase	O
)	O
were	O
similar	O
between	O
treatment	B-P
groups	O
.	O

TEAEs	O
,	O
including	O
headache	O
,	O
somnolence	O
/	O
fatigue	O
,	O
abdominal	O
pain	O
,	O
and	O
dizziness	O
,	O
were	O
consistent	O
with	O
the	O
known	O
safety	O
profile	O
of	O
GXR	O
.	O

No	O
differences	O
were	O
observed	O
between	O
treatment	B-P
groups	O
for	O
PARS	O
and	O
SCARED	O
scores	O
,	O
although	O
at	O
endpoint	O
,	O
a	O
higher	O
proportion	O
of	O
subjects	O
receiving	O
GXR	O
versus	O
placebo	O
demonstrated	O
CGI-I	O
scores	O
≤2	O
(	O
54.2	O
%	O
vs.	O
31.6	O
%	O
)	O
,	O
as	O
rated	O
by	O
the	O
clinician	O
investigator	O
.	O

GXR	O
was	O
well	O
tolerated	O
in	O
pediatric	O
subjects	O
with	O
GAD	O
,	O
SAD	O
,	O
and/or	O
social	O
anxiety	O
disorder	O
.	O

ClinicalTrials.gov	O
Identifier	O
:	O
NCT01470469	O
.	O

High	B-P
throughput	I-P
selection	O
of	O
antibiotic-resistant	O
transgenic	O
Arabidopsis	O
plants	O
.	O

Kanamycin	O
resistance	O
is	O
the	O
most	O
frequently	O
used	O
antibiotic-resistance	O
marker	O
for	O
Arabidopsis	O
transformations	O
,	O
however	O
,	O
this	O
method	O
frequently	O
causes	O
escape	O
of	O
untransformed	O
plants	O
,	O
particularly	O
at	O
the	O
high	O
seedling	O
density	O
during	O
the	O
selection	O
.	O

Here	O
we	O
developed	O
a	O
robust	O
high	O
-	O
density	O
selection	O
method	O
using	O
top	O
agar	O
for	O
Arabidopsis	O
thaliana	O
.	O

Top	O
agar	O
effectively	O
suppressed	O
growth	O
of	O
untransformed	O
wild-type	O
plants	O
on	O
selection	O
media	O
at	O
high	O
density	O
.	O

Survival	O
of	O
the	O
transformed	O
plants	O
during	O
the	O
selection	O
were	O
confirmed	O
by	O
production	O
of	O
green	O
true	O
leaves	O
and	O
expression	O
of	O
a	O
firefly	O
luciferase	O
reporter	O
gene	O
.	O

Top	O
agar	O
method	O
allowed	O
selection	O
using	O
a	O
large	O
amount	O
of	O
seeds	O
in	O
Arabidopsis	O
transformation	O
.	O

Predicting	O
frequent	O
hospital	O
admission	O
risk	O
in	O
Singapore	O
:	O
a	O
retrospective	O
cohort	O
study	O
to	O
investigate	O
the	O
impact	O
of	O
comorbidities	O
,	O
acute	O
illness	O
burden	O
and	O
social	O
determinants	O
of	O
health	O
.	O

To	O
evaluate	O
the	O
impact	O
of	O
comorbidities	O
,	O
acute	O
illness	O
burden	O
and	O
social	O
determinants	O
of	O
health	O
on	O
predicting	O
the	O
risk	O
of	O
frequent	O
hospital	O
admissions	O
.	O

Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
associate	O
the	O
predictive	O
variables	O
extracted	O
from	O
electronic	O
health	O
records	O
and	O
frequent	O
hospital	O
admission	O
risk	O
.	O

The	O
model	O
's	O
performance	O
of	O
our	O
predictive	O
model	O
was	O
evaluated	O
using	O
a	O
10-fold	O
cross-validation	O
.	O

A	O
single	O
tertiary	O
hospital	O
in	O
Singapore	O
.	O

All	O
adult	O
patients	O
admitted	O
to	O
the	O
hospital	O
between	O
1	O
January	O
2013	O
and	O
31	O
May	O
2014	O
(	O
n=25	O
244	O
)	O
.	O

Frequent	O
hospital	O
admissions	O
,	O
defined	O
as	O
3	O
or	O
more	O
inpatient	O
admissions	O
within	O
12	O
months	O
of	O
discharge	O
.	O

Ar	O
ea	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AUC	O
)	O
of	O
the	O
predictive	O
model	O
,	O
and	O
the	O
sensitivity	O
,	O
specificity	O
and	O
positive	O
predictive	O
values	O
for	O
various	O
cut-offs	O
.	O

4322	O
patients	O
(	O
17.1	O
%	O
)	O
met	O
the	O
primary	O
outcome	O
.	O

11	O
variables	O
were	O
observed	O
as	O
significant	O
predictors	O
and	O
included	O
in	O
the	O
final	O
regression	O
model	O
.	O

The	O
strongest	O
independent	O
predictor	O
was	O
treatment	B-P
with	O
antidepressants	O
in	O
the	O
past	O
1	O
year	O
(	O
adjusted	O
OR	O
2.51	O
,	O
95	O
%	O
CI	O
2.26	O
to	O
2.78	O
)	O
.	O

Other	O
notable	O
predictors	O
include	O
requiring	O
dialysis	B-P
and	O
treatment	B-P
with	O
intravenous	O
furosemide	O
during	O
the	O
index	O
admission	O
.	O

The	O
predictive	O
model	O
achieved	O
an	O
AUC	O
of	O
0.84	O
(	O
95	O
%	O
CI	O
0.83	O
to	O
0.85	O
)	O
for	O
predicting	O
frequent	O
hospital	O
admission	O
risk	O
,	O
with	O
a	O
sensitivity	O
of	O
73.9	O
%	O
(	O
95	O
%	O
CI	O
72.6	O
%	O
to	O
75.2	O
%	O
)	O
,	O
specificity	O
of	O
79.1	O
%	O
(	O
78.5	O
%	O
to	O
79.6	O
%	O
)	O
and	O
positive	O
predictive	O
value	O
of	O
42.2	O
%	O
(	O
95	O
%	O
CI	O
41.1	O
%	O
to	O
43.3	O
%	O
)	O
at	O
the	O
cut-off	O
of	O
0.235	O
.	O

We	O
have	O
identified	O
several	O
predictors	O
for	O
assessing	O
the	O
risk	O
of	O
frequent	O
hospital	O
admissions	O
that	O
achieved	O
high	O
discriminative	O
model	O
performance	O
.	O

Further	O
research	O
is	O
necessary	O
using	O
an	O
external	O
validation	O
cohort	O
.	O

Comparing	O
the	O
effects	O
of	O
different	O
dynamic	B-P
sitting	I-P
strategies	I-P
in	O
wheelchair	O
seating	O
on	O
lumbar-pelvic	O
angle	O
.	O

Prolonged	O
static	O
sitting	O
in	O
a	O
wheelchair	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
lower	O
back	O
pain	O
.	O

The	O
wheelchair	O
seating	O
system	O
is	O
a	O
key	O
factor	O
of	O
this	O
risk	O
because	O
it	O
affects	O
spinal	O
loading	O
in	O
the	O
sitting	O
position	O
.	O

In	O
this	O
study	O
,	O
7	O
dynamic	B-P
sitting	I-P
strategies	I-P
(	O
DSSs	B-P
)	O
are	O
examined	O
:	O
lumbar	B-P
prominent	I-P
dynamic	I-P
sitting	I-P
(	O
LPDS	B-P
)	O
,	O
back	B-P
reclined	I-P
dynamic	I-P
sitting	I-P
(	O
BRDS	B-P
)	O
,	O
femur	B-P
upward	I-P
dynamic	I-P
sitting	I-P
(	O
FUDS	B-P
)	O
,	O
lumbar	B-P
prominent	I-P
with	I-P
back	I-P
reclined	I-P
dynamic	I-P
sitting	I-P
(	O
LBDS	B-P
)	O
,	O
lumbar	B-P
prominent	I-P
with	I-P
femur	I-P
upward	I-P
dynamic	I-P
sitting	I-P
(	O
LFDS	B-P
)	O
,	O
back	B-P
reclined	I-P
with	I-P
femur	I-P
upward	I-P
dynamic	I-P
sitting	I-P
(	O
BFDS	B-P
)	O
,	O
and	O
lumbar	B-P
prominent	I-P
with	I-P
back	I-P
reclined	I-P
with	I-P
femur	I-P
upward	I-P
dynamic	I-P
sitting	I-P
(	O
LBFDS	B-P
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
biomechanical	O
effects	O
of	O
these	O
sitting	B-P
strategies	I-P
on	O
lumbar-pelvic	O
angles	O
.	O

Twenty	O
able-bodied	O
participants	O
were	O
recruited	O
for	O
the	O
study	O
.	O

All	O
participants	O
performed	O
LPDS	B-P
,	O
BRDS	B-P
,	O
FUDS	B-P
,	O
LBDS	B-P
,	O
LFDS	B-P
,	O
BFDS	B-P
,	O
and	O
LBFDS	B-P
in	O
a	O
random	O
order	O
.	O

All	O
lumbar-pelvic	O
angle	O
parameters	O
,	O
including	O
the	O
static	O
lumbar	O
angle	O
,	O
static	O
pelvic	O
angle	O
,	O
lumbar	O
range	O
of	O
motion	O
,	O
and	O
pelvic	O
range	O
of	O
motion	O
were	O
measured	O
and	O
compared	O
.	O

Results	O
show	O
that	O
LBDS	B-P
and	O
LBFDS	B-P
enabled	O
the	O
most	O
beneficial	O
lumbar	O
movements	O
,	O
although	O
the	O
difference	O
between	O
the	O
2	O
strategies	O
was	O
nonsignificant	O
.	O

BRDS	B-P
and	O
BFDS	B-P
enabled	O
the	O
most	O
beneficial	O
pelvic	B-P
movements	I-P
,	O
although	O
the	O
difference	O
between	O
the	O
2	O
strategies	O
was	O
nonsignificant	O
.	O

Among	O
all	O
the	O
upright	O
DSSs	B-P
,	O
LPDS	B-P
and	O
LFDS	B-P
enabled	O
the	O
most	O
beneficial	O
lumbar	O
and	O
pelvic	B-P
movements	I-P
,	O
although	O
no	O
significant	O
difference	O
was	O
observed	O
between	O
these	O
2	O
strategies	O
.	O

We	O
identified	O
the	O
effects	O
and	O
differences	O
among	O
7	O
DSSs	B-P
on	O
lumbar-pelvic	O
angles	O
.	O

Wheelchair	O
users	O
can	O
choose	O
the	O
most	O
suitable	O
DSS	B-P
that	O
meets	O
their	O
needs	O
.	O

These	O
findings	O
may	O
serve	O
as	O
a	O
reference	O
for	O
practicing	O
physicians	O
or	O
wheelchair	O
users	O
to	O
choose	O
an	O
appropriate	O
dynamic	O
wheelchair	O
seating	O
system	O
.	O

ISRCTN12389808	O
,	O
18th	O
November	O
2016	O
,	O
retrospectively	O
registered	O
.	O

Sonochemical	O
Effect	O
on	O
Activity	O
and	O
Conformation	O
of	O
Commercial	O
Lipases	O
.	O

The	O
enzyme	O
under	O
lower-intensity	O
ultrasonic	O
irradiation	O
leads	O
to	O
favourable	O
conformational	O
changes	O
,	O
thereby	O
enhancing	O
its	O
activity	O
.	O

The	O
augmentation	O
of	O
activity	O
of	O
ultrasound	O
-	O
treated	O
enzyme	O
is	O
strongly	O
dependent	O
on	O
ultrasound	O
intensity	O
,	O
duty	O
cycle	O
and	O
exposure	O
time	O
,	O
which	O
was	O
investigated	O
for	O
commercial	O
lipases	O
.	O

Thermomyces	O
lanuginosus	O
(	O
TL	O
)	O
lipase	O
showed	O
a	O
1.3-fold	O
enhanced	O
activity	O
after	O
irradiating	O
at	O
22	O
kHz	O
and	O
11.38	O
W	O
cm	O
(	O
-2	O
)	O
with	O
50	O
%	O
duty	O
cycle	O
for	O
25-min	O
ultrasonic	O
treatment	O
and	O
1.5-fold	O
enhanced	O
activity	O
was	O
observed	O
for	O
lipozyme	O
(	O
candida	O
antarctica	O
lipase	O
B	O
(	O
CALB	O
)	O
)	O
lipase	O
,	O
at	O
22	O
kHz	O
and	O
15.48	O
W	O
cm	O
(	O
-2	O
)	O
with	O
66.67	O
%	O
duty	O
cycle	O
for	O
20-min	O
ultrasonic	O
treatment	O
.	O

After	O
sonication	O
,	O
thermodynamic	O
parameters	O
viz	O
.	O

E	O
a	O
,	O
ΔH	O
,	O
ΔS	O
and	O
ΔG	O
were	O
evaluated	O
and	O
values	O
were	O
found	O
to	O
be	O
significantly	O
lower	O
for	O
both	O
lipases	O
.	O

In	O
addition	O
,	O
the	O
changes	O
in	O
secondary	O
structure	O
due	O
to	O
sonication	O
were	O
investigated	O
by	O
using	O
Fourier	B-P
transform	I-P
infrared	I-P
(	O
FT-IR	B-P
)	O
,	O
which	O
revealed	O
increase	O
in	O
a	O
certain	O
number	O
of	O
random	O
coiled	O
structure	O
,	O
loss	O
of	O
β-sheets	O
,	O
β-turns	O
and	O
α-helix	O
content	O
in	O
TL	O
lipase	O
and	O
CALB	O
lipase	O
.	O

Also	O
,	O
fluorescence	B-P
spectroscopy	I-P
exhibited	O
the	O
increased	O
number	O
of	O
tryptophan	O
on	O
surface	O
of	O
both	O
lipases	O
.	O

Moreover	O
,	O
particle	O
size	O
distribution	O
after	O
sonication	O
also	O
helped	O
to	O
improve	O
surface	O
area	O
and	O
enhanced	O
mass	O
transfer	O
,	O
which	O
contributed	O
to	O
improvement	O
in	O
lipase	O
activity	O
.	O

Dynamic	B-P
CT	I-P
myocardial	I-P
perfusion	I-P
imaging	I-P
identifies	O
early	O
perfusion	O
abnormalities	O
in	O
diabetes	O
and	O
hypertension	O
:	O
Insights	O
from	O
a	O
multicenter	O
registry	O
.	O

To	O
identify	O
patients	O
with	O
early	O
signs	O
of	O
myocardial	O
perfusion	O
reduction	O
,	O
a	O
reference	O
base	O
for	O
perfusion	O
measures	O
is	O
needed	O
.	O

To	O
analyze	O
perfusion	O
parameters	O
derived	O
from	O
dynamic	B-P
computed	I-P
tomography	I-P
perfusion	I-P
imaging	I-P
(	O
CTPI	B-P
)	O
in	O
patients	O
with	O
suspected	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
,	O
and	O
relationship	O
with	O
risk	O
factors	O
.	O

In	O
this	O
multicenter	O
study	O
,	O
coronary	B-P
CT	I-P
angiography	I-P
(	O
cCTA	B-P
)	O
and	O
dynamic	B-P
CTPI	I-P
were	O
performed	O
by	O
second-generation	B-P
dual-source	I-P
CT	I-P
in	O
patients	O
suspected	O
of	O
CAD	O
.	O

Risk	O
factors	O
were	O
collected	O
from	O
hospital	O
records	O
.	O

Patients	O
with	O
visual	O
perfusion	O
defects	O
on	O
CTPI	B-P
,	O
previous	O
coronary	B-P
intervention	I-P
,	O
or	O
missing	O
risk	O
factor	O
details	O
were	O
excluded	O
.	O

This	O
analysis	O
included	O
98	O
patients	O
(	O
mean	O
age	O
±	O
standard	O
deviation	O
[	O
SD	O
]	O
,	O
59.0	O
±	O
8.6yrs	O
;	O
73	O
male	O
)	O
.	O

Global	O
measures	O
of	O
left	O
ventricular	O
myocardial	O
blood	O
flow	O
(	O
MBF	O
)	O
,	O
myocardial	O
blood	O
volume	O
(	O
MBV	O
)	O
and	O
volume	O
transfer	O
constant	O
(	O
K	O
(	O
trans	O
)	O
)	O
were	O
calculated	O
.	O

Mean	O
MBF	O
was	O
139.3	O
±	O
31.4	O
mL/100	O
mL/min	O
,	O
MBV	O
19.1	O
±	O
2.7	O
mL/100	O
mL	O
,	O
and	O
Ktrans	O
85.0	O
±	O
17.5	O
mL/100	O
mL/min	O
.	O

No	O
significant	O
differences	O
in	O
perfusion	O
parameters	O
were	O
found	O
by	O
gender	O
or	O
age	O
category	O
.	O

Hypertension	O
and	O
diabetes	O
mellitus	O
resulted	O
in	O
lower	O
perfusion	O
parameters	O
(	O
hypertension	O
vs	O
normotension	O
:	O
MBV	O
18.5	O
±	O
3.0	O
vs	O
19.7	O
±	O
2.3	O
mL/100	O
mL	O
and	O
K	O
(	O
trans	O
)	O
82.0	O
±	O
18.0	O
vs	O
89.0	O
±	O
16.0	O
,	O
p	O
<	O
0.05	O
;	O
diabetes	O
vs	O
no	O
diabetes	O
:	O
MBF	O
128.5	O
±	O
31.5	O
vs	O
144.0	O
±	O
30.5	O
mL/100	O
mL/min	O
and	O
MBV	O
17.9	O
±	O
2.4	O
vs	O
19.4	O
±	O
2.8	O
mL/100	O
mL	O
,	O
p	O
<	O
0.05	O
)	O
.	O

In	O
patients	O
with	O
hyperlipidemia	O
,	O
MBF	O
was	O
higher	O
(	O
146.8	O
±	O
34.4	O
vs	O
130.7	O
±	O
24.3	O
mL/100	O
mL/min	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Smoking	O
and	O
family	O
history	O
did	O
not	O
show	O
perfusion	O
parameter	O
differences	O
.	O

Dynamic	B-P
CTPI	I-P
identifies	O
early	O
perfusion	O
disturbances	O
in	O
conditions	O
like	O
diabetes	O
and	O
hypertension	O
.	O

With	O
further	O
standardization	O
,	O
absolute	O
perfusion	O
measures	O
may	O
improve	O
CAD	O
risk	O
stratification	O
in	O
patients	O
without	O
visual	O
perfusion	O
defects	O
.	O

Corn	O
oil	O
intake	O
favorably	O
impacts	O
lipoprotein	O
cholesterol	O
,	O
apolipoprotein	B-P
and	O
lipoprotein	B-P
particle	O
levels	O
compared	O
with	O
extra-virgin	O
olive	O
oil	O
.	O

Corn	O
oil	O
(	O
CO	O
)	O
and	O
extra-virgin	O
olive	O
oil	O
(	O
EVOO	O
)	O
are	O
rich	O
sources	O
of	O
unsaturated	O
fatty	O
acids	O
(	O
UFA	O
)	O
,	O
but	O
UFA	O
profiles	O
differ	O
among	O
oils	O
,	O
which	O
may	O
affect	O
lipoprotein	B-P
levels	I-P
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
CO	O
versus	O
EVOO	O
intake	O
on	O
fasting	O
lipoprotein	B-P
and	O
subfraction	O
cholesterol	B-P
levels	I-P
,	O
apolipoprotein	B-P
(	I-P
apo	I-P
)	I-P
A1	I-P
,	O
apo	B-P
B	I-P
,	O
and	O
low-density	B-P
lipoprotein	I-P
particle	O
concentrations	O
in	O
men	O
and	O
women	O
.	O

As	O
part	O
of	O
a	O
weight	B-P
maintenance	I-P
diet	I-P
,	O
men	O
and	O
women	O
were	O
provided	O
with	O
food	O
items	O
prepared	O
with	O
54	O
g	O
per	O
day	O
of	O
CO	O
or	O
EVOO	O
(	O
21-day	O
treatment	O
,	O
21-day	O
washout	O
)	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
controlled-feeding	O
,	O
crossover	O
trial	O
.	O

Fasting	O
lipoprotein	O
cholesterol	O
and	O
related	O
variables	O
were	O
determined	O
with	O
density	B-P
gradient	I-P
ultracentrifugation	I-P
.	O

Among	O
the	O
54	O
completers	O
,	O
CO	O
reduced	O
total	O
cholesterol	O
,	O
low-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
LDL-C	B-P
)	O
,	O
very	B-P
low-density	I-P
lipoprotein	I-P
cholesterol	I-P
(	O
VLDL-C	B-P
)	O
,	O
non-high-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
non-HDL-C	B-P
)	O
,	O
apo	B-P
B	I-P
and	O
LDL	B-P
particle	O
concentration	O
to	O
a	O
greater	O
extent	O
compared	O
with	O
EVOO	O
intake	O
.	O

Changes	O
in	O
LDL-C	B-P
and	O
VLDL-C	B-P
contributed	O
to	O
the	O
larger	O
reduction	O
in	O
non-HDL-C	B-P
with	O
CO	O
compared	O
with	O
EVOO	O
intake	O
(	O
-0.39	O
mmol/l	O
vs	O
-0.04	O
mmol/l	O
;	O
P	O
<	O
0.001	O
)	O
.	O

The	O
larger	O
reduction	O
in	O
LDL-C	B-P
by	O
CO	O
intake	O
was	O
attributable	O
to	O
changes	O
(	O
P	O
<	O
0.05	O
)	O
caused	O
by	O
CO	O
vs	O
EVOO	O
in	O
large	O
LDL1+2-C	B-P
(	O
-0.22	O
mmol/l	O
)	O
and	O
intermediate-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
-0.12	O
mmol/l	O
)	O
.	O

HDL-C	B-P
responses	O
did	O
not	O
differ	O
between	O
treatments	O
,	O
but	O
apo	B-P
A1	I-P
increased	O
more	O
with	O
EVOO	O
compared	O
with	O
CO	O
intake	O
(	O
4.6	O
versus	O
0.7	O
mg/dl	O
,	O
respectively	O
,	O
P=0.016	O
)	O
.	O

CO	O
intake	O
reduced	O
atherogenic	O
lipoprotein	O
cholesterol	O
and	O
particle	O
concentrations	O
to	O
a	O
larger	O
extent	O
than	O
did	O
EVOO	O
,	O
which	O
may	O
have	O
implications	O
for	O
cardiovascular	O
disease	O
risk	O
.	O

Multi-hospital	O
occurrence	O
of	O
pan-resistant	O
Klebsiella	O
pneumoniae	O
ST147	O
with	O
an	O
ISEcp1	O
-directed	O
blaOXA-181	O
insertion	O
into	O
the	O
mgrB	O
gene	O
in	O
the	O
United	O
Arab	O
Emirates	O
.	O

The	O
emergence	O
of	O
pan-resistant	O
Klebsiella	O
pneumoniae	O
strains	O
is	O
an	O
increasing	O
concern	O
.	O

In	O
the	O
current	O
study	O
we	O
describe	O
a	O
cluster	O
of	O
9	O
pan-resistant	O
K.	O
pneumoniae	O
ST147	O
isolates	O
encountered	O
in	O
4	O
patients	O
over	O
nearly	O
one	O
year	O
in	O
3	O
hospitals	O
of	O
the	O
United	O
Arab	O
Emirates	O
.	O

The	O
isolates	O
exhibited	O
highly	O
similar	O
genotypes	O
.	O

All	O
produced	O
chromosomally	O
encoded	O
OXA-181	O
and	O
the	O
majority	O
also	O
produced	O
the	O
NDM-5	O
carbapenemase	O
.	O

Similarly	O
to	O
the	O
previously	O
described	O
single	O
isolate	O
from	O
the	O
UAE	O
,	O
MS6671	O
,	O
the	O
mgrB	O
was	O
disrupted	O
by	O
a	O
functional	O
,	O
ISEcp1	O
-driven	O
blaOXA-181	O
insertion	O
causing	O
resistance	O
to	O
carbapenems	O
.	O

The	O
mutation	O
was	O
successfully	O
complemented	O
with	O
an	O
intact	O
mgrB	O
gene	O
indicating	O
that	O
it	O
was	O
responsible	O
for	O
colistin	O
resistance	O
.	O

blaNDM-5	O
was	O
located	O
within	O
a	O
resistance	O
island	O
of	O
an	O
approximately	O
100	O
kb	O
IncFII	O
plasmid	O
carrying	O
ermB	O
,	O
mph	O
(	O
A	O
)	O
,	O
blaTEM-1B	O
,	O
rmtB	O
,	O
blaNDM-5	O
,	O
sul1	O
,	O
aadA2	O
and	O
dfrA12	O
resistance	O
genes	O
.	O

Sequencing	B-P
this	O
plasmid	O
(	O
pABC143-NDM	O
)	O
revealed	O
that	O
its	O
backbone	O
was	O
nearly	O
identical	O
to	O
that	O
of	O
plasmid	O
pMS6671E	O
from	O
which	O
several	O
resistance	O
genes	O
,	O
including	O
blaNDM-5	O
,	O
had	O
been	O
deleted	O
.	O

More	O
extensive	O
similarities	O
of	O
the	O
backbone	O
and	O
the	O
resistance	O
island	O
were	O
found	O
between	O
pABC143C-NDM	O
and	O
the	O
blaNDM-5	O
carrying	O
IncFII	O
plasmids	O
of	O
two	O
K.	O
pneumoniae	O
ST147	O
isolates	O
from	O
South	O
Korea	O
,	O
one	O
of	O
which	O
was	O
colistin	O
resistant	O
,	O
and	O
both	O
also	O
produced	O
OXA-181	O
.	O

Notably	O
one	O
of	O
these	O
strains	O
was	O
isolated	O
from	O
a	O
patient	O
transferred	O
from	O
the	O
UAE	O
.	O

Our	O
data	O
show	O
that	O
this	O
pan-resistant	O
clone	O
has	O
an	O
alarming	O
capacity	O
to	O
maintain	O
itself	O
over	O
an	O
extended	O
period	O
of	O
time	O
,	O
and	O
even	O
likely	O
to	O
be	O
transmitted	O
internationally	O
.	O

Proteome	O
changes	O
in	O
rat	O
serum	O
after	O
a	O
chronic	O
ingestion	O
of	O
enriched	O
uranium	O
:	O
Toward	O
a	O
biological	O
signature	O
of	O
internal	O
contamination	O
and	O
radiological	O
effect	O
.	O

The	O
civilian	O
and	O
military	O
use	O
of	O
uranium	O
results	O
in	O
an	O
increased	O
risk	O
of	O
human	O
exposure	O
.	O

The	O
toxicity	O
of	O
uranium	O
results	O
from	O
both	O
its	O
chemical	O
and	O
radiological	O
properties	O
that	O
vary	O
with	O
isotopic	O
composition	O
.	O

Validated	O
biomarkers	O
of	O
health	O
effects	O
associated	O
with	O
exposure	O
to	O
uranium	O
are	O
neither	O
sensitive	O
nor	O
specific	O
to	O
uranium	O
radiotoxicity	O
and/or	O
radiological	O
effect	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
if	O
serum	O
proteins	O
could	O
be	O
useful	O
as	O
biomarkers	O
of	O
both	O
uranium	O
exposure	O
and	O
radiological	O
effect	O
.	O

Male	O
Sprague-Dawley	O
rats	O
were	O
chronically	O
exposed	O
through	O
drinking	O
water	O
to	O
low	O
levels	O
(	O
40mg/L	O
,	O
corresponding	O
to	O
1mg	O
of	O
uranium	O
per	O
animal	O
per	O
day	O
)	O
of	O
either	O
4	O
%	O
(	O
235	O
)	O
U-enriched	O
uranium	O
(	O
EU	O
)	O
or	O
12	O
%	O
EU	O
during	O
6	O
weeks	O
.	O

A	O
proteomics	O
approach	O
based	O
on	O
two-dimensional	O
electrophoresis	O
(	O
2D-DIGE	B-P
)	O
and	O
mass	B-P
spectrometry	I-P
(	O
MS	B-P
)	O
was	O
used	O
to	O
establish	O
protein	O
expression	O
profiles	B-P
that	O
could	O
be	O
relevant	O
for	O
discriminating	O
between	O
groups	O
,	O
and	O
to	O
identify	O
some	O
differentially	O
expressed	O
proteins	O
following	O
uranium	O
ingestion	O
.	O

It	O
demonstrated	O
that	O
the	O
expressions	O
of	O
174	O
protein	O
spots	O
over	O
1045	O
quantified	O
spots	O
were	O
altered	O
after	O
uranium	O
exposure	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Using	O
both	O
inferential	O
and	O
non-supervised	O
multivariate	O
statistics	O
,	O
we	O
show	O
sets	O
of	O
spots	O
features	O
that	O
lead	O
to	O
a	O
clear	O
discrimination	O
between	O
controls	O
and	O
EU	O
exposed	O
groups	O
on	O
the	O
one	O
hand	O
(	O
21	O
spots	O
)	O
,	O
and	O
between	O
4	O
%	O
EU	O
and	O
12	O
%	O
EU	O
on	O
the	O
other	O
hand	O
(	O
7	O
spots	O
)	O
,	O
showing	O
that	O
investigation	O
of	O
the	O
serum	O
proteome	O
may	O
possibly	O
be	O
of	O
relevance	O
to	O
address	O
both	O
uranium	O
contamination	O
and	O
radiological	O
effect	O
.	O

Finally	O
,	O
using	O
bioinformatics	O
tools	O
,	O
pathway	O
analyses	O
of	O
differentially	O
expressed	O
MS	B-P
-	O
identified	O
proteins	O
find	O
that	O
acute	O
phase	O
,	O
inflammatory	O
and	O
immune	O
responses	O
as	O
well	O
as	O
oxidative	O
stress	O
are	O
likely	O
involved	O
in	O
the	O
response	O
to	O
contamination	O
,	O
suggesting	O
a	O
physiological	O
perturbation	O
,	O
but	O
that	O
does	O
not	O
necessarily	O
lead	O
to	O
a	O
toxic	O
effect	O
.	O

Characterization	O
of	O
electrocorticogram	B-P
high	O
-	O
gamma	O
signal	O
in	O
response	O
to	O
varying	O
upper	O
extremity	O
movement	O
velocity	O
.	O

The	O
mechanism	O
by	O
which	O
the	O
human	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
encodes	O
upper	O
extremity	O
movement	O
kinematics	O
is	O
not	O
fully	O
understood	O
.	O

For	O
example	O
,	O
human	O
electrocorticogram	B-P
(	O
ECoG	B-P
)	O
signals	O
have	O
been	O
shown	O
to	O
modulate	O
with	O
upper	O
extremity	O
movement	O
s	O
;	O
however	O
,	O
this	O
relationship	O
has	O
not	O
been	O
explicitly	O
characterized	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
recorded	O
high	O
-	O
density	O
ECoG	B-P
signals	O
from	O
patients	O
undergoing	O
epilepsy	O
surgery	B-P
evaluation	O
as	O
they	O
performed	O
elementary	O
upper	O
extremity	O
movements	O
while	O
systematically	O
varying	O
movement	O
speed	O
and	O
duration	O
.	O

Specifically	O
,	O
subjects	O
performed	O
intermittent	O
pincer	O
grasp	O
/	O
release	O
,	O
elbow	O
flexion	O
/	O
extension	O
,	O
and	O
shoulder	O
flexion	O
/	O
extension	O
at	O
slow	O
,	O
moderate	O
,	O
and	O
fast	O
speeds	O
.	O

In	O
all	O
movements	O
,	O
bursts	O
of	O
power	O
in	O
the	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
band	O
(	O
80-160	O
Hz	O
)	O
were	O
observed	O
in	O
M1	O
.	O

In	O
addition	O
,	O
the	O
amplitude	O
of	O
these	O
power	O
bursts	O
and	O
the	O
area	O
of	O
M1	O
with	O
elevated	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
were	O
directly	O
proportional	O
to	O
the	O
movement	O
speed	O
.	O

Likewise	O
,	O
the	O
duration	O
of	O
elevated	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
increased	O
with	O
movement	O
duration	O
.	O

Based	O
on	O
linear	O
regression	O
,	O
M1	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
power	O
amplitude	O
and	O
duration	O
covaried	O
with	O
movement	O
speed	O
and	O
duration	O
,	O
respectively	O
,	O
with	O
an	O
average	O
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
encoding	O
of	O
upper	O
extremity	O
movement	O
speed	O
by	O
M1	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
is	O
primarily	O
linear	O
.	O

Also	O
,	O
the	O
fact	O
that	O
this	O
activity	O
remained	O
elevated	O
throughout	O
a	O
movement	O
suggests	O
that	O
M1	O
does	O
not	O
merely	O
generate	O
transient	O
instructions	O
for	O
a	O
specific	O
movement	O
duration	O
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	O
of	O
the	O
movement	O
.	O

Finally	O
,	O
the	O
spatial	O
distribution	O
of	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
suggests	O
the	O
presence	O
of	O
a	O
recruitment	O
phenomenon	O
in	O
which	O
higher	O
speeds	O
or	O
increased	O
muscle	O
activity	O
involve	O
activation	O
of	O
larger	O
M1	O
area	O
s	O
.	O

A	O
prime	O
a	O
day	O
keeps	O
calories	O
away	O
:	O
The	O
effects	O
of	O
supraliminal	O
priming	O
on	O
food	O
consumption	O
and	O
the	O
moderating	O
role	O
of	O
gender	O
and	O
eating	O
restraint	O
.	O

The	O
link	O
between	O
intentions	O
and	O
action	O
in	O
weight	B-P
control	I-P
is	O
weaker	O
than	O
previously	O
thought	O
,	O
so	O
recent	O
research	O
has	O
called	O
for	O
further	O
investigation	O
of	O
ways	O
to	O
improve	O
weight	B-P
control	I-P
that	O
bypass	O
conscious	O
intentions	O
.	O

Priming	O
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
individual	O
behavior	O
in	O
a	O
variety	O
of	O
contexts	O
by	O
influencing	O
subconscious	O
cognition	O
.	O

This	O
paper	O
investigates	O
the	O
effects	O
of	O
semantic	O
priming	O
using	O
healthy	O
body	O
image	O
,	O
goal-oriented	O
words	O
on	O
food	O
consumption	O
.	O

The	O
moderating	O
role	O
of	O
both	O
restrained	O
eating	O
and	O
gender	O
is	O
investigated	O
.	O

161	O
participants	O
were	O
involved	O
in	O
an	O
experiment	O
using	O
a	O
novel	O
version	O
of	O
a	O
scrambled	O
sentence	O
priming	O
game	O
.	O

The	O
outcome	O
measure	O
was	O
the	O
number	O
of	O
kilocalories	O
consumed	B-P
,	O
examined	O
using	O
a	O
between	O
subjects	O
ANCOVA	O
with	O
priming	O
,	O
gender	O
,	O
restrained	O
eating	O
index	O
,	O
self-reported	O
BMI	O
,	O
and	O
two	O
interaction	O
terms	O
(	O
priming	O
x	O
gender	O
,	O
and	O
priming	O
x	O
restrained	O
eating	O
index	O
)	O
.	O

There	O
was	O
no	O
main	O
effect	O
of	O
priming	O
but	O
there	O
was	O
an	O
interaction	O
of	O
priming	O
with	O
gender	O
.	O

Females	O
consumed	O
significantly	O
fewer	O
kilocalories	O
after	O
being	O
exposed	O
to	O
priming	O
words	O
related	O
to	O
a	O
healthy	O
body	O
image	O
(	O
i.e	O
.	O

``	O
slim	O
''	O
,	O
``	O
fit	O
,	O
''	O
)	O
compared	O
to	O
females	O
receiving	O
the	O
neutral	O
prime	O
,	O
with	O
a	O
medium	O
effect	O
size	O
(	O
d	O
=	O
0.58	O
)	O
.	O

The	O
body	O
image	O
prime	O
did	O
not	O
significantly	O
affect	O
food	O
intake	O
for	O
males	O
,	O
nor	O
did	O
it	O
have	O
a	O
differential	O
effect	O
on	O
restrained	O
eaters	O
.	O

This	O
study	O
shows	O
that	O
priming	O
can	O
be	O
an	O
effective	O
method	O
for	O
influencing	O
females	O
to	O
reduce	O
food	O
intake	O
,	O
regardless	O
of	O
whether	O
they	O
are	O
restrained	O
or	O
unrestrained	O
eaters	O
.	O

Future	O
studies	O
could	O
investigate	O
whether	O
different	O
priming	O
words	O
related	O
to	O
a	O
male	O
's	O
healthy	O
body	O
image	O
goal	O
(	O
i.e	O
.	O

``	O
buff	O
,	O
''	O
``	O
muscles	O
,	O
''	O
etc	O
.	O
)	O

would	O
similarly	O
reduce	O
food	O
intake	O
for	O
males	O
.	O

Anger	O
and	O
aggression	O
in	O
borderline	O
personality	O
disorder	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
-	O
does	O
stress	O
matter	O
?	O
.	O

The	O
impact	O
of	O
stress	O
on	O
anger	O
and	O
aggression	O
in	O
Borderline	O
Personality	O
Disorder	O
(	O
BPD	O
)	O
and	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
has	O
not	O
been	O
thoroughly	O
investigated	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
different	O
aspects	O
of	O
anger	O
and	O
aggression	O
in	O
patients	O
with	O
these	O
disorders	O
.	O

Twenty-nine	O
unmedicated	O
female	O
BPD	O
patients	O
,	O
28	O
ADHD	O
patients	O
and	O
30	O
healthy	O
controls	O
(	O
HC	O
)	O
completed	O
self-reports	O
measuring	O
trait	O
anger	O
,	O
aggression	O
and	O
emotion	O
regulation	O
capacities	O
.	O

A	O
modified	O
version	O
of	O
the	O
Point	O
Subtraction	O
Aggression	O
Paradigm	O
and	O
a	O
state	O
anger	O
measurement	O
were	O
applied	O
under	O
resting	O
and	O
stress	O
conditions	O
.	O

Stress	O
was	O
induced	O
by	O
the	O
Mannheim	B-P
Multicomponent	I-P
Stress	I-P
Test	I-P
(	O
MMST	B-P
)	O
.	O

Both	O
patient	O
groups	O
scored	O
significantly	O
higher	O
on	O
all	O
self-report	O
measures	O
compared	O
to	O
HCs	O
.	O

Compared	O
to	O
ADHD	O
patients	O
,	O
BPD	O
patients	O
reported	O
higher	O
trait	O
aggression	O
and	O
hostility	O
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	O
when	O
provoked	O
and	O
to	O
direct	O
anger	O
inwardly	O
.	O

Furthermore	O
,	O
BPD	O
patients	O
exhibited	O
higher	O
state	O
anger	O
than	O
HCs	O
and	O
ADHD	O
patients	O
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress-dependent	O
anger	O
increase	O
.	O

At	O
the	O
behavioral	O
level	O
,	O
no	O
significant	O
effects	O
were	O
found	O
.	O

In	O
BPD	O
patients	O
,	O
aggression	O
and	O
anger	O
were	O
positively	O
correlated	O
with	O
emotion	O
regulation	O
deficits	O
.	O

Our	O
findings	O
suggest	O
a	O
significant	O
impact	O
of	O
stress	O
on	O
self-perceived	O
state	O
anger	O
in	O
BPD	O
patients	O
but	O
not	O
on	O
aggressive	O
behavior	O
towards	O
others	O
in	O
females	O
with	O
BPD	O
or	O
ADHD	O
.	O

However	O
,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	O
which	O
is	O
of	O
clinical	O
importance	O
in	O
BPD	O
patients	O
.	O

Predictive	O
Factors	O
for	O
Long-term	O
Outcome	O
of	O
Subthalamic	O
Nucleus	O
Deep	B-P
Brain	I-P
Stimulation	I-P
for	O
Parkinson	O
's	O
Disease	O
.	O

Despite	O
the	O
recognition	O
of	O
the	O
usefulness	O
of	O
subthalamic	O
nucleus	O
deep	B-P
brain	I-P
stimulation	I-P
(	O
STN	O
-	O
DBS	B-P
)	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
,	O
preoperative	O
predictive	O
factors	O
for	O
the	O
long-term	O
outcome	O
of	O
STN	O
-	O
DBS	B-P
are	O
not	O
sufficiently	O
established	O
.	O

We	O
performed	O
this	O
study	O
to	O
determine	O
such	O
predictive	O
factors	O
.	O

The	O
subjects	O
were	O
66	O
patients	O
who	O
were	O
classified	O
into	O
two	O
groups	O
on	O
the	O
basis	O
of	O
their	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
evaluated	O
five	O
years	O
after	O
the	O
STN	O
-	O
DBS	B-P
surgery	B-P
:	O
33	O
patients	O
were	O
assigned	O
to	O
the	O
independent	O
ADL	O
group	O
(	O
group	O
I	O
)	O
and	O
the	O
remaining	O
33	O
patients	O
to	O
the	O
dependent	O
ADL	O
group	O
(	O
group	O
D	O
)	O
.	O

Group	O
I	O
patients	O
showed	O
a	O
Schwab	O
and	O
England	O
(	O
S	O
&	O
E	O
)	O
scale	O
score	O
of	O
more	O
than	O
70	O
during	O
the	O
off-period	O
,	O
indicating	O
that	O
these	O
patients	O
can	O
maintain	O
their	O
independent	O
ADL	O
all	O
the	O
time	O
.	O

Group	O
D	O
patients	O
showed	O
a	O
score	O
of	O
70	O
or	O
lower	O
during	O
the	O
off-period	O
,	O
indicating	O
that	O
these	O
patients	O
can	O
not	O
maintain	O
their	O
independent	O
ADL	O
for	O
an	O
entire	O
day	O
.	O

We	O
studied	O
the	O
differences	O
in	O
the	O
preoperative	O
state	O
between	O
these	O
two	O
groups	O
.	O

Statistically	O
significant	O
differences	O
were	O
noted	O
in	O
PD	O
onset	O
age	O
,	O
age	O
at	O
surgery	B-P
,	O
preoperative	O
unified	O
Parkinson	O
's	O
disease	O
rating	O
scale	O
(	O
UPDRS	O
)	O
part	O
I	O
score	O
,	O
part	O
II	O
score	O
,	O
total	O
subscore	O
for	O
axial	O
symptoms	O
in	O
part	O
III	O
,	O
mini-mental	O
state	O
examination	O
(	O
MMSE	O
)	O
score	O
and	O
S	O
&	O
E	O
score	O
.	O

Multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
significant	O
independent	O
variables	O
related	O
to	O
long-term	O
independent	O
ADL	O
were	O
the	O
age	O
at	O
surgery	B-P
,	O
MMSE	O
score	O
and	O
preoperative	O
S	O
&	O
E	O
scale	O
score	O
during	O
the	O
off-period	O
.	O

The	O
PD	O
onset	O
age	O
,	O
age	O
at	O
surgery	B-P
,	O
preoperative	O
high	O
-	O
level	O
ADL	O
,	O
cognitive	O
function	O
,	O
and	O
axial	O
symptoms	O
are	O
important	O
predictive	O
factors	O
for	O
the	O
long-term	O
outcome	O
of	O
STN	O
-	O
DBS	B-P
.	O

Development	O
of	O
an	O
automaton	O
model	O
of	O
rotational	O
activity	O
driving	O
atrial	O
fibrillation	O
.	O

Atrial	O
fibrillation	O
(	O
AF	O
)	O
is	O
difficult	O
to	O
treat	B-P
effectively	O
,	O
owing	O
to	O
uncertainty	O
in	O
where	O
to	O
best	O
ablate	B-P
to	O
eliminate	O
arrhythmogenic	O
substrate	O
.	O

A	O
model	O
providing	O
insight	O
into	O
the	O
electrical	O
activation	O
events	O
would	O
be	O
useful	O
to	O
guide	O
catheter	B-P
ablation	I-P
strategy	I-P
.	O

Method	O
A	O
two-dimensional	O
,	O
576×576	O
node	O
automaton	O
was	O
developed	O
to	O
simulate	O
atrial	O
electrical	O
activity	O
.	O

The	O
substrate	O
field	O
was	O
altered	O
by	O
the	O
presence	O
of	O
differing	O
refractory	O
period	O
at	O
varying	O
locations	O
.	O

Fibrosis	O
was	O
added	O
in	O
the	O
form	O
of	O
short	O
,	O
randomly	O
positioned	O
lines	O
of	O
conduction	O
block	O
.	O

Larger	O
areas	O
of	O
block	O
were	O
used	O
to	O
simulate	O
ablation	O
lesions	O
.	O

Anisotropy	O
was	O
imposed	O
in	O
a	O
2:1	O
ratio	O
.	O

A	O
premature	O
electrical	O
impulse	O
from	O
one	O
of	O
four	O
grid	O
corners	O
was	O
utilized	O
to	O
initiate	O
activation	O
.	O

Rotational	O
activity	O
was	O
uninducible	O
when	O
refractory	O
patch	O
dimensions	O
were	O
less	O
than	O
20×20mm	O
.	O

For	O
larger	O
refractory	O
regions	O
,	O
a	O
single	O
premature	O
stimulus	O
was	O
capable	O
of	O
inducing	O
an	O
average	O
of	O
1.19±1.10	O
rotors	O
,	O
which	O
often	O
formed	O
near	O
the	O
patch	O
edges	O
.	O

A	O
maximum	O
of	O
5	O
rotors	O
formed	O
when	O
refractory	O
patch	O
dimensions	O
approached	O
the	O
size	O
of	O
the	O
entire	O
left	O
atrial	O
virtual	O
field	O
.	O

Rotors	O
formed	O
along	O
a	O
refractory	O
patch	O
edge	O
,	O
after	O
wavefront	O
arrival	O
was	O
delayed	O
at	O
turning	O
points	O
or	O
due	O
to	O
the	O
presence	O
of	O
a	O
fiber	O
cluster	O
of	O
sufficient	O
size	O
.	O

However	O
,	O
rotational	O
activity	O
could	O
also	O
occur	O
around	O
a	O
large	O
fiber	O
cluster	O
without	O
the	O
need	O
of	O
spatially	O
variable	O
refractoriness	O
.	O

When	O
obstacles	O
to	O
conduction	O
were	O
lacking	O
in	O
size	O
,	O
nascent	O
rotors	O
drifted	O
and	O
either	O
extinguished	O
,	O
or	O
stabilized	O
upon	O
anchoring	O
at	O
a	O
sufficiently	O
large	O
fiber	O
cluster	O
elsewhere	O
in	O
the	O
field	O
.	O

Transient	O
rotors	O
terminated	O
when	O
traversing	O
a	O
region	O
with	O
differing	O
refractory	O
periods	O
,	O
if	O
no	O
obstacle	O
to	O
conduction	O
was	O
present	O
to	O
sufficiently	O
delay	O
wavefront	O
arrival	O
beyond	O
the	O
longest	O
refractory	O
period	O
.	O

Other	O
rotors	O
were	O
annihilated	O
when	O
a	O
nearby	O
rotor	O
with	O
faster	O
spin	O
rate	O
gradually	O
interrupted	O
the	O
activation	O
pathway	O
.	O

Elimination	O
of	O
anchors	B-P
by	O
removal	B-P
,	O
or	O
by	O
simulated	O
ablation	B-P
over	O
a	O
sufficient	O
region	O
,	O
prevented	O
rotor	O
onset	O
at	O
a	O
particular	O
location	O
where	O
it	O
would	O
otherwise	O
form	O
.	O

The	O
presence	O
of	O
obstacles	O
to	O
conduction	O
and	O
spatial	O
differences	O
in	O
refractory	O
period	O
are	O
important	O
parameters	O
for	O
initiating	O
and	O
maintaining	O
rotational	O
activity	O
in	O
this	O
simulation	O
of	O
an	O
atrial	O
substrate	O
.	O

Performance	O
of	O
loop-mediated	B-P
isothermal	I-P
amplification	I-P
(	O
LAMP	B-P
)	O
for	O
the	O
diagnosis	O
of	O
malaria	O
among	O
malaria	O
suspected	O
pregnant	O
women	O
in	O
Northwest	O
Ethiopia	O
.	O

Malaria	O
is	O
a	O
major	O
public	O
health	O
problem	O
and	O
an	O
important	O
cause	O
of	O
maternal	O
and	O
infant	O
morbidity	O
in	O
sub-Saharan	O
Africa	O
,	O
including	O
Ethiopia	O
.	O

Early	B-P
and	O
accurate	O
diagnosis	O
of	O
malaria	O
with	O
effective	O
treatment	B-P
is	O
the	O
best	O
strategy	O
for	O
prevention	B-P
and	O
control	O
of	O
complications	O
during	O
pregnancy	O
and	O
infant	O
morbidity	O
and	O
mortality	O
.	O

However	O
,	O
laboratory	B-P
diagnosis	I-P
has	O
relied	O
on	O
the	O
identification	O
of	O
malaria	O
parasites	O
and	O
parasite	O
antigens	O
in	O
peripheral	O
blood	O
using	O
Giemsa-stained	B-P
microscopy	I-P
or	O
rapid	B-P
diagnostic	I-P
tests	I-P
(	O
RDTs	B-P
)	O
which	O
lack	O
analytical	O
and	O
clinical	O
sensitivity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
of	O
loop-mediated	B-P
isothermal	I-P
amplification	I-P
(	O
LAMP	B-P
)	O
for	O
the	O
diagnosis	O
of	O
malaria	O
among	O
malaria	O
suspected	O
pregnant	O
women	O
in	O
Northwest	O
Ethiopia	O
.	O

A	O
cross	O
sectional	O
study	O
was	O
conducted	O
from	O
January	O
to	O
April	O
2016	O
.	O

Pregnant	O
women	O
(	O
n	O
=	O
87	O
)	O
suspected	O
of	O
having	O
malaria	O
at	O
six	O
health	O
centres	O
were	O
enrolled	O
.	O

A	O
venous	O
blood	O
sample	O
was	O
collected	O
from	O
each	O
study	O
subject	O
,	O
and	O
analysed	O
for	O
Plasmodium	O
parasites	O
by	O
microscopy	B-P
,	O
RDT	B-P
,	O
and	O
LAMP	B-P
.	O

Diagnostic	O
accuracy	O
outcome	O
measures	O
(	O
sensitivity	O
,	O
specificity	O
,	O
predictive	O
values	O
,	O
and	O
Kappa	O
scores	O
)	O
of	O
microscopy	B-P
,	O
RDT	B-P
and	O
LAMP	B-P
were	O
compared	O
to	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
nPCR	O
)	O
as	O
the	O
gold	O
standard	O
.	O

Specimen	B-P
processing	I-P
and	O
reporting	O
times	O
were	O
documented	O
.	O

Using	O
nPCR	O
as	O
the	O
gold	O
standard	O
technique	O
,	O
the	O
sensitivity	O
of	O
microscopy	B-P
and	O
RDT	B-P
was	O
90	O
and	O
70	O
%	O
,	O
and	O
the	O
specificity	O
was	O
98.7	O
and	O
97.4	O
%	O
,	O
respectively	O
.	O

LAMP	B-P
assay	B-P
was	O
100	O
%	O
sensitive	O
and	O
93.5	O
%	O
specific	O
compared	O
to	O
nPCR	O
.	O

This	O
study	O
showed	O
higher	O
sensitivity	O
of	O
LAMP	B-P
compared	O
to	O
microscopy	B-P
and	O
RDT	B-P
for	O
the	O
detection	B-P
of	O
malaria	O
in	O
pregnancy	O
.	O

Increased	O
sensitivity	O
and	O
ease	O
of	O
use	O
with	O
LAMP	B-P
in	O
point-of-care	O
testing	O
for	O
malaria	O
in	O
pregnancy	O
was	O
noted	O
.	O

LAMP	B-P
warrants	O
further	O
evaluation	O
in	O
intermittent	O
screening	O
and	O
treatment	O
programmes	O
in	O
pregnancy	O
.	O

MicroRNA	O
101b	O
Is	O
Downregulated	O
in	O
the	O
Prefrontal	O
Cortex	O
of	O
a	O
Genetic	O
Model	O
of	O
Depression	O
and	O
Targets	O
the	O
Glutamate	O
Transporter	O
SLC1A1	O
(	O
EAAT3	O
)	O
in	O
Vitro	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
regulatory	O
molecules	O
that	O
cause	O
translational	O
repression	O
by	O
base	O
pairing	O
with	O
target	O
mRNAs	O
.	O

Cumulative	O
evidence	O
suggests	O
that	O
changes	O
in	O
miRNA	O
expression	O
may	O
in	O
part	O
underlie	O
the	O
pathophysiology	O
and	O
treatment	B-P
of	O
neuropsychiatric	O
disorders	O
,	O
including	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

A	O
miRNA	O
expression	O
assay	B-P
that	O
can	O
simultaneously	O
detect	O
423	O
rat	O
miRNAs	O
(	O
miRBase	O
v.17	O
)	O
was	O
used	O
to	O
profile	B-P
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
of	O
a	O
genetic	O
rat	O
model	O
of	O
MDD	O
(	O
the	O
Flinders	O
Sensitive	O
Line	O
[	O
FSL	O
]	O
)	O
and	O
the	O
controls	O
,	O
the	O
Flinders	O
Resistant	O
Line	O
(	O
FRL	O
)	O
.	O

Gene	O
expression	O
data	O
from	O
the	O
PFC	O
of	O
FSL	O
/	O
FRL	O
animals	O
(	O
GEO	O
accession	O
no	O
.	O

GSE20388	O
)	O
were	O
used	O
to	O
guide	O
mRNA	O
target	O
selection	O
.	O

Luciferase	B-P
reporter	I-P
assays	I-P
were	O
used	O
to	O
verify	O
miRNA	O
targets	O
in	O
vitro	O
.	O

We	O
identified	O
23	O
miRNAs	O
that	O
were	O
downregulated	O
in	O
the	O
PFC	O
of	O
the	O
FSL	O
model	O
compared	O
with	O
controls	O
.	O

Interestingly	O
,	O
one	O
of	O
the	O
identified	O
miRNAs	O
(	O
miR-101b	O
)	O
is	O
highly	O
conserved	O
between	O
rat	O
and	O
human	O
and	O
was	O
recently	O
found	O
to	O
be	O
downregulated	O
in	O
the	O
PFC	O
of	O
depressed	O
suicide	O
subjects	O
.	O

Using	O
a	O
combination	O
of	O
in	O
silico	O
and	O
in	O
vitro	O
analyses	O
,	O
we	O
found	O
that	O
miR-101b	O
targets	O
the	O
neuronal	O
glutamate	O
transporter	O
SLC1A1	O
(	O
also	O
known	O
as	O
EAAC1	O
or	O
EAAT3	O
)	O
.	O

Accordingly	O
,	O
both	O
mRNA	O
and	O
protein	O
levels	O
of	O
SLC1A1	O
were	O
found	O
to	O
be	O
upregulated	O
in	O
the	O
PFC	O
of	O
the	O
FSL	O
model	O
.	O

Besides	O
providing	O
a	O
list	O
of	O
novel	O
miRNAs	O
associated	O
with	O
depression-like	O
states	O
,	O
this	O
preclinical	O
study	O
replicated	O
the	O
human	O
association	O
of	O
miR-101	O
with	O
depression	O
.	O

In	O
addition	O
,	O
since	O
one	O
of	O
the	O
targets	O
of	O
miR-101b	O
appears	O
to	O
be	O
a	O
glutamate	O
transporter	O
,	O
our	O
preclinical	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	O
dysregulation	O
being	O
implicated	O
in	O
the	O
etiology	O
of	O
depression	O
.	O

Externally	O
Connected	O
Zirconia	O
Abutments	O
with	O
Standard	O
Platform	O
are	O
Successful	O
Long	O
Term	O
in	O
Anterior	O
Regions	O
.	O

Performance	O
of	O
zirconia	O
abutments	O
for	O
implant-supported	B-P
single-tooth	I-P
crowns	I-P
in	O
esthetic	O
areas	O
:	O
a	O
retrospective	O
study	O
up	O
to	O
12-year	O
follow-up	O
.	O

Passos	O
SP	O
,	O
Linke	O
B	O
,	O
Larjava	O
H	O
,	O
French	O
D.	O
Clin	O
Oral	O
Implants	O
Res	O
2016	O
;	O
27	O
(	O
1	O
)	O
:47-54	O
.	O

Information	O
not	O
available	O
Retrospective	O
cohort	O
study	O
.	O

Extensor	O
indicis	O
proprius	O
tendon	B-P
transfer	I-P
using	O
shear	B-P
wave	I-P
elastography	I-P
.	O

The	O
means	O
for	O
judging	O
optimal	O
tension	O
during	O
tendon	B-P
transfers	I-P
are	O
approximate	O
and	O
not	O
very	O
quantifiable	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
feasibility	O
of	O
quantitatively	O
assessing	O
muscular	O
mechanical	O
properties	O
intraoperatively	O
using	O
ultrasound	B-P
elastography	I-P
(	O
shear	B-P
wave	I-P
elastography	I-P
[	O
SWE	B-P
]	O
)	O
during	O
extensor	O
indicis	O
proprius	O
(	O
EIP	O
)	O
transfer	B-P
.	O

We	O
report	O
two	O
cases	O
of	O
EIP	O
transfer	B-P
for	O
post-traumatic	O
rupture	O
of	O
the	O
extensor	O
pollicis	O
longus	O
muscle	O
.	O

Ultrasound	O
acquisitions	O
measured	O
the	O
elasticity	O
modulus	O
of	O
the	O
EIP	O
muscle	O
at	O
different	O
stages	O
:	O
rest	O
,	O
active	O
extension	O
,	O
active	O
extension	O
against	O
resistance	O
,	O
EIP	O
section	O
,	O
distal	B-P
passive	I-P
traction	I-P
of	O
the	O
tendon	O
,	O
after	O
tendon	B-P
transfer	I-P
at	O
rest	O
and	O
then	O
during	O
active	O
extension	O
.	O

A	O
preliminary	O
analysis	O
was	O
conducted	O
of	O
the	O
distribution	O
of	O
values	O
for	O
this	O
modulus	O
at	O
the	O
various	O
transfer	B-P
steps	O
.	O

Different	O
shear	O
wave	O
velocity	O
and	O
elasticity	O
modulus	O
values	O
were	O
observed	O
at	O
the	O
various	O
transfer	B-P
steps	O
.	O

The	O
tension	O
applied	O
during	O
the	O
transfer	B-P
seemed	O
close	O
to	O
the	O
resting	O
tension	O
if	O
a	O
traditional	O
protocol	O
were	O
followed	O
.	O

The	O
elasticity	O
modulus	O
varied	O
by	O
a	O
factor	O
of	O
37	O
between	O
the	O
active	O
extension	O
against	O
resistance	O
step	O
(	O
565.1	O
kPa	O
)	O
and	O
after	O
the	O
tendon	O
section	O
(	O
15.3	O
kPa	O
)	O
.	O

The	O
elasticity	O
modulus	O
values	O
were	O
distributed	O
in	O
the	O
same	O
way	O
for	O
each	O
patient	O
.	O

The	O
therapeutic	O
benefit	O
of	O
SWE	B-P
elastography	B-P
was	O
studied	O
for	O
the	O
first	O
time	O
in	O
tendon	B-P
transfers	I-P
.	O

Quantitative	O
data	O
on	O
the	O
elasticity	O
modulus	O
during	O
this	O
test	O
may	O
make	O
it	O
an	O
effective	O
means	O
of	O
improving	O
intraoperative	O
adjustments	O
.	O

Molecular	B-P
Imaging	I-P
of	O
Tumor	O
Angiogenesis	O
and	O
Therapeutic	O
Effects	O
with	O
Dual	O
Bioluminescence	O
.	O

Angiogenesis	O
is	O
critical	O
for	O
the	O
growth	O
of	O
tumor	O
by	O
supplying	O
nutrients	O
and	O
oxygen	O
that	O
exacerbates	O
the	O
metastasis	O
and	O
progression	O
of	O
cancer	O
.	O

Noninvasive	O
imaging	B-P
of	O
angiogenesis	O
during	O
the	O
tumor	O
therapeutic	B-P
processes	I-P
may	O
provide	O
novel	O
opportunities	O
for	O
image-guided	B-P
tumor	O
management	O
.	O

Here	O
,	O
we	O
want	O
to	O
develop	O
a	O
mouse	O
animal	O
model	O
for	O
assessing	O
cancer	O
progression	O
and	O
angiogenesis	O
in	O
the	O
same	O
individuals	O
by	O
molecular	B-P
imaging	I-P
.	O

Breast	O
cancer	O
model	O
was	O
developed	O
with	O
mouse	O
breast	O
cancer	O
cell	O
line	O
4T1	O
carrying	O
a	O
reporter	O
system	O
encoding	O
a	O
triple	O
fusion	O
(	O
TF	O
)	O
reporter	O
gene	O
consisting	O
of	O
renilla	O
luciferase	O
(	O
Rluc	O
)	O
,	O
red	O
fluorescent	O
protein	O
(	O
RFP	O
)	O
and	O
herpes	O
simplex	O
virus	O
truncated	O
thymidine	O
kinase	O
(	O
HSV-ttk	O
)	O
in	O
transgenic	O
mice	O
,	O
which	O
expressed	O
firefly	O
luciferase	O
(	O
Fluc	O
)	O
under	O
the	O
promoter	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
(	O
Vegfr2-luc	O
)	O
.	O

The	O
mice	O
were	O
subsequently	O
treated	O
with	O
ganciclovir	O
(	O
GCV	O
)	O
and	O
the	O
tumor	O
angiogenesis	O
was	O
tracked	O
by	O
Fluc	O
imaging	B-P
and	O
the	O
growth	O
status	O
of	O
tumor	O
was	O
monitored	O
by	O
imaging	B-P
of	O
Rluc	O
simultaneously	O
.	O

Overall	O
,	O
this	O
traceable	O
breast	O
cancer	O
model	O
can	O
simultaneously	O
image	O
the	O
tumor	O
growth	O
and	O
angiogenesis	O
in	O
single	O
individual	O
,	O
which	O
may	O
facilitate	O
a	O
better	O
understanding	O
the	O
mechanisms	O
of	O
angiogenesis	O
in	O
the	O
progression	O
and	O
regression	O
of	O
tumor	O
.	O

Trisaccharide	O
containing	O
α2,3-linked	O
sialic	O
acid	O
is	O
a	O
receptor	O
for	O
mumps	O
virus	O
.	O

Mumps	O
virus	O
(	O
MuV	O
)	O
remains	O
an	O
important	O
pathogen	O
worldwide	O
,	O
causing	O
epidemic	O
parotitis	O
,	O
orchitis	O
,	O
meningitis	O
,	O
and	O
encephalitis	O
.	O

Here	O
we	O
show	O
that	O
MuV	O
preferentially	O
uses	O
a	O
trisaccharide	O
containing	O
α2,3-linked	O
sialic	O
acid	O
in	O
unbranched	O
sugar	O
chains	O
as	O
a	O
receptor	O
.	O

Crystal	O
structures	O
of	O
the	O
MuV	O
attachment	O
protein	O
hemagglutinin-neuraminidase	O
(	O
MuV	O
-	O
HN	O
)	O
alone	O
and	O
in	O
complex	O
with	O
the	O
α2,3-sialylated	O
trisaccharide	O
revealed	O
that	O
in	O
addition	O
to	O
the	O
interaction	O
between	O
the	O
MuV	O
-	O
HN	O
active	O
site	O
residues	O
and	O
sialic	O
acid	O
,	O
other	O
residues	O
,	O
including	O
an	O
aromatic	O
residue	O
,	O
stabilize	O
the	O
third	O
sugar	O
of	O
the	O
trisaccharide	O
.	O

The	O
importance	O
of	O
the	O
aromatic	O
residue	O
and	O
the	O
third	O
sugar	O
in	O
the	O
MuV	O
-	O
HN	O
-	O
receptor	O
interaction	O
was	O
confirmed	O
by	O
computational	O
energy	O
calculations	O
,	O
isothermal	O
titration	O
calorimetry	O
studies	O
,	O
and	O
glycan-binding	B-P
assays	I-P
.	O

Furthermore	O
,	O
MuV	O
-	O
HN	O
was	O
found	O
to	O
bind	O
more	O
efficiently	O
to	O
unbranched	O
α2,3-sialylated	O
sugar	O
chains	O
compared	O
with	O
branched	O
ones	O
.	O

Important	O
ly	O
,	O
the	O
strategically	O
located	O
aromatic	O
residue	O
is	O
conserved	O
among	O
the	O
HN	O
protein	O
s	O
of	O
sialic	O
acid	O
-using	O
paramyxoviruses	O
,	O
and	O
alanine	O
substitution	O
compromised	O
their	O
ability	O
to	O
support	O
cell-cell	O
fusion	O
.	O

These	O
results	O
suggest	O
that	O
not	O
only	O
the	O
terminal	O
sialic	O
acid	O
but	O
also	O
the	O
adjacent	O
sugar	O
moiety	O
contribute	O
to	O
receptor	O
function	O
for	O
mumps	O
and	O
these	O
paramyxoviruses	O
.	O

The	O
distribution	O
of	O
structurally	O
different	O
sialylated	O
glycans	O
in	O
tissues	O
and	O
organs	O
may	O
explain	O
in	O
part	O
MuV	O
's	O
distinct	O
tropism	O
to	O
glandular	O
tissues	O
and	O
the	O
central	O
nervous	O
system	O
.	O

In	O
the	O
crystal	O
structure	O
,	O
the	O
epitopes	O
for	O
neutralizing	O
antibodies	O
are	O
located	O
around	O
the	O
α-helices	O
of	O
MuV	O
-	O
HN	O
that	O
are	O
not	O
well	O
conserved	O
in	O
amino	O
acid	O
sequences	O
among	O
different	O
genotypes	O
of	O
MuV	O
.	O

This	O
may	O
explain	O
the	O
fact	O
that	O
MuV	O
reinfection	O
sometimes	O
occurs	O
.	O

Single-cell	O
RNA-seq	O
enables	O
comprehensive	O
tumour	O
and	O
immune	B-P
cell	I-P
profiling	I-P
in	O
primary	O
breast	O
cancer	O
.	O

Single-cell	O
transcriptome	O
profiling	O
of	O
tumour	O
tissue	O
isolates	O
allows	O
the	O
characterization	O
of	O
heterogeneous	O
tumour	O
cells	O
along	O
with	O
neighbouring	O
stromal	O
and	O
immune	O
cells	O
.	O

Here	O
we	O
adopt	O
this	O
powerful	O
approach	O
to	O
breast	O
cancer	O
and	O
analyse	O
515	O
cells	O
from	O
11	O
patients	O
.	O

Inferred	O
copy	O
number	O
variations	O
from	O
the	O
single-cell	O
RNA-seq	O
data	O
separate	O
carcinoma	O
cells	O
from	O
non-cancer	O
cells	O
.	O

At	O
a	O
single-cell	O
resolution	O
,	O
carcinoma	O
cells	O
display	O
common	O
signatures	O
within	O
the	O
tumour	O
as	O
well	O
as	O
intratumoral	O
heterogeneity	O
regarding	O
breast	O
cancer	O
subtype	O
and	O
crucial	O
cancer-related	O
pathways	O
.	O

Most	O
of	O
the	O
non-cancer	O
cells	O
are	O
immune	O
cells	O
,	O
with	O
three	O
distinct	O
clusters	O
of	O
T	O
lymphocytes	O
,	O
B	O
lymphocytes	O
and	O
macrophages	O
.	O

T	O
lymphocytes	O
and	O
macrophages	O
both	O
display	O
immunosuppressive	O
characteristics	O
:	O
T	O
cells	O
with	O
a	O
regulatory	O
or	O
an	O
exhausted	O
phenotype	O
and	O
macrophages	O
with	O
an	O
M2	O
phenotype	O
.	O

These	O
results	O
illustrate	O
that	O
the	O
breast	O
cancer	O
transcriptome	O
has	O
a	O
wide	O
range	O
of	O
intratumoral	O
heterogeneity	O
,	O
which	O
is	O
shaped	O
by	O
the	O
tumour	O
cells	O
and	O
immune	O
cells	O
in	O
the	O
surrounding	O
microenvironment	O
.	O

Morpho	O
-	O
Molecular	O
Characterization	O
of	O
Soil	O
Inhabitant	O
Dermatophytes	O
from	O
Ahvaz	O
,	O
Southwest	O
of	O
Iran	O
,	O
a	O
High	O
Occurrence	O
of	O
Microsporum	O
fulvum	O
.	O

Occurrence	O
and	O
diversity	O
of	O
dermatophyte	O
mycoflora	O
in	O
298	O
soil	O
samples	O
from	O
Ahvaz	O
,	O
Southwest	O
of	O
Iran	O
was	O
investigated	O
by	O
using	O
the	O
hair-baiting	O
technique	O
.	O

The	O
samples	O
were	O
collected	O
during	O
spring	O
(	O
n	O
=	O
210	O
)	O
and	O
autumn	O
(	O
n	O
=	O
88	O
)	O
of	O
2015	O
,	O
and	O
the	O
fungal	O
isolates	O
were	O
identified	O
based	O
on	O
the	O
macro	O
-	O
and	O
micro-morphology	O
of	O
colonies	O
and	O
with	O
further	O
ITS-rDNA	B-P
RFLP	I-P
and	O
sequencing	B-P
.	O

Totally	O
,	O
60	O
soil	O
samples	O
(	O
20.1	O
%	O
)	O
were	O
positive	O
for	O
dermatophyte	O
growth	O
whose	O
pH	O
varied	O
from	O
7.0	O
to	O
7.9	O
.	O

The	O
highest	O
(	O
26.6	O
%	O
)	O
and	O
the	O
lowest	O
(	O
14.3	O
%	O
)	O
recovery	O
rates	O
were	O
from	O
the	O
animal	O
resorts	O
and	O
the	O
streets	O
soils	O
samples	O
,	O
respectively	O
.	O

Seasonally	O
,	O
16.7	O
%	O
of	O
the	O
spring	O
samples	O
and	O
28.4	O
%	O
of	O
the	O
autumn	O
samples	O
were	O
positive	O
.	O

Based	O
on	O
molecular	O
identification	O
,	O
three	O
species	O
of	O
two	O
genera	O
were	O
identified	O
viz	O
.	O

M.	O
fulvum	O
(	O
n	O
=	O
57	O
)	O
,	O
M.	O
canis	O
(	O
n	O
=	O
2	O
)	O
and	O
zoophilic	O
Trichophyton	O
interdigitale	O
(	O
n	O
=	O
1	O
)	O
.	O

As	O
a	O
specific	O
goal	O
in	O
the	O
study	O
,	O
differentiation	O
of	O
the	O
species	O
in	O
Microsporum	O
gypseum	O
complex	O
was	O
established	O
by	O
measuring	O
the	O
mean	O
length	O
and	O
width	O
of	O
macroconidia	O
in	O
some	O
strains	O
of	O
M.	O
gypseum	O
,	O
M.	O
fulvum	O
and	O
M.	O
incurvatum	O
.	O

Mean	O
size	O
for	O
macroconidia	O
length	O
and	O
width	O
in	O
three	O
species	O
showed	O
that	O
M.	O
gypseum	O
and	O
M.	O
incurvatum	O
can	O
morphologically	O
be	O
differentiated	O
from	O
M.	O
fulvum	O
but	O
not	O
from	O
each	O
other	O
.	O

M.	O
fulvum	O
was	O
the	O
most	O
abundant	O
species	O
isolated	O
from	O
the	O
soils	O
of	O
Ahvaz	O
;	O
however	O
,	O
to	O
comprehensively	O
specify	O
the	O
distribution	O
pattern	O
of	O
geophilic	O
dermatophytes	O
in	O
the	O
soils	O
of	O
this	O
city	O
further	O
investigations	O
are	O
needed	O
.	O

Identification	O
based	O
on	O
micro-morphometric	O
is	O
not	O
effective	O
for	O
species	O
distinction	O
in	O
M.	O
gypseum	O
complex	O
,	O
while	O
molecular	O
procedures	O
based	O
on	O
sequencing	B-P
of	O
certain	O
DNA	O
regions	O
are	O
the	O
most	O
reliable	O
and	O
applicable	O
strategies	O
for	O
this	O
purpose	O
.	O

Utilization	O
Pattern	O
and	O
Drug	O
Use	O
of	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
Medicine	O
,	O
and	O
Integrated	O
Chinese-Western	O
Medicine	O
Treatments	B-P
for	O
Allergic	O
Rhinitis	O
Under	O
the	O
National	O
Health	O
Insurance	O
Program	O
in	O
Taiwan	O
.	O

Patients	O
in	O
Taiwan	O
with	O
allergic	O
rhinitis	O
seek	O
not	O
only	O
Western	O
medicine	O
treatment	B-P
but	O
also	O
Traditional	O
Chinese	O
Medicine	O
treatment	B-P
or	O
integrated	O
Chinese-Western	O
medicine	O
treatment	B-P
.	O

Various	O
studies	O
have	O
conducted	O
pairwise	O
comparison	O
on	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
medicine	O
,	O
and	O
integrated	O
Chinese-Western	O
medicine	O
treatments	B-P
.	O

However	O
,	O
none	O
conducted	O
simultaneous	O
analysis	O
of	O
the	O
three	O
treatments	B-P
.	O

This	O
study	O
analyzed	O
patients	O
with	O
allergic	O
rhinitis	O
receiving	O
the	O
three	O
treatments	B-P
to	O
identify	O
differences	O
in	O
demographic	O
characteristic	O
and	O
medical	O
use	O
and	O
thereby	O
to	O
determine	O
drug	O
use	O
patterns	O
of	O
different	O
treatments	B-P
.	O

The	O
National	O
Health	O
Insurance	O
Research	O
Database	O
was	O
the	O
data	O
source	O
,	O
and	O
included	O
patients	O
were	O
those	O
diagnosed	O
with	O
allergic	O
rhinitis	O
(	O
International	O
Classification	O
of	O
Diseases	O
,	O
Ninth	O
Revision	O
,	O
Clinical	O
Modification	O
codes	O
470-478	O
)	O
.	O

Chi-square	O
test	O
and	O
Tukey	O
studentized	O
range	O
(	O
honest	O
significant	O
difference	O
)	O
test	O
were	O
conducted	O
to	O
investigate	O
the	O
differences	O
among	O
the	O
three	O
treatments	B-P
.	O

Visit	O
frequency	O
for	O
allergic	O
rhinitis	O
treatment	B-P
was	O
higher	O
in	O
female	O
than	O
male	O
patients	O
,	O
regardless	O
of	O
treatment	B-P
with	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
medicine	O
,	O
or	O
integrated	O
Chinese-Western	O
medicine	O
.	O

Persons	O
aged	O
0-19	O
years	O
ranked	O
the	O
highest	O
in	O
proportion	O
of	O
visits	O
for	O
allergic	O
rhinitis	O
.	O

Traditional	O
Chinese	O
Medicine	O
treatment	B-P
had	O
more	O
medical	O
items	O
per	O
person-time	O
and	O
daily	O
drug	O
cost	O
per	O
person-time	O
and	O
had	O
the	O
lowest	O
total	O
expenditure	O
per	O
person-time	O
.	O

In	O
contrast	O
,	O
Western	O
medicine	O
had	O
the	O
lowest	O
daily	O
drug	O
cost	O
per	O
person-time	O
and	O
the	O
highest	O
total	O
expenditure	O
per	O
person-time	O
.	O

The	O
total	O
expenditure	O
per	O
person-time	O
,	O
daily	O
drug	O
cost	O
per	O
person-time	O
,	O
and	O
medical	O
items	O
per	O
person-time	O
of	O
integrated	O
Chinese-Western	O
medicine	O
treatment	B-P
lay	O
between	O
those	O
seen	O
with	O
Traditional	O
Chinese	O
Medicine	O
and	O
Western	O
medicine	O
treatments	B-P
.	O

Although	O
only	O
6.82	O
%	O
of	O
patients	O
with	O
allergic	O
rhinitis	O
chose	O
integrated	O
Chinese-Western	O
medicine	O
treatment	B-P
,	O
the	O
visit	O
frequency	O
per	O
person-year	O
of	O
integrated	O
Chinese-Western	O
medicine	O
ranked	O
highest	O
.	O

In	O
addition	O
,	O
multiple-composition	O
medicines	O
were	O
used	O
more	O
frequently	O
than	O
single-composition	O
medicines	O
,	O
and	O
mar	O
huang	O
(	O
Ephedra	O
sinica	O
Stapf	O
)	O
was	O
seldom	O
used	O
to	O
decrease	O
the	O
risk	O
of	O
combining	O
medications	O
.	O

Morphological	O
characteristics	O
regulating	O
phallic	O
glans	O
engorgement	O
in	O
the	O
American	O
alligator	O
.	O

The	O
distal	O
part	O
of	O
the	O
crocodilian	O
phallus	O
consists	O
of	O
a	O
bulbous	O
glans	O
containing	O
well-developed	O
vascular	O
tissues	O
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	O
activity	O
,	O
enlarging	O
and	O
elaborating	O
the	O
glans	O
into	O
a	O
complex	O
,	O
though	O
still	O
functionally	O
undefined	O
,	O
copulatory	O
structure	O
.	O

An	O
enlarged	O
glans	O
putatively	O
interacts	O
with	O
the	O
female	O
cloaca	O
and	O
may	O
change	O
the	O
shape	O
of	O
her	O
reproductive	O
tract	O
to	O
facilitate	O
insemination	O
and	O
increase	O
the	O
probability	O
of	O
fertilization	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
cellular-level	O
properties	O
of	O
the	O
glans	O
and	O
other	O
inflatable	O
phallic	O
tissues	O
associated	O
with	O
the	O
sperm	O
-conducting	O
sulcus	O
spermaticus	O
in	O
the	O
American	O
alligator	O
(	O
Alligator	O
mississippiensis	O
)	O
.	O

Using	O
histochemical	B-P
staining	I-P
,	O
we	O
visualized	O
and	O
defined	O
collagen	O
and	O
elastin	O
fiber	O
densities	O
and	O
orientations	O
in	O
these	O
tissues	O
.	O

Extracellular	O
matrix	O
architectures	O
provided	O
insights	O
about	O
phallic	O
glans	O
material	O
properties	O
and	O
how	O
they	O
may	O
affect	O
tissue	O
strength	O
and	O
flexibility	O
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	O
forces	O
.	O

We	O
also	O
investigated	O
the	O
potential	O
sources	O
of	O
fluids	O
that	O
induce	O
inflation	O
in	O
alligator	O
phalli	O
.	O

Combining	O
serial	B-P
sectioning	I-P
and	O
three-dimensional	B-P
reconstruction	I-P
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	O
plexus	O
vascular	O
bodies	O
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	O
phallus	O
that	O
extend	O
distally	O
adjacent	O
to	O
ventro-medial	O
sulcus	O
tissues	O
.	O

Together	O
,	O
our	O
gross	O
and	O
histological	O
examination	O
of	O
the	O
American	O
alligator	O
phallic	O
glans	O
suggests	O
that	O
its	O
tissues	O
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	O
inflation	O
to	O
expand	O
the	O
glans	O
to	O
a	O
specific	O
and	O
repeatable	O
shape	O
,	O
and	O
potentially	O
release	O
secretory	O
products	O
into	O
the	O
female	O
reproductive	O
tract	O
.	O

Both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	O
sexual	O
selection	O
,	O
by	O
mechanically	O
and/or	O
chemically	O
affecting	O
female	O
reproductive	O
physiology	O
.	O

Mining	O
for	O
Candidate	O
Genes	O
in	O
an	O
Introgression	O
Line	O
by	O
Using	O
RNA	O
Sequencing	O
:	O
The	O
Anthocyanin	O
Overaccumulation	O
Phenotype	O
in	O
Brassica	O
.	O

Introgression	O
breeding	O
is	O
a	O
widely	O
used	O
method	O
for	O
the	O
genetic	B-P
improvement	I-P
of	O
crop	O
plants	O
;	O
however	O
,	O
the	O
mechanism	O
underlying	O
candidate	O
gene	O
flow	O
patterns	O
during	O
hybridization	O
is	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
powerful	O
pipeline	O
to	O
investigate	O
a	O
Chinese	O
cabbage	O
(	O
Brassica	O
rapa	O
L.	O
ssp	O
.	O

pekinensis	O
)	O
introgression	O
line	O
with	O
the	O
anthocyanin	O
overaccumulation	O
phenotype	O
.	O

Our	O
purpose	O
was	O
to	O
analyze	O
the	O
gene	O
flow	O
patterns	O
during	O
hybridization	O
and	O
elucidate	O
the	O
genetic	O
factors	O
responsible	O
for	O
the	O
accumulation	O
of	O
this	O
important	O
pigment	O
compound	O
.	O

We	O
performed	O
RNA-seq	O
analysis	O
by	O
using	O
two	O
pipelines	O
,	O
one	O
with	O
and	O
one	O
without	O
a	O
reference	O
sequence	O
,	O
to	O
obtain	O
transcriptome	O
data	O
.	O

We	O
identified	O
930	O
significantly	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
between	O
the	O
purple	O
-	O
leaf	O
introgression	O
line	O
and	O
B.	O
rapa	O
green	O
cultivar	O
,	O
namely	O
,	O
389	O
up-regulated	O
and	O
541	O
down-regulated	O
DEGs	O
that	O
mapped	O
to	O
the	O
B.	O
rapa	O
reference	O
genome	O
.	O

Since	O
only	O
one	O
anthocyanin	O
pathway	O
regulatory	O
gene	O
was	O
identified	O
,	O
i.e.	O
,	O
Bra037887	O
(	O
bHLH	O
)	O
,	O
we	O
mined	O
unmapped	O
reads	O
,	O
revealing	O
2031	O
de	O
novo	O
assembled	O
unigenes	O
,	O
including	O
c3563g1i2	O
.	O

Phylogenetic	O
analysis	O
suggested	O
that	O
c3563g1i2	O
,	O
which	O
was	O
transferred	O
from	O
the	O
Brassica	O
B	O
genome	O
of	O
the	O
donor	O
parental	O
line	O
Brassica	O
juncea	O
,	O
may	O
represent	O
an	O
R2R3-MYB	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
ternary	O
transcriptional	O
activation	O
complex	O
responsible	O
for	O
the	O
anthocyanin	O
overaccumulation	O
phenotype	O
of	O
the	O
B.	O
rapa	O
introgression	O
line	O
.	O

We	O
also	O
identified	O
genes	O
involved	O
in	O
cold	O
and	O
light	O
reaction	O
pathways	O
that	O
were	O
highly	O
upregulated	O
in	O
the	O
introgression	O
line	O
,	O
as	O
confirmed	O
using	O
quantitative	O
real-time	O
PCR	O
analysis	O
.	O

The	O
results	O
of	O
this	O
study	O
shed	O
light	O
on	O
the	O
mechanisms	O
underlying	O
the	O
purple	O
leaf	O
trait	O
in	O
Brassica	O
plants	O
and	O
may	O
facilitate	O
the	O
use	O
of	O
introgressive	O
hybridization	O
for	O
many	O
traits	O
of	O
interest	O
.	O

The	O
E3	O
Ligase	O
CHIP	O
Mediates	O
p21	O
Degradation	O
to	O
Maintain	O
Radioresistance	O
.	O

Lung	O
cancer	O
resists	O
radiotherapy	B-P
,	O
making	O
it	O
one	O
of	O
the	O
deadliest	O
forms	O
of	O
cancer	O
.	O

Here	O
,	O
we	O
show	O
that	O
human	O
lung	O
cancer	O
cell	O
lines	O
can	O
be	O
rendered	O
sensitive	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
by	O
RNAi	O
knockdown	O
of	O
C-terminus	O
of	O
Hsc70-interacting	O
protein	O
(	O
CHIP	O
/	O
STUB1	O
)	O
,	O
a	O
U-box-type	O
E3	O
ubiquitin	O
ligase	O
that	O
targets	O
a	O
number	O
of	O
stress-induced	O
proteins	O
.	O

Mechanistically	O
,	O
ubiquitin-dependent	O
degradation	O
of	O
the	O
cyclin-dependent	O
kinase	O
(	O
CDK	O
)	O
inhibitor	O
,	O
p21	O
protein	O
,	O
is	O
reduced	O
by	O
CHIP	O
knockdown	O
,	O
leading	O
to	O
enhanced	O
senescence	O
of	O
cells	O
in	O
response	O
to	O
exposure	O
to	O
IR	O
.	O

Cellular	O
senescence	O
and	O
sensitivity	O
to	O
IR	O
is	O
prevented	O
by	O
CRISPR	O
/	O
Cas9	O
-mediated	O
deletion	O
of	O
the	O
p21	O
gene	O
(	O
CDKN1A	O
)	O
in	O
CHIP	O
knockdown	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
CHIP	O
potentiates	O
p21	O
degradation	O
and	O
promotes	O
greater	O
radioresistance	O
of	O
lung	O
cancer	O
cells	O
.	O

In	O
vitro	O
and	O
cell	O
-based	O
assays	B-P
demonstrate	O
that	O
p21	O
is	O
a	O
novel	O
and	O
direct	O
ubiquitylation	O
substrate	O
of	O
CHIP	O
that	O
also	O
requires	O
the	O
CHIP	O
-	O
associated	O
chaperone	O
HSP70	O
.	O

These	O
data	O
reveal	O
that	O
the	O
inhibition	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
CHIP	O
promotes	O
radiosensitivity	O
,	O
thus	O
suggesting	O
a	O
novel	O
strategy	O
for	O
the	O
treatment	B-P
of	O
lung	O
cancer	O
.	O

Implications	O
:	O
The	O
CHIP	O
-	O
HSP70	O
-	O
p21	O
ubiquitylation	O
/	O
degradation	O
axis	O
identified	O
here	O
could	O
be	O
exploited	O
to	O
enhance	O
the	O
efficacy	O
of	O
radiotherapy	B-P
in	O
patients	O
with	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Mol	O
Cancer	O
Res	O
;	O
1-9	O
.	O

©2017	O
AACR	O
.	O

Semi-preparative	B-P
HPLC	I-P
separation	I-P
followed	O
by	O
HPLC/UV	B-P
and	O
tandem	O
mass	O
spectrometric	O
analysis	O
of	O
phorbol	O
esters	O
in	O
Jatropha	O
seed	O
.	O

Phorbol	O
esters	O
(	O
PEs	O
)	O
are	O
well	O
known	O
as	O
the	O
main	O
toxic	O
compounds	O
in	O
Jatropha	O
curcas	O
Linnaeus	O
(	O
JCL	O
)	O
,	O
the	O
seed	O
oil	O
of	O
which	O
has	O
been	O
considered	O
as	O
a	O
major	O
feedstock	O
for	O
the	O
production	O
of	O
biodiesel	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
a	O
series	O
of	O
PEs	O
extracted	B-P
from	O
JCL	O
seed	O
kernels	O
with	O
methanol	O
(	O
MeOH	O
)	O
,	O
and	O
identified	O
more	O
than	O
seven	O
components	O
contained	O
in	O
the	O
PEs	O
.	O

The	O
isolation	O
of	O
main	O
five	O
components	O
of	O
a	O
series	O
of	O
PEs	O
was	O
revised	B-P
using	O
a	O
semi-preparative	B-P
reversed	I-P
phase	I-P
HPLC	I-P
analysis	I-P
of	O
ODS-3	O
column	O
.	O

The	O
five	O
peaks	O
of	O
components	O
were	O
successfully	O
isolated	O
,	O
and	O
peaks	O
of	O
J2	O
,	O
J3	O
,	O
J5	O
,	O
and	O
J7	O
were	O
assigned	O
to	O
be	O
Jatropha	O
factors	O
C1	O
,	O
C2	O
,	O
C3	O
,	O
and	O
C4/5	O
,	O
but	O
J6	O
was	O
a	O
mixture	O
of	O
Jatropha	O
factor	O
C6	O
and	O
its	O
isomer	O
based	O
on	O
the	O
data	O
of	O
UV	B-P
and	O
LC-MS	B-P
/	O
MS	B-P
,	O
and	O
J2	O
was	O
identified	O
using	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
analysis	I-P
.	O

By	O
characterization	O
using	O
LC-MS	B-P
/	O
MS	B-P
analysis	I-P
,	O
all	O
components	O
of	O
a	O
series	O
of	O
PEs	O
were	O
elucidated	O
to	O
be	O
the	O
12-deoxy-16-hydroxyphorbol	O
esters	O
composed	O
of	O
isomeric	O
form	O
of	O
dicarboxylic	O
groups	O
with	O
same	O
m/z	O
value	O
of	O
380	O
.	O

Multivariate	O
Imaging	B-P
Genetics	O
Study	O
of	O
MRI	B-P
Gray	O
Matter	O
Volume	O
and	O
SNPs	O
Reveals	O
Biological	O
Pathways	O
Correlated	O
with	O
Brain	O
Structural	O
Differences	O
in	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
.	O

Attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
is	O
a	O
prevalent	O
neurodevelopmental	O
disorder	O
affecting	O
children	O
,	O
adolescents	O
,	O
and	O
adults	O
.	O

Its	O
etiology	O
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	O
from	O
diverse	O
pathophysiologies	O
that	O
affect	O
the	O
structure	O
and	O
function	O
of	O
specific	O
brain	O
circuits	O
.	O

Although	O
one	O
of	O
the	O
best-studied	O
neurobiological	O
abnormalities	O
in	O
ADHD	O
is	O
reduced	O
fronto-striatal-cerebellar	O
gray	O
matter	O
(	O
GM	O
)	O
volume	O
,	O
its	O
specific	O
genetic	O
correlates	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
T1-weighted	B-P
MR	I-P
images	I-P
of	I-P
brain	I-P
structure	I-P
were	O
collected	O
from	O
198	O
adolescents	O
(	O
63	O
ADHD	O
-	O
diagnosed	O
)	O
.	O

A	O
multivariate	O
parallel	O
independent	O
component	O
analysis	O
(	O
Para-ICA	O
)	O
technique	O
-identified	O
imaging	B-P
genetic	O
relationships	O
between	O
regional	O
GM	O
volume	O
and	O
single	O
nucleotide	O
polymorphism	O
data	O
.	O

Para-ICA	O
analyses	O
extracted	O
14	O
components	O
from	O
genetic	O
data	O
and	O
9	O
from	O
MR	B-P
data	O
.	O

An	O
iterative	O
cross-validation	O
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	O
of	O
these	O
ICA	O
solutions	O
.	O

A	O
series	O
of	O
partial	O
correlation	O
analyses	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
and	O
ethnicity	O
revealed	O
two	O
genotype-phenotype	O
component	O
pairs	O
significantly	O
differed	O
between	O
ADHD	O
and	O
non-ADHD	O
groups	O
,	O
after	O
a	O
Bonferroni	O
correction	O
for	O
multiple	O
comparisons	O
.	O

The	O
brain	O
phenotype	O
component	O
not	O
only	O
included	O
structures	O
frequently	O
found	O
to	O
have	O
abnormally	O
low	O
volume	O
in	O
previous	O
ADHD	O
studies	O
but	O
was	O
also	O
significantly	O
associated	O
with	O
ADHD	O
differences	O
in	O
symptom	O
severity	O
and	O
performance	O
on	O
cognitive	O
tests	O
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	O
diagnosed	O
with	O
the	O
disorder	O
.	O

Pathway	O
analysis	O
of	O
the	O
genotype	O
component	O
identified	O
several	O
different	O
biological	O
pathways	O
linked	O
to	O
these	O
structural	O
abnormalities	O
in	O
ADHD	O
.	O

Some	O
of	O
these	O
pathways	O
implicate	O
well-known	O
dopaminergic	O
neurotransmission	O
and	O
neurodevelopment	O
hypothesized	O
to	O
be	O
abnormal	O
in	O
ADHD	O
.	O

Other	O
more	O
recently	O
implicated	O
pathways	O
included	O
glutamatergic	O
and	O
GABA-eric	O
physiological	O
systems	O
;	O
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
ADHD	O
,	O
such	O
as	O
sleep	O
abnormalities	O
.	O

Genome-Wide	O
Detection	O
of	O
Selective	O
Signatures	O
in	O
Chicken	O
through	O
High	O
Density	O
SNPs	O
.	O

Chicken	O
is	O
recognized	O
as	O
an	O
excellent	O
model	O
for	O
studies	O
of	O
genetic	O
mechanism	O
of	O
phenotypic	O
and	O
genomic	O
evolution	O
,	O
with	O
large	O
effective	O
population	O
size	O
and	O
strong	O
human	O
-driven	O
selection	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
Extended	O
Haplotype	O
Homozygosity	O
(	O
EHH	O
)	O
tests	O
to	O
identify	O
significant	O
core	O
regions	O
employing	O
600K	O
SNP	O
Chicken	O
chip	O
in	O
an	O
F2	O
population	O
of	O
1,534	O
hens	O
,	O
which	O
was	O
derived	O
from	O
reciprocal	O
crosses	O
between	O
White	O
Leghorn	O
and	O
Dongxiang	O
chicken	O
.	O

Results	O
indicated	O
that	O
a	O
total	O
of	O
49,151	O
core	O
regions	O
with	O
an	O
average	O
length	O
of	O
9.79	O
Kb	O
were	O
identified	O
,	O
which	O
occupied	O
approximately	O
52.15	O
%	O
of	O
genome	O
across	O
all	O
autosomes	O
,	O
and	O
806	O
significant	O
core	O
regions	O
attracted	O
us	O
mostly	O
.	O

Genes	O
in	O
candidate	O
regions	O
may	O
experience	O
positive	B-P
selection	I-P
and	O
were	O
considered	O
to	O
have	O
possible	O
influence	O
on	O
beneficial	O
economic	O
traits	O
.	O

A	O
panel	O
of	O
genes	O
including	O
AASDHPPT	O
,	O
GDPD5	O
,	O
PAR3	O
,	O
SOX6	O
,	O
GPC1	O
and	O
a	O
signal	O
pathway	O
of	O
AKT1	O
were	O
detected	O
with	O
the	O
most	O
extreme	O
P-values	O
.	O

Further	O
enrichment	O
analyses	O
indicated	O
that	O
these	O
genes	O
were	O
associated	O
with	O
immune	O
function	O
,	O
sensory	O
organ	O
development	O
and	O
neurogenesis	O
,	O
and	O
may	O
have	O
experienced	O
positive	B-P
selection	I-P
in	O
chicken	O
.	O

Moreover	O
,	O
some	O
of	O
core	O
regions	O
exactly	O
overlapped	O
with	O
genes	O
excavated	O
in	O
our	O
previous	O
GWAS	O
,	O
suggesting	O
that	O
these	O
genes	O
have	O
undergone	O
positive	B-P
selection	I-P
may	O
affect	O
egg	O
production	O
.	O

Findings	O
in	O
our	O
study	O
could	O
draw	O
a	O
comparatively	O
integrate	O
genome-wide	O
map	O
of	O
selection	O
signature	O
in	O
the	O
chicken	O
genome	O
,	O
and	O
would	O
be	O
worthy	O
for	O
explicating	O
the	O
genetic	O
mechanisms	O
of	O
phenotypic	O
diversity	O
in	O
poultry	O
breeding	O
.	O

Systems	O
Toxicology	O
:	O
Real	O
World	O
Applications	O
and	O
Opportunities	O
.	O

Systems	O
Toxicology	O
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	O
are	O
characterized	O
from	O
empirical	O
end	O
points	O
to	O
describing	O
modes	O
of	O
action	O
as	O
adverse	O
outcome	O
pathways	O
and	O
perturbed	O
networks	O
.	O

Toward	O
this	O
aim	O
,	O
Systems	O
Toxicology	O
entails	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
toxicity	O
data	O
with	O
computational	O
modeling	O
.	O

This	O
evolving	O
approach	O
depends	O
critically	O
on	O
data	O
reliability	O
and	O
relevance	O
,	O
which	O
in	O
turn	O
depends	O
on	O
the	O
quality	O
of	O
experimental	O
models	O
and	O
bioanalysis	O
techniques	O
used	O
to	O
generate	O
toxicological	O
data	O
.	O

Systems	O
Toxicology	O
involves	O
the	O
use	O
of	O
large-scale	O
data	O
streams	O
(	O
``	O
big	O
data	O
``	O
)	O
,	O
such	O
as	O
those	O
derived	O
from	O
omics	O
measurements	O
that	O
require	O
computational	O
means	O
for	O
obtaining	O
informative	O
results	O
.	O

Thus	O
,	O
integrative	O
analysis	O
of	O
multiple	O
molecular	O
measurements	O
,	O
particularly	O
acquired	O
by	O
omics	B-P
strategies	I-P
,	O
is	O
a	O
key	O
approach	O
in	O
Systems	O
Toxicology	O
.	O

In	O
recent	O
years	O
,	O
there	O
have	O
been	O
significant	O
advances	O
centered	O
on	O
in	O
vitro	O
test	O
systems	O
and	O
bioanalytical	B-P
strategies	I-P
,	O
yet	O
a	O
frontier	O
challenge	O
concerns	O
linking	O
observed	O
network	O
perturbations	O
to	O
phenotypes	O
,	O
which	O
will	O
require	O
understanding	O
pathways	O
and	O
networks	O
that	O
give	O
rise	O
to	O
adverse	O
responses	O
.	O

This	O
summary	O
perspective	O
from	O
a	O
2016	O
Systems	O
Toxicology	O
meeting	O
,	O
an	O
international	O
conference	O
held	O
in	O
the	O
Alps	O
of	O
Switzerland	O
,	O
describes	O
the	O
limitations	O
and	O
opportunities	O
of	O
selected	O
emerging	O
applications	O
in	O
this	O
rapidly	O
advancing	O
field	O
.	O

Systems	O
Toxicology	O
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	O
are	O
characterized	O
,	O
from	O
empirical	O
end	O
points	O
to	O
pathways	O
of	O
toxicity	O
.	O

This	O
requires	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
data	O
with	O
computational	O
modeling	O
.	O

Test	O
systems	O
and	O
bioanalytical	B-P
technologies	I-P
have	O
made	O
significant	O
advances	O
,	O
but	O
ensuring	O
data	O
reliability	O
and	O
relevance	O
is	O
an	O
ongoing	O
concern	O
.	O

The	O
major	O
challenge	O
facing	O
the	O
new	O
pathway	O
approach	O
is	O
determining	O
how	O
to	O
link	O
observed	O
network	O
perturbations	O
to	O
phenotypic	O
toxicity	O
.	O

Cross-reactivity	O
features	O
of	O
deoxynivalenol	O
(	O
DON	O
)	O
-targeted	O
immunoaffinity	B-P
columns	O
aiming	O
to	O
achieve	O
simultaneous	O
analysis	B-P
of	O
DON	O
and	O
major	O
conjugates	O
in	O
cereal	O
samples	O
.	O

Immunoafﬁnity	B-P
columns	O
(	O
IACs	O
)	O
are	O
a	O
well-established	O
tool	O
in	O
the	O
determination	O
of	O
regulated	O
mycotoxins	O
in	O
food	O
and	O
feed	O
commodities	O
.	O

However	O
,	O
they	O
also	O
have	O
the	O
potential	O
to	O
become	O
attractive	O
pre-concentration	O
and	O
clean-up	O
materials	O
for	O
the	O
determination	O
of	O
masked	O
(	O
also	O
called	O
modified	O
)	O
mycotoxins	O
,	O
which	O
have	O
been	O
recognised	O
as	O
important	O
contributors	O
to	O
the	O
toxicological	O
hazard	O
deriving	O
from	O
fungal	O
spoilage	O
of	O
goods	O
.	O

However	O
,	O
the	O
information	O
available	O
in	O
the	O
literature	O
concerning	O
the	O
cross-reactivity	O
of	O
DON	O
-	O
IACs	O
against	O
the	O
major	O
conjugates	O
(	O
DON-3-G	O
,	O
15-AcDON	O
and	O
3-AcDON	O
)	O
is	O
incomplete	O
and	O
often	O
contradictory	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
characterisation	O
of	O
the	O
cross-reactivity	O
of	O
the	O
four	O
main	O
IACs	O
brands	O
against	O
DON	O
and	O
its	O
conjugates	O
as	O
well	O
as	O
an	O
assessment	O
of	O
the	O
competition	O
among	O
the	O
analytes	O
.	O

Only	O
one	O
IAC	O
enabled	O
the	O
simultaneous	O
analysis	B-P
of	O
all	O
relevant	O
DON	O
forms	O
while	O
two	O
missed	O
15-AcDON	O
and	O
the	O
fourth	O
one	O
missed	O
DON-3-G	O
and	O
3-AcDON	O
.	O

In	O
the	O
case	O
of	O
the	O
multivalent	O
IAC	O
,	O
the	O
analytes	O
modified	O
at	O
the	O
C-3	O
position	O
compete	O
for	O
the	O
antibody	O
binding	O
with	O
preference	O
for	O
3-AcDON	O
(	O
less	O
spatially	O
hindered	O
)	O
while	O
DON-3-G	O
has	O
the	O
more-hindered	O
access	O
to	O
the	O
active	O
sites	O
.	O

Taking	O
into	O
consideration	O
the	O
levels	O
of	O
DON	O
conjugates	O
existing	O
in	O
real	O
samples	O
,	O
the	O
cross-reactivity	O
of	O
one	O
DON	O
-	O
IAC	O
allows	O
a	O
quantitative	O
analysis	O
of	O
all	O
of	O
these	O
analytes	O
.	O

Important	O
but	O
rather	O
neglected	O
aspects	O
such	O
as	O
the	O
continuous	O
supply	O
of	O
IACs	O
with	O
identical	O
characteristics	O
,	O
and	O
of	O
columns	O
which	O
are	O
strictly	O
blank	O
,	O
are	O
also	O
addressed	O
in	O
this	O
paper	O
.	O

Quantification	O
of	O
intact	O
plasma	O
AGT	O
consisting	O
of	O
oxidized	O
and	O
reduced	O
conformations	O
using	O
a	O
modified	O
ELISA	B-P
.	O

The	O
pleiotropic	O
actions	O
of	O
the	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
depend	O
on	O
the	O
availability	O
of	O
angiotensinogen	O
(	O
AGT	O
)	O
which	O
generates	O
angiotensin	O
I	O
(	O
ANG	O
I	O
)	O
when	O
cleaved	O
by	O
renin	O
.	O

Thus	O
,	O
quantification	O
of	O
the	O
intact	O
AGT	O
(	O
iAGT	O
)	O
concentrations	O
is	O
important	O
to	O
evaluate	O
the	O
actual	O
renin	O
substrate	O
available	O
.	O

The	O
iAGT	O
conformation	O
exists	O
as	O
oxidized	O
AGT	O
(	O
oxi-AGT	O
)	O
and	O
reduced	O
AGT	O
(	O
red-AGT	O
)	O
in	O
a	O
disulfide	O
bond	O
,	O
and	O
oxi-AGT	O
has	O
a	O
higher	O
affinity	O
for	O
renin	O
,	O
which	O
may	O
exacerbate	O
RAS	O
-	O
associated	O
diseases	O
.	O

Accordingly	O
,	O
we	O
determined	O
iAGT	O
,	O
oxi-AGT	O
,	O
and	O
red-AGT	O
levels	O
in	O
plasma	O
from	O
rats	O
and	O
mice	O
.	O

Blood	O
samples	O
were	O
obtained	O
by	O
cardiac	B-P
puncture	I-P
and	O
then	O
immediately	O
mixed	O
with	O
an	O
inhibitor	O
solution	O
containing	O
a	O
renin	O
inhibitor	O
.	O

Total	O
AGT	O
(	O
tAGT	O
)	O
levels	O
were	O
measured	O
by	O
tAGT	O
ELISA	B-P
which	O
detects	O
both	O
cleaved	O
and	O
iAGT	O
.	O

iAGT	O
levels	O
were	O
determined	O
by	O
iAGT	O
ELISA	B-P
which	O
was	O
found	O
to	O
only	O
detect	O
red-AGT	O
.	O

Thus	O
,	O
it	O
was	O
necessary	O
to	O
treat	O
samples	O
with	O
dithiothreitol	O
,	O
a	O
reducing	O
agent	O
,	O
to	O
quantify	O
total	O
iAGT	O
concentration	O
.	O

tAGT	O
levels	O
in	O
rat	O
and	O
mouse	O
plasma	O
were	O
1,839	O
±	O
139	O
and	O
1,082	O
±	O
77	O
ng/ml	O
,	O
respectively	O
.	O

iAGT	O
levels	O
were	O
53	O
%	O
of	O
tAGT	O
in	O
rat	O
plasma	O
but	O
only	O
22	O
%	O
in	O
mouse	O
plasma	O
,	O
probably	O
reflecting	O
the	O
greater	O
plasma	O
renin	O
activity	O
in	O
mice	O
.	O

The	O
ratios	O
of	O
oxi-AGT	O
and	O
red-AGT	O
were	O
∼4:1	O
(	O
rat	O
)	O
and	O
16:1	O
(	O
mouse	O
)	O
.	O

Plasma	O
iAGT	O
consists	O
of	O
oxi-AGT	O
and	O
red-AGT	O
,	O
suggesting	O
that	O
oxidative	O
stress	O
can	O
influence	O
ANG	O
I	O
generation	O
by	O
the	O
AGT	O
conformation	O
switch	O
.	O

Furthermore	O
,	O
the	O
lower	O
availability	O
of	O
plasma	O
iAGT	O
in	O
mice	O
suggests	O
that	O
it	O
may	O
serve	O
as	O
a	O
limiting	O
factor	O
in	O
ANG	O
I	O
formation	O
in	O
this	O
species	O
.	O

Tofacitinib	O
versus	O
methotrexate	O
in	O
rheumatoid	O
arthritis	O
:	O
patient-reported	O
outcomes	O
from	O
the	O
randomised	O
phase	O
III	O
ORAL	O
Start	O
trial	O
.	O

To	O
compare	O
patient-reported	O
outcomes	O
(	O
PROs	O
)	O
in	O
methotrexate	O
(	O
MTX	O
)	O
-	O
naive	O
patients	O
(	O
defined	O
as	O
no	O
prior	O
treatment	O
or	O
≤3	O
doses	O
)	O
receiving	O
tofacitinib	O
versus	O
MTX	O
.	O

In	O
the	O
24-	O
month	O
,	O
phase	O
III	O
,	O
randomised	O
,	O
controlled	O
,	O
ORAL	O
Start	O
trial	O
(	O
NCT01039688	O
)	O
,	O
patients	O
were	O
randomised	O
2:2:1	O
to	O
receive	O
tofacitinib	O
5	O
mg	O
two	O
times	O
per	O
day	O
(	O
n=373	O
)	O
,	O
tofacitinib	O
10	O
mg	O
two	O
times	O
per	O
day	O
(	O
n=397	O
)	O
or	O
MTX	O
(	O
n=186	O
)	O
.	O

PROs	O
assessed	O
included	O
Patient	O
Global	O
Assessment	O
of	O
disease	O
(	O
PtGA	O
)	O
,	O
pain	O
,	O
Health	O
Assessment	O
Questionnaire-Disability	O
Index	O
(	O
HAQ-DI	O
)	O
,	O
Functional	O
Assessment	O
of	O
Chronic	O
Illness	O
Therapy-Fatigue	O
(	O
FACIT-F	O
)	O
and	O
health-related	O
quality	O
of	O
life	O
(	O
Short	O
Form-36	O
[	O
SF-36	O
]	O
)	O
.	O

PROs	O
improved	O
following	O
tofacitinib	O
and	O
MTX	O
treatment	O
:	O
benefits	O
were	O
sustained	O
over	O
24	O
months	O
.	O

Patients	O
receiving	O
tofacitinib	O
reported	O
earlier	O
responses	O
which	O
were	O
significantly	O
different	O
between	O
each	O
tofacitinib	O
dose	O
and	O
MTX	O
at	O
month	O
3	O
through	O
month	O
24	O
.	O

At	O
month	O
6	O
(	O
primary	O
end	O
point	O
)	O
,	O
significant	O
improvements	O
versus	O
MTX	O
were	O
observed	O
in	O
PtGA	O
,	O
pain	O
,	O
HAQ-DI	O
,	O
SF-36	O
Physical	O
Component	O
Summary	O
(	O
PCS	O
)	O
,	O
5/8	O
domain	O
scores	O
and	O
FACIT-F	O
with	O
tofacitinib	O
5	O
mg	O
two	O
times	O
per	O
day	O
;	O
all	O
PROs	O
,	O
except	O
SF-36	O
Mental	O
Component	O
Summary	O
Score	O
and	O
Medical	O
Outcomes	O
Survey	O
-	O
Sleep	O
,	O
with	O
tofacitinib	O
10	O
mg	O
two	O
times	O
per	O
day	O
.	O

At	O
month	O
6	O
,	O
the	O
proportion	O
of	O
patients	O
reporting	O
improvements	O
≥	O
minimum	O
clinically	O
important	O
difference	O
were	O
significant	O
versus	O
MTX	O
with	O
tofacitinib	O
5	O
mg	O
two	O
times	O
per	O
day	O
in	O
PtGA	O
and	O
3/8	O
SF-36	O
domains	O
;	O
and	O
with	O
tofacitinib	O
10	O
mg	O
two	O
times	O
per	O
day	O
in	O
PtGA	O
,	O
pain	O
,	O
HAQ-DI	O
,	O
SF-36	O
PCS	O
,	O
4/8	O
domains	O
and	O
FACIT-F	O
.	O

Patients	O
with	O
rheumatoid	O
arthritis	O
receiving	O
tofacitinib	O
5	O
and	O
10	O
mg	O
two	O
times	O
per	O
day	O
monotherapy	B-P
versus	O
MTX	O
reported	O
statistically	O
significant	O
and	O
clinically	O
meaningful	O
improvements	O
in	O
multiple	O
PROs	O
over	O
24	O
months	O
;	O
onset	O
of	O
benefit	O
with	O
tofacitinib	O
treatment	O
occurred	O
earlier	O
.	O

NCT01039688	O
.	O

The	O
2016	O
Infusion	B-P
Therapy	I-P
Standards	O
of	O
Practice	O
.	O

Approximately	O
every	O
5	O
years	O
,	O
the	O
Infusion	O
Nurses	O
Society	O
publishes	O
evidence-based	O
practice	O
standards	O
.	O

This	O
article	O
provides	O
an	O
overview	O
of	O
the	O
process	O
used	O
in	O
standards	O
development	O
,	O
describes	O
the	O
format	O
of	O
the	O
standards	O
,	O
and	O
provides	O
a	O
short	O
summary	O
of	O
selected	O
standards	O
as	O
applied	O
to	O
home	O
care	O
.	O

The	O
Standards	O
are	O
an	O
important	O
document	O
that	O
should	O
be	O
available	O
to	O
every	O
home	O
care	O
organization	O
that	O
provides	O
home	B-P
infusion	I-P
therapy	I-P
.	O

Analysis	B-P
of	O
tilianin	O
and	O
acacetin	O
in	O
Agastache	O
rugosa	O
by	O
high-performance	B-P
liquid	I-P
chromatography	I-P
with	O
ionic	O
liquids	O
-	O
ultrasound	O
based	O
extraction	B-P
.	O

Ionic	O
liquid	O
1-butyl-3-methylimidazolium	O
bromide	O
-	O
methanol	O
-based	O
ultrasonic	O
-assisted	O
extraction	B-P
(	O
ILUAE	B-P
)	O
was	O
used	O
to	O
extract	B-P
tilianin	O
and	O
acacetin	O
from	O
the	O
aerial	O
parts	O
of	O
Agastache	O
rugose	O
(	O
A.	O
rugose	O
)	O
,	O
and	O
simultaneously	O
determined	O
by	O
reversed	B-P
phase	I-P
high	I-P
performance	I-P
liquid	I-P
chromatographic	I-P
(	O
RP-HPLC	B-P
)	O
method	O
with	O
ultraviolet	O
detection	O
(	O
RP-HPLC-UV	O
)	O
.	O

An	O
InertSustain	O
RP-C18	O
column	O
was	O
used	O
with	O
the	O
mobile	O
phase	O
consisting	O
of	O
methanol	O
and	O
0.2	O
%	O
acetic	O
acid	O
as	O
gradient	O
elution	B-P
at	O
the	O
detection	O
wavelength	O
of	O
332	O
nm	O
.	O

The	O
flow	O
rate	O
was	O
0.8	O
mL/min	O
,	O
and	O
the	O
column	O
temperature	O
was	O
30	O
°C	O
.	O

Under	O
the	O
optimized	O
conditions	O
,	O
tilianin	O
and	O
acacetin	O
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0.0595-4.76	O
and	O
0.0585-4.68	O
μg/mL	O
,	O
respectively	O
,	O
with	O
the	O
average	O
recoveries	O
being	O
96.93	O
and	O
97.88	O
%	O
,	O
respectively	O
.	O

The	O
method	O
of	O
ILUAE	B-P
was	O
compared	O
with	O
the	O
traditional	O
methods	O
,	O
it	O
exhibited	O
higher	O
efficiency	O
,	O
higher	O
reproducibility	O
and	O
environmental	O
friendly	O
in	O
analyzing	O
the	O
active	O
compounds	O
in	O
traditional	O
Chinese	O
medicines	O
(	O
TCMs	O
)	O
.	O

Validating	O
Signs	O
and	O
Symptoms	O
From	O
An	O
Actual	O
Mass	O
Casualty	O
Incident	O
to	O
Characterize	O
An	O
Irritant	O
Gas	O
Syndrome	O
Agent	O
(	O
IGSA	O
)	O
Exposure	O
:	O
A	O
First	O
Step	O
in	O
The	O
Development	O
of	O
a	O
Novel	O
IGSA	O
Triage	B-P
Algorithm	O
.	O

Chemical	O
exposures	O
can	O
pose	O
a	O
significant	O
threat	O
to	O
life	O
.	O

Rapid	O
assessment	O
by	O
first	O
responders	O
/	O
emergency	O
nurses	O
is	O
required	O
to	O
reduce	O
death	O
and	O
disability	O
.	O

Currently	O
,	O
no	O
informatics	O
tools	O
for	O
irritant	O
gas	O
syndrome	O
agent	O
s	O
(	O
IGSA	O
)	O
exposures	O
exist	O
to	O
process	O
victims	O
efficiently	O
,	O
continuously	O
monitor	O
for	O
latent	O
signs/symptoms	O
,	O
or	O
make	O
triage	B-P
recommendations	O
.	O

This	O
study	O
describes	O
the	O
first	O
step	O
in	O
developing	O
ED	O
informatics	O
tools	O
for	O
chemical	O
incidents	O
:	O
validation	O
of	O
signs/symptoms	O
that	O
characterize	O
an	O
IGSA	O
syndrome	O
.	O

Data	O
abstracted	O
from	O
146	O
patients	O
treated	B-P
for	O
chlorine	O
exposure	O
in	O
one	O
emergency	O
department	O
during	O
a	O
2005	O
train	O
derailment	O
and	O
152	O
patients	O
not	O
exposed	O
to	O
chlorine	O
(	O
a	O
comparison	O
group	O
)	O
were	O
mapped	O
to	O
93	O
possible	O
signs/symptoms	O
within	O
2	O
tools	O
(	O
WISER	O
and	O
CHEMM-IST	O
)	O
designed	O
to	O
assist	O
emergency	O
responders	O
/	O
emergency	O
nurses	O
with	O
managing	O
hazardous	O
material	O
exposures	O
.	O

Inferential	O
statistics	O
(	O
χ	O
(	O
2	O
)	O
/	O
Fisher	O
's	O
exact	O
test	O
)	O
and	O
diagnostics	B-P
tests	I-P
were	O
used	O
to	O
examine	O
mapped	O
signs/symptoms	O
of	O
persons	O
who	O
were	O
and	O
were	O
not	O
exposed	O
to	O
chlorine	O
.	O

Three	O
clusters	O
of	O
signs/symptoms	O
are	O
statistically	O
associated	O
with	O
an	O
IGSA	O
syndrome	O
(	O
P	O
<	O
.01	O
)	O
:	O
respiratory	O
(	O
shortness	O
of	O
breath	O
,	O
wheezing	O
,	O
coughing	O
,	O
and	O
choking	O
)	O
;	O
chest	O
discomfort	O
(	O
tightness	O
,	O
pain	O
,	O
and	O
burning	O
)	O
,	O
and	O
eye	O
,	O
nose	O
and/or	O
throat	O
(	O
pain	O
,	O
irritation	O
,	O
and	O
burning	O
)	O
.	O

The	O
syndrome	O
requires	O
the	O
presence	O
of	O
signs/symptoms	O
from	O
at	O
least	O
2	O
of	O
these	O
clusters	O
.	O

The	O
latency	O
period	O
must	O
also	O
be	O
considered	O
for	O
exposed	O
/	O
potentially	O
exposed	O
persons	O
.	O

This	O
study	O
uses	O
actual	O
patient	O
data	O
from	O
a	O
chemical	O
incident	O
to	O
characterize	O
and	O
validate	O
signs/symptoms	O
of	O
an	O
IGSA	O
syndrome	O
.	O

Validating	O
signs/symptoms	O
is	O
the	O
first	O
step	O
in	O
developing	O
new	O
ED	O
informatics	O
tools	O
with	O
the	O
potential	O
to	O
revolutionize	O
the	O
process	O
by	O
which	O
emergency	O
nurses	O
manage	O
triage	B-P
victims	O
of	O
chemical	O
incidents	O
.	O

Cardiovascular	O
comorbidity	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
in	O
the	O
Canary	O
Islands	O
(	O
CCECAN	O
study	O
)	O
.	O

Numerous	O
studies	B-P
have	O
shown	O
a	O
high	O
prevalence	O
of	O
cardiovascular	O
disease	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
prevalence	O
of	O
cardiovascular	O
risk	O
factors	O
and	O
comorbidity	O
in	O
a	O
Canary	O
Islands	O
population	O
diagnosed	O
with	O
COPD	O
,	O
and	O
compared	O
it	O
with	O
data	O
from	O
the	O
general	O
population	O
.	O

A	O
cross-sectional	O
study	O
was	O
carried	O
out	O
in	O
300	O
patients	O
with	O
COPD	O
and	O
524	O
subjects	O
without	O
respiratory	O
disease	O
(	O
control	O
group	O
)	O
.	O

The	O
two	O
groups	O
were	O
compared	O
using	O
standard	O
bivariate	O
methods	O
.	O

Logistic	O
regression	O
models	O
were	O
used	O
to	O
estimate	O
the	O
cardiovascular	O
risks	O
in	O
COPD	O
patients	O
compared	O
to	O
control	O
group	O
.	O

Patients	O
with	O
COPD	O
showed	O
a	O
high	O
prevalence	O
of	O
hypertension	O
(	O
72	O
%	O
)	O
,	O
dyslipidaemia	O
(	O
73	O
%	O
)	O
,	O
obesity	O
(	O
41	O
%	O
)	O
,	O
diabetes	O
type	O
2	O
(	O
39	O
%	O
)	O
,	O
and	O
sleep	O
apnoea	O
syndrome	O
(	O
30	O
%	O
)	O
from	O
mild	O
stages	B-P
of	I-P
the	I-P
disease	I-P
(	O
GOLD	O
2009	O
)	O
.	O

There	O
was	O
a	O
22	O
%	O
prevalence	O
of	O
cardiac	O
arrhythmia	O
,	O
16	O
%	O
of	O
ischaemic	O
heart	O
disease	O
,	O
16	O
%	O
heart	O
failure	O
,	O
12	O
%	O
peripheral	O
vascular	O
disease	O
,	O
and	O
8	O
%	O
cerebrovascular	O
disease	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
patients	O
with	O
COPD	O
had	O
a	O
higher	O
risk	O
of	O
dyslipidaemia	O
(	O
OR	O
3.24	O
,	O
95	O
%	O
CI	O
;	O
2.21-4.75	O
)	O
,	O
diabetes	O
type	O
2	O
(	O
OR	O
1.52	O
,	O
95	O
%	O
CI	O
;	O
1.01-2,28	O
)	O
,	O
and	O
ischaemic	O
heart	O
disease	O
(	O
OR	O
2.34	O
,	O
95	O
%	O
CI	O
;	O
1.22-4.49	O
)	O
.	O

In	O
the	O
case	O
of	O
dyslipidaemia	O
,	O
an	O
increased	O
risk	O
was	O
obtained	O
when	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
and	O
consumption	O
of	O
tobacco	O
(	O
OR	O
5.04	O
,	O
95	O
%	O
CI	O
;	O
2.36-10.74	O
)	O
.	O

Patients	O
with	O
COPD	O
resident	O
in	O
the	O
Canary	O
Islands	O
have	O
a	O
high	O
prevalence	O
of	O
hypertension	O
,	O
dyslipidaemia	O
,	O
ischaemic	O
heart	O
disease	O
,	O
and	O
cardiac	O
arrhythmia	O
.	O

Compared	O
to	O
general	O
population	O
,	O
patients	O
with	O
COPD	O
have	O
a	O
significant	O
increase	O
in	O
the	O
risk	O
of	O
dyslipidaemia	O
.	O

Use	O
of	O
bacterial	O
whole-genome	O
sequencing	O
to	O
understand	O
and	O
improve	O
the	O
management	O
of	O
invasive	O
Staphylococcus	O
aureus	O
infections	O
.	O

Management	O
of	O
invasive	O
Staphylococcus	O
aureus	O
infections	O
is	O
complex	O
.	O

Dramatic	O
improvements	O
in	O
bacterial	O
whole	O
genome	O
sequencing	O
(	O
WGS	O
)	O
offer	O
new	O
opportunities	O
for	O
personalising	O
the	O
treatment	B-P
of	O
S.	O
aureus	O
infections	O
.	O

Areas	O
covered	O
:	O
We	O
address	O
recent	O
achievements	O
in	O
S.	O
aureus	O
genomics	O
,	O
describe	O
genetic	O
determinants	O
of	O
antibiotic	O
resistance	O
and	O
summarise	O
studies	O
that	O
have	O
defined	O
molecular	O
characteristics	O
associated	O
with	O
risk	O
and	O
outcome	O
of	O
S.	O
aureus	O
invasive	O
infections	O
.	O

Potential	O
clinical	O
use	O
of	O
WGS	O
for	O
resistance	O
prediction	O
,	O
infection	O
outcome	O
stratification	O
and	O
management	O
of	O
persisten	O
t	O
/	O
relapsing	O
infections	O
is	O
critically	O
discussed	O
.	O

Expert	O
commentary	O
:	O
WGS	O
is	O
not	O
only	O
providing	O
invaluable	O
information	O
to	O
track	O
the	O
emergence	O
and	O
spread	O
of	O
important	O
S.	O
aureus	O
clones	O
,	O
but	O
also	O
allows	O
rapid	O
determination	B-P
of	O
resistance	O
genotypes	O
in	O
the	O
clinical	O
environment	O
.	O

An	O
evolving	O
opportunity	O
is	O
to	O
infer	O
clinically	O
important	O
outcomes	O
and	O
optimal	O
therapeutic	B-P
approaches	I-P
from	O
widely	O
available	O
S.	O
aureus	O
genome	O
data	O
,	O
with	O
the	O
goal	O
of	O
individualizing	O
management	O
of	O
invasive	O
S.	O
aureus	O
infections	O
.	O

Antidiabetic	O
potential	O
of	O
bioactive	O
molecules	O
coated	O
chitosan	O
nanoparticles	O
in	O
experimental	O
rats	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
examine	O
the	O
antidiabetic	O
effects	O
of	O
chitosan	O
nanoparticles	O
(	O
CNPs	O
)	O
loaded	O
with	O
(	O
Stevia	O
rebaudiana	O
leaf	O
extract	O
-	O
SRLE	O
)	O
bioactive	O
molecules	O
in	O
a	O
rat	O
model	O
of	O
streptozotocin	O
(	O
STZ	O
)	O
induced	O
diabetes	O
mellitus	O
.	O

Successful	O
crosslinking	O
of	O
the	O
bioactive	O
molecules	O
to	O
the	O
chitosan	O
nanoparticles	O
was	O
confirmed	O
by	O
Fourier	O
Transform	O
Infrared	O
Spectroscopy	O
(	O
FTIR	O
)	O
.	O

The	O
colloidal	O
characteristics	O
of	O
the	O
synthesized	O
nanoparticles	O
were	O
revealed	O
by	O
X-ray	B-P
Diffraction	I-P
(	I-P
XRD	I-P
)	I-P
analysis	I-P
.	O

Morphological	O
analysis	O
by	O
Transmission	B-P
Electron	I-P
Microscopy	I-P
(	O
TEM	B-P
)	O
revealed	O
that	O
the	O
bioactive	O
molecule	O
-loaded	O
CNPs	O
were	O
well-dispersed	O
and	O
spherical	O
or	O
polygonal	O
in	O
shape	O
with	O
an	O
average	O
size	O
of	O
<	O
73.27nm	O
than	O
the	O
z-average	O
value	O
(	O
327nm	O
)	O
as	O
measured	O
by	O
Dynamic	B-P
Light	I-P
Scattering	I-P
(	O
DLS	B-P
)	O
.	O

SRLE	O
CNP	O
-	O
treated	O
diabetic	O
rats	O
showed	O
a	O
significant	O
reduction	O
in	O
their	O
mean	O
fasting	O
blood	O
glucose	O
level	O
compared	O
with	O
the	O
diabetic	O
control	O
group	O
.	O

The	O
serum	O
levels	O
of	O
various	O
enzymes	O
viz.	O
,	O
serum	O
glutamic	O
oxaloacetic	O
transaminase	O
(	O
SGOT	O
)	O
,	O
serum	O
glutamic	O
pyruvic	O
transaminase	O
(	O
SGPT	O
)	O
,	O
alkaline	O
phosphatases	O
(	O
ALP	O
)	O
,	O
lipid	O
peroxidation	O
,	O
and	O
antioxidant	O
such	O
as	O
catalase	O
(	O
CAT	O
)	O
,	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
and	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
in	O
the	O
SRLE	O
CNP	O
-	O
treated	O
group	O
were	O
closer	O
to	O
normal	O
levels	O
than	O
those	O
in	O
the	O
diabetic	O
control	O
group	O
.	O

Impact	O
of	O
hospital	O
transfer	O
on	O
surgical	O
outcomes	O
of	O
intestinal	O
atresia	O
.	O

Examine	O
effects	O
of	O
hospital	O
transfer	O
into	O
a	O
quaternary	O
care	O
center	O
on	O
surgical	O
outcomes	O
of	O
intestinal	O
atresia	O
.	O

Children	O
<	O
1	O
yo	O
principally	O
diagnosed	O
with	O
intestinal	O
atresia	O
were	O
identified	O
using	O
the	O
Kids	O
'	O
Inpatient	O
Database	O
(	O
2012	O
)	O
.	O

Exposure	O
variable	O
was	O
patient	O
transfer	O
status	O
.	O

Outcomes	O
measured	O
were	O
inpatient	O
mortality	O
,	O
hospital	O
length	O
of	O
stay	O
(	O
LOS	O
)	O
and	O
discharge	O
status	O
.	O

Linearized	O
standard	O
errors	O
,	O
design-based	O
F	O
tests	O
,	O
and	O
multivariable	O
logistic	O
regression	O
were	O
performed	O
.	O

1672	O
weighted	O
discharges	O
represented	O
a	O
national	O
cohort	O
.	O

The	O
highest	O
income	O
group	O
and	O
those	O
with	O
private	O
insurance	O
had	O
significantly	O
lower	O
odds	O
of	O
transfer	O
(	O
OR:0.53	O
and	O
0.74	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Rural	O
patients	O
had	O
significantly	O
higher	O
transfer	O
rates	O
(	O
OR	O
:	O
2.73	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Multivariate	O
analysis	O
revealed	O
no	O
difference	O
in	O
mortality	O
(	O
OR:0.71	O
,	O
p	O
=	O
0.464	O
)	O
or	O
non-home	O
discharge	O
(	O
OR	O
:	O
0.79	O
,	O
p	O
=	O
0.166	O
)	O
,	O
but	O
showed	O
prolonged	O
LOS	O
(	O
OR:1.79	O
,	O
p	O
<	O
0.05	O
)	O
amongst	O
transferred	O
patients	O
.	O

Significant	O
differences	O
in	O
hospital	O
LOS	O
and	O
treatment	B-P
access	O
reveal	O
a	O
potential	O
healthcare	O
gap	O
.	O

Post-acute	O
care	O
resources	O
should	O
be	O
improved	O
for	O
transferred	O
patients	O
.	O

H2O2	O
-Responsive	O
Vesicles	O
Integrated	O
with	O
Transcutaneous	B-P
Patches	O
for	O
Glucose	O
-Mediated	O
Insulin	O
Delivery	O
.	O

A	O
self-regulated	O
``	O
smart	O
''	O
insulin	O
administration	O
system	O
would	O
be	O
highly	O
desirable	O
for	O
diabetes	B-P
management	I-P
.	O

Here	O
,	O
a	O
glucose	O
-responsive	O
insulin	O
delivery	O
device	O
,	O
which	O
integrates	O
H2O2	O
-responsive	O
polymeric	O
vesicles	O
(	O
PVs	O
)	O
with	O
a	O
transcutaneous	B-P
microneedle	O
-array	O
patch	O
was	O
prepared	O
to	O
achieve	O
a	O
fast	O
response	O
,	O
excellent	O
biocompatibility	O
,	O
and	O
painless	O
administration	B-P
.	O

The	O
PVs	O
are	O
self-assembled	O
from	O
block	O
copolymer	O
incorporated	O
with	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
and	O
phenylboronic	O
ester	O
(	O
PBE	O
)	O
-	O
conjugated	O
polyserine	O
(	O
designated	O
mPEG-b-P	O
(	O
Ser-PBE	O
)	O
)	O
and	O
loaded	O
with	O
glucose	O
oxidase	O
(	O
GOx	O
)	O
and	O
insulin	O
.	O

The	O
polymeric	O
vesicles	O
function	O
as	O
both	O
moieties	O
of	O
the	O
glucose	O
sensing	O
element	O
(	O
GOx	O
)	O
and	O
the	O
insulin	O
release	O
actuator	O
to	O
provide	O
basal	O
insulin	O
release	O
as	O
well	O
as	O
promote	O
insulin	O
release	O
in	O
response	O
to	O
hyperglycemic	O
states	O
.	O

In	O
the	O
current	O
study	O
,	O
insulin	O
release	O
responds	O
quickly	O
to	O
elevated	O
glucose	O
and	O
its	O
kinetics	O
can	O
be	O
modulated	O
by	O
adjusting	O
the	O
concentration	O
of	O
GOx	O
loaded	O
into	O
the	O
microneedles	O
.	O

In	O
vivo	O
testing	O
indicates	O
that	O
a	O
single	O
patch	O
can	O
regulate	O
glucose	O
levels	O
effectively	O
with	O
reduced	O
risk	O
of	O
hypoglycemia	O
.	O

Elicitation	B-P
of	O
Phenolics	O
from	O
the	O
Micropropagated	B-P
Endangered	O
Medicinal	O
Plant	O
Calligonum	O
polygonoides	O
L.	O
(	O
Polygonoaceae	O
)	O
.	O

Calligonum	O
polygonoides	O
L.	O
subsp	O
.	O

comosum	O
(	O
L'Hér	O
.	O
)	O

Sosk	O
.	O

is	O
a	O
plant	O
species	O
belonging	O
to	O
family	O
Polygonaceae	O
.	O

Susceptibility	O
to	O
threaten	O
,	O
presence	O
of	O
various	O
chemical	O
constituents	O
,	O
and	O
many	O
medicinal	O
effects	O
reported	O
for	O
this	O
plant	O
in	O
addition	O
to	O
rareness	O
of	O
in	O
vitro	O
culture	B-P
studies	I-P
have	O
fuelled	O
the	O
need	O
for	O
its	O
micropropagation	B-P
and	O
phytochemical	O
investigations	O
of	O
the	O
produced	O
cultures	B-P
.	O

To	O
employ	O
in	O
vitro	O
culture	B-P
technique	I-P
for	O
ex	B-P
situ	I-P
conservation	I-P
of	O
C.	O
polygonoides	O
,	O
using	O
the	O
fruit	O
as	O
an	O
explant	O
;	O
establish	O
callus	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
from	O
in	O
vitro	O
germinated	O
plantlets	O
;	O
investigate	O
the	O
production	O
of	O
phenolics	O
through	O
callus	O
,	O
redifferentiated	O
shoot	O
,	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
;	O
attempt	O
to	O
enhance	O
cell	O
capacity	O
to	O
accumulate	O
phenolics	O
using	O
salicylic	O
acid	O
and	O
yeast	O
extract	O
and	O
provide	O
a	O
brief	O
demonstration	O
of	O
biosynthetic	O
pathway	O
leading	O
to	O
phenolic	O
production	O
.	O

Modified	O
Murashige	O
and	O
Skoog	O
media	O
supplemented	O
with	O
growth	O
hormones	O
such	O
as	O
kinetin	O
,	O
1-naphthaleneacetic	O
acid	O
,	O
6-benzylaminopurine	O
,	O
and	O
indole-3-acetic	O
acid	O
were	O
used	O
to	O
establish	O
callus	O
,	O
redifferentiated	O
shoots	O
,	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
.	O

Elicitation	B-P
of	O
cell	B-P
suspension	I-P
culture	I-P
was	O
performed	O
using	O
salicylic	O
acid	O
and	O
yeast	O
extracts	O
.	O

A	O
reversed	B-P
phase-high	I-P
performance	I-P
liquid	I-P
chromatography	I-P
method	O
for	O
determination	B-P
of	O
phenolic	O
content	O
in	O
the	O
aforementioned	B-P
cultures	I-P
was	O
developed	O
.	O

The	O
unorganized	O
callus	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
contained	O
fewer	O
amounts	O
of	O
phenolic	O
compounds	O
than	O
redifferentiated	O
shoots	O
.	O

Elicitation	B-P
produced	O
massive	O
quantitative	O
reprogramming	O
of	O
phenolic	O
content	O
.	O

The	O
present	O
study	O
offers	O
an	O
alternative	O
and	O
renewable	O
source	O
for	O
this	O
valuable	O
natural	O
plant	O
,	O
provide	O
a	O
chance	O
to	O
improve	O
secondary	O
metabolite	O
yield	O
and	O
serve	O
as	O
a	O
useful	O
tool	O
for	O
studying	O
the	O
biosynthesis	O
of	O
these	O
compounds	O
and	O
its	O
regulation	O
in	O
plant	O
cells	O
.	O

In	O
vitro	O
culture	B-P
techniques	I-P
provided	O
a	O
strategy	O
for	O
ex	B-P
situ	I-P
conservation	I-P
of	O
the	O
endangered	O
C.	O
polygonoides	O
.Unorganized	O
callus	O
and	O
cell	B-P
suspension	I-P
cultures	I-P
accumulated	O
less	O
phenolic	O
content	O
than	O
re-differentiated	O
shoots	O
.	O

Elicitation	B-P
produced	O
massive	O
quantitative	O
reprogramming	O
of	O
phenolic	O
content	O
.	O

Phenolic	O
biosynthesis	O
was	O
discussed	O
briefly	O
.	O

Abbreviation	O
used	O
:	O
H2O2	O
:	O
Hydrogen	O
peroxide	O
,	O
Kin	O
:	O
Kinetin	O
,	O
NAA	O
:	O
Naphthaleneacetic	O
acid	O
,	O
BAP	O
:	O
6-benzylaminopurine	O
,	O
IAA	O
:	O
Indole-3-acetic	O
acid	O
,	O
HPLC	B-P
:	O
High-performance	B-P
liquid	I-P
chromatography	I-P
.	O

Fabrication	O
of	O
cerebral	O
aneurysm	O
simulator	O
with	O
a	O
desktop	O
3D	O
printer	O
.	O

Now	O
,	O
more	O
and	O
more	O
patients	O
are	O
suffering	O
cerebral	O
aneurysm	O
.	O

However	O
,	O
long	O
training	O
time	O
limits	O
the	O
rapid	O
growth	O
of	O
cerebrovascular	O
neurosurgeons	O
.	O

Here	O
we	O
developed	O
a	O
novel	O
cerebral	O
aneurysm	O
simulator	O
which	O
can	O
be	O
better	O
represented	O
the	O
dynamic	O
bulging	O
process	O
of	O
cerebral	O
aneurysm	O
The	O
proposed	O
simulator	O
features	O
the	O
integration	O
of	O
a	O
hollow	O
elastic	O
vascular	O
model	O
,	O
a	O
skull	O
model	O
and	O
a	O
brain	O
model	O
,	O
which	O
can	O
be	O
affordably	O
fabricated	O
at	O
the	O
clinic	O
(	O
Fab	O
@	O
Clinic	O
)	O
,	O
under	O
$	O
25.00	O
each	O
with	O
the	O
help	O
of	O
a	O
low-cost	O
desktop	O
3D	O
printer	O
.	O

Moreover	O
,	O
the	O
clinical	O
blood	O
flow	O
and	O
pulsation	O
pressure	O
similar	O
to	O
the	O
human	O
can	O
be	O
well	O
simulated	O
,	O
which	O
can	O
be	O
used	O
to	O
train	O
the	O
neurosurgical	O
residents	O
how	O
to	O
clip	B-P
aneurysms	O
more	O
effectively	O
.	O

Are	O
TMCs	O
the	O
Mechanotransduction	O
Channels	O
of	O
Vertebrate	O
Hair	O
Cells	O
?	O
.	O

Sensory	O
transduction	O
in	O
vertebrate	O
hair	O
cells	O
and	O
the	O
molecules	O
that	O
mediate	O
it	O
have	O
long	O
been	O
of	O
great	O
interest	O
.	O

Some	O
components	O
of	O
the	O
mechanotransduction	O
apparatus	O
have	O
been	O
identified	O
,	O
most	O
as	O
deafness	O
gene	O
products	O
.	O

Although	O
prior	O
candidates	O
for	O
the	O
mechanotransduction	O
channel	O
have	O
been	O
proposed	O
,	O
each	O
has	O
faded	O
with	O
new	O
evidence	O
.	O

Now	O
,	O
two	O
strong	O
candidates	O
,	O
TMC1	O
and	O
TMC2	O
(	O
transmembrane	O
channel-like	O
)	O
,	O
have	O
emerged	O
from	O
discovery	O
of	O
deafness	O
genes	O
in	O
humans	O
and	O
mice	O
.	O

They	O
are	O
expressed	O
at	O
the	O
right	O
time	O
during	O
development	O
:	O
exactly	O
at	O
the	O
onset	O
of	O
mechanosensitivity	O
.	O

They	O
are	O
expressed	O
in	O
the	O
right	O
place	O
:	O
in	O
hair	O
cells	O
but	O
not	O
surrounding	O
cells	O
.	O

Fluorescently	B-P
tagged	I-P
TMCs	O
localize	O
to	O
the	O
tips	O
of	O
stereocilia	O
,	O
the	O
site	O
of	O
the	O
transduction	O
channels	O
.	O

TMCs	O
bind	O
other	O
proteins	O
essential	O
for	O
mechanosensation	O
,	O
suggesting	O
a	O
larger	O
transduction	O
complex	O
.	O

Although	O
TMC1	O
and	O
TMC2	O
can	O
substitute	O
for	O
each	O
other	O
,	O
genetic	O
deletion	O
of	O
both	O
renders	O
mouse	O
hair	O
cells	O
mechanically	O
insensitive	O
.	O

Finally	O
,	O
the	O
conductance	O
and	O
Ca	O
(	O
2+	O
)	O
selectivity	O
of	O
the	O
transduction	O
channels	O
depend	O
on	O
the	O
TMC	O
proteins	O
,	O
differing	O
when	O
hair	O
cells	O
express	O
one	O
or	O
the	O
other	O
TMC	O
,	O
and	O
differing	O
if	O
TMC1	O
harbors	O
a	O
point	O
mutation	O
.	O

Some	O
contrary	O
evidence	O
has	O
emerged	O
:	O
a	O
current	O
activated	O
in	O
hair	O
cells	O
by	O
negative	O
pressure	O
,	O
with	O
some	O
similarity	O
to	O
the	O
transduction	O
current	O
,	O
persists	O
in	O
TMC	O
knock-outs	O
.	O

But	O
it	O
is	O
not	O
clear	O
that	O
this	O
anomalous	O
current	O
is	O
carried	O
by	O
the	O
same	O
proteins	O
.	O

Further	O
evidence	O
is	O
desired	O
,	O
such	O
as	O
production	O
of	O
a	O
mechanically	O
gated	O
conductance	O
by	O
pure	O
TMCs	O
.	O

But	O
the	O
great	O
majority	O
of	O
evidence	O
is	O
consistent	O
with	O
these	O
TMCs	O
as	O
pore-forming	O
subunits	O
of	O
the	O
long-sought	O
hair-cell	O
transduction	O
channel	O
.	O

The	O
Optical	B-P
Coherence	I-P
Tomographic	I-P
Profile	O
of	O
Leber	O
Hereditary	O
Optic	O
Neuropathy	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
changes	O
in	O
the	O
retinal	O
ganglion	O
cell	O
complex	O
(	O
GCC	O
)	O
relative	O
to	O
the	O
retinal	O
nerve	O
fibre	O
layer	O
(	O
RNFL	O
)	O
over	O
time	O
in	O
Leber	O
hereditary	O
optic	O
neuropathy	O
(	O
LHON	O
)	O
patients	O
.	O

Average	O
RNFL	O
and	O
GCC	O
thickness	O
was	O
measured	O
in	O
seven	O
patients	O
in	O
the	O
early	O
acute	O
(	O
123	O
,	O
68.4	O
μm	O
)	O
,	O
late	O
acute	O
(	O
113.5	O
,	O
57.4	O
μm	O
)	O
,	O
and	O
chronic	O
(	O
72.7	O
,	O
50.8	O
μm	O
)	O
phases	O
.	O

Patients	O
showed	O
thinning	O
of	O
the	O
GCC	O
with	O
RNFL	O
swelling	O
in	O
the	O
early	O
acute	O
phase	O
.	O

GCC	O
thinning	O
became	O
severe	O
within	O
weeks	O
and	O
persisted	O
.	O

RNFL	O
swelling	O
normalised	O
during	O
the	O
late	O
acute	O
phase	O
with	O
eventual	O
thinning	O
in	O
the	O
chronic	O
phase	O
.	O

GCC	O
changes	O
appear	O
at	O
the	O
commencement	O
of	O
visual	O
loss	O
and	O
in	O
some	O
cases	O
prior	O
to	O
vision	O
loss	O
.	O

These	O
findings	O
define	O
an	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
OCT	B-P
)	O
profile	O
in	O
LHON	O
.	O

Comparison	O
of	O
Leishmania	O
typing	B-P
results	O
obtained	O
from	O
16	O
European	O
clinical	O
laboratories	O
in	O
2014	O
.	O

Leishmaniasis	O
is	O
endemic	O
in	O
southern	O
Europe	O
,	O
and	O
in	O
other	O
European	O
countries	O
cases	O
are	O
diagnosed	O
in	O
travellers	O
who	O
have	O
visited	O
affected	O
areas	O
both	O
within	O
the	O
continent	O
and	O
beyond	O
.	O

Prompt	O
and	O
accurate	O
diagnosis	O
poses	O
a	O
challenge	O
in	O
clinical	O
practice	O
in	O
Europe	O
.	O

Different	O
methods	O
exist	O
for	O
identification	O
of	O
the	O
infecting	O
Leishmania	O
species	O
.	O

Sixteen	O
clinical	O
laboratories	O
in	O
10	O
European	O
countries	O
,	O
plus	O
Israel	O
and	O
Turkey	O
,	O
conducted	O
a	O
study	O
to	O
assess	O
their	O
genotyping	B-P
performance	O
.	O

DNA	O
from	O
21	O
promastigote	O
cultures	O
of	O
13	O
species	O
was	O
analysed	O
blindly	O
by	O
the	O
routinely	O
used	O
typing	B-P
method	O
.	O

Five	O
different	O
molecular	O
targets	O
were	O
used	O
,	O
which	O
were	O
analysed	O
with	O
PCR-based	O
methods	O
.	O

Different	O
levels	O
of	O
identification	O
were	O
achieved	O
,	O
and	O
either	O
the	O
Leishmania	O
subgenus	O
,	O
species	O
complex	O
,	O
or	O
actual	O
species	O
were	O
reported	O
.	O

The	O
overall	O
error	O
rate	O
of	O
strains	O
placed	O
in	O
the	O
wrong	O
complex	O
or	O
species	O
was	O
8.5	O
%	O
.	O

Various	O
reasons	O
for	O
incorrect	O
typing	B-P
were	O
identified	O
.	O

The	O
study	O
shows	O
there	O
is	O
considerable	O
room	O
for	O
improvement	O
and	O
standardisation	O
of	O
Leishmania	O
typing	B-P
.	O

The	O
use	O
of	O
well	O
validated	O
standard	O
operating	O
procedures	O
is	O
recommended	O
,	O
covering	O
testing	O
,	O
interpretation	O
,	O
and	O
reporting	O
guidelines	O
.	O

Application	O
of	O
the	O
internal	O
transcribed	O
spacer	O
1	O
of	O
the	O
rDNA	O
array	O
should	O
be	O
restricted	O
to	O
Old	O
World	O
samples	O
,	O
while	O
the	O
heat-shock	O
protein	O
70	O
gene	O
and	O
the	O
mini-exon	O
can	O
be	O
applied	O
globally	O
.	O

Efficient	O
Reverse	O
Genetic	O
Systems	O
for	O
Rapid	O
Genetic	O
Manipulation	O
of	O
Emergent	O
and	O
Preemergent	O
Infectious	O
Coronaviruses	O
.	O

Emergent	O
and	O
preemergent	O
coronaviruses	O
(	O
CoVs	O
)	O
pose	O
a	O
global	O
threat	O
that	O
requires	O
immediate	O
intervention	B-P
.	O

Rapid	B-P
intervention	I-P
necessitates	O
the	O
capacity	O
to	O
generate	O
,	O
grow	O
,	O
and	O
genetically	O
manipulate	O
infectious	O
CoVs	O
in	O
order	O
to	O
rapidly	O
evaluate	O
pathogenic	O
mechanisms	O
,	O
host	O
and	O
tissue	O
permissibility	O
,	O
and	O
candidate	O
antiviral	B-P
therapeutic	I-P
efficacy	I-P
.	O

CoVs	O
encode	O
the	O
largest	O
viral	O
RNA	O
genomes	O
at	O
about	O
28-32,000	O
nucleotides	O
in	O
length	O
,	O
and	O
thereby	O
complicate	O
efficient	O
engineering	O
of	O
the	O
genome	O
.	O

Deconstructing	O
the	O
genome	O
into	O
manageable	O
fragments	O
affords	O
the	O
plasticity	O
necessary	O
to	O
rapidly	O
introduce	O
targeted	O
genetic	O
changes	O
in	O
parallel	O
and	O
assort	O
mutated	O
fragments	O
while	O
maximizing	O
genome	O
stability	O
over	O
time	O
.	O

In	O
this	O
protocol	O
we	O
describe	O
a	O
well-developed	O
reverse	O
genetic	O
platform	O
strategy	O
for	O
CoVs	O
that	O
is	O
comprised	O
of	O
partitioning	O
the	O
viral	O
genome	O
into	O
5-7	O
independent	O
DNA	O
fragments	O
(	O
depending	O
on	O
the	O
CoV	O
genome	O
)	O
,	O
each	O
subcloned	O
into	O
a	O
plasmid	O
for	O
increased	O
stability	O
and	O
ease	O
of	O
genetic	O
manipulation	O
and	O
amplification	O
.	O

Coronavirus	O
genomes	O
are	O
conveniently	O
partitioned	O
by	O
introducing	O
type	O
IIS	O
or	O
IIG	O
restriction	O
enzyme	O
recognition	O
sites	O
that	O
confer	O
directional	O
cloning	O
.	O

Since	O
each	O
restriction	O
site	O
leaves	O
a	O
unique	O
overhang	O
between	O
adjoining	O
fragments	O
,	O
reconstruction	O
of	O
the	O
full-length	O
genome	O
can	O
be	O
achieved	O
through	O
a	O
standard	O
DNA	O
ligation	O
comprised	O
of	O
equal	O
molar	O
ratios	O
of	O
each	O
fragment	O
.	O

Using	O
this	O
method	O
,	O
recombinant	O
CoVs	O
can	O
be	O
rapidly	O
generated	O
and	O
used	O
to	O
investigate	O
host	O
range	O
,	O
gene	O
function	O
,	O
pathogenesis	O
,	O
and	O
candidate	O
therapeutics	B-P
for	O
emerging	O
and	O
preemergent	O
CoVs	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
lipid-polyethylene	O
glycol-polymer	O
hybrid	O
nanoparticles	O
for	O
treatment	B-P
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid-polyethylene	O
glycol	O
(	O
PEG	O
)	O
-polymer	O
hybrid	O
nanoparticles	O
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	O
with	O
active	O
ingredient	O
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	O
,	O
farnesylthiosalicylic	O
acid	O
(	O
FTA	O
)	O
for	O
treatment	B-P
of	O
glioblastoma	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
poly	O
(	O
lactic-co-glycolic	O
acid	O
)	O
-1,2	O
distearoyl-glycerol-3-phospho-ethanolamine-N	O
[	O
methoxy	O
(	O
PEG	O
)	O
-2000	O
]	O
ammonium	O
salt	O
(	O
PLGA-DSPE-PEG	O
)	O
with	O
or	O
without	O
1,2-dioleoyl-3-trimethylammonium-propane	O
(	O
DOTAP	O
)	O
hybrid	O
nanoparticles	O
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in-vitro	O
characterization	O
.	O

Cytotoxicity	O
of	O
FTA-loaded	O
nanoparticles	O
along	O
with	O
its	O
efficacy	O
on	O
rat	O
glioma-2	O
(	O
RG2	O
)	O
cells	O
was	O
also	O
evaluated	O
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non-malignant	O
cell	O
line	O
,	O
L929	O
)	O
and	O
in	O
vivo	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
studies	I-P
showed	O
that	O
all	O
formulations	O
prepared	O
had	O
smooth	O
surface	O
and	O
spherical	O
in	O
shape	O
.	O

FTA	O
and	O
FTA-loaded	O
nanoparticles	O
have	O
cytotoxic	O
activity	O
against	O
RG2	O
glioma	O
cell	O
lines	O
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
DOTAP	O
.	O

Magnetic	B-P
resonance	I-P
imaging	I-P
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	O
cells	O
in	O
rat	O
glioma	O
model	O
(	O
49	O
female	O
Wistar	O
rats	O
,	O
250-300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA-loaded	O
nanoparticles	O
reduced	O
tumour	O
size	O
significantly	O
in	O
in-vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Farnesylthiosalicylic	O
acid	O
-loaded	O
PLGA-DSPE-PEG-DOTAP	O
hybrid	O
nanoparticles	O
are	O
proven	O
to	O
be	O
effective	O
against	O
glioblastoma	O
in	O
both	O
in-vitro	O
and	O
in-vivo	O
experiments	O
.	O

One-hour	O
post-load	O
hyperglycemia	O
combined	O
with	O
HbA1c	O
identifies	O
pre-diabetic	O
individuals	O
with	O
a	O
higher	O
cardio-metabolic	O
risk	O
burden	O
.	O

Evidence	O
suggests	O
that	O
combining	O
1-hour	O
plasma	O
glucose	O
≥155	O
mg/dl	O
during	O
an	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	O
OGTT	B-P
)	O
with	O
glycosylated	O
hemoglobin	O
(	O
HbA1c	O
)	O
significantly	O
increases	O
their	O
predictive	O
power	O
for	O
incident	O
diabetes	O
,	O
while	O
their	O
individual	O
and	O
joint	O
associations	O
with	O
cardio-metabolic	O
risk	O
factors	O
remain	O
undefined	O
.	O

Herein	O
,	O
we	O
evaluated	O
whether	O
1-hour	O
post-load	O
plasma	O
glucose	O
≥155	O
mg/dl	O
combined	O
with	O
HbA1c	O
may	O
identify	O
pre-diabetic	O
individuals	O
with	O
a	O
higher	O
cardio-metabolic	O
risk	O
.	O

Anthropometric	B-P
and	O
metabolic	O
characteristics	O
,	O
insulin	O
sensitivity	O
and	O
insulin	O
secretion	O
assessed	O
by	O
OGTT	B-P
-derived	O
indexes	O
,	O
carotid	O
intima-media	O
thickness	O
(	O
IMT	O
)	O
,	O
pulse	O
pressure	O
,	O
and	O
rate	O
pressure	O
product	O
were	O
evaluated	O
in	O
1495	O
individuals	O
.	O

As	O
compared	O
with	O
subjects	O
with	O
1-hour	O
post-load	O
glucose	O
<	O
155	O
mg/dl	O
,	O
individuals	O
with	O
1-hour	O
post-load	O
glucose	O
≥155	O
mg/dl	O
exhibited	O
a	O
significantly	O
worse	O
cardio	O
metabolic	O
profile	O
,	O
both	O
in	O
the	O
group	O
with	O
HbA1c	O
<	O
5.7	O
%	O
,	O
and	O
in	O
the	O
group	O
with	O
prediabetes	O
(	O
HbA1c	O
5.7-6.4	O
%	O
)	O
.	O

Specifically	O
,	O
in	O
both	O
groups	O
,	O
subjects	O
with	O
1-hour	O
post-load	O
glucose	O
≥155	O
mg/dl	O
had	O
higher	O
fasting	O
and	O
2-h	O
post-load	O
glucose	O
(	O
p	O
<	O
0.0001	O
for	O
all	O
in	O
both	O
group	O
s	O
)	O
,	O
higher	O
HOMA-IR	B-P
(	O
p	O
<	O
0.0001	O
in	O
both	O
groups	O
)	O
,	O
and	O
carotid	O
IMT	O
(	O
p	O
=	O
0.05	O
in	O
the	O
group	O
with	O
HbA1c	O
<	O
5.7	O
%	O
and	O
p	O
=	O
0.03	O
in	O
the	O
group	O
HbA1c	O
5.7-6.4	O
%	O
)	O
,	O
as	O
well	O
as	O
lower	O
Matsuda	O
index	O
,	O
insulinogenic	O
index	O
and	O
disposition	O
index	O
(	O
p	O
<	O
0.0001	O
in	O
both	O
groups	O
)	O
,	O
and	O
lower	O
insulin	O
-	O
stimulated	B-P
glucose	O
disposal	O
(	O
p	O
<	O
0.0001	O
in	O
the	O
group	O
with	O
HbA1c	O
<	O
5.7	O
%	O
and	O
p	O
=	O
0.03	O
in	O
the	O
group	O
HbA1c	O
5.7-6.4	O
%	O
)	O
.	O

Hyperglycemia	O
at	O
1-hour	O
during	O
an	O
OGTT	B-P
may	O
be	O
a	O
useful	O
tool	B-P
to	O
identify	O
a	O
subset	O
of	O
individuals	O
within	O
HbA1c	O
-defined	O
glycemic	O
categories	O
at	O
higher	O
risk	O
of	O
developing	O
type	O
2	O
diabetes	O
and	O
cardiovascular	O
disease	O
.	O

Systematic	O
mapping	O
of	O
functional	O
enhancer	O
-	O
promoter	O
connections	O
with	O
CRISPR	B-P
interference	I-P
.	O

Gene	O
expression	O
in	O
mammals	O
is	O
regulated	O
by	O
noncoding	O
elements	O
that	O
can	O
affect	O
physiology	O
and	O
disease	O
,	O
yet	O
the	O
functions	O
and	O
target	O
genes	O
of	O
most	O
noncoding	O
elements	O
remain	O
unknown	O
.	O

We	O
present	O
a	O
high-throughput	O
approach	O
that	O
uses	O
clustered	B-P
regularly	I-P
interspaced	I-P
short	I-P
palindromic	I-P
repeats	I-P
(	I-P
CRISPR	I-P
)	I-P
interference	I-P
(	O
CRISPRi	B-P
)	O
to	O
discover	O
regulatory	O
elements	O
and	O
identify	O
their	O
target	O
genes	O
.	O

We	O
assess	O
>	O
1	O
megabase	O
of	O
sequence	O
in	O
the	O
vicinity	O
of	O
two	O
essential	O
transcription	O
factors	O
,	O
MYC	O
and	O
GATA1	O
,	O
and	O
identify	O
nine	O
distal	O
enhancers	O
that	O
control	O
gene	O
expression	O
and	O
cellular	O
proliferation	O
.	O

Quantitative	O
features	O
of	O
chromatin	O
state	O
and	O
chromosome	O
conformation	O
distinguish	O
the	O
seven	O
enhancers	O
that	O
regulate	O
MYC	O
from	O
other	O
elements	O
that	O
do	O
not	O
,	O
suggesting	O
a	O
strategy	O
for	O
predicting	O
enhancer	O
-	O
promoter	O
connectivity	O
.	O

This	O
CRISPRi	B-P
-based	O
approach	O
can	O
be	O
applied	O
to	O
dissect	O
transcriptional	O
networks	O
and	O
interpret	O
the	O
contributions	O
of	O
noncoding	O
genetic	O
variation	O
to	O
human	O
disease	O
.	O

Perioperative	O
Transfusion	B-P
of	O
Leukocyte	O
-	O
depleted	O
Blood	O
Products	O
in	O
Contemporary	O
Radical	B-P
Cystectomy	I-P
Cohort	O
Does	O
Not	O
Adversely	O
Impact	O
Short-term	O
Survival	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
leukoreduced	O
-only	O
perioperative	O
blood	B-P
transfusion	I-P
(	O
PBT	B-P
)	O
and	O
corresponding	O
survival	O
outcomes	O
in	O
a	O
radical	B-P
cystectomy	I-P
cohort	O
of	O
patients	O
.	O

We	O
analyzed	O
data	O
from	O
1026	O
patients	O
who	O
underwent	O
radical	B-P
cystectomy	I-P
at	O
our	O
institution	O
.	O

PBT	B-P
was	O
defined	O
as	O
transfusion	B-P
in	O
the	O
intraoperative	O
or	O
within	O
the	O
postoperative	O
hospitalization	O
period	O
.	O

Multivariable	O
analyses	O
using	O
Cox	O
proportional	O
hazards	O
were	O
performed	O
to	O
measure	O
the	O
association	O
between	O
PBT	B-P
,	O
patient	O
variables	O
,	O
and	O
3	O
primary	O
end	O
points	O
:	O
recurrence-free	O
survival	O
,	O
disease-specific	O
survival	O
,	O
and	O
overall	O
survival	O
.	O

Kaplan-Meier	O
curves	O
estimated	O
survival	O
times	O
and	O
were	O
compared	O
with	O
log-rank	B-P
test	I-P
.	O

Overall	O
,	O
of	O
a	O
total	O
of	O
1026	O
patients	O
,	O
341	O
(	O
33.2	O
%	O
)	O
received	O
leukoreduced	O
PBT	B-P
.	O

The	O
median	O
follow-up	O
was	O
27.5	O
months	O
.	O

Transfused	O
patients	O
were	O
more	O
likely	O
to	O
be	O
female	O
,	O
had	O
higher	O
estimated	O
blood	O
loss	O
,	O
lower	O
preoperative	O
hemoglobin	O
,	O
were	O
more	O
likely	O
to	O
have	O
received	O
neoadjuvant	B-P
chemotherapy	B-P
,	O
or	O
had	O
undergone	O
a	O
continent	B-P
urinary	I-P
diversion	I-P
.	O

Higher	O
pathologic	O
tumor	O
and	O
nodal	O
stage	O
were	O
observed	O
more	O
frequently	O
in	O
patients	O
who	O
received	O
PBT	B-P
.	O

On	O
multivariable	O
analysis	O
,	O
PBT	B-P
was	O
not	O
associated	O
with	O
worse	O
recurrence-free	O
survival	O
,	O
disease-specific	O
survival	O
,	O
and	O
overall	O
survival	O
(	O
all	O
P	O
>	O
.05	O
)	O
.	O

Kaplan-Meier	O
curves	O
did	O
not	O
show	O
any	O
significant	O
differences	O
(	O
all	O
P	O
>	O
.05	O
)	O
between	O
the	O
transfused	O
and	O
nontransfused	O
groups	O
.	O

In	O
addition	O
,	O
no	O
differences	O
were	O
found	O
in	O
regard	O
to	O
timing	O
of	O
transfusion	B-P
,	O
that	O
is	O
,	O
intraoperative	O
vs	O
postoperative	O
,	O
in	O
distinct	O
analysis	O
.	O

No	O
significant	O
association	O
was	O
found	O
between	O
leukoreduced	O
PBT	B-P
and	O
worse	O
survival	O
outcomes	O
at	O
short-term	O
follow-up	O
in	O
a	O
contemporary	O
cohort	O
of	O
cystectomy	B-P
patients	O
.	O

Prospective	O
long-term	O
follow-up	O
is	O
warranted	O
.	O

Passive	O
case	O
detection	O
of	O
malaria	O
in	O
Ratanakiri	O
Province	O
(	O
Cambodia	O
)	O
to	O
detect	O
villages	O
at	O
higher	O
risk	O
for	O
malaria	O
.	O

Cambodia	O
reduced	O
malaria	O
incidence	O
by	O
more	O
than	O
75	O
%	O
between	O
2000	O
and	O
2015	O
,	O
a	O
target	O
of	O
the	O
Millennium	O
Development	O
Goal	O
6	O
.	O

The	O
Cambodian	O
Government	O
aims	O
to	O
eliminate	O
all	O
forms	O
of	O
malaria	O
by	O
2025	O
.	O

The	O
country	O
's	O
malaria	O
incidence	O
is	O
highly	O
variable	O
at	O
provincial	O
level	O
,	O
but	O
less	O
is	O
known	O
at	O
village	O
level	O
.	O

This	O
study	O
used	O
passive	O
case	O
detection	O
(	O
PCD	O
)	O
data	O
at	O
village	O
level	O
in	O
Ratanakiri	O
Province	O
from	O
2010	O
to	O
2014	O
to	O
describe	O
incidence	O
trends	O
and	O
identify	O
high-risk	O
areas	O
of	O
malaria	O
to	O
be	O
primarily	O
targeted	O
towards	O
malaria	O
elimination	O
.	O

In	O
2010	O
,	O
the	O
Cambodian	O
malaria	O
programme	O
created	O
a	O
Malaria	O
Information	O
System	O
(	O
MIS	O
)	O
to	O
capture	O
malaria	O
information	O
at	O
village	O
level	O
through	O
PCD	O
by	O
village	O
malaria	O
workers	O
and	O
health	O
facilities	O
.	O

The	O
MIS	O
data	O
of	O
Ratanakiri	O
Province	O
2010-2014	O
were	O
used	O
to	O
calculate	O
annual	O
incidence	O
rates	O
by	O
Plasmodium	O
species	O
at	O
province	O
and	O
commune	O
levels	O
.	O

For	O
estimating	O
the	O
trend	O
at	O
provincial	O
level	O
only	O
villages	O
reporting	O
each	O
year	O
were	O
selected	O
.	O

The	O
communal	O
incidences	O
and	O
the	O
number	O
of	O
cases	O
per	O
village	O
were	O
visualized	O
on	O
a	O
map	O
per	O
Plasmodium	O
species	O
and	O
per	O
year	O
.	O

Analysis	O
of	O
spatial	O
clustering	O
of	O
village	O
malaria	O
cases	O
by	O
Plasmodium	O
species	O
was	O
performed	O
by	O
year	O
.	O

Overall	O
,	O
malaria	O
annual	O
incidence	O
rates	O
per	O
1000	O
inhabitants	O
decreased	O
from	O
86	O
(	O
2010	O
)	O
to	O
30	O
(	O
2014	O
)	O
.	O

Falciparum	O
incidence	O
decreased	O
(	O
by	O
79	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
76-82	O
%	O
)	O
more	O
rapidly	O
than	O
vivax	O
incidence	O
(	O
by	O
19	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
5-32	O
%	O
)	O
.	O

There	O
were	O
ten	O
to	O
16	O
significant	O
spatial	O
clusters	O
each	O
year	O
.	O

Big	O
clusters	O
tended	O
to	O
extend	O
along	O
the	O
Cambodian-Vietnamese	O
border	O
and	O
along	O
the	O
Sesan	O
River	O
.	O

Three	O
clusters	O
appeared	O
throughout	O
all	O
years	O
(	O
2010-2014	O
)	O
:	O
one	O
with	O
21	O
villages	O
appeared	O
each	O
year	O
,	O
the	O
second	O
shrunk	O
progressively	O
from	O
2012	O
to	O
2014	O
and	O
the	O
third	O
was	O
split	O
into	O
two	O
smaller	O
clusters	O
in	O
2013	O
and	O
2014	O
.	O

The	O
decline	O
of	O
malaria	O
burden	O
can	O
be	O
attributed	O
to	O
intensive	O
malaria	O
control	O
activities	O
implemented	O
in	O
the	O
areas	O
:	O
distribution	O
of	O
a	O
long-lasting	O
insecticidal	O
net	O
per	O
person	O
and	O
early	B-P
diagnosis	I-P
and	O
prompt	O
treatment	O
.	O

Dihydro-artemisinin	O
piperaquine	O
was	O
the	O
only	O
first-line	B-P
treatment	I-P
for	O
all	O
malaria	O
cases	O
.	O

No	O
radical	O
treatment	O
with	O
primaquine	O
was	O
provided	O
for	O
Plasmodium	O
vivax	O
cases	O
,	O
which	O
could	O
explain	O
the	O
slow	O
decrease	O
of	O
P.	O
vivax	O
due	O
to	O
relapses	O
.	O

To	O
achieve	O
malaria	O
elimination	O
by	O
2025	O
,	O
priority	O
should	O
be	O
given	O
to	O
the	O
control	O
of	O
stable	O
malaria	O
clusters	O
appearing	O
over	O
time	O
.	O

Nationwide	O
reduction	O
in	O
the	O
number	O
of	O
corneal	B-P
transplantations	I-P
for	O
keratoconus	O
following	O
the	O
implementation	O
of	O
cross-linking	B-P
.	O

Keratoconus	O
is	O
characterized	O
by	O
corneal	O
ectasia	O
and	O
irregular	O
astigmatism	O
,	O
which	O
can	O
lead	O
to	O
diminished	O
vision	O
and	O
corneal	O
scarring	O
.	O

Approximately	O
10-20	O
%	O
of	O
patients	O
with	O
keratoconus	O
eventually	O
require	O
a	O
corneal	B-P
transplant	I-P
.	O

Corneal	B-P
cross-linking	I-P
(	O
CXL	B-P
)	O
is	O
a	O
relatively	O
new	O
treatment	B-P
that	O
may	O
help	O
prevent	O
the	O
need	O
for	O
corneal	B-P
transplantation	I-P
.	O

Here	O
,	O
we	O
investigated	O
whether	O
the	O
introduction	O
of	O
CXL	B-P
has	O
reduced	O
the	O
number	O
of	O
corneal	B-P
transplants	I-P
performed	O
annually	O
.	O

Data	O
regarding	O
the	O
transplantation	B-P
procedures	I-P
performed	O
in	O
patients	O
under	O
the	O
age	O
of	O
50	O
years	O
were	O
extracted	O
from	O
the	O
Dutch	O
National	O
Organ	O
Transplant	O
Registry	O
.	O

The	O
number	O
of	O
corneal	B-P
transplants	I-P
performed	O
prior	O
to	O
(	O
i.e	O
.	O

in	O
2005	O
through	O
2007	O
)	O
and	O
following	O
the	O
introduction	O
of	O
CXL	B-P
(	O
i.e	O
.	O

in	O
2012	O
through	O
2014	O
)	O
were	O
compared	O
.	O

Furthermore	O
,	O
a	O
trend	O
analysis	O
on	O
annual	O
keratoplasties	B-P
over	O
time	O
was	O
performed	O
.	O

Approximately	O
25	O
%	O
fewer	O
corneal	B-P
transplants	I-P
were	O
performed	O
in	O
the	O
3-	O
year	O
period	O
following	O
the	O
introduction	O
of	O
CXL	B-P
compared	O
to	O
the	O
3-	O
year	O
period	O
prior	O
to	O
the	O
introduction	O
of	O
CXL	B-P
(	O
201	O
versus	O
269	O
transplants	B-P
,	O
respectively	O
;	O
p	O
=	O
0.005	O
)	O
.	O

Age	O
,	O
gender	O
and	O
visual	O
acuity	O
were	O
similar	O
between	O
the	O
patient	O
groups	O
in	O
the	O
two	O
time	O
periods	O
.	O

Trend	O
analysis	O
also	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
the	O
amount	O
of	O
corneal	B-P
transplants	I-P
(	O
p	O
=	O
0.001	O
)	O
.	O

Significantly	O
fewer	O
corneal	B-P
transplants	I-P
were	O
performed	O
for	O
treating	O
keratoconus	O
following	O
the	O
nationwide	O
introduction	O
of	O
CXL	B-P
.	O

This	O
reduction	O
suggests	O
that	O
corneal	B-P
cross-linking	I-P
can	O
significantly	O
reduce	O
the	O
need	O
for	O
corneal	B-P
transplantation	I-P
.	O

Hepatitis	O
C	O
virus	O
impairs	O
natural	O
killer	O
cell	O
activity	O
via	O
viral	O
serine	O
protease	O
NS3	O
.	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
high	O
frequency	O
of	O
chronic	O
cases	O
owing	O
to	O
the	O
impairment	O
of	O
innate	O
and	O
adaptive	O
immune	O
responses	O
.	O

The	O
modulation	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
functions	O
by	O
HCV	O
leads	O
to	O
an	O
impaired	O
innate	O
immune	O
response	O
.	O

However	O
,	O
the	O
underling	O
mechanisms	O
and	O
roles	O
of	O
HCV	O
proteins	O
in	O
this	O
immune	O
evasion	O
are	O
controversial	O
,	O
especially	O
in	O
the	O
early	O
phase	O
of	O
HCV	O
infection	O
.	O

To	O
investigate	O
the	O
role	O
of	O
HCV	O
nonstructural	O
proteins	O
especially	O
NS3	O
in	O
the	O
impairment	O
of	O
NK	O
functions	O
,	O
NK	O
cells	O
were	O
isolated	O
from	O
the	O
PBMCs	O
by	O
negative	B-P
selection	I-P
.	O

To	O
assess	O
the	O
direct	O
cytotoxicity	O
and	O
IFN-γ	O
production	O
capability	O
of	O
NK	O
cells	O
,	O
co-cultured	B-P
with	O
uninfected	O
,	O
HCV-infected	O
,	O
HCV-NS3	O
DNA	O
-	O
transfected	O
Huh-7.5	O
,	O
or	O
HCV-NS	O
replicon	O
cells	O
.	O

To	O
determine	O
the	O
effect	O
of	O
an	O
NS3	O
serine	O
protease	O
inhibitor	O
,	O
HCV	O
-infected	O
Huh-7.5	O
cells	O
were	O
treated	B-P
with	I-P
BILN-2061	O
.	O

Then	O
,	O
NK	O
cells	O
were	O
harvested	B-P
and	O
further	O
co-cultured	B-P
with	O
K-562	O
target	O
cells	O
.	O

NK	O
cell	O
functions	O
were	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
and	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

When	O
co-cultured	B-P
with	O
HCV-infected	O
Huh-7.5	O
cells	O
,	O
the	O
natural	O
cytotoxicity	O
and	O
IFN-γ	O
production	O
capability	O
of	O
NK	O
cells	O
were	O
significantly	O
reduced	O
.	O

NK	O
cell	O
functions	O
were	O
inhibited	O
to	O
similar	O
levels	O
upon	O
co-culture	B-P
with	O
HCV-NS	O
replicon	O
cells	O
,	O
NS3	O
-	O
transfected	O
cells	O
,	O
and	O
HCV-infected	O
Huh-7.5	O
cells	O
.	O

These	O
reductions	O
were	O
restored	O
by	O
BILN-2061	O
-	O
treatment	O
.	O

Furthermore	O
,	O
BILN-2061	O
-	O
treatment	O
significantly	O
increased	O
degranulation	O
against	O
K-562	O
target	O
cells	O
and	O
IFN-γ	O
productivity	O
in	O
NK	O
cells	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
the	O
expression	O
levels	O
of	O
activating	O
NK	O
cell	O
receptors	O
,	O
such	O
as	O
NKp46	O
and	O
NKp30	O
,	O
were	O
also	O
increased	O
.	O

In	O
HCV-infected	O
cells	O
,	O
the	O
serine	O
protease	O
NS3	O
may	O
play	O
a	O
role	O
in	O
the	O
abrogation	O
of	O
NK	O
cell	O
functions	O
in	O
the	O
early	O
phase	O
of	O
infection	O
through	O
downregulation	O
of	O
NKp46	O
and	O
NKp30	O
receptors	O
on	O
NK	O
cells	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NS3	O
represents	O
a	O
novel	O
drug	O
target	O
for	O
the	O
treatment	O
of	O
HCV	O
infections	O
.	O

The	O
relationship	O
between	O
anthropometry	O
and	O
body	O
composition	O
from	O
computed	B-P
tomography	I-P
:	O
The	O
Mediators	O
of	O
Atherosclerosis	O
in	O
South	O
Asians	O
Living	O
in	O
America	O
Study	O
.	O

Few	O
studies	O
examine	O
the	O
relationships	O
between	O
anthropometry	O
and	O
the	O
body	O
composition	O
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	O
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	O
in	O
South	O
Asians	O
living	O
in	O
the	O
US	O
.	O

We	O
conducted	O
a	O
cross-sectional	O
study	O
of	O
871	O
participants	O
in	O
the	O
Mediators	O
of	O
Atherosclerosis	O
in	O
South	O
Asians	O
Living	O
in	O
America	O
(	O
MASALA	O
)	O
Study	O
who	O
had	O
BMI	O
<	O
40	O
kg/m	O
(	O
2	O
)	O
and	O
underwent	O
abdominal	B-P
CT	I-P
scans	I-P
for	O
measurement	O
of	O
visceral	O
and	O
subcutaneous	O
fat	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
model	O
the	O
associations	O
between	O
anthropometric	O
measures	O
and	O
naturally	O
log-transformed	O
body	O
composition	O
measures	O
.	O

All	O
measures	O
of	O
anthropometry	O
,	O
except	O
height	O
,	O
were	O
significantly	O
associated	O
with	O
visceral	O
fat	O
and	O
had	O
a	O
significant	O
non-linear	O
component	O
(	O
p	O
<	O
.05	O
)	O
.	O

The	O
only	O
associations	O
for	O
visceral	O
fat	O
that	O
exhibited	O
significant	O
heterogeneity	O
by	O
sex	O
were	O
waist	O
circumference	O
(	O
%	O
difference	O
in	O
visceral	O
fat	O
slope	O
:	O
women	O
1.92	O
,	O
men	O
2.74	O
,	O
p	O
=	O
.007	O
for	O
interaction	O
)	O
and	O
waist-to-hip	O
ratio	O
(	O
women	O
25.9	O
,	O
men	O
717.4	O
,	O
p	O
<	O
.001	O
)	O
.	O

Except	O
for	O
height	O
,	O
all	O
measures	O
of	O
anthropometry	O
were	O
significantly	O
associated	O
with	O
subcutaneous	O
fat	O
,	O
had	O
a	O
significant	O
quadratic	O
component	O
,	O
and	O
significant	O
heterogeneity	O
by	O
sex	O
(	O
weight	O
(	O
kg	O
)	O
:	O
2.74	O
for	O
women	O
,	O
4.08	O
for	O
men	O
;	O
BMI	O
(	O
kg/m	O
(	O
2	O
)	O
)	O
:	O
10.3	O
,	O
14.0	O
;	O
waist	O
circumference	O
(	O
cm	O
)	O
:	O
1.51	O
,	O
3.36	O
;	O
hip	O
circumference	O
(	O
cm	O
)	O
:	O
2.53	O
,	O
4.50	O
)	O
with	O
p	O
<	O
.001	O
for	O
each	O
.	O

In	O
MASALA	O
participants	O
,	O
the	O
relationships	O
of	O
anthropometric	O
measures	O
with	O
visceral	O
and	O
subcutaneous	O
fat	O
appear	O
similar	O
to	O
other	O
race	O
/	O
ethnic	O
groups	O
,	O
but	O
with	O
weaker	O
non-linearity	O
and	O
heterogeneity	O
by	O
sex	O
.	O

Given	O
these	O
results	O
,	O
researchers	O
should	O
consider	O
separate	O
models	O
by	O
sex	O
for	O
US	O
South	O
Asians	O
when	O
approximating	O
subcutaneous	O
fat	O
or	O
when	O
using	O
waist	O
circumference	O
to	O
approximate	O
visceral	O
fat	O
.	O

Identification	O
and	O
Functional	O
Characterization	O
of	O
a	O
Tonoplast	O
Dicarboxylate	O
Transporter	O
in	O
Tomato	O
(	O
Solanum	O
lycopersicum	O
)	O
.	O

Acidity	O
plays	O
an	O
important	O
role	O
in	O
flavor	O
and	O
overall	O
organoleptic	O
quality	O
of	O
fruit	O
and	O
is	O
mainly	O
due	O
to	O
the	O
presence	O
of	O
organic	O
acids	O
.	O

Understanding	O
the	O
molecular	O
basis	O
of	O
organic	O
acid	O
metabolism	O
is	O
thus	O
of	O
primary	O
importance	O
for	O
fruit	O
quality	O
improvement	O
.	O

Here	O
,	O
we	O
cloned	O
a	O
putative	O
tonoplast	O
dicarboxylate	O
transporter	O
gene	O
(	O
SlTDT	O
)	O
from	O
tomato	O
,	O
and	O
submitted	O
it	O
to	O
the	O
NCBI	O
database	O
(	O
GenBank	O
accession	O
number	O
:	O
KC733165	O
)	O
.	O

SlTDT	O
protein	O
contained	O
13	O
putative	O
transmembrane	O
domains	O
in	O
silico	O
analysis	O
.	O

Confocal	B-P
microscopic	I-P
study	O
using	O
green	O
fluorescent	O
fusion	O
proteins	O
revealed	O
that	O
SlTDT	O
was	O
localized	O
on	O
tonoplast	O
.	O

The	O
expression	O
patterns	O
of	O
SlTDT	O
in	O
tomato	O
were	O
analyzed	O
by	O
RT-qPCR	O
.	O

The	O
results	O
indicated	O
that	O
SlTDT	O
expressed	O
in	O
leaves	O
,	O
roots	O
,	O
flowers	O
and	O
fruits	O
at	O
different	O
ripening	O
stages	O
,	O
suggesting	O
SlTDT	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
different	O
tissues	O
.	O

To	O
further	O
explore	O
the	O
function	O
of	O
SlTDT	O
,	O
we	O
constructed	O
both	O
overexpression	O
and	O
RNAi	O
vectors	O
and	O
obtained	O
transgenic	O
tomato	O
plants	O
by	O
agrobacterium	O
-mediated	O
method	O
.	O

Gas	B-P
chromatography-mass	I-P
spectrometer	I-P
(	O
GC-MS	B-P
)	I-P
analysis	I-P
showed	O
that	O
overexpression	O
of	O
SlTDT	O
significantly	O
increased	O
malate	O
content	O
,	O
and	O
reduced	O
citrate	O
content	O
in	O
tomato	O
fruit	O
.	O

By	O
contrast	O
,	O
repression	O
of	O
SlTDT	O
in	O
tomato	O
reduced	O
malate	O
content	O
of	O
and	O
increased	O
citrate	O
content	O
.	O

These	O
results	O
indicated	O
that	O
SlTDT	O
played	O
an	O
important	O
role	O
in	O
remobilization	O
of	O
malate	O
and	O
citrate	O
in	O
fruit	O
vacuoles	O
.	O

c-Src	O
Suppresses	O
Dendritic	O
Cell	O
Antitumor	O
Activity	O
via	O
T	O
Cell	O
Ig	O
and	O
Mucin	O
Protein-3	O
Receptor	O
.	O

The	O
enhanced	O
expression	O
of	O
T	O
cell	O
Ig	O
and	O
mucin	O
protein-3	O
(	O
TIM-3	O
)	O
on	O
tumor	O
-	O
associated	O
dendritic	O
cells	O
(	O
DCs	O
)	O
attenuates	O
antitumor	O
effects	O
of	O
DNA	O
vaccines	O
.	O

To	O
identify	O
a	O
potential	O
target	O
(	O
or	O
targets	O
)	O
for	O
reducing	O
TIM-3	O
expression	O
on	O
tumor	O
-	O
associated	O
DCs	O
,	O
we	O
explored	O
the	O
molecular	O
mechanisms	O
regulating	O
TIM-3	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
novel	O
signaling	O
pathway	O
(	O
c-Src	O
→	O
Bruton	O
's	O
tyrosine	O
kinase	O
→	O
transcription	O
factors	O
Ets1	O
,	O
Ets2	O
,	O
USF1	O
,	O
and	O
USF2	O
)	O
necessary	O
for	O
TIM-3	O
upregulation	O
on	O
DCs	O
.	O

Both	O
IL-10	O
and	O
TGF-β	O
,	O
which	O
are	O
produced	O
in	O
the	O
tumor	O
microenvironment	O
,	O
upregulated	O
TIM-3	O
expression	O
on	O
DCs	O
via	O
this	O
pathway	O
.	O

Suppressed	O
expression	O
of	O
c-Src	O
or	O
downstream	O
Bruton	O
's	O
tyrosine	O
kinase	O
,	O
Ets1	O
,	O
Ets2	O
,	O
USF1	O
,	O
or	O
USF2	O
blocked	O
IL-10-	O
and	O
TGF-β	O
-	O
induced	O
TIM-3	O
upregulation	O
on	O
DCs	O
.	O

Notably	O
,	O
in	O
vivo	O
knockdown	O
of	O
c-Src	O
in	O
mice	O
reduced	O
TIM-3	O
expression	O
on	O
tumor	O
-	O
associated	O
DCs	O
.	O

Furthermore	O
,	O
adoptive	B-P
transfer	I-P
of	O
c-Src	O
-	O
silenced	O
DCs	O
in	O
mouse	O
tumors	O
enhanced	O
the	O
in	O
vivo	O
antitumor	O
effects	O
of	O
immunostimulatory	O
CpG	O
DNA	O
;	O
however	O
,	O
TIM-3	O
overexpression	O
in	O
c-Src	O
-	O
silenced	O
DCs	O
blocked	O
this	O
effect	O
.	O

Collectively	O
,	O
our	O
data	O
reveal	O
the	O
molecular	O
mechanism	O
regulating	O
TIM-3	O
expression	O
in	O
DCs	O
and	O
identify	O
c-Src	O
as	O
a	O
target	O
for	O
improving	O
the	O
efficacy	O
of	O
nucleic	O
acid	O
-mediated	O
anticancer	B-P
therapy	I-P
.	O

Impact	O
of	O
Blood	B-P
Transfusions	I-P
on	O
Survival	O
of	O
Locally	O
Advanced	O
Cervical	O
Cancer	O
Patients	O
Undergoing	O
Neoadjuvant	B-P
Chemotherapy	I-P
Plus	O
Radical	B-P
Surgery	I-P
.	O

Transfusions	B-P
represent	O
one	O
of	O
the	O
main	O
progresses	O
of	O
modern	O
medicine	O
.	O

However	O
,	O
accumulating	O
evidence	O
supports	O
that	O
transfusions	B-P
correlate	O
with	O
worse	O
survival	O
outcomes	O
in	O
patients	O
affected	O
by	O
solid	O
cancers	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
perioperative	O
blood	B-P
transfusion	I-P
in	O
locally	O
advanced	O
cervical	O
cancer	O
.	O

Data	O
of	O
consecutive	O
patients	O
affected	O
by	O
locally	O
advanced	O
cervical	O
cancer	O
scheduled	O
to	O
undergo	O
neoadjuvant	B-P
chemotherapy	I-P
plus	O
radical	B-P
surgery	I-P
were	O
retrospectively	O
searched	O
to	O
test	O
the	O
impact	O
of	O
perioperative	O
transfusions	B-P
on	O
survival	O
outcomes	O
.	O

Five-	O
year	O
survival	O
outcomes	O
were	O
evaluated	O
using	O
Kaplan-Meier	O
and	O
Cox	O
models	O
.	O

The	O
study	O
included	O
275	O
patients	O
.	O

Overall	O
,	O
170	O
(	O
62	O
%	O
)	O
patients	O
had	O
blood	B-P
transfusion	I-P
.	O

Via	O
univariate	O
analysis	O
,	O
we	O
observed	O
that	O
transfusion	B-P
correlated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
recurrence	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
2.2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.09-4.40	O
;	O
P	O
=	O
0.02	O
)	O
.	O

Other	O
factors	O
associated	O
with	O
5-	O
year	O
disease-free	O
survival	O
were	O
noncomplete	O
clinical	O
response	O
after	O
neoadjuvant	B-P
chemotherapy	I-P
(	O
HR	O
,	O
2.99	O
;	O
95	O
%	O
CI	O
,	O
0.92-9.63	O
;	O
P	O
=	O
0.06	O
)	O
and	O
pathological	O
(	O
P	O
=	O
0.03	O
)	O
response	O
at	O
neoadjuvant	B-P
chemotherapy	I-P
as	O
well	O
as	O
parametrial	O
(	O
P	O
=	O
0.004	O
)	O
,	O
vaginal	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
lymph	O
node	O
(	O
P	O
=	O
0.002	O
)	O
involvements	O
.	O

However	O
,	O
via	O
multivariate	O
analysis	O
,	O
only	O
vaginal	O
(	O
HR	O
,	O
3.07	O
;	O
95	O
%	O
CI	O
,	O
1.20-7.85	O
;	O
P	O
=	O
0.01	O
)	O
and	O
lymph	O
node	O
involvements	O
(	O
HR	O
,	O
2.4	O
;	O
95	O
%	O
CI	O
,	O
1.00-6.06	O
;	O
P	O
=	O
0.05	O
)	O
correlate	O
with	O
worse	O
disease-free	O
survival	O
.	O

No	O
association	O
with	O
worse	O
outcomes	O
was	O
observed	O
for	O
patients	O
undergoing	O
blood	B-P
transfusion	I-P
(	O
HR	O
,	O
2.71	O
;	O
95	O
%	O
CI	O
,	O
0.91-8.03	O
;	O
P	O
=	O
0.07	O
)	O
.	O

Looking	O
at	O
factors	O
influencing	O
overall	O
survival	O
,	O
we	O
observed	O
that	O
lymph	O
node	O
status	O
(	O
P	O
=	O
0.01	O
)	O
and	O
vaginal	O
involvement	O
(	O
P	O
=	O
0.06	O
)	O
were	O
independently	O
associated	O
with	O
survival	O
.	O

The	O
role	O
of	O
blood	B-P
transfusions	I-P
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	O
in	O
LAAC	O
patients	O
treated	B-P
by	O
neoadjuvant	B-P
chemotherapy	I-P
plus	O
radical	B-P
surgery	I-P
remains	O
unclear	O
;	O
further	O
prospective	O
studies	O
are	O
warranted	O
.	O

Acute	O
Ph-negative	O
lymphoblastic	O
leukemias	O
in	O
adults	O
:	O
Risk	O
factors	O
in	O
the	O
use	O
of	O
the	O
ALL-2009	O
protocol	O
.	O

to	O
analyze	O
well-known	O
risk	O
factors	O
(	O
RFs	O
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	B-P
,	O
baseline	O
leukocytosis	O
,	O
enhanced	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
activity	O
,	O
time	O
to	O
achieve	O
complete	O
remission	O
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	O
abnormalities	O
)	O
in	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
in	O
the	O
use	O
of	O
the	O
ALL-2009	O
protocol	O
.	O

The	O
protocol	O
covered	O
298	O
patients	O
(	O
137	O
women	O
(	O
including	O
13	O
pregnant	O
women	O
)	O
and	O
161	O
men	O
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph-negative	O
ALL	O
.	O

The	O
phenotype	O
was	O
unknown	O
in	O
6	O
patients	O
.	O

Three	O
(	O
1	O
%	O
)	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant	O
.	O

182	O
(	O
62.4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B-cell	O
ALL	O
(	O
early	O
pre-B	O
ALL	O
(	O
n=51	O
)	O
;	O
common	O
ALL	O
(	O
n=92	O
)	O
,	O
and	O
pre-B	O
ALL	O
(	O
n=39	O
)	O
;	O
107	O
(	O
36.6	O
%	O
)	O
patients	O
had	O
T-cell	O
ALL	O
(	O
early	O
T-ALL	O
(	O
n=56	O
)	O
;	O
thymic	O
T-ALL	O
(	O
n=41	O
)	O
,	O
and	O
mature	O
T-ALL	O
(	O
n=10	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	O
parameters	O
(	O
leukocytosis	O
of	O
30·109/l	O
and	O
more	O
for	O
B-ALL	O
;	O
and	O
that	O
of	O
100·109/l	O
and	O
more	O
for	O
T-ALL	O
;	O
phenotype	O
В-I	O
for	O
B-ALL	O
,	O
phenotype	O
Т-I-II-IV	O
for	O
T-ALL	O
;	O
LDH	O
activity	O
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	O
of	O
translocation	O
t	O
(	O
4	O
;	O
11	O
)	O
)	O
,	O
the	O
high-risk	O
group	O
included	O
most	O
patients	O
with	O
B-ALL	O
(	O
n=110	O
(	O
72.8	O
%	O
)	O
)	O
and	O
T-ALL	O
(	O
n=76	O
(	O
76	O
%	O
)	O
)	O
.	O

Thirty-five	O
patients	O
with	O
T-ALL	O
underwent	O
autologous	B-P
bone	I-P
marrow	I-P
transplantation	I-P
(	O
BMT	B-P
)	O
.	O

Allogeneic	B-P
BMT	I-P
was	O
performed	O
in	O
18	O
(	O
7	O
%	O
)	O
of	O
the	O
258	O
patients	O
who	O
had	O
undergone	O
an	O
induction	O
phase	O
.	O

Five-year	O
overall	O
survival	O
for	O
all	O
the	O
patients	O
included	O
in	O
the	O
investigation	O
was	O
59	O
%	O
;	O
relapse-free	B-P
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	O
with	O
B-ALL	O
and	O
in	O
those	O
with	O
T-ALL	O
:	O
the	O
overall	O
survival	O
rates	O
were	O
53.3	O
and	O
67.5	O
%	O
(	O
p=0.1	O
)	O
;	O
the	O
relapse-free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p=0.005	O
)	O
,	O
respectively	O
.	O

Multivariate	O
analysis	O
including	O
the	O
well-known	O
RFs	O
demonstrated	O
that	O
the	O
latter	O
for	O
T-ALL	O
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	O
's	O
age	O
was	O
identified	O
for	O
B-ALL	O
(	O
p=0.013	O
)	O
.	O

A	O
lower	O
chemotherapeutic	O
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	B-P
BMTs	I-P
did	O
not	O
affect	O
total	O
positive	O
treatment	B-P
results	O
in	O
adult	O
patients	O
with	O
ALL	O
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	O
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	O
loading	O
dose	O
.	O

The	O
results	O
of	O
the	O
Russian	O
investigation	O
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	B-P
BMTs	I-P
in	O
adult	O
patients	O
with	O
ALL	O
.	O

Effects	O
of	O
Elevated	O
CO2	O
on	O
the	O
Swainsonine	O
Chemotypes	O
of	O
Astragalus	O
lentiginosus	O
and	O
Astragalus	O
mollissimus	O
.	O

Rapid	O
changes	O
in	O
the	O
Earth	O
's	O
atmosphere	O
and	O
climate	O
associated	O
with	O
human	O
activity	O
can	O
have	O
significant	O
impacts	O
on	O
agriculture	O
including	O
livestock	O
production	O
.	O

CO2	O
concentration	O
has	O
risen	O
from	O
the	O
industrial	O
revolution	O
to	O
the	O
current	O
time	O
,	O
and	O
is	O
expected	O
to	O
continue	O
to	O
rise	O
.	O

Climatic	O
changes	O
alter	O
physiological	O
processes	O
,	O
growth	O
,	O
and	O
development	O
in	O
numerous	O
plant	O
species	O
,	O
potentially	O
changing	O
concentrations	O
of	O
plant	O
secondary	O
compounds	O
.	O

These	O
physiological	O
changes	O
may	O
influence	O
plant	O
population	O
density	O
,	O
growth	O
,	O
fitness	O
,	O
and	O
toxin	O
concentrations	O
and	O
thus	O
influence	O
the	O
risk	O
of	O
toxic	O
plants	O
to	O
grazing	O
livestock	O
.	O

Locoweeds	O
,	O
swainsonine	O
-	O
containing	O
Astragalus	O
species	O
,	O
are	O
one	O
group	O
of	O
plants	O
that	O
may	O
be	O
influenced	O
by	O
climate	O
change	O
.	O

We	O
evaluated	O
how	O
two	O
different	O
swainsonine	O
-	O
containing	O
Astragalus	O
species	O
responded	O
to	O
elevated	O
CO2	O
concentrations	O
.	O

Measurements	O
of	O
biomass	O
,	O
crude	B-P
protein	I-P
,	O
water	O
soluble	O
carbohydrates	B-P
and	O
swainsonine	B-P
concentrations	I-P
were	O
measured	O
in	O
two	O
chemotypes	O
(	O
positive	O
and	O
negative	O
for	O
swainsonine	O
)	O
of	O
each	O
species	O
after	O
growth	O
at	O
CO2	B-P
levels	I-P
near	O
present	O
day	O
and	O
at	O
projected	O
future	O
concentrations	O
.	O

Biomass	O
and	O
water	O
soluble	O
carbohydrate	O
concentrations	O
responded	O
positively	O
while	O
crude	B-P
protein	I-P
concentrations	I-P
responded	O
negatively	O
to	O
elevated	O
CO2	O
in	O
the	O
two	O
species	O
.	O

Swainsonine	O
concentrations	O
were	O
not	O
strongly	O
affected	O
by	O
elevated	O
CO2	O
in	O
the	O
two	O
species	O
.	O

In	O
the	O
different	O
chemotypes	O
,	O
biomass	O
responded	O
negatively	O
and	O
crude	B-P
protein	I-P
concentrations	I-P
responded	O
positively	O
in	O
the	O
swainsonine	O
-	O
positive	O
plants	O
compared	O
to	O
the	O
swainsonine	O
-	O
negative	O
plants	O
.	O

Ultimately	O
,	O
changes	O
in	O
CO2	O
and	O
endophyte	O
status	O
will	O
likely	O
alter	O
multiple	O
physiological	O
responses	O
in	O
toxic	O
plants	O
such	O
as	O
locoweed	O
,	O
but	O
it	O
is	O
difficult	O
to	O
predict	O
how	O
these	O
changes	O
will	O
impact	O
plant	O
herbivore	O
interactions	O
.	O

Adverse	O
events	O
risk	O
associated	O
with	O
angiogenesis	O
inhibitors	O
addition	O
to	O
therapy	B-P
in	O
ovarian	O
cancer	O
:	O
a	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O

Inhibition	O
of	O
angiogenesis	O
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	B-P
strategy	I-P
for	O
advanced	O
or	O
recurrent	O
ovarian	O
cancer	O
.	O

We	O
conduct	O
this	O
meta-analysis	O
to	O
investigate	O
the	O
risk	O
of	O
adverse	O
events	O
of	O
special	O
interest	O
related	O
to	O
angiogenesis	O
inhibitors	O
(	O
AIs	O
)	O
in	O
ovarian	O
cancer	O
.	O

Databases	O
from	O
PubMed	O
,	O
Web	O
of	O
Science	O
and	O
Cochrane	O
library	O
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	O
.	O

Eligible	O
studies	O
included	O
prospective	O
randomized	O
controlled	O
phase	O
II/III	O
clinical	O
trials	O
evaluating	O
therapy	B-P
with	O
or	O
without	O
AIs	O
for	O
ovarian	O
cancer	O
.	O

Summary	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
using	O
random-effects	O
or	O
fixed-effects	O
according	O
to	O
the	O
heterogeneity	O
among	O
included	O
trials	O
.	O

A	O
total	O
of	O
7,761	O
patients	O
from	O
ten	O
clinical	O
trials	O
were	O
included	O
in	O
the	O
meta-analysis	O
.	O

Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
AIs	O
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	O
thromboembolic	O
events	O
(	O
RR	O
=	O
2.0	O
)	O
,	O
gastrointestinal	O
(	O
GI	O
)	O
perforation	O
(	O
RR	O
=	O
3.86	O
)	O
,	O
proteinuria	O
(	O
RR	O
=	O
2.44	O
)	O
,	O
and	O
hypertension	O
(	O
RR	O
=	O
5.39	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
for	O
hemorrhagic	O
events	O
(	O
p	O
=	O
0.07	O
)	O
,	O
venous	O
thromboembolic	O
events	O
(	O
p	O
=	O
0.13	O
)	O
,	O
or	O
fatal	O
adverse	O
events	O
(	O
p	O
=	O
0.26	O
)	O
.	O

The	O
addition	O
of	O
AIs	O
to	O
therapy	B-P
in	O
ovarian	O
cancer	O
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	O
thromboembolic	O
events	O
,	O
GI	O
perforation	O
,	O
proteinuria	O
and	O
hypertension	O
,	O
but	O
not	O
for	O
venous	O
thromboembolic	O
events	O
,	O
hemorrhagic	O
events	O
,	O
or	O
fatal	O
adverse	O
events	O
.	O

Silk	O
fibroin	O
based	O
carrier	O
system	O
for	O
delivery	O
of	O
fibrinogen	O
and	O
thrombin	O
as	O
coagulant	O
supplements	O
.	O

The	O
control	O
of	O
bleeding	O
is	O
one	O
of	O
the	O
most	O
important	O
interventions	B-P
after	O
a	O
traumatic	O
injury	O
.	O

Hemostatic	O
devices	O
delivering	O
blood	O
clotting	O
accelerating	O
agents	O
such	O
as	O
fibrinogen	O
are	O
increasingly	O
used	O
due	O
to	O
their	O
efficacy	O
and	O
their	O
ease	O
of	O
application	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
a	O
method	O
to	O
incorporate	O
the	O
coagulant	O
supplements	O
fibrinogen	O
and	O
thrombin	O
in	O
silk	O
protein	O
sponges	O
by	O
mixing	O
the	O
coagulants	O
with	O
an	O
aqueous	O
silk	O
solution	O
,	O
followed	O
by	O
molding	B-P
,	O
freeze-drying	B-P
and	O
water	B-P
annealing	I-P
.	O

In	O
this	O
combination	O
system	O
we	O
demonstrate	O
the	O
delivery	O
of	O
fibrinogen	O
while	O
maintaining	O
its	O
hemostatic	O
potential	O
.	O

Concentration	O
ratios	O
of	O
silk	O
to	O
fibrinogen	O
of	O
1.0	O
%	O
/2.8	O
%	O
,	O
2.3	O
%	O
/1.5	O
%	O
and	O
3.0	O
%	O
/0.8	O
%	O
were	O
used	O
.	O

The	O
thrombin	O
-induced	O
fibrin	O
polymeric	O
network	O
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	O
spongy	O
structure	O
but	O
also	O
remained	O
interconnected	O
to	O
the	O
silk	O
,	O
providing	O
an	O
intact	O
network	O
.	O

The	O
mechanical	O
characterization	O
of	O
the	O
fibrinogen-releasing	O
silk	O
sponges	O
before	O
and	O
after	O
the	O
induction	O
of	O
the	O
fibrinogen	O
polymerization	O
demonstrated	O
that	O
the	O
fibrin	O
network	O
resulted	O
in	O
reduced	O
permanent	O
deformation	O
from	O
21.1	O
%	O
to	O
6.5	O
%	O
,	O
19.6	O
%	O
to	O
5.7	O
%	O
and	O
12.7	O
%	O
to	O
9.4	O
%	O
for	O
the	O
2.8	O
%	O
,	O
1.5	O
%	O
and	O
0.8	O
%	O
fibrinogen	O
-containing	O
silk	O
sponges	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
fibrin	O
formation	O
lead	O
to	O
a	O
more	O
linear	O
elastic	O
behavior	O
over	O
longer	O
strain	O
ranges	O
.	O

In	O
combination	O
,	O
the	O
Calcein-AM	O
/	O
PI	O
stainings	O
and	O
MTT	O
assay	O
results	O
indicate	O
uniform	O
cell	O
adhesion	O
on	O
the	O
surface	O
and	O
cytocompatibility	O
of	O
the	O
silk	O
/	O
fibrin	O
sponges	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
co-delivery	O
of	O
thrombin	O
with	O
fibrinogen	O
via	O
silk	O
as	O
carrier	O
material	O
is	O
described	O
,	O
offering	O
a	O
more	O
mechanically	O
robust	O
and	O
durable	O
system	O
while	O
preserving	O
hemostatic	O
features	O
of	O
the	O
coagulant	O
substances	O
for	O
the	O
generation	O
of	O
hemostatic	O
devices	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Pharmacological	O
Actions	O
of	O
Glucagon-Like	O
Peptide-1	O
,	O
Gastric	O
Inhibitory	O
Polypeptide	O
,	O
and	O
Glucagon	O
.	O

Glucagon	O
family	O
of	O
peptide	O
hormones	O
is	O
a	O
group	O
of	O
structurally	O
related	O
brain-gut	O
peptides	O
that	O
exert	O
their	O
pleiotropic	O
actions	O
through	O
interactions	O
with	O
unique	O
members	O
of	O
class	O
B1	O
G	O
protein-coupled	O
receptors	O
(	O
GPCRs	O
)	O
.	O

They	O
are	O
key	O
regulators	O
of	O
hormonal	O
homeostasis	O
and	O
are	O
important	O
drug	O
targets	O
for	O
metabolic	O
disorders	O
such	O
as	O
type-2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
,	O
obesity	O
,	O
and	O
dysregulations	O
of	O
the	O
nervous	O
systems	O
such	O
as	O
migraine	O
,	O
anxiety	O
,	O
depression	O
,	O
neurodegeneration	O
,	O
psychiatric	O
disorders	O
,	O
and	O
cardiovascular	O
diseases	O
.	O

The	O
current	O
review	O
aims	O
to	O
provide	O
a	O
detailed	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
pharmacological	O
actions	O
and	O
therapeutic	B-P
advances	I-P
of	O
three	O
members	O
within	O
this	O
family	O
including	O
glucagon-like	O
peptide-1	O
(	O
GLP-1	O
)	O
,	O
gastric	O
inhibitory	O
polypeptide	O
(	O
GIP	O
)	O
,	O
and	O
glucagon	O
.	O

Antihypertensive	O
medicines	O
utilization	O
:	O
A	O
decade-long	O
nationwide	O
study	O
of	O
octogenarians	O
,	O
nonagenarians	O
and	O
centenarians	O
.	O

Gaining	O
an	O
insight	O
into	O
the	O
utilization	O
of	O
antihypertensive	O
medicines	O
against	O
a	O
background	O
of	O
evolving	O
hypertension	O
treatment	O
guidelines	O
that	O
might	O
not	O
be	O
relevant	O
to	O
the	O
oldest	O
old	O
is	O
important	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
characterize	O
the	O
overall	O
trends	O
in	O
the	O
utilization	O
of	O
antihypertensive	O
medicines	O
in	O
the	O
oldest	O
old	O
by	O
therapeutic	O
class	O
and	O
chemical	O
type	O
,	O
stratified	O
by	O
age	O
and	O
sex	O
over	O
a	O
decade	O
.	O

Antihypertensive	O
medicines	O
utilization	O
was	O
examined	O
using	O
the	O
therapeutic	B-P
and	O
chemical	O
groups	O
based	O
on	O
the	O
World	O
Health	O
Organization	O
Collaborating	O
Center	O
for	O
Drug	O
Statistics	O
Mythology	O
's	O
Anatomical	O
Therapeutic	O
Chemical	O
classification	O
system	O
for	O
all	O
individuals	O
aged	O
≥80	O
years	O
.	O

Regression	O
and	O
repeated	O
cross-sectional	O
analyses	O
was	O
carried	O
out	O
,	O
and	O
defined	O
daily	O
dose	O
was	O
used	O
to	O
describe	O
the	O
utilization	O
per	O
thousand	O
older	O
people	O
per	O
day	O
.	O

Utilization	O
of	O
antihypertensive	O
medicines	O
increased	O
over	O
the	O
decade	O
from	O
187.28	O
in	O
2005	O
to	O
205.01	O
defined	O
daily	O
dose	O
per	O
thousand	O
older	O
people	O
per	O
day	O
in	O
2014	O
,	O
and	O
shifted	O
from	O
mainly	O
diuretics	O
to	O
angiotensin-converting	O
enzyme	O
inhibitors	O
.	O

Interestingly	O
,	O
with	O
the	O
exception	O
of	O
diuretics	O
,	O
utilization	O
of	O
all	O
medicines	O
decreased	O
gradually	O
with	O
increasing	O
age	O
.	O

Single	O
products	O
use	O
increased	O
by	O
1.48-fold	O
in	O
2014	O
compared	O
with	O
2005	O
,	O
and	O
for	O
fixed-dose	O
combinations	O
the	O
increase	O
was	O
1.41-fold	O
for	O
the	O
same	O
period	O
.	O

The	O
increased	O
utilization	O
of	O
angiotensin-converting	O
enzyme	O
inhibitors	O
is	O
consistent	O
with	O
recommendations	O
from	O
cardiovascular	O
guidelines	O
formulated	O
from	O
large	O
randomized	O
control	O
trials	O
that	O
often	O
exclude	O
the	O
oldest	O
old	O
.	O

Interestingly	O
,	O
the	O
utilization	O
of	O
beta-blockers	O
decreased	O
and	O
diuretics	O
increased	O
in	O
centenarians	O
.	O

The	O
utilization	O
of	O
calcium	O
channel	O
blockers	O
and	O
angiotensin-converting	O
enzyme	O
inhibitors	O
across	O
the	O
study	O
period	O
increased	O
in	O
all	O
age	O
categories	O
.	O

Geriatr	O
Gerontol	O
Int	O
2016	O
;	O
••	O
:	O
••-••	O
.	O

Prevalence	O
and	O
risk	O
factors	O
of	O
anxiety	O
and	O
depression	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
in	O
Southwest	O
China	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
patients	O
have	O
high	O
risk	O
for	O
anxiety	O
and	O
depression	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
prevalence	O
and	O
risk	O
factors	O
of	O
anxiety	O
and	O
depression	O
in	O
SLE	O
patients	O
in	O
Southwest	O
China	O
.	O

Participants	O
were	O
recruited	O
by	O
convenience	O
sampling	B-P
from	O
Rheumatic	O
Outpatient	O
Clinic	O
of	O
West	O
China	O
Hospital	O
Sichuan	O
University	O
between	O
August	O
and	O
October	O
2014	O
.	O

The	O
prevalence	O
of	O
anxiety	O
and	O
depression	O
was	O
evaluated	O
using	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
(	O
HADS	O
)	O
.	O

Risk	O
factors	O
were	O
explored	O
by	O
multiple	O
logistic	O
regression	O
analyses	O
.	O

A	O
total	O
of	O
352	O
participants	O
were	O
enrolled	O
,	O
of	O
who	O
64	O
(	O
18.2	O
%	O
)	O
met	O
the	O
HADS	O
criteria	O
for	O
anxiety	O
and	O
82	O
(	O
23.3	O
%	O
)	O
for	O
depression	O
.	O

In	O
multivariable	O
analysis	O
,	O
higher	O
levels	O
of	O
pain	O
(	O
OR	O
=	O
1.17	O
,	O
P	O
=	O
0.02	O
)	O
and	O
fatigue	O
(	O
OR	O
=	O
1.19	O
,	O
P	O
<	O
0.01	O
)	O
predicted	O
a	O
higher	O
risk	O
of	O
anxiety	O
.	O

Similarly	O
,	O
a	O
higher	O
level	O
of	O
fatigue	O
(	O
OR	O
=	O
1.2	O
,	O
P	O
<	O
0.01	O
)	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
depression	O
.	O

The	O
results	O
suggest	O
that	O
anxiety	O
and	O
depression	O
are	O
common	O
in	O
patients	O
with	O
SLE	O
in	O
Southwest	O
China	O
.	O

Health	O
care	O
providers	O
and	O
SLE	O
patients	O
should	O
take	O
some	O
measures	O
to	O
cope	O
with	O
them	O
as	O
early	O
as	O
possible	O
.	O

Strengthening	O
management	O
of	O
pain	O
and	O
fatigue	O
may	O
be	O
useful	O
.	O

But	O
further	O
studies	O
are	O
needed	O
to	O
verify	O
these	O
findings	O
.	O

Dabigatran	O
:	O
A	O
new	O
oral	O
anticoagulant	O
.	O

Guidelines	O
to	O
follow	O
in	O
oral	O
surgery	O
procedures	O
.	O

A	O
systematic	O
review	O
of	O
the	O
literature	O
.	O

Dabigatran	O
is	O
a	O
newly	O
commercialized	O
drug	O
that	O
is	O
replacing	O
other	O
anticoagulants	O
in	O
the	O
prevention	O
of	O
venous	O
thromboembolism	O
,	O
stroke	O
and	O
systemic	O
arterial	O
valve	O
embolism	O
.	O

It	O
acts	O
directly	O
on	O
thrombin	O
presenting	O
in	O
a	O
dynamic	O
and	O
predictable	O
way	O
,	O
which	O
does	O
not	O
require	O
monitoring	O
these	O
patients	O
.	O

Therefore	O
,	O
we	O
consider	O
the	O
need	O
to	O
assess	O
whether	O
their	O
use	O
increases	O
the	O
risk	O
of	O
bleeding	O
involved	O
before	O
any	O
dental	B-P
treatment	I-P
.	O

We	O
performed	O
a	O
systematic	O
review	O
with	O
a	O
bibliographic	O
search	O
in	O
PubMed	O
/	O
Medline	O
along	O
with	O
the	O
Cochrane	O
Library	O
.	O

We	O
excluded	O
articles	O
dealing	O
with	O
all	O
anticoagulants	O
other	O
than	O
dabigatran	O
,	O
and	O
works	O
about	O
surgical	B-P
treatments	I-P
in	O
anatomical	O
locations	O
other	O
than	O
the	O
oral	O
cavity	O
.	O

We	O
included	O
a	O
total	O
of	O
13	O
papers	O
of	O
which	O
1	O
was	O
a	O
randomized	O
clinical	O
trial	O
,	O
9	O
narrative	O
literature	O
reviews	O
,	O
1	O
case	O
series	O
,	O
2	O
clinical	O
cases	O
and	O
1	O
expert	O
opinion	O
.	O

Because	O
we	O
did	O
not	O
obtain	O
any	O
properly	O
designed	O
clinical	O
trials	O
,	O
we	O
were	O
unable	O
to	O
conduct	O
a	O
meta-analysis	O
.	O

Currently	O
,	O
there	O
is	O
no	O
consensus	O
on	O
the	O
procedure	B-P
to	O
be	O
followed	O
in	O
patients	O
taking	O
dabigatran	O
.	O

However	O
,	O
all	O
authors	O
agree	O
to	O
treat	O
each	O
case	O
individually	O
in	O
accordance	O
to	O
the	O
risk	O
of	O
embolism	O
,	O
postoperative	O
bleeding	O
and	O
renal	O
function	O
.	O

Also	O
,	O
it	O
is	O
necessary	O
to	O
perform	O
minimally	O
invasive	B-P
interventions	I-P
,	O
and	O
take	O
the	O
appropriate	O
local	O
anti-hemolytic	B-P
measures	I-P
.	O

Functional	O
Impairment	O
in	O
Children	O
With	O
Externalizing	O
Behavior	O
Disorders	O
:	O
Psychometric	B-P
Properties	O
of	O
the	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale-Parent	O
Report	O
in	O
a	O
German	O
Clinical	O
Sample	O
.	O

To	O
examine	O
the	O
psychometric	B-P
properties	O
of	O
a	O
German	O
adaptation	O
of	O
the	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale-Parent	O
Report	O
(	O
WFIRS-P	O
)	O
in	O
a	O
clinical	O
sample	O
of	O
children	O
(	O
4-12	O
years	O
)	O
with	O
externalizing	O
behavior	O
disorders	O
.	O

Data	O
were	O
collected	O
within	O
two	O
clinical	O
trials	O
(	O
N	O
=	O
264	O
)	O
.	O

Factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
from	O
symptoms	O
of	O
ADHD	O
and	O
oppositional	O
defiant	O
disorder	O
(	O
ODD	O
)	O
were	O
assessed	O
.	O

Confirmatory	O
factor	O
analyses	O
revealed	O
that	O
a	O
bifactor	O
model	O
consistent	O
with	O
the	O
theoretical	O
assumption	O
of	O
a	O
general	O
construct	O
of	O
impairment	O
(	O
total	O
scale	O
)	O
and	O
additional	O
specific	O
factors	O
(	O
subscales	O
)	O
provided	O
satisfactory	O
data	O
fit	O
.	O

Model	O
-based	O
reliability	O
estimates	O
showed	O
that	O
both	O
the	O
general	O
construct	O
and	O
specific	O
factors	O
accounted	O
for	O
item	O
variance	O
.	O

Internal	O
consistencies	O
were	O
>	O
.70	O
,	O
part-whole	O
corrected	O
item-scale	O
correlations	O
mostly	O
>	O
.30	O
.	O

Correlations	O
between	O
the	O
WFIRS-P	O
Scales	O
and	O
ADHD	O
and	O
ODD	O
symptoms	O
were	O
low	O
to	O
moderate	O
.	O

The	O
results	O
support	O
the	O
factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
of	O
the	O
WFIRS-P	O
.	O

Delayed	O
Axillary	O
Artery	O
Occlusion	O
after	O
Reverse	O
Total	B-P
Shoulder	I-P
Arthroplasty	I-P
.	O

Axillary	O
artery	O
injury	O
has	O
been	O
associated	O
with	O
shoulder	O
dislocation	O
and	O
surgery	B-P
.	O

We	O
describe	O
a	O
case	O
of	O
delayed	O
axillary	O
artery	O
occlusion	O
after	O
reverse	O
total	B-P
shoulder	I-P
arthroplasty	I-P
.	O

The	O
injury	O
was	O
confirmed	O
by	O
Doppler	B-P
and	O
angiography	B-P
and	O
was	O
treated	B-P
with	I-P
angioplasty	B-P
and	O
stenting	B-P
.	O

Early	B-P
recognition	I-P
and	O
treatment	B-P
of	O
this	O
injury	O
are	O
mandatory	O
for	O
patients	O
'	O
recovery	O
.	O

Subsolid	O
pulmonary	O
nodule	O
morphology	O
and	O
associated	O
patient	O
characteristics	O
in	O
a	O
routine	O
clinical	O
population	O
.	O

To	O
determine	O
the	O
presence	O
and	O
morphology	O
of	O
subsolid	O
pulmonary	O
nodules	O
(	O
SSNs	O
)	O
in	O
a	O
non-screening	O
setting	O
and	O
relate	O
them	O
to	O
clinical	O
and	O
patient	O
characteristics	O
.	O

A	O
total	O
of	O
16,890	O
reports	O
of	O
clinically	O
obtained	O
chest	B-P
CT	I-P
(	O
06/2011	O
to	O
11/2014	O
,	O
single-centre	O
)	O
were	O
searched	O
describing	O
an	O
SSN	O
.	O

Subjects	O
with	O
a	O
visually	O
confirmed	O
SSN	O
and	O
at	O
least	O
two	O
thin-slice	B-P
CTs	I-P
were	O
included	O
.	O

Nodule	O
volumes	O
were	O
measured	O
.	O

Progression	O
was	O
defined	O
as	O
volume	O
increase	O
exceeding	O
the	O
software	B-P
interscan	I-P
variation	O
.	O

Nodule	O
morphology	O
,	O
location	O
,	O
and	O
patient	O
characteristics	O
were	O
evaluated	O
.	O

Fifteen	O
transient	O
and	O
74	O
persistent	O
SSNs	O
were	O
included	O
(	O
median	O
follow-up	O
19.6	O
[	O
8.3-36.8	O
]	O
months	O
)	O
.	O

Subjects	O
with	O
an	O
SSN	O
were	O
slightly	O
older	O
than	O
those	O
without	O
(	O
62	O
vs.	O
58	O
years	O
;	O
p	O
=	O
0.01	O
)	O
,	O
but	O
no	O
gender	O
predilection	O
was	O
found	O
.	O

SSNs	O
were	O
mostly	O
located	O
in	O
the	O
upper	O
lobes	O
.	O

Women	O
showed	O
significantly	O
more	O
often	O
persistent	O
lesions	O
than	O
men	O
(	O
94	O
%	O
vs.	O
69	O
%	O
;	O
p	O
=	O
0.002	O
)	O
.	O

Part-solid	O
lesions	O
were	O
larger	O
(	O
1638	O
vs.	O
383	O
mm	O
(	O
3	O
)	O
;	O
p	O
<	O
0.001	O
)	O
and	O
more	O
often	O
progressive	O
(	O
68	O
%	O
vs.	O
38	O
%	O
;	O
p	O
=	O
0.02	O
)	O
,	O
compared	O
to	O
pure	O
ground-glass	O
nodules	O
.	O

Progressive	O
SSNs	O
were	O
rare	O
under	O
the	O
age	O
of	O
50	O
years	O
.	O

Logistic	O
regression	O
analysis	O
did	O
not	O
identify	O
additional	O
nodule	O
parameters	O
of	O
future	O
progression	O
,	O
apart	O
from	O
part-solid	O
nature	O
.	O

This	O
study	O
confirms	O
previously	O
reported	O
characteristics	O
of	O
SSNs	O
and	O
associated	O
factors	O
in	O
a	O
European	O
,	O
routine	O
clinical	O
population	O
.	O

•	O
SSNs	O
in	O
women	O
are	O
significantly	O
more	O
often	O
persistent	O
compared	O
to	O
men	O
.	O

•	O
SSN	O
persistence	O
is	O
not	O
associated	O
with	O
age	O
or	O
prior	O
malignancy	O
.	O

•	O
The	O
majority	O
of	O
(	O
persistent	O
)	O
SSNs	O
are	O
located	O
in	O
the	O
upper	O
lung	O
lobes	O
.	O

•	O
A	O
part-solid	O
nature	O
is	O
associated	O
with	O
future	O
nodule	O
growth	O
.	O

•	O
Progressive	O
solitary	O
SSNs	O
are	O
rare	O
under	O
the	O
age	O
of	O
50	O
years	O
.	O

Caregiver	O
satisfaction	O
with	O
paediatric	O
HIV	O
treatment	B-P
and	O
care	O
in	O
Nigeria	O
and	O
equity	O
implications	O
for	O
children	O
living	O
with	O
HIV	O
.	O

Caregiver	O
satisfaction	O
has	O
the	O
potential	O
to	O
promote	O
equity	O
for	O
children	O
living	O
with	O
HIV	O
,	O
by	O
influencing	O
health-seeking	O
behaviour	O
.	O

We	O
measured	O
dimensions	O
of	O
caregiver	O
satisfaction	O
with	O
paediatric	O
HIV	O
treatment	B-P
in	O
Nigeria	O
,	O
and	O
discuss	O
its	O
implications	O
for	O
equity	O
by	O
conducting	O
facility-based	O
exit	O
interviews	O
for	O
caregivers	O
of	O
children	O
receiving	O
antiretroviral	B-P
therapy	I-P
in	O
20	O
purposively	O
selected	O
facilities	O
within	O
5	O
geopolitical	O
zones	O
.	O

Descriptive	O
analysis	O
and	O
factor	O
analysis	O
were	O
performed	O
.	O

Due	O
to	O
the	O
hierarchical	O
nature	O
of	O
the	O
data	O
,	O
multilevel	O
regression	O
modelling	O
was	O
performed	O
to	O
investigate	O
relationships	O
between	O
satisfaction	O
factors	O
and	O
socio-demographic	O
variables	O
.	O

Of	O
1550	O
caregivers	O
interviewed	O
,	O
63	O
%	O
(	O
95	O
%	O
CI	O
:	O
60.6-65.4	O
)	O
reported	O
being	O
very	O
satisfied	O
overall	O
;	O
however	O
,	O
satisfaction	O
varied	O
in	O
some	O
dimensions	O
:	O
only	O
55.6	O
%	O
(	O
53.1-58.1	O
)	O
of	O
caregivers	O
could	O
talk	O
privately	O
with	O
health	O
workers	O
,	O
56.9	O
%	O
(	O
54.4-59.3	O
)	O
reported	O
that	O
queues	O
to	O
see	O
health	O
workers	O
were	O
too	O
long	O
,	O
and	O
89.9	O
%	O
(	O
88.4-91.4	O
)	O
said	O
that	O
some	O
health	O
workers	O
did	O
not	O
treat	O
patients	O
living	O
with	O
HIV	O
with	O
sufficient	O
respect	O
.	O

Based	O
on	O
factor	O
analysis	O
,	O
two	O
underlying	O
factors	O
,	O
labelled	O
Availability	O
and	O
Attitude	O
,	O
were	O
identified	O
.	O

In	O
multilevel	O
regression	O
,	O
the	O
satisfaction	O
with	O
availability	O
of	O
services	O
correlated	O
with	O
formal	O
employment	O
status	O
(	O
p	O
<	O
.01	O
)	O
,	O
whereas	O
caregivers	O
receiving	O
care	O
in	O
private	O
facilities	O
were	O
less	O
likely	O
satisfied	O
with	O
both	O
availability	O
(	O
p	O
<	O
.01	O
)	O
and	O
attitude	O
of	O
health	O
workers	O
(	O
p	O
<	O
.05	O
)	O
.	O

State	O
and	O
facility	O
levels	O
influenced	O
attitudes	O
of	O
the	O
health	O
workers	O
(	O
p	O
<	O
.01	O
)	O
,	O
but	O
not	O
availability	O
of	O
services	O
.	O

We	O
conclude	O
that	O
high	O
levels	O
of	O
overall	O
satisfaction	O
among	O
caregivers	O
masked	O
dissatisfaction	O
with	O
some	O
aspects	O
of	O
services	O
.	O

The	O
two	O
underlying	O
satisfaction	O
factors	O
are	O
part	O
of	O
access	O
typology	O
critical	O
for	O
closing	O
equity	O
gaps	O
in	O
access	O
to	O
HIV	O
treatment	B-P
between	O
adults	O
and	O
children	O
,	O
and	O
across	O
socio-economic	O
groups	O
.	O

Neural	O
correlates	O
of	O
experimental	O
trauma	O
memory	O
retrieval	O
.	O

Traumatic	O
memories	O
such	O
as	O
intrusions	O
and	O
flashbacks	O
play	O
a	O
major	O
role	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
post-traumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O

A	O
thorough	O
understanding	O
of	O
the	O
neural	O
mechanisms	O
underlying	O
traumatic	O
memories	O
is	O
indispensable	O
for	O
precise	O
diagnosis	O
,	O
for	O
personalized	O
treatment	B-P
and	O
prevention	B-P
.	O

In	O
particular	O
,	O
the	O
identification	O
of	O
early	O
neural	O
predictor	O
variables	O
for	O
intrusion	O
development	O
shortly	O
after	O
trauma	O
exposure	O
requires	O
detailed	O
investigation	O
.	O

Here	O
,	O
we	O
examined	O
the	O
neural	O
correlates	O
of	O
early	O
experimental	O
trauma	O
memory	O
retrieval	O
in	O
a	O
traumatic	O
film	O
paradigm	O
in	O
42	O
young	O
healthy	O
females	O
,	O
using	O
both	O
implicit	O
and	O
explicit	O
retrieval	O
tasks	O
.	O

We	O
show	O
that	O
implicit	O
experimental	O
trauma	O
retrieval	O
specifically	O
involved	O
the	O
retrosplenial	O
cortex	O
and	O
the	O
anterior	O
cingulate	O
cortex	O
(	O
ACC	O
)	O
,	O
while	O
both	O
retrieval	O
tasks	O
resulted	O
in	O
trauma-related	O
activity	O
in	O
the	O
posterior	O
cingulate	O
cortex	O
(	O
PCC	O
)	O
and	O
the	O
precuneus	O
.	O

Importantly	O
,	O
neural	O
activity	O
early	O
after	O
experimental	O
trauma	O
exposure	O
predicted	O
later	O
intrusion	O
development	O
,	O
with	O
independent	O
contributions	O
from	O
activity	O
in	O
the	O
retrosplenial	O
cortex	O
(	O
implicit	O
retrieval	O
)	O
and	O
the	O
PCC	O
(	O
explicit	O
retrieval	O
)	O
.	O

Additional	O
analyses	O
revealed	O
a	O
stronger	O
connectivity	O
between	O
the	O
bilateral	O
amygdala	O
and	O
the	O
supplementary	O
motor	O
area	O
,	O
precentral	O
and	O
paracentral	O
lobule	O
for	O
the	O
control	O
group	O
compared	O
to	O
the	O
experimental	O
trauma	O
group	O
.	O

Our	O
study	O
gives	O
new	O
insights	O
in	O
the	O
neural	O
correlates	O
of	O
experimental	O
trauma	O
memory	O
retrieval	O
and	O
their	O
predictive	O
value	O
for	O
subsequent	O
symptom	O
development	O
.	O

Our	O
results	O
could	O
provide	O
the	O
basis	O
for	O
personalized	O
early	O
treatment	O
and	O
prevention	O
of	O
PTSD	O
.	O

Hum	O
Brain	O
Mapp	O
,	O
2017	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Overview	O
of	O
findings	O
from	O
a	O
2-	O
year	O
study	O
of	O
claimants	O
who	O
had	O
sustained	O
a	O
mild	O
or	O
moderate	O
injury	O
in	O
a	O
road	O
traffic	O
crash	O
:	O
prospective	O
study	O
.	O

Studies	O
have	O
shown	O
that	O
in	O
people	O
injured	O
in	O
a	O
road	O
traffic	O
crash	O
,	O
persistent	O
symptoms	O
are	O
common	O
and	O
can	O
lead	O
to	O
significant	O
ongoing	O
personal	O
impact	O
.	O

Hence	O
,	O
elucidating	O
factors	O
associated	O
with	O
the	O
human	O
costs	O
are	O
key	O
to	O
reducing	O
the	O
socio-economic	O
burden	O
of	O
road	O
traffic	O
injuries	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
we	O
aimed	O
to	O
track	O
the	O
experience	O
and	O
key	O
outcomes	O
of	O
persons	O
who	O
had	O
sustained	O
mild	O
/	O
moderate	O
injuries	O
as	O
they	O
returned	O
to	O
health	O
(	O
and	O
work	O
,	O
where	O
relevant	O
)	O
following	O
a	O
road	O
traffic	O
crash	O
.	O

It	O
is	O
an	O
inception	O
study	O
cohort	O
of	O
adults	O
who	O
had	O
sustained	O
mild	O
to	O
moderate	O
injuries	O
(	O
that	O
is	O
,	O
except	O
serious	O
injuries	O
)	O
in	O
motor	O
vehicle	O
crashes	O
in	O
New	O
South	O
Wales	O
,	O
Australia	O
,	O
who	O
were	O
recruited	O
and	O
interviewed	O
at	O
baseline	O
(	O
within	O
3	O
months	O
of	O
the	O
crash	O
)	O
and	O
at	O
6	O
,	O
12	O
and	O
24	O
months	O
post-injury	O
.	O

We	O
found	O
that	O
minor	O
injuries	O
had	O
major	O
impacts	O
on	O
pain	O
ratings	O
,	O
physical	O
and	O
mental	O
well-being	O
,	O
health	O
-related	O
quality	O
of	O
life	O
and	O
return	O
to	O
work	O
and	O
pre-injury	O
participation	O
during	O
the	O
24	O
months	O
post-injury	O
phase	O
.	O

Further	O
,	O
for	O
mild	O
to	O
moderately	O
severe	O
injuries	O
,	O
biopsychosocial	O
factors	O
appear	O
to	O
be	O
prognostic	O
indicators	O
of	O
recovery	O
(	O
not	O
the	O
location	O
or	O
type	O
of	O
injury	O
)	O
.	O

Examples	O
of	O
key	O
biopsychosocial	O
factors	O
are	O
:	O
age	O
;	O
preinjury	O
health	O
;	O
quality	O
of	O
life	O
;	O
reactions	O
to	O
injury	O
(	O
catastrophising	O
,	O
and	O
pain	O
)	O
;	O
social	O
support	O
and	O
the	O
third	O
party	O
insurance	O
compensation	O
system	O
.	O

This	O
study	O
highlights	O
the	O
considerable	O
impact	O
of	O
apparently	O
``	O
minor	O
``	O
road	O
traffic	O
crash	O
injuries	O
at	O
a	O
population	O
level	O
and	O
suggests	O
targeted	O
approaches	O
to	O
the	O
tertiary	B-P
prevention	I-P
of	O
long-term	O
morbidity	O
and	O
disability	O
.	O

Study	O
findings	O
have	O
also	O
reiterated	O
the	O
importance	O
of	O
looking	O
beyond	O
the	O
injury	O
to	O
the	O
'whole	O
person	O
'	O
.	O

Effect	O
of	O
an	O
immunomodulatory	B-P
regimen	I-P
for	O
cancer	B-P
prevention	I-P
:	O
A	O
case	O
report	O
.	O

In	O
the	O
present	O
case	O
study	O
,	O
an	O
immunomodulatory	B-P
regimen	I-P
for	O
cancer	B-P
prevention	I-P
is	O
reported	O
.	O

A	O
patient	O
with	O
an	O
abnormally	O
high	O
level	O
of	O
the	O
tumor	O
markers	O
,	O
carbohydrate	O
antigen-724	O
(	O
CA724	O
)	O
,	O
CA19-9	O
and	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
,	O
although	O
without	O
any	O
detectable	O
tumor	O
,	O
was	O
treated	B-P
with	I-P
an	O
immunomodulatory	B-P
therapy	I-P
featuring	O
an	O
infusion	B-P
of	O
cytokine-induced	O
autologous	O
killer	O
cells	O
(	O
CIKs	O
)	O
at	O
the	O
request	O
of	O
the	O
patient	O
.	O

Following	O
the	O
therapy	B-P
,	O
the	O
three	O
tumor	O
markers	O
rapidly	O
decreased	O
to	O
below	O
the	O
normal	O
reference	O
level	O
,	O
although	O
there	O
still	O
were	O
slight	O
fluctuations	O
within	O
a	O
narrow	O
range	O
frequently	O
.	O

The	O
patient	O
was	O
monitored	O
for	O
21	O
months	O
to	O
the	O
present	O
day	O
and	O
no	O
abnormality	O
was	O
observed	O
.	O

The	O
results	O
indicated	O
that	O
this	O
therapy	B-P
may	O
be	O
applied	O
as	O
a	O
novel	O
strategy	O
that	O
is	O
effective	O
and	O
reliable	O
for	O
cancer	B-P
prevention	I-P
.	O

As	O
there	O
is	O
no	O
promising	O
regimen	B-P
for	O
the	O
prevention	B-P
of	I-P
malignancies	I-P
to	O
date	O
,	O
such	O
a	O
treatment	B-P
may	O
become	O
a	O
major	O
cancer	O
prophylactic	B-P
regimen	I-P
,	O
particularly	O
for	O
patients	O
who	O
are	O
at	O
a	O
high	O
risk	O
of	O
cancer	O
.	O

Mechanosignaling	O
activation	O
of	O
TGFβ	O
maintains	O
intervertebral	O
disc	O
homeostasis	O
.	O

Intervertebral	O
disc	O
(	O
IVD	O
)	O
degeneration	O
is	O
the	O
leading	O
cause	O
of	O
disability	O
with	O
no	O
disease	O
-	O
modifying	O
treatment	O
.	O

IVD	O
degeneration	O
is	O
associated	O
with	O
instable	O
mechanical	O
loading	O
in	O
the	O
spine	O
,	O
but	O
little	O
is	O
known	O
about	O
how	O
mechanical	O
stress	O
regulates	O
nucleus	O
notochordal	O
(	O
NC	O
)	O
cells	O
to	O
maintain	O
IVD	O
homeostasis	O
.	O

Here	O
we	O
report	O
that	O
mechanical	O
stress	O
can	O
result	O
in	O
excessive	O
integrin	O
αvβ6	O
-mediated	O
activation	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGFβ	O
)	O
,	O
decreased	O
NC	O
cell	O
vacuoles	O
,	O
and	O
increased	O
matrix	O
proteoglycan	O
production	O
,	O
and	O
results	O
in	O
degenerative	O
disc	O
disease	O
(	O
DDD	O
)	O
.	O

Knockout	O
of	O
TGFβ	O
type	O
II	O
receptor	O
(	O
TβRII	O
)	O
or	O
integrin	O
αv	O
in	O
the	O
NC	O
cells	O
inhibited	O
functional	B-P
activity	I-P
of	O
postnatal	O
NC	O
cells	O
and	O
also	O
resulted	O
in	O
DDD	O
under	O
mechanical	O
loading	O
.	O

Administration	O
of	O
RGD	O
peptide	O
,	O
TGFβ	O
,	O
and	O
αvβ6	O
-	O
neutralizing	O
antibodies	O
attenuated	O
IVD	O
degeneration	O
.	O

Thus	O
,	O
integrin	O
-mediated	O
activation	O
of	O
TGFβ	O
plays	O
a	O
critical	O
role	O
in	O
mechanical	O
signaling	O
transduction	O
to	O
regulate	O
IVD	O
cell	O
function	O
and	O
homeostasis	O
.	O

Manipulation	B-P
of	O
this	O
signaling	O
pathway	O
may	O
be	O
a	O
potential	O
therapeutic	O
target	O
to	O
modify	O
DDD	O
.	O

A	O
novel	O
role	O
for	O
poly	O
(	O
C	O
)	O
binding	O
proteins	O
in	O
programmed	O
ribosomal	O
frameshifting	O
.	O

Translational	O
control	O
through	O
programmed	O
ribosomal	O
frameshifting	O
(	O
PRF	O
)	O
is	O
exploited	O
widely	O
by	O
viruses	O
and	O
increasingly	O
documented	O
in	O
cellular	O
genes	O
.	O

Frameshifting	O
is	O
induced	O
by	O
mRNA	O
secondary	O
structures	O
that	O
compromise	O
ribosome	O
fidelity	O
during	O
decoding	O
of	O
a	O
heptanucleotide	O
'slippery	O
'	O
sequence	O
.	O

The	O
nsp2	O
PRF	O
signal	O
of	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
is	O
distinctive	O
in	O
directing	O
both	O
-2	O
and	O
-1	O
PRF	O
and	O
in	O
its	O
requirement	O
for	O
a	O
trans-acting	O
protein	O
factor	O
,	O
the	O
viral	O
replicase	O
subunit	O
nsp1β	O
.	O

Here	O
we	O
show	O
that	O
the	O
the	O
trans-activation	O
of	O
frameshifting	O
is	O
carried	O
out	O
by	O
a	O
protein	O
complex	O
composed	O
of	O
nsp1β	O
and	O
a	O
cellular	O
poly	O
(	O
C	O
)	O
binding	O
protein	O
(	O
PCBP	O
)	O
.	O

From	O
the	O
results	O
of	O
in	O
vitro	O
translation	O
and	O
electrophoretic	B-P
mobility	I-P
shift	I-P
assays	I-P
,	O
we	O
demonstrate	O
that	O
a	O
PCBP	O
/	O
nsp1β	O
complex	O
binds	O
to	O
a	O
C-rich	O
sequence	O
downstream	O
of	O
the	O
slippery	O
sequence	O
and	O
here	O
mimics	O
the	O
activity	O
of	O
a	O
structured	O
mRNA	O
stimulator	O
of	O
PRF	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
role	O
for	O
a	O
trans-acting	O
cellular	O
protein	O
in	O
PRF	O
.	O

The	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	O
associated	O
with	O
poly	O
(	O
C	O
)	O
binding	O
proteins	O
and	O
prototypes	O
a	O
new	O
class	O
of	O
virus	O
-	O
host	O
interactions	O
.	O

Proliferation	O
-enhancing	O
effects	O
of	O
gastrodin	O
on	O
RSC96	O
Schwann	O
cells	O
by	O
regulating	O
ERK1	O
/	O
2	O
and	O
PI3K	O
signaling	O
pathways	O
.	O

The	O
proliferation	O
and	O
migration	O
of	O
Schwann	O
cells	O
(	O
SCs	O
)	O
are	O
essential	O
in	O
the	O
process	O
of	O
peripheral	B-P
nerve	I-P
repair	I-P
.	O

A	O
large	O
amount	O
of	O
studies	O
focused	O
on	O
the	O
promotion	O
of	O
the	O
growth	O
of	O
SCs	O
for	O
cell	B-P
based	I-P
therapy	I-P
.	O

Gastrodin	O
(	O
GAS	O
)	O
,	O
the	O
main	O
constituent	O
of	O
a	O
Chinese	O
traditional	O
herbal	O
medicine	O
named	O
Gastrodia	O
elata	O
Blume	O
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
neuroprotective	O
properties	O
.	O

Besides	O
,	O
GAS	O
activated	O
MAPK	O
and	O
PI3K	O
signaling	O
pathways	O
which	O
are	O
often	O
involved	O
in	O
growth	O
of	O
nerve	O
cells	O
were	O
also	O
reported	O
.	O

Based	O
on	O
the	O
hypothesis	O
that	O
GAS	O
may	O
have	O
an	O
effect	O
on	O
SCs	O
growth	O
,	O
we	O
studied	O
the	O
effect	O
of	O
GAS	O
on	O
rat	O
RSC96	O
Schwann	O
cells	O
(	O
SCs	O
)	O
and	O
further	O
explored	O
the	O
underlying	O
mechanism	O
.	O

Various	O
concentration	O
of	O
GAS	O
(	O
0μM	O
,	O
50μM	O
,	O
100μM	O
,	O
and	O
200μM	O
)	O
was	O
used	O
for	O
treatment	B-P
of	O
RSC96	O
SCs	O
,	O
with	O
the	O
cell	O
proliferation	O
and	O
gene	O
expression	O
of	O
several	O
neurotrophic	O
factors	O
to	O
be	O
detected	O
.	O

Regulation	O
of	O
MAPK	O
and	O
PI3K	O
signaling	O
pathways	O
were	O
assayed	O
by	O
detecting	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
Akt	O
.	O

The	O
results	O
showed	O
that	O
GAS	O
could	O
effectively	O
promote	O
proliferation	O
of	O
RSC96	O
SCs	O
in	O
a	O
dose	O
-	O
and	O
time	O
-dependent	O
manner	O
.	O

The	O
best	O
performance	O
was	O
obtained	O
at	O
the	O
concentration	O
of	O
200μM	O
.	O

Exploration	B-P
of	O
the	O
underlying	O
mechanism	O
showed	O
that	O
GAS	O
probably	O
affects	O
SCs	O
metabolism	O
through	O
inhibiting	O
ERK1	O
/	O
2	O
phosphorylation	O
and	O
activating	O
Akt	O
phosphorylation	O
in	O
RSC96	O
SCs	O
.	O

This	O
study	O
may	O
provide	O
reference	O
for	O
its	O
application	O
in	O
treatment	B-P
of	O
peripheral	O
nerve	O
injuries	O
.	O

Gastrostomy	B-P
in	O
patients	O
with	O
prion	O
disease	O
.	O

Patients	O
with	O
prion	O
diseases	O
can	O
live	O
for	O
long	O
periods	O
of	O
time	O
in	O
a	O
state	O
of	O
akinetic	O
mutism	O
given	O
appropriate	O
management	B-P
of	I-P
their	I-P
symptoms	I-P
.	O

To	O
study	O
symptom	O
support	O
in	O
these	O
cases	O
,	O
we	O
performed	O
gastrostomies	B-P
on	O
3	O
patients	O
with	O
V180I	O
genetic	O
Creutzfeldt-Jakob	O
disease	O
(	O
CJD	O
)	O
who	O
had	O
become	O
akinetic	O
and	O
mute	O
,	O
and	O
compared	O
them	O
to	O
14	O
other	O
similar	O
patients	O
being	O
fed	B-P
by	I-P
tube	I-P
.	O

In	O
the	O
3	O
gastrostomy	B-P
cases	O
,	O
there	O
were	O
no	O
direct	O
complications	O
due	O
to	O
the	O
gastrostomy	B-P
or	O
tube	B-P
feeding	I-P
,	O
nor	O
were	O
there	O
episodes	O
of	O
discontinuation	O
of	O
tube	B-P
feeding	I-P
or	O
initiation	B-P
of	I-P
continuous	I-P
drip	I-P
infusion	I-P
due	O
to	O
severe	O
complications	O
.	O

Antibiotics	B-P
were	I-P
administered	I-P
for	O
mild	O
infections	O
,	O
a	O
complication	O
of	O
CJD	O
,	O
with	O
0.2	O
%	O
and	O
8.8	O
%	O
of	O
the	O
total	O
time	O
after	O
gastrostomy	B-P
being	O
used	O
for	O
intravenous	O
or	O
transluminal	O
administration	O
,	O
respectively	O
.	O

We	O
compared	O
the	O
present	O
patient	O
series	O
with	O
that	O
of	O
our	O
previous	O
report	O
statistically	O
,	O
and	O
found	O
that	O
patients	O
undergoing	O
gastrostomy	B-P
required	O
significantly	O
fewer	O
discontinuations	O
of	O
tube	B-P
feeding	I-P
than	O
those	O
who	O
did	O
not	O
.	O

No	O
significant	O
difference	O
in	O
antibiotic	B-P
administration	I-P
was	O
found	O
between	O
groups	O
,	O
however	O
.	O

It	O
is	O
our	O
conclusion	O
that	O
gastrostomy	B-P
should	O
be	O
allowed	O
for	O
symptom	O
support	O
in	O
akinetic	O
patients	O
with	O
prion	O
disease	O
,	O
but	O
adequate	O
informed	O
consent	O
must	O
be	O
provided	O
to	O
the	O
patient	O
's	O
family	O
.	O

A	O
Case	O
of	O
Koch	O
's	O
Spine	O
Treated	O
with	O
Modified	O
Transpedicular	B-P
Vertebral	I-P
Curettage	I-P
and	O
Posterior	O
Fixation	B-P
:	O
A	O
Novel	O
Technique	O
.	O

Tuberculosis	O
(	O
TB	O
)	O
is	O
a	O
chronic	O
granulomatous	O
infection	O
caused	O
by	O
acid-fast	O
mycobacterium	O
tuberculosis	O
bacilli	O
.	O

Spinal	O
involvement	O
occurs	O
in	O
less	O
than	O
one	O
percent	O
of	O
TB	O
.	O

Spinal	O
TB	O
(	O
Pott	O
's	O
disease	O
)	O
accounts	O
for	O
50	O
%	O
of	O
skeletal	O
TB	O
.	O

Though	O
it	O
most	O
commonly	O
affects	O
the	O
thoracolumbar	O
junction	O
,	O
it	O
can	O
occur	O
at	O
any	O
level	O
of	O
the	O
spine	O
.	O

Early	O
diagnosis	O
and	O
treatment	B-P
is	O
mandatory	O
in	O
order	O
to	O
avoid	O
neurological	O
complications	O
and	O
spinal	O
deformity	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
young	O
female	O
with	O
tuberculosis	O
of	O
D12-L1	O
who	O
was	O
treated	O
with	O
posterior	O
decompression	B-P
using	O
a	O
modified	O
transpedicular	B-P
approach	I-P
and	O
posterior	O
instrumentation	B-P
with	O
a	O
successful	O
outcome	O
.	O

Synthesis	O
,	O
characterization	O
and	O
drug	O
loading	O
property	O
of	O
Monomethoxy-Poly	O
(	O
ethylene	O
glycol	O
)	O
-Poly	O
(	O
ε-caprolactone	O
)	O
-Poly	O
(	O
D	O
,	O
L-lactide	O
)	O
(	O
MPEG-PCLA	O
)	O
copolymers	O
.	O

Amphiphilic	O
block	O
copolymers	O
have	O
attracted	O
a	O
great	O
deal	O
of	O
attention	O
in	O
drug	O
delivery	O
systems	O
.	O

In	O
this	O
work	O
,	O
a	O
series	O
of	O
monomethoxy-poly	O
(	O
ethylene	O
glycol	O
)	O
-poly	O
(	O
ε-caprolactone-co-D	O
,	O
L-lactide	O
)	O
(	O
MPEG-PCLA	O
)	O
copolymers	O
with	O
variable	O
composition	O
of	O
poly	O
(	O
ε-caprolactone	O
)	O
(	O
PCL	O
)	O
and	O
poly	O
(	O
D	O
,	O
L-lactide	O
)	O
(	O
PDLLA	O
)	O
were	O
prepared	O
via	O
ring-opening	O
copolymerization	O
of	O
ε-CL	O
and	O
D	O
,	O
L-LA	O
in	O
the	O
presence	O
of	O
MPEG	O
and	O
stannous	O
octoate	O
.	O

The	O
structure	O
and	O
molecular	O
weight	O
were	O
characterized	O
by	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
and	O
gel	B-P
permeation	I-P
chromatography	I-P
(	O
GPC	B-P
)	O
.	O

The	O
crystallinity	O
,	O
hydrophilicity	O
,	O
thermal	O
stability	O
and	O
hydrolytic	O
degradation	O
behavior	O
were	O
investigated	O
in	O
detail	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
the	O
prepared	O
amphiphilic	O
MPEG-PCLA	O
copolymers	O
have	O
adjustable	O
properties	O
by	O
altering	O
the	O
composition	O
of	O
PCLA	O
,	O
which	O
make	O
it	O
convenient	O
for	O
clinical	O
applications	O
.	O

Besides	O
,	O
the	O
drug	O
loading	O
properties	O
were	O
also	O
studied	O
.	O

Docetaxel	O
(	O
DTX	O
)	O
could	O
be	O
entrapped	O
in	O
MPEG-PCLA	O
micelles	O
with	O
high	O
loading	O
capacity	O
and	O
encapsulation	O
efficiency	O
.	O

And	O
all	O
lyophilized	O
DTX	O
-loaded	O
MPEG-PCLA	O
micelles	O
except	O
MPEG-PCL	O
micelles	O
were	O
readily	O
re-dissolved	O
in	O
normal	O
saline	O
at	O
25	O
°C	O
.	O

In	O
addition	O
,	O
DTX	O
-loaded	O
MPEG-PCLA	O
micelles	O
showed	O
a	O
slightly	O
enhanced	O
antitumor	O
activity	O
compared	O
with	O
free	O
DTX	O
.	O

Furthermore	O
,	O
DTX	O
micelles	O
exhibited	O
a	O
slower	O
and	O
sustained	O
release	O
behavior	O
in	O
vitro	O
,	O
and	O
higher	O
DTX	O
concentration	O
and	O
longer	O
retention	O
time	O
in	O
vivo	O
.	O

The	O
results	O
suggested	O
that	O
the	O
MPEG-PCLA	O
copolymer	O
with	O
the	O
adjustable	O
ratio	O
of	O
PCL	O
to	O
PDLLA	O
may	O
be	O
a	O
promising	O
drug	O
delivery	O
carrier	O
for	O
DTX	O
.	O

Impact	O
of	O
seniority	O
on	O
operative	O
time	O
and	O
short-term	O
outcome	O
in	O
laparoscopic	B-P
cholecystectomy	I-P
:	O
Experience	O
of	O
an	O
academic	O
Surgical	O
Department	O
in	O
a	O
developing	O
country	O
.	O

Resident	O
participation	O
in	O
laparoscopic	B-P
cholecystectomy	I-P
(	O
LC	B-P
)	O
is	O
one	O
of	O
the	O
first	O
steps	O
of	O
laparoscopic	O
training	O
.	O

The	O
impact	O
of	O
this	O
training	O
is	O
not	O
well-defined	O
,	O
especially	O
in	O
developing	O
countries	O
.	O

However	O
,	O
this	O
training	O
is	O
of	O
critical	O
importance	O
to	O
monitor	O
surgical	O
teaching	O
programmes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
impact	O
of	O
seniority	O
on	O
operative	O
time	O
and	O
short-term	O
outcome	O
of	O
LC	B-P
.	O

We	O
performed	O
a	O
retrospective	O
study	O
of	O
all	O
consecutive	O
laparoscopic	B-P
cholecystectomies	I-P
for	O
gallbladder	O
lithiasis	O
performed	O
over	O
2	O
academic	O
years	O
in	O
an	O
academic	O
Surgical	O
Department	O
in	O
Morocco	O
.	O

These	O
operations	B-P
were	O
performed	O
by	O
junior	O
residents	O
(	O
post-graduate	O
year	O
[	O
PGY	O
]	O
4-5	O
)	O
or	O
senior	O
residents	O
(	O
PGY	O
6	O
)	O
,	O
or	O
attending	O
surgeons	O
assisted	O
by	O
junior	O
residents	O
,	O
none	O
of	O
whom	O
had	O
any	O
advanced	O
training	O
in	O
laparoscopy	B-P
.	O

All	O
data	O
concerning	O
demographics	O
(	O
American	O
Society	O
of	O
Anesthesiologists	O
,	O
body	O
mass	O
index	O
and	O
indications	O
)	O
,	O
surgeons	O
,	O
operative	O
time	O
(	O
from	O
skin	B-P
incision	I-P
to	O
closure	B-P
)	O
,	O
conversion	O
rate	O
and	O
operative	O
complications	O
(	O
Clavien-Dindo	O
classification	O
)	O
were	O
recorded	O
and	O
analysed	O
.	O

One-way	O
analysis	O
of	O
variance	O
,	O
Student	O
's	O
t-test	O
and	O
Chi-square	O
tests	O
were	O
used	O
as	O
appropriate	O
with	O
statistical	O
significance	O
attributed	O
to	O
P	O
<	O
0.05	O
.	O

One	O
hundred	O
thirty-eight	O
LC	B-P
were	O
performed	O
.	O

No	O
differences	O
were	O
found	O
on	O
univariate	O
analysis	O
between	O
groups	O
in	O
demographics	O
or	O
diagnosis	O
category	O
.	O

The	O
overall	O
rate	O
of	O
operative	O
complications	O
or	O
conversions	O
and	O
hospital	O
stay	O
were	O
not	O
significantly	O
different	O
between	O
the	O
three	O
groups	O
.	O

However	O
,	O
mean	O
operative	O
time	O
was	O
significantly	O
longer	O
for	O
junior	O
residents	O
(	O
n	O
=	O
27	O
;	O
115	O
±	O
24	O
min	O
)	O
compared	O
to	O
senior	O
residents	O
(	O
n	O
=	O
37	O
;	O
77	O
±	O
35	O
min	O
)	O
and	O
attending	O
surgeons	O
(	O
n	O
=	O
66	O
;	O
55	O
±	O
17	O
min	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

LC	B-P
performed	O
by	O
residents	O
appears	O
to	O
be	O
safe	O
without	O
a	O
significant	O
difference	O
in	O
complication	O
rate	O
;	O
however	O
,	O
seniority	O
influences	O
operative	O
time	O
.	O

This	O
information	O
supports	O
early	O
resident	O
involvement	O
in	O
laparoscopic	B-P
procedures	I-P
and	O
also	O
the	O
need	O
to	O
develop	O
cost-effective	O
laboratory	O
training	O
programmes	O
.	O

Development	O
of	O
Dual	B-P
Quantitative	I-P
Lateral	I-P
Flow	I-P
Immunoassay	I-P
for	O
the	O
Detection	O
of	O
Mycotoxins	O
.	O

Lateral	B-P
flow	I-P
immunoassays	I-P
have	O
been	O
widely	O
used	O
in	O
recent	O
years	O
for	O
detection	O
of	O
toxins	O
,	O
heavy	O
metals	O
,	O
and	O
biomarkers	O
.	O

To	O
improve	O
the	O
efficiency	O
of	O
individual	B-P
lateral	I-P
flow	I-P
immunoassays	I-P
,	O
multiplex	O
analytical	O
strips	O
play	O
an	O
important	O
role	O
in	O
the	O
detection	O
of	O
several	O
important	O
analytes	O
.	O

In	O
this	O
chapter	O
,	O
development	O
of	O
a	O
dual	B-P
lateral	I-P
flow	I-P
immunoassay	I-P
is	O
presented	O
for	O
detection	O
of	O
a	O
variety	O
of	O
low	O
molecular	O
weight	O
molecules	O
.	O

Various	O
buffers	O
,	O
additives	O
,	O
and	O
materials	O
are	O
introduced	O
and	O
evaluated	O
.	O

Depending	O
on	O
the	O
analyte	O
to	O
be	O
tested	O
,	O
the	O
technique	O
allows	O
for	O
selection	O
of	O
optimum	O
buffers	O
,	O
additives	O
,	O
and	O
other	O
materials	O
.	O

Tenofovir	O
alafenamide	O
versus	O
tenofovir	O
disoproxil	O
fumarate	O
for	O
the	O
treatment	O
of	O
HBeAg-positive	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
:	O
a	O
randomised	O
,	O
double-blind	O
,	O
phase	O
3	O
,	O
non-inferiority	O
trial	O
.	O

Tenofovir	O
alafenamide	O
is	O
a	O
novel	O
prodrug	O
formulated	O
to	O
deliver	O
the	O
active	O
metabolite	O
to	O
target	O
cells	O
more	O
efficiently	O
than	O
tenofovir	O
disoproxil	O
fumarate	O
at	O
a	O
lower	O
dose	O
,	O
thereby	O
reducing	O
systemic	O
exposure	O
.	O

In	O
patients	O
with	O
HIV	O
,	O
tenofovir	O
alafenamide	O
was	O
as	O
efficacious	O
as	O
tenofovir	O
disoproxil	O
fumarate	O
,	O
with	O
reduced	O
bone	O
and	O
renal	O
toxic	O
effects	O
.	O

We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
two	O
drugs	O
in	O
patients	O
with	O
HBeAg-positive	O
chronic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
in	O
a	O
non-inferiority	O
study	O
.	O

We	O
did	O
this	O
ongoing	O
double-blind	O
,	O
non-inferiority	O
study	O
in	O
161	O
outpatient	O
centres	O
in	O
19	O
countries	O
.	O

Patients	O
with	O
chronic	O
HBV	O
infection	O
who	O
were	O
positive	O
for	O
the	O
hepatitis	O
B	O
e	O
antigen	O
(	O
HBeAg	O
)	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
25	O
mg	O
tenofovir	O
alafenamide	O
or	O
300	O
mg	O
tenofovir	O
disoproxil	O
fumarate	O
with	O
matching	O
placebo	B-P
.	O

Randomisation	O
was	O
done	O
by	O
a	O
computer	O
-	O
generated	O
allocation	O
sequence	O
(	O
block	O
size	O
six	O
)	O
stratified	O
by	O
plasma	B-P
HBV	I-P
DNA	I-P
concentration	I-P
and	O
previous	O
treatment	O
experience	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
proportion	O
of	O
patients	O
with	O
HBV	O
DNA	O
less	O
than	O
29	O
IU/mL	O
at	O
week	O
48	O
in	O
all	O
patients	O
who	O
were	O
randomly	O
assigned	O
and	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
using	O
a	O
missing-equals-failed	O
approach	O
.	O

The	O
pre-specified	O
non-inferiority	O
margin	O
was	O
10	O
%	O
.	O

Key	O
prespecified	O
safety	O
endpoints	O
were	O
bone	O
and	O
renal	O
parameters	O
at	O
week	O
48	O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT01940471	O
.	O

Of	O
the	O
1473	O
patients	O
screened	O
from	O
Sept	O
11	O
,	O
2013	O
,	O
to	O
Dec	O
20	O
,	O
2014	O
,	O
875	O
eligible	O
patients	O
were	O
randomly	O
assigned	O
and	O
873	O
received	O
treatment	O
(	O
581	O
with	O
tenofovir	O
alafenamide	O
and	O
292	O
with	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
.	O

371	O
(	O
64	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
had	O
HBV	O
DNA	O
less	O
than	O
29	O
IU/mL	O
at	O
week	O
48	O
,	O
which	O
was	O
non-inferior	O
to	O
the	O
195	O
(	O
67	O
%	O
)	O
of	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
who	O
had	O
HBV	O
DNA	O
less	O
than	O
29	O
IU/mL	O
(	O
adjusted	O
difference	O
-3·6	O
%	O
[	O
95	O
%	O
CI	O
-9·8	O
to	O
2·6	O
]	O
;	O
p	O
=0·25	O
)	O
.	O

Patients	O
given	O
tenofovir	O
alafenamide	O
had	O
a	O
significantly	O
smaller	O
decrease	O
in	O
bone	O
mineral	O
density	O
at	O
hip	O
(	O
mean	O
change	O
-0·10	O
%	O
[	O
95	O
%	O
CI	O
-0·29	O
to	O
0·09	O
]	O
vs	O
-1·72	O
%	O
[	O
-2·02	O
to	O
-1·41	O
]	O
;	O
adjusted	O
difference	O
1·62	O
[	O
1·27	O
to	O
1·96	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
and	O
at	O
spine	O
(	O
mean	O
change	O
-0·42	O
%	O
[	O
-0·66	O
to	O
-0·17	O
]	O
vs	O
-2·29	O
%	O
[	O
-2·67	O
to	O
-1·92	O
]	O
;	O
adjusted	O
difference	O
1·88	O
[	O
1·44	O
to	O
2·31	O
]	O
;	O
p	O
<	O
0·0001	O
)	O
as	O
well	O
as	O
smaller	O
mean	O
increases	O
in	O
serum	O
creatinine	O
at	O
week	O
48	O
(	O
0·01	O
mg/dL	O
[	O
0·00-0·02	O
]	O
vs	O
0·03	O
mg/dL	O
[	O
0·02-0·04	O
]	O
;	O
p	O
=0·02	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
overall	O
were	O
upper	O
respiratory	O
tract	O
infection	O
(	O
51	O
[	O
9	O
%	O
]	O
of	O
581	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
vs	O
22	O
[	O
8	O
%	O
]	O
of	O
292	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
,	O
nasopharyngitis	O
(	O
56	O
[	O
10	O
%	O
]	O
vs	O
16	O
[	O
5	O
%	O
]	O
)	O
,	O
and	O
headache	O
(	O
42	O
[	O
7	O
%	O
]	O
vs	O
22	O
[	O
8	O
%	O
]	O
)	O
.	O

22	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
and	O
12	O
(	O
4	O
%	O
)	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
experienced	O
serious	O
adverse	O
events	O
,	O
none	O
of	O
which	O
was	O
deemed	O
by	O
the	O
investigator	O
to	O
be	O
related	O
to	O
study	O
treatment	O
.	O

187	O
(	O
32	O
%	O
)	O
of	O
581	O
patients	O
in	O
the	O
tenofovir	O
alafenamide	O
group	O
and	O
96	O
(	O
33	O
%	O
)	O
of	O
292	O
patients	O
in	O
the	O
tenofovir	O
disoproxil	O
fumarate	O
group	O
had	O
grade	O
3	O
or	O
4	O
laboratory	O
abnormalities	O
,	O
the	O
most	O
common	O
of	O
which	O
were	O
elevations	O
in	O
ALT	B-P
(	O
62	O
[	O
11	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
and	O
36	O
[	O
13	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
and	O
AST	B-P
(	O
20	O
[	O
3	O
%	O
]	O
of	O
577	O
patients	O
receiving	O
tenofovir	O
alafenamide	O
and	O
19	O
[	O
7	O
%	O
]	O
of	O
288	O
patients	O
receiving	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
.	O

In	O
patients	O
with	O
HBeAg-positive	O
HBV	O
infection	O
,	O
tenofovir	O
alafenamide	O
was	O
non-inferior	O
to	O
tenofovir	O
disoproxil	O
fumarate	O
,	O
and	O
had	O
improved	O
bone	O
and	O
renal	O
effects	O
.	O

Longer	O
term	O
follow-up	O
is	O
needed	O
to	O
better	O
understand	O
the	O
clinical	O
impact	O
of	O
these	O
changes	O
.	O

Gilead	O
Sciences	O
.	O

ASPEN	O
Safe	O
Practices	O
for	O
Enteral	B-P
Nutrition	I-P
Therapy	I-P
.	O

Enteral	B-P
nutrition	I-P
(	O
EN	B-P
)	O
is	O
a	O
valuable	O
clinical	B-P
intervention	I-P
for	O
patients	O
of	O
all	O
ages	O
in	O
a	O
variety	O
of	O
care	O
settings	O
.	O

Along	O
with	O
its	O
many	O
outcome	O
benefits	O
come	O
the	O
potential	O
for	O
adverse	O
effects	O
.	O

These	O
safety	O
issues	O
are	O
the	O
result	O
of	O
clinical	O
complications	O
and	O
of	O
process-related	O
errors	O
.	O

The	O
latter	O
can	O
occur	O
at	O
any	O
step	O
from	O
patient	O
assessment	O
,	O
prescribing	O
,	O
and	O
order	O
review	O
,	O
to	O
product	O
selection	O
,	O
labeling	O
,	O
and	O
administration	B-P
.	O

To	O
maximize	O
the	O
benefits	O
of	O
EN	B-P
while	O
minimizing	O
adverse	O
events	O
requires	O
that	O
a	O
systematic	O
approach	O
of	O
care	O
be	O
in	O
place	O
.	O

This	O
includes	O
open	O
communication	O
,	O
standardization	O
,	O
and	O
incorporation	O
of	O
best	O
practices	O
into	O
the	O
EN	B-P
process	O
.	O

This	O
document	O
provides	O
recommendations	O
based	O
on	O
the	O
available	O
evidence	O
and	O
expert	O
consensus	O
for	O
safe	O
practices	O
,	O
across	O
each	O
step	O
of	O
the	O
process	O
,	O
for	O
all	O
those	O
involved	O
in	O
caring	O
for	O
patients	O
receiving	O
EN	B-P
.	O

Argininosuccinic	O
Acid	O
Lyase	O
Deficiency	O
Missed	O
by	O
Newborn	B-P
Screen	I-P
.	O

Argininosuccinic	O
acid	O
lyase	O
(	O
ASL	O
)	O
deficiency	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
ASL	O
gene	O
(	O
OMIM	O
:	O
608310	O
)	O
is	O
a	O
urea	O
cycle	O
disorder	O
that	O
has	O
pleiotropic	O
presentations	O
.	O

On	O
the	O
mild	O
end	O
,	O
ASL	O
deficiency	O
can	O
manifest	O
as	O
nonspecific	O
neurocognitive	O
abnormalities	O
without	O
readily	O
identifiable	O
signs	O
to	O
differentiate	O
it	O
from	O
other	O
causes	O
of	O
intellectual	O
disability	O
or	O
learning	O
disabilities	O
.	O

Dietary	O
management	O
and	O
arginine	O
supplementation	B-P
,	O
if	O
initiated	O
early	O
,	O
may	O
ameliorate	O
symptoms	O
.Because	O
of	O
the	O
nonspecific	O
nature	O
of	O
the	O
symptoms	O
and	O
the	O
possibility	O
for	O
therapeutic	O
management	O
,	O
ASL	O
deficiency	O
is	O
part	O
of	O
the	O
recommended	O
uniform	B-P
screening	I-P
panel	I-P
for	O
newborn	B-P
screening	I-P
in	O
the	O
USA	O
.	O

We	O
report	O
here	O
a	O
case	O
of	O
ASL	O
deficiency	O
that	O
was	O
missed	O
on	O
newborn	B-P
screening	I-P
in	O
the	O
USA	O
.The	O
case	O
reported	O
here	O
has	O
two	O
known	O
pathogenic	O
mutations	O
-	O
one	O
with	O
no	O
residual	O
activity	O
and	O
one	O
with	O
reported	O
10	O
%	O
residual	O
activity	O
.	O

Review	O
of	O
this	O
newborn	B-P
screening	I-P
results	O
showed	O
subtle	O
elevation	O
of	O
citrulline	O
,	O
overlapping	O
the	O
normal	O
range	O
.	O

These	O
findings	O
suggest	O
that	O
newborn	B-P
screening	I-P
may	O
be	O
missing	O
other	O
patients	O
with	O
ASL	O
deficiency	O
with	O
at	O
least	O
one	O
hypomorphic	O
allele	O
.	O

This	O
case	O
was	O
diagnosed	O
incidentally	O
,	O
but	O
in	O
retrospect	O
had	O
symptoms	O
best	O
attributed	O
in	O
full	O
or	O
in	O
part	O
to	O
his	O
ASA	O
deficiency	O
,	O
including	O
protein	O
aversion	O
,	O
developmental	O
delay	O
,	O
and	O
seizures	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
considering	O
ASL	O
deficiency	O
in	O
patients	O
with	O
nonspecific	O
abnormal	O
neurocognitive	O
signs	O
,	O
such	O
as	O
epilepsy	O
and	O
developmental	O
delay	O
,	O
even	O
when	O
newborn	B-P
screening	I-P
was	O
normal	O
.	O

Beta-Adrenergic	O
Receptor	O
Blockers	O
in	O
Hypertension	O
:	O
Alive	O
and	O
Well	O
.	O

Beta-adrenergic	O
receptor	O
blockers	O
(	O
β-blockers	O
)	O
are	O
an	O
appropriate	O
treatment	B-P
for	O
patients	O
having	O
systemic	O
hypertension	O
(	O
HTN	O
)	O
who	O
have	O
concomitant	O
ischemic	O
heart	O
disease	O
(	O
IHD	O
)	O
,	O
heart	O
failure	O
,	O
obstructive	O
cardiomyopathy	O
,	O
aortic	O
dissection	O
or	O
certain	O
cardiac	O
arrhythmias	O
.	O

β-Blockers	O
can	O
be	O
used	O
in	O
combination	O
with	O
other	O
antiHTN	O
drugs	O
to	O
achieve	O
maximal	O
blood	O
pressure	O
control	O
.	O

Labetalol	O
can	O
be	O
used	O
in	O
HTN	O
emergencies	O
and	O
urgencies	O
.	O

β-Blockers	O
may	O
be	O
useful	O
in	O
HTN	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	O
,	O
tachycardia	O
,	O
HTN	O
,	O
and	O
anxiety	O
)	O
,	O
migraine	O
headache	O
,	O
and	O
essential	O
tremor	O
.	O

β-Blockers	O
are	O
highly	O
heterogeneous	O
with	O
respect	O
to	O
various	O
pharmacologic	O
properties	O
:	O
degree	O
of	O
intrinsic	O
sympathomimetic	O
activity	O
,	O
membrane	O
stabilizing	O
activity	O
,	O
β1	O
selectivity	O
,	O
α1-adrenergic	O
blocking	O
effects	O
,	O
tissue	O
solubility	O
,	O
routes	O
of	O
systemic	O
elimination	O
,	O
potencies	O
and	O
duration	O
of	O
action	O
,	O
and	O
specific	O
properties	O
may	O
be	O
important	O
in	O
the	O
selection	O
of	O
a	O
drug	O
for	O
clinical	O
use	O
.	O

β-Blocker	O
usage	O
to	O
reduce	O
perioperative	O
myocardial	O
ischemia	O
and	O
cardiovascular	O
(	O
CV	O
)	O
complications	O
may	O
not	O
benefit	O
as	O
many	O
patients	O
as	O
was	O
once	O
hoped	O
,	O
and	O
may	O
actually	O
cause	O
harm	O
in	O
some	O
individuals	O
.	O

Currently	O
the	O
best	O
evidence	O
supports	O
perioperative	O
β-blocker	O
use	O
in	O
two	O
patient	O
groups	O
:	O
patients	O
undergoing	O
vascular	B-P
surgery	I-P
with	O
known	O
IHD	O
or	O
multiple	O
risk	O
factors	O
for	O
it	O
,	O
and	O
for	O
those	O
patients	O
already	O
receiving	O
β-blockers	O
for	O
known	O
CV	O
conditions	O
.	O

Haemophilus	O
influenzae	O
type	O
b	O
meningitis	O
in	O
a	O
vaccinated	B-P
and	O
immunocompetent	O
child	O
.	O

Invasive	O
Haemophilus	O
influenzae	O
type	O
b	O
(	O
Hib	O
)	O
disease	O
decreased	O
dramatically	O
after	O
the	O
introduction	O
of	O
conjugate	O
vaccine	O
in	O
routine	O
immunization	B-P
schedules	I-P
.	O

We	O
report	O
a	O
case	O
of	O
a	O
fifteen-months-old	O
girl	O
,	O
previously	O
healthy	O
and	O
vaccinated	B-P
,	O
admitted	O
in	O
the	O
emergency	O
room	O
with	O
fever	O
and	O
vomiting	O
.	O

She	O
was	O
irritable	O
and	O
the	O
Brudzinski	O
's	O
sign	O
was	O
positive	O
.	O

The	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
analysis	O
showed	O
pleocytosis	O
and	O
high	O
protein	O
level	O
.	O

Empiric	O
intravenous	O
antibiotics	O
(	O
ceftriaxone	O
and	O
vancomycin	O
)	O
were	O
administered	B-P
for	O
suspected	O
bacterial	O
meningitis	O
during	O
10	O
days	O
.	O

Serotyping	B-P
of	O
the	O
Haemophilus	O
influenzae	O
strain	O
found	O
in	O
CSF	O
revealed	O
a	O
serotype	O
b	O
.	O

After	O
one	O
year	O
of	O
follow-up	O
no	O
Hib	O
meningitis	O
sequelae	O
were	O
noted	O
.	O

Despite	O
vaccination	B-P
compliance	O
and	O
absence	O
of	O
risk	O
factors	O
,	O
invasive	O
Hib	O
disease	O
can	O
occur	O
due	O
to	O
vaccine	O
failure	O
.	O

Efforts	O
to	O
keep	O
the	O
low	O
incidence	O
of	O
invasive	O
Hib	O
disease	O
should	O
be	O
directed	O
to	O
the	O
maintenance	O
of	O
high	O
vaccination	B-P
coverage	O
rates	O
,	O
combined	O
with	O
the	O
notification	O
and	O
surveillance	B-P
strategies	I-P
already	O
implemented	O
in	O
each	O
country	O
.	O

Effect	O
of	O
Low	O
-	O
Dose	O
MDCT	B-P
and	O
Iterative	B-P
Reconstruction	I-P
on	O
Trabecular	O
Bone	O
Microstructure	O
Assessment	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
low	O
-	O
dose	O
multi	B-P
detector	I-P
computed	I-P
tomography	I-P
(	O
MDCT	B-P
)	O
in	O
combination	O
with	O
statistical	B-P
iterative	I-P
reconstruction	I-P
algorithms	O
on	O
trabecular	O
bone	O
microstructure	O
parameters	O
.	O

Twelve	O
donated	O
vertebrae	O
were	O
scanned	B-P
with	O
the	O
routine	O
radiation	B-P
exposure	I-P
used	O
in	O
our	O
department	O
(	O
standard-dose	O
)	O
and	O
a	O
low	O
-	O
dose	O
protocol	B-P
.	O

Reconstructions	B-P
were	O
performed	O
with	O
filtered	B-P
backprojection	I-P
(	O
FBP	B-P
)	O
and	O
maximum-likelihood	O
based	O
statistical	B-P
iterative	I-P
reconstruction	I-P
(	O
SIR	B-P
)	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
were	O
assessed	O
and	O
statistically	O
compared	O
for	O
each	O
reconstruction	B-P
.	O

Moreover	O
,	O
fracture	O
loads	O
of	O
the	O
vertebrae	O
were	O
biomechanically	B-P
determined	O
and	O
correlated	O
to	O
the	O
assessed	O
microstructure	O
parameters	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
based	O
on	O
low	O
-	O
dose	O
MDCT	B-P
and	O
SIR	B-P
significantly	O
correlated	O
with	O
vertebral	O
bone	O
strength	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
microstructure	O
parameters	O
calculated	O
on	O
low	O
-	O
dose	O
SIR	B-P
and	O
standard	O
-	O
dose	O
FBP	B-P
images	O
.	O

However	O
,	O
the	O
results	O
revealed	O
a	O
strong	O
dependency	O
on	O
the	O
regularization	O
strength	O
applied	O
during	O
SIR	B-P
.	O

It	O
was	O
observed	O
that	O
stronger	O
regularization	O
might	O
corrupt	O
the	O
microstructure	O
analysis	O
,	O
because	O
the	O
trabecular	O
structure	O
is	O
a	O
very	O
small	O
detail	O
that	O
might	O
get	O
lost	O
during	O
the	O
regularization	O
process	O
.	O

As	O
a	O
consequence	O
,	O
the	O
introduction	O
of	O
SIR	B-P
for	O
trabecular	O
bone	O
microstructure	O
analysis	O
requires	O
a	O
specific	O
optimization	O
of	O
the	O
regularization	O
parameters	O
.	O

Moreover	O
,	O
in	O
comparison	O
to	O
other	O
approaches	O
,	O
superior	O
noise	O
-	O
resolution	O
trade-offs	O
can	O
be	O
found	O
with	O
the	O
proposed	O
methods	O
.	O

High-throughput	B-P
analysis	I-P
of	O
sub-visible	O
mAb	O
aggregate	O
particles	O
using	O
automated	B-P
fluorescence	I-P
microscopy	I-P
imaging	I-P
.	O

Aggregation	O
of	O
therapeutic	O
proteins	O
is	O
a	O
major	O
concern	O
as	O
aggregates	O
lower	O
the	O
yield	O
and	O
can	O
impact	O
the	O
efficacy	O
of	O
the	O
drug	O
as	O
well	O
as	O
the	O
patient	B-P
's	I-P
safety	I-P
.	O

It	O
can	O
occur	O
in	O
all	O
production	O
stages	O
;	O
thus	O
,	O
it	O
is	O
essential	O
to	O
perform	O
a	O
detailed	O
analysis	O
for	O
protein	O
aggregates	O
.	O

Several	O
methods	O
such	O
as	O
size	B-P
exclusion	I-P
high-performance	I-P
liquid	I-P
chromatography	I-P
(	O
SE-HPLC	B-P
)	O
,	O
light	O
scattering	O
,	O
turbidity	O
,	O
light	B-P
obscuration	I-P
,	O
and	O
microscopy-based	B-P
approaches	O
are	O
used	O
to	O
analyze	O
aggregates	O
.	O

None	O
of	O
these	O
methods	O
allows	O
determination	B-P
of	O
all	O
types	O
of	O
higher	O
molecular	O
weight	O
(	O
HMW	O
)	O
species	O
due	O
to	O
a	O
limited	O
size	O
range	O
.	O

Furthermore	O
,	O
quantification	O
and	O
specification	O
of	O
different	O
HMW	O
species	O
are	O
often	O
not	O
possible	O
.	O

Moreover	O
,	O
automation	O
is	O
a	O
perspective	O
challenge	O
coming	O
up	O
with	O
automated	O
robotic	O
laboratory	O
systems	O
.	O

Hence	O
,	O
there	O
is	O
a	O
need	O
for	O
a	O
fast	O
,	O
high-throughput-compatible	O
method	O
,	O
which	O
can	O
detect	O
a	O
broad	O
size	O
range	O
and	O
enable	O
quantification	O
and	O
classification	O
.	O

We	O
describe	O
a	O
novel	O
approach	O
for	O
the	O
detection	O
of	O
aggregates	O
in	O
the	O
size	O
range	O
1	O
to	O
1000	O
μm	O
combining	O
fluorescent	O
dyes	O
for	O
protein	O
aggregate	O
labelling	O
and	O
automated	B-P
fluorescence	I-P
microscope	I-P
imaging	I-P
(	O
aFMI	B-P
)	O
.	O

After	O
appropriate	O
selection	O
of	O
the	O
dye	O
and	O
method	O
optimization	O
,	O
our	O
method	O
enabled	O
us	O
to	O
detect	O
various	O
types	O
of	O
HMW	O
species	O
of	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
.	O

Using	O
10	O
μmol	O
L	O
(	O
-1	O
)	O
4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonate	O
(	O
Bis-ANS	O
)	O
in	O
combination	O
with	O
aFMI	B-P
allowed	O
the	O
analysis	O
of	O
mAb	O
aggregates	O
induced	O
by	O
different	O
stresses	O
occurring	O
during	O
downstream	O
processing	O
,	O
storage	O
,	O
and	O
administration	O
.	O

Validation	O
of	O
our	O
results	O
was	O
performed	O
by	O
SE-HPLC	B-P
,	O
UV-Vis	B-P
spectroscopy	I-P
,	O
and	O
dynamic	B-P
light	I-P
scattering	I-P
.	O

With	O
this	O
new	O
approach	O
,	O
we	O
could	O
not	O
only	O
reliably	O
detect	O
different	O
HMW	O
species	O
but	O
also	O
quantify	O
and	O
classify	O
them	O
in	O
an	O
automated	O
approach	O
.	O

Our	O
method	O
achieves	O
high-throughput	B-P
requirements	O
and	O
the	O
selection	O
of	O
various	O
fluorescent	O
dyes	O
enables	O
a	O
broad	O
range	O
of	O
applications	O
.	O

L1	O
retrotransposon	O
expression	O
in	O
circulating	O
tumor	O
cells	O
.	O

Long	O
interspersed	O
nuclear	O
element	O
1	O
(	O
LINE-1	O
or	O
L1	O
)	O
belongs	O
to	O
the	O
non-long	O
terminal	O
repeat	O
(	O
non-LTR	O
)	O
retrotransposon	O
family	O
,	O
which	O
has	O
been	O
implicated	O
in	O
carcinogenesis	O
and	O
disease	O
progression	O
.	O

Circulating	O
tumor	O
cells	O
(	O
CTCs	O
)	O
are	O
also	O
known	O
to	O
be	O
involved	O
in	O
cancer	O
progression	O
.	O

The	O
present	O
study	O
aimed	O
to	O
compare	O
the	O
L1	O
expression	O
between	O
circulating	O
tumor	O
cells	O
and	O
non-cancerous	O
samples	O
.	O

Blood	O
samples	O
were	O
collected	O
from	O
10	O
healthy	O
individuals	O
and	O
22	O
patients	O
with	O
different	O
types	O
of	O
cancer	O
.	O

The	O
whole	O
blood	O
cells	O
were	O
isolated	O
using	O
enrichment	O
protocols	O
and	O
the	O
DNA	O
and	O
RNA	O
were	O
extracted	O
.	O

RT-qPCR	O
was	O
performed	O
for	O
L1-ORF1	O
(	O
open	O
reading	O
frame	O
1	O
)	O
and	O
L1-ORF2	O
,	O
using	O
18S	O
rRNA	O
as	O
the	O
reference	O
gene	O
.	O

The	O
data	O
were	O
analyzed	O
with	O
the	O
Livak	O
method	O
and	O
statistical	O
analyses	O
were	O
carried	O
out	O
with	O
the	O
Mann-Whitney	O
and	O
Kruskal-Wallis	O
tests	O
.	O

In	O
parallel	O
with	O
the	O
above	O
molecular	O
biology	O
experiments	O
,	O
FISH	O
experiments	O
were	O
performed	O
on	O
the	O
interphase	O
nuclei	O
of	O
the	O
cells	O
for	O
the	O
detection	O
of	O
ORF2	O
RNA	O
.	O

DNA	B-P
analysis	I-P
revealed	O
the	O
presence	O
of	O
both	O
ORF1	O
and	O
ORF2	O
in	O
all	O
samples	O
.	O

RNA	O
expression	O
experiments	O
demonstrated	O
that	O
ORF1	O
was	O
not	O
expressed	O
in	O
all	O
samples	O
,	O
while	O
ORF2	O
was	O
expressed	O
at	O
varying	O
levels	O
in	O
the	O
non-cancer	O
samples	O
and	O
the	O
samples	O
representing	O
the	O
different	O
cancer	O
types	O
.	O

A	O
significant	O
difference	O
in	O
ORF2	O
expression	O
was	O
observed	O
between	O
the	O
CTCs	O
and	O
non-cancer	O
samples	O
(	O
p	O
=	O
0,00043	O
)	O
,	O
and	O
significant	O
differences	O
were	O
also	O
observed	O
between	O
normal	O
and	O
lung	O
(	O
p	O
=	O
0,034	O
)	O
,	O
pancreatic	O
(	O
p	O
=	O
0,022	O
)	O
,	O
prostate	O
(	O
p	O
=	O
0,014	O
)	O
,	O
and	O
unknown	O
primary	O
of	O
origin	O
(	O
p	O
=	O
0,0039	O
)	O
cancer	O
samples	O
.	O

Cytogenetic	O
analysis	O
revealed	O
higher	O
levels	O
of	O
ORF2	O
in	O
the	O
nuclei	O
of	O
CTCs	O
than	O
in	O
normal	O
samples	O
.	O

This	O
study	O
highlights	O
the	O
significant	O
difference	O
in	O
L1-ORF2	O
expression	O
between	O
CTCs	O
and	O
normal	O
samples	O
.	O

The	O
increased	O
expression	O
levels	O
observed	O
for	O
CTCs	O
may	O
be	O
correlated	O
with	O
the	O
characteristic	O
features	O
of	O
these	O
cells	O
.	O

Synthesis	O
and	O
In	O
Vitro	O
Cytotoxic	O
Properties	O
of	O
Polycarbo-Substituted	O
4-	O
(	O
Arylamino	O
)	O
quinazolines	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
synthesis	O
of	O
novel	O
unsymmetrical	O
polycarbo-substituted	O
4-anilinoquinazolines	O
derived	O
from	O
the	O
2-aryl-6-bromo-8-iodoquinazolines	O
via	O
one-pot	O
three-step	O
reaction	O
sequences	O
involving	O
initial	O
amination	O
and	O
subsequent	O
double	O
cross-coupling	O
(	O
bis-Suzuki	O
,	O
Sonogashira/Stille	O
or	O
Sonogashira/Suzuki-Miyaura	O
)	O
reactions	O
with	O
different	O
cross	O
coupling	O
partners	O
for	O
the	O
two	O
carbon-carbon	O
bond	O
formation	O
steps	O
.	O

The	O
4-anilinoquinazolines	O
were	O
evaluated	O
for	O
potential	O
cytotoxicity	O
against	O
three	O
cancer	O
cell	O
lines	O
,	O
namely	O
,	O
human	O
breast	O
adenocarcinoma	O
(	O
MCF-7	O
)	O
cells	O
,	O
human	O
cervical	O
cancer	O
(	O
HeLa	O
)	O
and	O
human	O
lung	O
cancer	O
(	O
A549	O
)	O
cells	O
.	O

The	O
most	O
active	O
compounds	O
,	O
2b	O
,	O
2c	O
,	O
3c	O
,	O
4a	O
,	O
4c	O
and	O
5a	O
,	O
were	O
found	O
to	O
be	O
more	O
selective	O
against	O
the	O
MCF-7	O
and	O
HeLa	O
cell	O
lines	O
than	O
the	O
human	O
lung	O
carcinoma	O
(	O
A549	O
)	O
cells	O
.	O

We	O
selected	O
compounds	O
2c	O
,	O
3c	O
and	O
7a	O
as	O
representatives	O
for	O
further	O
evaluation	O
for	O
potential	O
to	O
induce	O
apoptosis	O
and/or	O
necrotic	O
properties	O
in	O
the	O
three	O
cancer	O
cell	O
lines	O
.	O

Compound	O
2c	O
induced	O
apoptosis	O
of	O
MCF-7	O
cells	O
through	O
cell	O
membrane	O
alteration	O
.	O

Treatment	O
of	O
Hela	O
and	O
A549	O
cell	O
lines	O
with	O
compounds	O
3c	O
and	O
7a	O
,	O
respectively	O
,	O
led	O
to	O
caspase-3	O
activation	O
in	O
both	O
cell	O
lines	O
.	O

Compound	O
3c	O
,	O
on	O
the	O
other	O
hand	O
,	O
caused	O
more	O
necrosis	O
than	O
apoptosis	O
induction	O
in	O
the	O
membrane	O
alteration	O
assay	B-P
.	O

Lack	O
of	O
evidence	O
of	O
lower	O
30-day	O
all-cause	O
readmission	O
in	O
Medicare	O
beneficiaries	O
with	O
heart	O
failure	O
and	O
reduced	O
ejection	O
fraction	O
discharged	O
on	O
spironolactone	O
.	O

Therapy	B-P
with	O
evidence	O
-based	O
heart	O
failure	O
(	O
HF	O
)	O
medications	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
lower	O
risk	O
of	O
30-day	O
all-cause	O
readmission	O
in	O
patients	O
with	O
HF	O
and	O
reduced	O
ejection	O
fraction	O
(	O
HFrEF	O
)	O
.	O

We	O
examined	O
the	O
association	O
of	O
aldosterone	O
antagonist	O
use	O
with	O
30-day	O
all-cause	O
readmission	O
in	O
this	O
population	O
.	O

Of	O
the	O
2443	O
Medicare	O
beneficiaries	O
with	O
HF	O
and	O
left	O
ventricular	O
EF	O
≤35	O
%	O
discharged	B-P
home	I-P
from	O
106	O
Alabama	O
hospitals	O
during	O
1998-2001	O
,	O
2060	O
were	O
eligible	O
for	O
spironolactone	O
therapy	B-P
(	O
serum	O
creatinine	O
≤2.5	O
for	O
men	O
and	O
≤2mg/dl	O
for	O
women	O
,	O
and	O
serum	B-P
potassium	I-P
<	O
5mEq/L	O
)	O
.	O

After	O
excluding	O
186	O
patients	O
already	O
receiving	O
spironolactone	O
on	O
admission	O
,	O
the	O
inception	O
cohort	O
consisted	O
of	O
1874	O
patients	O
eligible	O
for	O
a	O
new	O
discharge	O
prescription	O
for	O
spironolactone	O
,	O
of	O
which	O
329	O
received	O
one	O
.	O

Using	O
propensity	O
scores	O
for	O
initiation	O
of	O
spironolactone	O
therapy	B-P
,	O
we	O
assembled	O
a	O
matched	O
cohort	O
of	O
324	O
pairs	O
of	O
patients	O
receiving	O
and	O
not	O
receiving	O
spironolactone	O
balanced	O
on	O
34	O
baseline	O
characteristics	O
(	O
mean	O
age	O
72years	O
,	O
42	O
%	O
women	O
,	O
33	O
%	O
African	O
American	O
)	O
.	O

Thirty-day	O
all-cause	O
readmission	O
occurred	O
in	O
17	O
%	O
and	O
19	O
%	O
of	O
matched	O
patients	O
receiving	O
and	O
not	O
receiving	O
spironolactone	O
,	O
respectively	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.92	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.64-1.32	O
;	O
p=0.650	O
)	O
.	O

Spironolactone	O
had	O
no	O
association	O
with	O
30-day	O
all-cause	O
mortality	O
(	O
HR	O
,	O
0.84	O
;	O
95	O
%	O
CI	O
,	O
0.38-1.88	O
;	O
p=0.678	O
)	O
or	O
HF	O
readmission	O
(	O
HR	O
,	O
0.74	O
;	O
95	O
%	O
CI	O
,	O
0.41	O
1.31	O
;	O
p=0.301	O
)	O
.	O

These	O
associations	O
remained	O
unchanged	O
during	O
12months	O
of	O
post-discharge	O
follow-up	O
.	O

A	O
discharge	O
prescription	O
for	O
spironolactone	O
had	O
no	O
association	O
with	O
30-day	O
all-cause	O
readmission	O
among	O
older	O
,	O
hospitalized	O
Medicare	O
beneficiaries	O
with	O
HFrEF	O
eligible	O
for	O
spironolactone	O
therapy	B-P
.	O

Effects	O
of	O
Static	B-P
Cold	I-P
Storage	I-P
and	O
Hypothermic	B-P
Machine	I-P
Perfusion	I-P
on	O
Oxidative	B-P
Stress	I-P
Factors	I-P
,	O
Adhesion	O
Molecules	O
,	O
and	O
Zinc	O
Finger	O
Transcription	O
Factor	O
Proteins	O
Before	O
and	O
After	O
Liver	B-P
Transplantation	I-P
.	O

BACKGROUND	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static	B-P
cold	I-P
storage	I-P
(	O
SCS	B-P
)	O
and	O
hypothermic	B-P
machine	I-P
perfusion	I-P
(	O
HMP	B-P
)	O
on	O
the	O
oxidative	B-P
stress	I-P
factors	I-P
(	O
OSF	B-P
)	O
,	O
adhesion	O
molecules	O
(	O
AM	O
)	O
,	O
and	O
zinc	O
finger	O
transcription	O
factor	O
(	O
Snail	O
)	O
before	O
and	O
after	O
liver	B-P
transplantation	I-P
.	O

MATERIAL	O
AND	O
METHODS	O
Experimental	O
dogs	O
were	O
randomly	O
divided	O
into	O
donor	O
(	O
group	O
A	O
)	O
,	O
SCS	B-P
(	O
group	O
B	O
)	O
,	O
and	O
HMP	B-P
(	O
group	O
C	O
)	O
(	O
n=30	O
)	O
groups	O
.	O

Livers	B-P
retrieved	I-P
from	O
group	O
A	O
were	O
transplanted	B-P
into	O
group	O
B	O
after	O
SCS	B-P
,	O
and	O
the	O
livers	O
sampled	O
from	O
group	O
B	O
were	O
transplanted	B-P
into	O
group	O
C	O
after	O
HMP	B-P
.	O

The	O
dogs	O
in	O
group	O
A	O
were	O
euthanized	O
and	O
discarded	O
,	O
and	O
the	O
livers	O
sampled	O
from	O
group	O
C	O
were	O
used	O
for	O
other	O
experiments	O
.	O

Twenty	O
dogs	O
with	O
successful	O
liver	B-P
transplants	I-P
were	O
randomly	O
selected	O
from	O
groups	O
B	O
and	O
C	O
for	O
analysis	O
.	O

RESULTS	O
During	O
the	O
liver	O
sampling	O
process	O
,	O
the	O
levels	O
of	O
OSF	B-P
,	O
AM	O
,	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0.05	O
)	O
;	O
before	O
the	O
transplantation	B-P
,	O
the	O
levels	O
of	O
chemokine	O
CXCL14	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0.05	O
)	O
,	O
and	O
compared	O
with	O
group	O
B	O
,	O
HIF-1α	O
and	O
P-selectin	O
in	O
group	O
C	O
were	O
lower	O
(	O
P	O
<	O
0.01	O
)	O
;	O
60	O
min	O
after	O
the	O
transplantation	B-P
,	O
HIF-1α	O
,	O
chemokine	O
CXCL14	O
,	O
P-selectin	O
,	O
and	O
Snail	O
in	O
group	O
C	O
were	O
lower	O
than	O
that	O
in	O
group	O
B	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
HMP	B-P
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
OSF	B-P
and	O
inflammatory	O
factors	O
,	O
which	O
is	O
conducive	O
for	O
liver	B-P
transplantation	I-P
.	O

The	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	O
during	O
lung	B-P
resection	I-P
surgery	I-P
:	O
A	O
retrospective	O
matched	O
cohort	O
analysis	O
of	O
real	O
-	O
world	O
data	O
.	O

The	O
objective	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
quantify	O
the	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	O
in	O
lung	B-P
resection	I-P
surgery	I-P
in	O
the	O
US	O
.	O

This	O
study	O
utilized	O
2009-2012	O
data	O
from	O
the	O
Premier	O
Perspective	O
Database	O
(	O
TM	O
)	O
.	O

Adult	O
patients	O
with	O
primary	B-P
pulmonary	I-P
lobectomy	I-P
or	O
segmentectomy	B-P
procedures	I-P
were	O
categorized	O
by	O
the	O
surgical	O
approach	O
(	O
VATS	B-P
vs	O
open	B-P
)	O
and	O
primary	O
diagnosis	O
(	O
primary	B-P
or	O
metastatic	B-P
lung	I-P
cancer	I-P
vs	O
non-lung	B-P
cancer	I-P
)	O
.	O

Patients	O
requiring	O
≥3	O
units	O
of	O
blood	O
products	O
with	O
at	O
least	O
1	O
unit	O
of	O
PRBCs	O
:	O
``	O
significant	O
bleeding	O
``	O
cohort	O
;	O
those	O
requiring	O
<	O
3	O
units	O
:	O
``	O
non-significant	O
bleeding	O
``	O
cohort	O
;	O
and	O
those	O
not	O
requiring	O
blood	O
products	O
:	O
``	O
no	O
bleeding	O
``	O
cohort	O
.	O

A	O
matched	O
cohort	O
analysis	O
was	O
performed	O
between	O
the	O
``	O
significant	O
bleeding	O
``	O
and	O
the	O
``	O
no	O
bleeding	O
cohort	O
``	O
using	O
matching	O
variables	O
:	O
hospital	O
,	O
lung	B-P
cancer	I-P
diagnosis	I-P
,	O
year	O
of	O
surgery	O
,	O
APR-DRG	O
severity	O
score	O
,	O
procedure	O
type	O
and	O
approach	O
,	O
age	O
,	O
and	O
gender	O
.	O

The	O
``	O
All	O
-	O
patient	O
``	O
cohort	O
comprised	O
21,429	O
patients	O
:	O
213	O
``	O
significant	O
bleeding	O
``	O
;	O
2,780	O
``	O
non-significant	O
bleeding	O
``	O
;	O
and	O
18,436	O
``	O
no	O
bleeding	O
``	O
.	O

Overall	O
incidence	O
of	O
significant	O
chest	O
bleeding	O
was	O
0.99	O
%	O
.	O

Patients	O
from	O
``	O
significant	O
bleeding	O
``	O
cohort	O
and	O
``	O
non-significant	O
bleeding	O
``	O
cohort	O
had	O
2.5	O
days	O
and	O
2	O
days	O
(	O
p	O
<	O
0.0001	O
)	O
longer	O
length	O
of	O
stay	O
in	O
the	O
hospital	O
compared	O
to	O
those	O
in	O
the	O
``	O
no	O
bleeding	O
``	O
cohort	O
,	O
respectively	O
.	O

Overall	O
,	O
hospital	O
costs	O
for	O
``	O
significant	O
bleeding	O
``	O
cohort	O
were	O
higher	O
than	O
``	O
no	O
bleeding	O
``	O
cohort	O
for	O
those	O
who	O
were	O
covered	O
under	O
Medicare	O
(	O
$	O
59,871	O
vs	O
$	O
23,641	O
)	O
,	O
were	O
≥76	O
years	O
of	O
age	O
(	O
$	O
64,010	O
vs	O
$	O
24,243	O
)	O
,	O
had	O
greater	O
severity	O
of	O
illness	O
(	O
$	O
97,813	O
vs	O
$	O
51,871	O
)	O
and	O
underwent	O
open	O
segmentectomy	B-P
(	O
$	O
74,220	O
vs	O
$	O
21,903	O
)	O
.	O

Hospital	O
costs	O
for	O
``	O
significant	O
bleeding	O
``	O
cohort	O
and	O
``	O
non-significant	O
bleeding	O
``	O
were	O
significantly	O
higher	O
(	O
$	O
11,589	O
and	O
$	O
5,280	O
,	O
respectively	O
,	O
p	O
<	O
0.0001	O
)	O
than	O
no	O
bleeding	O
cohort	O
.	O

Although	O
significant	O
bleeding	O
during	O
lung	B-P
resection	I-P
surgery	I-P
is	O
rare	O
,	O
patients	O
with	O
such	O
complication	O
could	O
stay	O
longer	O
at	O
the	O
hospital	O
and	O
cost	O
an	O
average	O
of	O
$	O
13,103	O
more	O
than	O
those	O
without	O
.	O

Staged	O
Fowler-Stephens	O
and	O
Single-stage	B-P
Laparoscopic	I-P
Orchiopexy	I-P
for	O
Intra-abdominal	O
Testes	O
:	O
Is	O
There	O
a	O
Difference	O
?	O

A	O
Single	O
Institution	O
Experience	O
.	O

To	O
compare	O
single-stage	B-P
laparoscopic	I-P
orchiopexy	I-P
(	O
SSLO	B-P
)	O
and	O
staged	O
Fowler-Stephens	O
(	O
SFS	O
)	O
procedures	O
in	O
the	O
management	O
of	O
intra-abdominal	O
undescended	O
testes	O
,	O
and	O
to	O
analyze	O
postoperative	O
atrophy	O
and	O
malpositioning	O
as	O
end	O
points	O
.	O

A	O
retrospective	O
chart	O
review	O
identified	O
laparoscopic	B-P
orchiopexy	I-P
patients	O
with	O
intra-abdominal	O
testes	O
between	O
November	O
2006	O
and	O
November	O
2014	O
.	O

Of	O
167	O
patients	O
who	O
had	O
laparoscopic	B-P
orchiopexy	I-P
,	O
73	O
(	O
85	O
testes	O
)	O
were	O
identified	O
as	O
having	O
laparoscopic	B-P
orchiopexy	I-P
.	O

Baseline	O
characteristics	O
,	O
as	O
well	O
as	O
testicular	O
scrotal	O
position	O
and	O
size	O
at	O
follow-up	O
,	O
were	O
recorded	O
.	O

Regression	O
analysis	O
was	O
performed	O
to	O
compare	O
outcomes	O
between	O
patients	O
who	O
underwent	O
SFS	O
and	O
SSLO	B-P
.	O

Of	O
the	O
85	O
laparoscopic	B-P
orchiopexies	I-P
,	O
35	O
underwent	O
SFS	O
and	O
50	O
had	O
SSLO	B-P
.	O

Patient	O
demographics	O
were	O
comparable	O
in	O
both	O
groups	O
.	O

The	O
median	O
age	O
at	O
surgery	O
was	O
12	O
months	O
(	O
5-151	O
months	O
)	O
,	O
and	O
the	O
average	O
follow-up	O
was	O
17.3	O
months	O
.	O

On	O
follow-up	O
,	O
there	O
were	O
0	O
recorded	O
cases	O
of	O
SFS	O
patients	O
with	O
abnormally	O
positioned	O
testes	O
postoperatively	O
,	O
whereas	O
there	O
were	O
10	O
(	O
20.0	O
%	O
)	O
SSLO	B-P
patients	O
who	O
had	O
abnormally	O
positioned	O
testes	O
(	O
odds	O
ratio	O
:	O
0.05	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
0.01-0.44	O
)	O
.	O

Differences	O
in	O
atrophy	O
rates	O
were	O
not	O
significant	O
.	O

These	O
results	O
suggest	O
that	O
there	O
may	O
be	O
no	O
difference	O
between	O
the	O
2	O
approaches	O
in	O
terms	O
of	O
postoperative	O
atrophy	O
.	O

However	O
,	O
the	O
SFS	O
appears	O
to	O
be	O
more	O
successful	O
in	O
securing	O
a	O
favorable	O
scrotal	O
position	O
.	O

Atrophy	O
does	O
not	O
seem	O
to	O
be	O
associated	O
with	O
other	O
patient	O
factors	O
.	O

Prospective	O
,	O
randomized	O
studies	O
are	O
indicated	O
to	O
further	O
explore	O
outcome	O
differences	O
between	O
the	O
2	O
approaches	O
.	O

Regional	O
Odontodysplasia	O
with	O
Generalised	O
Enamel	O
Defect	O
.	O

Regional	O
odontodysplasia	O
(	O
ROD	O
)	O
is	O
uncommon	O
developmental	O
anomaly	O
,	O
which	O
tends	O
to	O
be	O
localised	O
and	O
involves	O
the	O
ectodermal	O
and	O
mesodermal	O
tooth	O
components	O
.	O

A	O
five-year-old	O
female	O
was	O
referred	O
to	O
Department	O
of	O
Child	O
Dental	O
Health	O
at	O
the	O
Leeds	O
Dental	O
Institute	O
regarding	O
malformed	O
primary	O
teeth	O
.	O

On	O
examination	O
64	O
,	O
74	O
,	O
and	O
72	O
had	O
localised	O
hypomineralized	O
enamel	O
defect	O
.	O

The	O
crown	O
of	O
55	O
was	O
broken	O
down	O
with	O
only	O
the	O
root	O
remaining	O
below	O
the	O
gingival	O
level	O
.	O

54	O
has	O
a	O
yellowish	O
brown	O
discolouration	O
with	O
rough	O
irregular	O
surface	O
.	O

The	O
upper	O
anterior	O
teeth	O
show	O
mild	O
enamel	O
opacity	O
.	O

Radiographically	B-P
,	O
55	O
and	O
54	O
had	O
thin	O
radioopaque	O
contour	O
,	O
showing	O
poor	O
distinction	O
between	O
the	O
enamel	O
and	O
dentine	O
and	O
the	O
classic	O
feature	O
of	O
a	O
wide	O
pulp	O
chamber	O
.	O

15	O
,	O
16	O
,	O
and	O
17	O
were	O
developmentally	O
delayed	O
and	O
were	O
displaying	O
the	O
characteristic	O
``	O
ghost	O
appearance	O
.	O
''	O

Comprehensive	O
dental	O
care	O
was	O
done	O
under	O
local	B-P
anaesthesia	I-P
and	O
it	O
included	O
extraction	B-P
of	O
the	O
primary	O
molars	O
affected	O
by	O
ROD	O
,	O
stainless	O
steel	O
crown	O
on	O
64	O
,	O
and	O
caries	O
prevention	O
program	O
.	O

Fifteen	O
months	O
following	O
the	O
initial	O
assessment	O
the	O
patient	O
's	O
oral	O
condition	O
remains	O
stable	O
and	O
she	O
is	O
under	O
regular	O
follow-up	O
at	O
the	O
department	O
.	O

Paediatric	O
dentists	O
should	O
be	O
aware	O
of	O
this	O
anomaly	O
as	O
it	O
involves	O
both	O
dentitions	O
and	O
usually	O
requires	O
multidisciplinary	O
care	O
.	O

Stem	O
cell	O
registry	O
programme	O
for	O
patients	O
with	O
ischemic	O
cardiomyopathy	O
undergoing	O
coronary	B-P
artery	I-P
bypass	I-P
grafting	I-P
:	O
what	O
benefits	O
does	O
it	O
derive	O
?	O
.	O

Standardization	O
of	O
stem	B-P
cell	I-P
therapy	I-P
requires	O
application	O
of	O
appropriate	O
methods	O
to	O
evaluate	O
safety	O
and	O
efficac	O
y	O
,	O
including	O
long-term	O
pharmacovigilance	O
.	O

To	O
accomplish	O
this	O
objective	O
,	O
a	O
long-term	O
registry	O
programme	O
was	O
installed	O
.	O

We	O
analysed	O
150	O
patients	O
with	O
ischemic	O
cardiomyopathy	O
,	O
who	O
received	O
intramyocardial	O
CD133+	O
bone	O
marrow	O
mononuclear	O
stem	O
cell	O
treatment	B-P
combined	O
with	O
coronary	B-P
artery	I-P
bypass	I-P
grafting	I-P
(	O
CABG	B-P
)	O
or	O
CABG	B-P
alone	O
.	O

The	O
mortality	O
rate	O
,	O
major	O
adverse	O
cerebral	O
and	O
cardiac	O
events	O
,	O
and	O
functional	O
outcome	O
parameters	O
were	O
evaluated	O
for	O
the	O
time	O
period	O
up	O
to	O
14	O
years	O
follow-up	O
.	O

As	O
a	O
result	O
,	O
we	O
have	O
stratified	O
the	O
patient	O
population	O
(	O
96	O
patients	O
)	O
into	O
responders	O
and	O
non-responders	O
.	O

Furthermore	O
,	O
the	O
analysis	O
of	O
relevant	O
predictors	O
of	O
good	O
response	O
to	O
CD133+	O
bone	O
marrow	O
mononuclear	O
stem	O
cell	O
treatment	B-P
was	O
performed	O
.	O

Several	O
positive	O
tendencies	O
related	O
to	O
stem	B-P
cells	I-P
transplantation	I-P
were	O
demonstrated	O
.	O

First	O
,	O
no	O
significant	O
difference	O
in	O
major	O
adverse	O
cardiovascular	O
and	O
cerebral	O
events	O
was	O
observed	O
between	O
stem	O
cell	O
and	O
control	O
group	O
up	O
to	O
14	O
years	O
follow-up	O
.	O

Second	O
,	O
an	O
improvement	O
of	O
left	O
ventricle	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
in	O
stem	O
cell	O
group	O
retained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
CABG	B-P
-	O
only	O
group	O
,	O
where	O
no	O
significant	O
changes	O
in	O
LVEF	O
after	O
2	O
years	O
were	O
observed	O
.	O

In	O
addition	O
,	O
LVEF	O
under	O
30	O
%	O
and	O
left	B-P
ventricle	I-P
end	I-P
diastolic	I-P
diameter	I-P
above	O
60	O
mm	O
were	O
independent	O
predictors	O
of	O
functional	O
response	O
to	O
CD133+	O
cell	O
therapy	B-P
.	O

Participants	O
with	O
overt	O
heart	O
failure	O
benefit	O
most	O
from	O
CABG	B-P
combined	O
with	O
intramyocardial	O
injection	B-P
of	O
CD133+	O
bone	O
marrow	O
mononuclear	O
cell	O
within	O
the	O
group	O
.	O

An	O
improvement	O
LVEF	O
in	O
stem	O
cell	O
group	O
remained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
the	O
CABG	B-P
-	O
only	O
group	O
.	O

The	O
patients	O
,	O
in	O
whom	O
the	O
improvement	O
of	O
both	O
LVEF	O
and	O
LVED	B-P
was	O
observed	O
,	O
have	O
benefited	O
by	O
increased	O
life	O
expectancy	O
.	O

A	O
Tobramycin	O
Vector	O
Enhances	O
Synergy	O
and	O
Efficacy	O
of	O
Efflux	O
Pump	O
Inhibitors	O
against	O
Multidrug-Resistant	O
Gram-Negative	O
Bacteria	O
.	O

Drug	O
efflux	O
mechanisms	O
interact	O
synergistically	O
with	O
the	O
outer	O
membrane	O
permeability	O
barrier	O
of	O
Gram-negative	O
bacteria	O
,	O
leading	O
to	O
intrinsic	O
resistance	O
that	O
presents	O
a	O
major	O
challenge	O
for	O
antibiotic	O
drug	O
development	O
.	O

Efflux	O
pump	O
inhibitors	O
(	O
EPIs	O
)	O
which	O
block	O
the	O
efflux	O
of	O
antibiotics	O
synergize	O
antibiotics	O
,	O
but	O
the	O
clinical	O
development	O
of	O
EPI	O
/	O
antibiotic	O
combination	B-P
therapy	I-P
to	O
treat	B-P
multidrug-resistant	O
(	O
MDR	O
)	O
Gram-negative	O
infections	O
has	O
been	O
challenging	O
.	O

This	O
is	O
in	O
part	O
caused	O
by	O
the	O
inefficiency	O
of	O
current	O
EPIs	O
to	O
penetrate	O
the	O
outer	O
membrane	O
and	O
resist	O
efflux	O
.	O

We	O
demonstrate	O
that	O
conjugation	O
of	O
a	O
tobramycin	O
(	O
TOB	O
)	O
vector	O
to	O
EPIs	O
like	O
NMP	O
,	O
paroxetine	O
,	O
or	O
DBP	O
enhances	O
synergy	O
and	O
efficacy	O
of	O
EPIs	O
in	O
combination	O
with	O
tetracycline	O
antibiotics	O
against	O
MDR	O
Gram-negative	O
bacteria	O
including	O
Pseudomonas	O
aeruginosa	O
.	O

Besides	O
potentiating	O
tetracycline	O
antibiotics	O
,	O
TOB	O
-	O
EPI	O
conjugates	O
can	O
also	O
suppress	O
resistance	O
development	O
to	O
the	O
tetracycline	O
antibiotic	O
minocycline	O
,	O
thereby	O
providing	O
a	O
strategy	O
to	O
develop	O
more	O
effective	O
adjuvants	O
to	O
rescue	O
tetracycline	O
antibiotics	O
from	O
resistance	O
in	O
MDR	O
Gram-negative	O
bacteria	O
.	O

Mutation	O
profiles	O
of	O
synchronous	O
colorectal	O
cancers	O
from	O
a	O
patient	O
with	O
Lynch	O
syndrome	O
suggest	O
distinct	O
oncogenic	O
pathways	O
.	O

Patients	O
with	O
Lynch	O
syndrome	O
often	O
present	O
with	O
multiple	O
synchronous	O
or	O
metachronous	O
colorectal	O
cancers	O
(	O
CRCs	O
)	O
.	O

The	O
presence	O
of	O
multiple	O
CRCs	O
with	O
distinct	O
genetic	B-P
profiles	I-P
and	O
driver	O
mutations	O
could	O
complicate	O
treatment	O
as	O
each	O
cancer	O
may	O
respond	O
differently	O
to	O
therapy	B-P
.	O

Studies	O
of	O
sporadic	O
CRCs	O
suggested	O
that	O
synchronous	O
tumors	O
have	O
distinct	O
etiologies	O
,	O
but	O
could	O
not	O
rule	O
out	O
differences	O
in	O
genetic	O
background	O
.	O

The	O
presence	O
of	O
multiple	O
cancers	O
in	O
a	O
patient	O
with	O
a	O
predisposing	O
mutation	O
provides	O
an	O
opportunity	O
to	O
profile	O
synchronous	O
cancers	O
in	O
the	O
same	O
genetic	O
background	O
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
patient	O
with	O
Lynch	O
syndrome	O
that	O
presented	O
with	O
six	O
synchronous	O
CRCs	O
.	O

Microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
genomic	B-P
profiling	I-P
indicated	O
that	O
each	O
lesion	O
had	O
a	O
unique	O
pattern	O
of	O
instability	O
and	O
a	O
distinct	O
profile	O
of	O
affected	O
genes	O
.	O

These	O
findings	O
support	O
the	O
idea	O
that	O
in	O
Lynch	O
syndrome	O
,	O
synchronous	O
CRCs	O
can	O
develop	O
in	O
parallel	O
with	O
distinct	O
mutation	O
profiles	O
and	O
that	O
these	O
differences	O
may	O
inform	O
treatment	O
decisions	O
.	O

Glucose	O
metabolism	O
-	O
weighted	B-P
imaging	I-P
with	O
chemical	B-P
exchange-sensitive	I-P
MRI	I-P
of	O
2-deoxyglucose	O
(	O
2DG	O
)	O
in	O
brain	O
:	O
Sensitivity	O
and	O
biological	O
sources	O
.	O

Recent	O
proof-of-principle	O
studies	O
have	O
demonstrated	O
the	O
feasibility	O
of	O
measuring	O
the	O
uptake	O
and	O
metabolism	O
of	O
non-labeled	O
2-deoxy-D-glucose	O
(	O
2DG	O
)	O
by	O
a	O
chemical	B-P
exchange-sensitive	I-P
spin-lock	I-P
(	I-P
CESL	I-P
)	I-P
MRI	I-P
approach	I-P
.	O

In	O
order	O
to	O
gain	O
better	O
understanding	O
of	O
this	O
new	O
approach	O
,	O
we	O
performed	O
dynamic	O
in	O
vivo	O
CESL	B-P
MRI	I-P
on	O
healthy	O
rat	O
brains	O
with	O
an	O
intravenous	O
injection	O
of	O
2DG	O
under	O
various	O
conditions	O
at	O
9.4T	O
.	O

For	O
three	O
2DG	O
doses	O
of	O
0.25	O
,	O
0.5	O
and	O
1g/kg	O
,	O
we	O
found	O
that	O
2DG	O
-	O
CESL	B-P
signals	O
increased	O
linearly	O
with	O
injection	B-P
dose	O
at	O
the	O
initial	O
(	O
<	O
20min	O
)	O
but	O
not	O
the	O
later	O
period	O
(	O
>	O
40min	O
)	O
suggesting	O
time-dependent	O
differential	O
weightings	O
of	O
2DG	O
transport	O
and	O
metabolism	O
.	O

Remaining	O
2DG	O
-	O
CESL	B-P
studies	O
were	O
performed	O
with	O
0.25g/kg	O
2DG	O
.	O

Since	O
a	O
higher	O
isoflurane	O
level	O
reduces	O
glucose	O
metabolism	O
and	O
increases	O
blood	O
flow	O
,	O
2DG	O
-	O
CESL	B-P
was	O
measured	O
under	O
0.5	O
%	O
,	O
1.5	O
%	O
and	O
2.2	O
%	O
isoflurane	O
.	O

The	O
2DG	O
-	O
CESL	B-P
signal	O
was	O
reduced	O
at	O
higher	O
isoflurane	O
levels	O
correlating	O
well	O
with	O
the	O
2DG	O
phosphorylation	O
in	O
the	O
intracellular	O
space	O
.	O

To	O
detect	O
regional	O
heterogeneities	O
of	O
glucose	O
metabolism	O
,	O
2DG	O
-	O
CESL	B-P
with	O
0.33×0.33×1.50mm	O
(	O
3	O
)	O
resolution	O
was	O
obtained	O
,	O
which	O
indeed	O
showed	O
a	O
higher	O
response	O
in	O
the	O
cortex	O
compared	O
to	O
the	O
corpus	O
callosum	O
.	O

Lastly	O
,	O
unlike	O
CESL	B-P
MRI	I-P
with	O
the	O
injection	B-P
of	O
non-transportable	O
mannitol	O
,	O
the	O
2DG	O
-	O
CESL	B-P
response	O
decreased	O
with	O
an	O
increased	O
spin-lock	O
pulse	O
power	O
confirming	O
that	O
2DG	O
-	O
CESL	B-P
is	O
dominated	O
by	O
chemical	O
exchange	O
processes	O
in	O
the	O
extravascular	O
space	O
.	O

Taken	O
together	O
,	O
our	O
results	O
showed	O
that	O
2DG	O
-	O
CESL	B-P
MRI	I-P
signals	O
mainly	O
indicate	O
glucose	O
transport	O
and	O
metabolism	O
and	O
may	O
be	O
a	O
useful	O
biomarker	O
for	O
metabolic	O
studies	O
of	O
normal	O
and	O
diseased	O
brains	O
.	O

